AU8823498A

AU8823498A - Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4

Info

Publication number: AU8823498A
Application number: AU88234/98A
Authority: AU
Inventors: Reinhardt Bernhard Baudy; Francine S. Grant; Andrei W. Konradi; Anthony Kreft; Michael A. Pleiss; Dimitrios Sarantakis; Christopher M. Semko; Eugene D. Thorsett
Original assignee: Elan Pharmaceuticals LLC; American Home Products Corp
Current assignee: Wyeth LLC; Elan Pharmaceuticals LLC
Priority date: 1997-07-31
Filing date: 1998-07-31
Publication date: 1999-02-22
Also published as: WO1999006437A1; KR20010022405A; NO20000452L; EP0994896A1; JP2001512139A; HUP0003921A3; PL338457A1; CN1265672A; IL133637A0; HUP0003921A2; NO20000452D0; CA2290748A1; BR9811594A

Description

WO 99/06437 PCT/US98/16070 1 5 SULFONYLATED DIPEPTIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 10 BACKGROUND OF THE INVENTION Field of the Invention This invention relates to compounds which inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. 15 References The following publications, patents and patent applications are cited in this application as superscript numbers: 20 Hemler and Takada, European Patent Application Publication No. 330,506, published August 30, 1989 2 Elices, et al., Cell 60:577-584 (1990) 25 Springer, Nature, 346:425-434 (1990) 4 Osborn, Cell, 62:3-6 (1990) Vedder, et al., Surgery, 106:509 (1989) 30 6 Pretolani, et al., . Exp. Med., 180:795 (1994) Abraham, et al., J. Clin. Invest., 93:776 (1994) 35 8 Mulligan, et al., J Immunology, 150:2407 (1993) WO 99/06437 PCT/US98/16070 2 S Cybulsky, et al., Science 251:788 (1991) 10 Li, et al.,Arterioscler. Thromb., 13:197 (1993) 5 1 Sasseville, et al., Am. J Path., 144:27 (1994) 12 Yang, et al., Proc. Nat. Acad Science (USA), 90:10494 (1993) 10 3 Burkly, et al., Diabetes 43:529 (1994) 14 Baron, et al., J. Clin. Invest., 93:1700 (1994) 15 Hamann, et al., J. Immunology, 152:3238 (1994) 15 16 Yednock, et al., Nature 356:63 (1992) 17 Baron, et al., J. Exp. Med, 177:57 (1993) 20 18 van Dinther-Janssen, et al., J. Immunology, 147:4207 (1991) 19 van Dinther-Janssen, et al., Annals. Rheumatic Dis., 52:672 (1993) 25 20 Elices, et al., J. Clin. Invest., 93:405 (1994) 21 Postigo, et al., J. Clin. Invest., 89:1445 (1991) 22 Paul, et al., Transpl. Proceed., 25:813 (1993) 30 23 Okarhara, et al., Can. Res., 54:3233 (1994) 24 Paavonen, et al., Int. J Can., 58:298 (1994) 35 25 Schadendorf, et al., J Path., 170:429 (1993) 26 Bao, et al., Diff, 52:239 (1993) 27 Lauri, et al., British J Cancer, 68:862 (1993) 40 28 Kawaguchi, et al., Japanese J. Cancer Res., 83:1304 (1992) 29 Kogan, et al., US. PatentNo. 5,510,332, issued April 23, 1996 45 30 International Patent Appl. Publication No. WO 96/01644 WO 99/06437 PCT/US98/16070 3 All of the above publications, patents and patent applications are herein incorporated by reference in their entirety to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety. 5 State of the Art VLA-4 (also referred to as a 4

P

1 integrin and CD49d/CD29), first identified by Hemler and Takada' is a member of the P 1 integrin family of cell surface receptors, each of which comprises two subunits, an a chain and 10 a P3 chain. VLA-4 contains an a4 chain and a 1Pl chain. There are at least nine P31 integrins, all sharing the same P1l chain and each having a distinct a chain. These nine receptors all bind a different complement of the various cell matrix molecules, such as fibronectin, laminin, and collagen. VLA-4, for example, binds to fibronectin. VLA-4 also binds non-matrix molecules 15 that are expressed by endothelial and other cells. These non-matrix molecules include VCAM-1, which is expressed on cytokine-activated human umbilical vein endothelial cells in culture. Distinct epitopes of VLA 4 are responsible for the fibronectin and VCAM-1 binding activities and each activity has been shown to be inhibited independently.

2 20 Intercellular adhesion mediated by VLA-4 and other cell surface receptors is associated with a number of inflammatory responses. At the site of an injury or other inflammatory stimulus, activated vascular endothelial cells express molecules that are adhesive for leukocytes. The mechanics of 25 leukocyte adhesion to endothelial cells involves, in part, the recognition and binding of cell surface receptors on leukocytes to the corresponding cell surface molecules on endothelial cells. Once bound, the leukocytes migrate across the blood vessel wall to enter the injured site and release chemical mediators to combat infection. For reviews of adhesion receptors of the 30 immune system, see, for example, Springer 3 and Osborn 4

.

WO 99/06437 PCT/US98/16070 4 Inflammatory brain disorders, such as experimental autoimmune encephalomyelitis (EAE), multiple sclerosis (MS) and meningitis, are examples of central nervous system disorders in which the endothelium/leukocyte adhesion mechanism results in destruction to 5 otherwise healthy brain tissue. Large numbers of leukocytes migrate across the blood brain barrier (BBB) in subjects with these inflammatory diseases. The leukocytes release toxic mediators that cause extensive tissue damage resulting in impaired nerve conduction and paralysis. 10 In other organ systems, tissue damage also occurs via an adhesion mechanism resulting in migration or activation of leukocytes. For example, it has been shown that the initial insult following myocardial ischemia to heart tissue can be further complicated by leukocyte entry to the injured tissue causing still further insult (Vedder et al.'). Other inflammatory 15 conditions mediated by an adhesion mechanism include, by way of example, asthma'-' 6 , Alzheimer's disease, atherosclerosis 9- 0 , AIDS dementia", diabetes 12 -1 4 (including acute juvenile onset diabetis), inflammatory bowel disease" 5 (including ulcerative colitis and Crohn's disease), multiple sclerosis 6- 1 7 , rheumatoid arthritis -z1 , tissue transplantation 2 2 , tumor 20 metastasis 23 -28 , meningitis, encephalitis, stroke, and other cerebral traumas, nephritis, retinitis, atopic dermatitis, psoriasis, myocardial ischemia and acute leukocyte-mediated lung injury such as that which occurs in adult respiratory distress syndrome. 25 In view of the above, assays for determining the VLA-4 level in a biological sample containing VLA-4 would be useful, for example, to diagnosis VLA-4 mediated conditions. Additionally, despite these advances in the understanding of leukocyte adhesion, the art has only recently addressed the use of inhibitors of adhesion in the treatment of inflammatory 30 brain diseases and other inflammatory conditions 29, 3 0 . The present invention addresses these and other needs.

WO 99/06437 PCT/US98/16070 5 SUMMARY OF THE INVENTION This invention provides compounds which bind to VLA-4. Such compounds can be used, for example, to assay for the presence of VLA-4 in a sample and, in pharmaceutical compositions, to inhibit cellular adhesion 5 mediated by VLA-4, for example, binding of VCAM-1 to VLA-4. The compounds of this invention have a binding affinity to VLA-4 as expressed by an IC 5 0 of about 15 pM or less (as measured using the procedure shown in Example 203 below) which compounds are defined by formula I below: 10 R 3 O

R'-S

O

2

-N(R

2 )-C-Q-CH-C-OH I I I H R 5 15 where R' is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocylic, heteroaryl and substituted heteroaryl; 20 R 2 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heterocyclic, substituted heterocyclic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, and R' and R 2 together with the nitrogen atom bound to R 2 and the SO2 group bound to R 1 can form a heterocyclic or a 25 substituted heterocyclic group;

R

3 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic and where R2 and R 3 together with the nitrogen atom bound to R2 and the carbon 30 atom bound to R 3 can form a saturated heterocyclic group or a saturated substituted heterocyclic group with the proviso that when monosubstituted, the substituent on said saturated substituted heterocyclic group is not carboxyl; WO 99/06437 PCT/US98/16070 6 Ar is aryl, heteroaryl, substituted aryl or substituted heteroaryl; x is an integer of from 1 to 4; Q is -C(X)NR 7 - wherein R 7 is selected from the group consisting of hydrogen and alkyl; 5 X is selected from the group consisting of oxygen and sulfur;

R

5 is -CH 2 X where X is selected from the group consisting of hydrogen, hydroxyl, acylamino, alkyl, alkoxy, aryloxy, aryl, aryloxyaryl, carboxyl, carboxylalkyl, carboxyl-substituted alkyl, carboxyl-cycloalkyl, carboxyl-substituted cycloalkyl, carboxylaryl, carboxyl-substituted aryl, 10 carboxylheteroaryl, carboxyl-substituted heteroaryl, carboxylheterocyclic, carboxyl-substituted heterocyclic, cycloalkyl, substituted alkyl, substituted alkoxy, substituted aryl, substituted aryloxy, substituted aryloxyaryl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic; 15 with the further provisos that: A. R 5 is not selected from the group consisting of -(CH 2 )n-aryl and -(CH 2 )n-heteroaryl where n is an integer equal to 1 to 4 when R 2 and R 3 together with the nitrogen atom bound to R 2 and the carbon atom bound to R 3 form a saturated heterocyclic group or a saturated substituted heterocyclic 20 group; B. R 5 is not -(CH 2 )x-Ar-R ' where R 5 ' is selected from the group consisting of -O-Z-NRSR 8 ' and -O-Z-R 12 wherein Ar is aryl, heteroaryl, substituted aryl or substituted heteroaryl, x is an integer of from 1 to 4, R 8 and R 8 ' are independently selected from the group consisting of hydrogen, 25 alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclic, and substituted heterocyclic, and where R 8 and R 8 ' are joined to form a ' heterocycle or a substituted heterocycle, R 1 2 is selected from the group consisting of heterocycles and substituted heterocycles, and Z is selected from the group consisting of -C(O)- and -SO 2

-;

WO 99/06437 PCT/US98/16070 7 C. R 5 is not -(CH 2 )x-Ar-R 5 ' where Ar is aryl, substituted aryl, heteroaryl or substituted heteroaryl, x is an integer of from 1 to 4, R 5 ' is selected from the group consisting of -NR 24 C(Z')NR'R' and

-NR

24

C(Z')R

3 wherein Z' is selected from the group consisting of oxygen, 5 sulfur and NR 24 , R 24 is selected from the group consisting of hydrogen, alkyl and aryl, R 8 and R 8 ' are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocyclic, heteroaryl and substituted heteroaryl provided that when Z' is oxygen, at least one of R 8 and 10 R 8 ' is sustituted alkyl, cycloalkyl, substituted cycloalkyl, saturated heterocyclic other than morpholino and thiomorpholino, substituted heterocyclic or R 8 and R 8 ' are joined to form a saturated heterocycle other than morpholino or thiomorpholino, a saturated substituted heterocycle or a saturated/unsaturated heterocycle having an amino group substituted with an 15 alkoxycarbonyl substituent, and further provided that when Z' is sulfur, at least one of R 8 and R 8 ' is a group other than aryl, substituted aryl, heteroaryl or substituted heteroaryl, and R" 3 is selected from the group consisting of substituted heterocyles and saturated heterocycles other than morpholino and thiomorpholino; 20 D. R 5 is not -ALK-X where ALK is an alkyl group of from 1 to 10 carbon atoms attached via a methylene group (-CH 2 -) to the carbon atom to which it is attached; X is selected from the group consisting of substituted alkylcarbonylamino, substituted alkenylcarbonylamino, substituted alkynylcarbonylamino, heterocyclylcarbonylamino, substituted 25 heterocyclylcarbonylamino, acyl, acyloxy, aminocarbonyloxy, acylamino, oxycarbonylamino, alkoxycarbonyl, substituted alkoxycarbonyl, aryloxycarbonyl, substituted aryloxycarbonyl, cycloalkoxycarbonyl, substituted cycloalkoxycarbonyl, heteroaryloxycarbonyl, substituted heteroaryloxycarbonyl, heterocyclyloxycarbonyl, substituted 30 heterocyclyloxycarbonyl, cycloalkyl, substituted cycloalkyl, saturated heterocyclic, substituted saturated heterocyclic, substituted alkoxy, WO 99/06437 PCT/US98/16070 8 substituted alkenoxy, substituted alkynoxy, heterocyclyloxy, substituted heterocycloxy, substituted thioalkyl, substituted thioalkenyl, substituted thioalkynyl, aminocarbonylamino, aminothiocarbonylamino, guanidino, amidino, alkylamidino, thioamidino, halogen, cyano, nitro, -OS(O) 2 -alkyl, 5 -OS(O) 2 -substituted alkyl, -OS(O) 2 -cycloalkyl, -OS(O) 2 -substituted cycloalkyl, -OS(O) 2 -aryl, -OS(O) 2 -substituted aryl, -OS(O)2-heteroaryl,

-OS(O)

2 -substituted heteroaryl, -OS(O) 2 -heterocyclic, -OS(O)2-substituted heterocyclic, -OSO 2 -NRR where R is hydrogen or alkyl, -NRS(O) 2 -alkyl,

-NRS(O)

2 -substituted alkyl, -NRS(O) 2 -cycloalkyl, -NRS(O) 2 -substituted 10 cycloalkyl, -NRS(O) 2 -aryl, -NRS(O) 2 -substituted aryl, -NRS(O)2-heteroaryl,

-NRS(O)

2 -substituted heteroaryl, -NRS(O)2-heterocyclic,

-NRS(O)

2 substituted heterocyclic, -NRS(O) 2 -NR-alkyl, -NRS(O) 2 -NR-substituted alkyl, -NRS(O) 2 -NR-cycloalkyl, -NRS(O)2-NR-substituted cycloalkyl, -NRS(O)2,-NR-aryl, -NRS(O) 2 -NR-substituted aryl, -NRS(O),-NR 15 heteroaryl, -NRS(O) 2 -NR-substituted heteroaryl, -NRS(0)2-NR-heterocyclic,

-NRS(O)

2 -NR-substituted heterocyclic where R is hydrogen or alkyl, -S(O) 2 alkyl, -S(O)2-substituted alkyl, -S(O) 2 -aryl, -S(O) 2 -substituted aryl, -S(O) 2 substituted heteroaryl, -S(O) 2 -substituted heteroaryl, -S(O) 2 -heterocyclic,

-S(O)

2 -substituted heterocyclic, mono- and di-(substituted alkyl)amino, N,N 20 (alkyl, substituted alkyl)amino, N,N-(aryl, substituted alkyl)amino, N,N (substituted aryl, substituted alkyl)amino, N,N-(heteroaryl, substituted alkyl)amino, N,N-(substituted heteroaryl, substituted alkyl)amino, N,N (heterocyclic, substituted alkyl)amino, N,N-N,N-(substituted heterocyclic, substituted alkyl)amino, mono- and di-(heterocyclic)amino, mono- and di 25 (substituted heterocyclic)amino, N,N-(alkyl, heterocyclic)amino, N,N-(alkyl, substituted heterocyclic)amino, N,N-(aryl, heterocyclic)amino, N,N (substituted aryl, heterocyclic)amino, N,N-(aryl, substituted heterocyclic)amino, N,N-(substituted aryl, substituted heterocyclic)amino, N,N-(heteroaryl, heterocyclic)amino, N,N-(heteroaryl, substituted 30 heterocyclic)amino, N,N-(substituted heteroaryl, heterocyclic)amino, and N,N-(substituted heteroaryl, substituted heterocyclic)amino; and WO 99/06437 PCT/US98/16070 9 E. R 5 is not -(CH 2 )x-Ar-R ' where R" ' is a substituent selected from the group consisting of: (a) substituted alkylcarbonylamino with the proviso that at least one of the substituents on the substituted alkyl moiety is selected from the group 5 consisting of alkoxy, substituted alkoxy, acyl, acylamino, thiocarbonylamino, acyloxy, alkenyl, amino, amidino, alkyl amidino, thioamidino, aminoacyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aryloxy, substituted aryloxy, cyano, nitro, halogen, hydroxyl, carboxyl, carboxylalkyl, carboxyl-substituted alkyl, carboxyl 10 cycloalkyl, carboxyl-substituted cycloalkyl, carboxylaryl, carboxyl substituted aryl, carboxylheteroaryl, carboxyl-substituted heteroaryl, carboxylheterocyclic, carboxyl-substituted heterocyclic, cycloalkyl, substituted cycloalkyl, guanidino, guanidinosulfone, thiol, thioalkyl, substituted thioalkyl, thioaryl, substituted thioaryl, thiocycloalkyl, 15 substituted thiocycloalkyl, thioheteroaryl, substituted thioheteroaryl, thioheterocyclic, substituted thioheterocyclic, heterocyclic, substituted heterocyclic, cycloalkoxy, substituted cycloalkyoxy, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy, oxycarbonylamino, oxythiocarbonylamino, -OS(O)2-alkyl, -OS(O) 2 20 substituted alkyl, -OS(O) 2 -aryl, -OS(O) 2 -substituted aryl, -OS(O) 2 -heteroaryl,

-OS(O)

2 -substituted heteroaryl, -OS(O) 2 -heterocyclic, -OS(O) 2 -substituted heterocyclic, -OSO, 2 -NRR, -NRS(O) 2 -alkyl, -NRS(O)2-substituted alkyl, NRS(O) 2 -aryl, -NRS(O) 2 -substituted aryl, -NRS(O) 2 -heteroaryl, -NRS(O) 2 substituted heteroaryl, -NRS(O) 2 -heterocyclic, 25 -NRS(O) 2 -substituted heterocyclic, -NRS(O) 2 -NR-alkyl, -NRS(O) 2

-NR

substituted alkyl, -NRS(O) 2 -NR-aryl, -NRS(O) 2 -NR-substituted aryl,

-NRS(O)

2 -NR-heteroaryl, -NRS(O) 2 -NR-substituted heteroaryl, -NRS(O) 2 NR-heterocyclic, -NRS(O) 2 -NR-substituted heterocyclic, mono- and di alkylamino, mono- and di-(substituted alkyl)amino, mono- and di-arylamino, 30 mono- and di-(substituted aryl)amino, mono- and di-heteroarylamino, mono and di-(substituted heteroaryl)amino, mono- and di-heterocyclic amino, WO 99/06437 PCT/US98/16070 10 mono- and di-(substituted heterocyclic) amino, unsymmetric di-substituted amines having different substituents selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic, substituted alkyl groups 5 having amino groups blocked by conventional blocking groups (such as Boc, Cbz, formyl, and the like), and alkyl/substituted alkyl groups substituted with

-SO

2 -alkyl, -SO 2 -substituted alkyl, -SO2-alkenyl, -SO2-substituted alkenyl,

-SO

2 -cycloalkyl, -SO 2 -substituted cycloalkyl, -SO2-aryl, -SO 2 -substituted aryl, -SO,-heteroaryl, -SO 2 -substituted heteroaryl, -SO,-heterocyclic, -SO 2 10 substituted heterocyclic or -SO 2 NRR, where R is hydrogen or alkyl; (b) alkoxyaryl substituted on the alkoxy moiety with a substituent selected from the group consisting of carboxyl and -COOR 2 3 where R 23 is alkyl, substituted alkyl, cycloalkyl, aryl, heteroaryl or heterocyclic, (c) aryl and heteroaryl; 15 (d) -NR'R' wherein each R' is independently selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclic and substituted heterocyclic with the proviso that at least one of R' is substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclic and substituted 20 heterocyclic and with the further proviso that when R' is substituted alkyl at least one of the substituents on the substituted alkyl moiety is selected from the group consisting of alkoxy, substituted alkoxy, acyl, acylamino, thiocarbonylamino, acyloxy, alkenyl, amino, amidino, alkyl amidino, thioamidino, aminoacyl, aminocarbonylamino, aminothiocarbonylamino, 25 aminocarbonyloxy, aryloxy, substituted aryloxy, cyano, nitro, halogen, hydroxyl, carboxyl, carboxylalkyl, carboxyl-substituted alkyl, carboxyl cycloalkyl, carboxyl-substituted cycloalkyl, carboxylaryl, carboxyl substituted aryl, carboxylheteroaryl, carboxyl-substituted heteroaryl, carboxylheterocyclic, carboxyl-substituted heterocyclic, cycloalkyl, 30 substituted cycloalkyl, guanidino, guanidinosulfone, thiol, thioalkyl, substituted thioalkyl, thioaryl, substituted thioaryl, thiocycloalkyl, WO 99/06437 PCT/US98/16070 11 substituted thiocycloalkyl, thioheteroaryl, substituted thioheteroaryl, thioheterocyclic, substituted thioheterocyclic, heterocyclic, substituted heterocyclic, cycloalkoxy, substituted cycloalkyoxy, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy, 5 oxycarbonylamino, oxythiocarbonylamino,

-OS(O)

2 -alkyl, -OS(O)2 substituted alkyl, -OS(O) 2 -aryl, -OS(O) 2 -substituted aryl, -OS(O) 2 -heteroaryl,

-OS(O)

2 -substituted heteroaryl, -OS(O) 2 -heterocyclic, -OS(O) 2 -substituted heterocyclic, -OSO 2 -NRR, -NRS(O) 2 -alkyl, -NRS(O) 2 -substituted alkyl,

-NRS(O)

2 -aryl, -NRS(O) 2 -substituted aryl, -NRS(O) 2 -heteroaryl, -NRS(O) 2 10 substituted heteroaryl, -NRS(O) 2 -heterocyclic, -NRS(O) 2 -substituted heterocyclic, -NRS(O) 2 -NR-alkyl, -NRS(O) 2 -NR-substituted alkyl,

-NRS(O)

2 -NR-aryl, -NRS(O)2-NR-substituted aryl, -NRS(O) 2

-NR

heteroaryl, -NRS(O) 2 -NR-substituted heteroaryl, -NRS(O) 2 -NR-heterocyclic, -NRS(O)2-NR-substituted heterocyclic, mono- and di-alkylamino, mono- and 15 di-(substituted alkyl)amino, mono- and di-arylamino, mono- and di (substituted aryl)amino, mono- and di-heteroarylamino, mono- and di (substituted heteroaryl)amino, mono- and di-heterocyclic amino, mono- and di-(substituted heterocyclic) amino, and unsymmetric di-substituted amines having different substituents, wherein the substituents are selected from the 20 group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic, substituted alkyl groups having amino groups blocked by conventional blocking groups (such as Boc, Cbz, formyl, and the like), and alkyl/substituted alkyl groups substituted with -SO 2 -alkyl, -SO2-substituted alkyl, -SO 2 -alkenyl, -SO 2 25 substituted alkenyl, -SO 2 -cycloalkyl, -SO 2 -substituted cycloalkyl, -SO 2 -aryl, -SO2-substituted aryl, -SO,-heteroaryl, -SO 2 -substituted heteroaryl, -SO 2 heterocyclic, -SO 2 -substituted heterocyclic or -SO 2 NRR, where R is hydrogen or alkyl; (e) -alkoxy-NR"R" wherein each R" is independently selected from 30 the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, WO 99/06437 PCT/US98/16070 12 heterocyclic, and substituted heterocyclic with the proviso that when each R" is substituted alkyl then at least one of the substituents on the substituted alkyl moiety is selected from the group consisting of alkoxy, substituted alkoxy, acyl, acylamino, thiocarbonylamino, acyloxy, alkenyl, amino, 5 amidino, alkyl amidino, thioamidino, aminoacyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aryloxy, substituted aryloxy, cyano, nitro, halogen, hydroxyl, carboxyl, carboxylalkyl, carboxyl substituted alkyl, carboxyl-cycloalkyl, carboxyl-substituted cycloalkyl, carboxylaryl, carboxyl-substituted aryl, carboxylheteroaryl, carboxyl 10 substituted heteroaryl, carboxylheterocyclic, carboxyl-substituted heterocyclic, cycloalkyl, substituted cycloalkyl, guanidino, guanidinosulfone, thiol, thioalkyl, substituted thioalkyl, thioaryl, substituted thioaryl, thiocycloalkyl, substituted thiocycloalkyl, thioheteroaryl, substituted thioheteroaryl, thioheterocyclic, substituted thioheterocyclic, heterocyclic, 15 substituted heterocyclic, cycloalkoxy, substituted cycloalkyoxy, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy, oxycarbonylamino, oxythiocarbonylamino, -OS(O)2-alkyl, OS(O) 2 -substituted alkyl, -OS(O),-aryl, -OS(O) 2 -substituted aryl, -OS(O) 2 heteroaryl, -OS(O) 2 -substituted heteroaryl, -OS(O) 2 -heterocyclic, -OS(O) 2 20 substituted heterocyclic, -OSO,-NRR, -NRS(O)2-alkyl, -NRS(O)2-substituted alkyl, -NRS(O) 2 -aryl, -NRS(O) 2 -substituted aryl, -NRS(O),-heteroaryl, NRS(O) 2 -substituted heteroaryl, -NRS(O) 2 -heterocyclic, -NRS(O)2 substituted heterocyclic, -NRS(O)2-NR-alkyl, -NRS(O) 2 -NR-substituted alkyl, -NRS(O) 2 -NR-aryl, -NRS(O) 2 -NR-substituted aryl, -NRS(O) 2

-NR

25 heteroaryl, -NRS(O) 2 -NR-substituted heteroaryl, -NRS(O) 2 -NR-heterocyclic, -NRS(O)2-NR-substituted heterocyclic, mono- and di-alkylamino, mono- and di-(substituted alkyl)amino, mono- and di-arylamino, mono- and di (substituted aryl)amino, mono- and di-heteroarylamino, mono- and di (substituted heteroaryl)amino, mono- and di-heterocyclic amino, mono- and 30 di-(substituted heterocyclic) amino, unsymmetric di-substituted amines having different substituents selected from the group consisting of alkyl, WO 99/06437 PCT/US98/16070 13 substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic, substituted alkyl groups having amino groups blocked by conventional blocking groups (such as Boc, Cbz, formyl, and the like), and alkyl/substituted alkyl groups substituted with 5 SO 2 -alkyl, -S02-substituted alkyl, -SO 2 -alkenyl, -SO 2 -substituted alkenyl, SO 2 -cycloalkyl, -SO2-substituted cycloalkyl, -SO,-aryl, -SO 2 -substituted aryl,

-SO

2 -heteroaryl, -SO 2 -substituted heteroaryl, -SO,-heterocyclic, -SO 2 substituted heterocyclic or -SO 2 NRR, where R is hydrogen or alkyl; (f) substituted alkenyl or substituted alkynyl with the proviso that at 10 least one of the substituents on the substituted alkenyl/alkynyl moiety is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic with the proviso that when substituted with substituted alkyl, then at least one of the substituents 15 on the substituted alkyl moiety is selected from the group consisting of alkoxy, substituted alkoxy, acyl, acylamino, thiocarbonylamino, acyloxy, alkenyl, amino, amidino, alkyl amidino, thioamidino, aminoacyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aryloxy, substituted aryloxy, cyano, nitro, halogen, hydroxyl, carboxyl, carboxylalkyl, 20 carboxyl-substituted alkyl, carboxyl-cycloalkyl, carboxyl-substituted cycloalkyl, carboxylaryl, carboxyl-substituted aryl, carboxylheteroaryl, carboxyl-substituted heteroaryl, carboxylheterocyclic, carboxyl-substituted heterocyclic, cycloalkyl, substituted cycloalkyl, guanidino, guanidinosulfone, thiol, thioalkyl, substituted thioalkyl, thioaryl, substituted thioaryl, 25 thiocycloalkyl, substituted thiocycloalkyl, thioheteroaryl, substituted thioheteroaryl, thioheterocyclic, substituted thioheterocyclic, heterocyclic, substituted heterocyclic, cycloalkoxy, substituted cycloalkyoxy, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy, oxycarbonylamino, oxythiocarbonylamino, -OS(O),-alkyl, 30 OS(O) 2 -substituted alkyl, -OS(O),-aryl, -OS(O) 2 -substituted aryl, -OS(O) 2 heteroaryl, -OS(O) 2 -substituted heteroaryl, -OS(O),-heterocyclic, -0S(0)2- WO 99/06437 PCT/US98/16070 14 substituted heterocyclic, -OSO,-NRR, -NRS(O) 2 -alkyl, -NRS(O) 2 -substituted alkyl, -NRS(0) 2 -aryl, -NRS(0) 2 -substituted aryl, -NRS(0) 2 -heteroaryl, NRS(0) 2 -substituted heteroaryl, -NRS(O) 2 -heterocyclic, -NRS(0) 2 substituted heterocyclic, -NRS(0) 2 -NR-alkyl, -NRS(O) 2 -NR-substituted 5 alkyl, -NRS(0) 2 -NR-aryl, -NRS(O) 2 -NR-substituted aryl, -NRS(O) 2

-NR

heteroaryl, -NRS(0) 2 -NR-substituted heteroaryl, -NRS(0) 2 -NR-heterocyclic, -NRS(0) 2 -NR-substituted heterocyclic or mono- and di-alkylamino, mono and di-(substituted alkyl)amino, mono- and di-arylamino, mono- and di (substituted aryl)amino, mono- and di-heteroarylamino, mono- and di 10 (substituted heteroaryl)amino, mono- and di-heterocyclic amino, mono- and di-(substituted heterocyclic) amino, unsymmetric di-substituted amines having different substituents selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic, substituted alkyl groups having 15 amino groups blocked by conventional blocking groups (such as Boc, Cbz, formyl, and the like) and alkyl/substituted alkyl groups substituted with SO,-alkyl, -SO 2 -substituted alkyl, -SO 2 -alkenyl, -SO, 2 -substituted alkenyl, SO 2 -cycloalkyl, -SO,-substituted cycloalkyl, -SO,-aryl, -SO,-substituted aryl,

-SO

2 -heteroaryl, -SO,-substituted heteroaryl, -SO, 2 -heterocyclic, -SO2 20 substituted heterocyclic or -SO 2 NRR, where R is hydrogen or alkyl; (g) substituted aryloxy and substituted heteroaryloxy with the proviso that at least one substituent on the substituted aryloxy/heteroaryloxy is other than halogen, hydroxyl, amino, nitro, trifluoromethyl, trifluoromethoxy, alkyl, alkenyl, alkynyl, 1,2-dioxymethylene, 1,2-dioxyethylene, alkoxy, 25 alkenoxy, alkynoxy, alkylamino, alkenylamino, alkynylamino, alkylcarbonyloxy, acyl, alkylcarbonylamino, alkoxycarbonylamino, alkylsulfonylamino, N-alkyl or N,N-dialkylurea; (h) -alkoxy-saturated heterocyclic, -alkoxy-saturated substituted heterocyclic, -substituted alkoxy-heterocyclic and -substituted alkoxy 30 substituted saturated heterocyclic; (i) -O-heterocyclic and -O-substituted heterocyclic; WO 99/06437 PCT/US98/16070 15 (j) tetrazolyl; (k) -NR-SO,-substituted alkyl where R is hydrogen, alkyl or aryl, with the proviso that at least one substituent on the alkyl moiety of the substituted alkylsulfonylamino is other than halogen, hydroxyl, amino, nitro, 5 trifluoromethyl, trifluoromethoxy, alkyl, alkenyl, alkynyl, 1,2 dioxymethylene, 1,2-dioxyethylene, alkoxy, alkenoxy, alkynoxy, alkylamino, alkenylamino, alkynylamino, alkylcarbonyloxy, acyl, alkylcarbonylamino, alkoxycarbonylamino, alkylsulfonylamino, N-alkyl or N,N-dialkylurea; 10 (1) alkenylsulfonylamino, alkynylsulfonylamino, substituted alkenylsulfonylamino and substituted alkynylsulfonylamino; (m) substituted alkoxy with the proviso that the substitution on the alkyl moiety of said substituted alkoxy does not include alkoxy-NR"R" as defined above, unsaturated heterocyclyl, alkyloxy, aryloxy, heteroaryloxy, 15 aryl, heteroaryl or aryl/heteroaryl substituted with halogen, hydroxyl, amino, nitro, trifluoromethyl, trifluoromethoxy, alkyl, alkenyl, alkynyl, 1,2 dioxymethylene, 1,2-dioxyethylene, alkoxy, alkenoxy, alkynoxy, alkylamino, alkenylamino, alkynylamino, alkylcarbonyloxy, acyl, alkylcarbonylamino, alkoxycarbonylamino, alkylsulfonylamino, N-alkyl or 20 N,N-dialkylurea; (n) amidine and amidine substituted with from 1 to 3 substituents independently selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, heteroaryl and heterocyclic; 25 (o) -C(O)NR"'R"' where each R'" is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic with the proviso that when one R' is unsaturated 30 heterocyclic, aryl, heteroaryl or aryl/heteroaryl substituted with halogen, hydroxyl, amino, nitro, trifluoromethyl, trifluoromethoxy, alkyl, alkenyl, WO 99/06437 PCT/US98/16070 16 alkynyl, 1,2-dioxymethylene, 1,2-dioxyethylene, alkoxy, alkenoxy, alkynoxy, alkylamino, alkenylamino, alkynylamino, alkylcarbonyloxy, acyl, alkylcarbonylamino, alkoxycarbonylamino, alkylsulfonylamino, N-alkyl or N,N-dialkylurea, then the other R"' is alkyl, substituted alkyl (other than 5 unsaturated heterocyclyl substituted-alkyl), cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, heterocyclic or substituted heterocyclic; (p) -NR 22

C(O)-R'"

8 where R" is selected from the group consisting of alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted 10 aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic, and R 22 is alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic or substituted heterocyclic; (q) -SO 2 -aryl, -SO2-substituted aryl, -SO,-heteroaryl, -SO,-substituted 15 heteroaryl or -SO,-alkyl; (r) -NR'C(O)NR 9

R

1 9 wherein R' is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic and each R 19 is independently selected from the 20 group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic: (s) -NR'C(O)OR 9 wherein R' is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl. substituted 25 cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic and R 19 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic; (t) -aminocarbonyl-(N-formylheterocylcyl); and 30 (u) -alkyl-C(O)NH-heterocyclyl and -alkyl-C(O)NH-substituted heterocyclyl; WO 99/06437 PCT/US98/16070 17 and pharmaceutically acceptable salts thereof; and still further with the following provisos excluding the following compounds: A. when R 1 is p-methylphenyl, R 2 and R 3 together with their pendent 5 nitrogen and carbon atoms form a pyrrolidinyl ring and Q is -C(O)NH-, then

R

5 is not -CH 2 COOH or -CH 2

CH

2 COOH; and B. when R' is p-methylphenyl, R 2 and R 3 together with their pendent nitrogen and carbon atoms form a pyrrolidinyl ring and Q is -C(O)NH-, then

R

5 is not 2,4,6-trimethylbenzyl. 10 In another embodiment, the compounds of this invention can also be provided as prodrugs which convert (e.g., hydrolyze, metabolize, etc.) in vivo to a compound of formula I above. In a preferred example of such an embodiment, the carboxylic acid in the compound of formula I is modified 15 into a group which, in vivo, will convert to the carboxylic acid (including salts thereof). In a particularly preferred embodiment, such prodrugs are represented by compounds of formula IA: R 3 201 20 III

R'-S

O

2

-N(R

2

)-C-Q-CH-C-R

6 IA I I H R 5 25 where R' is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocylic, heteroaryl and substituted heteroaryl;

R

2 is selected from the group consisting of hydrogen, alkyl, 30 substituted alkyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heterocyclic, substituted heterocyclic, aryl, substituted aryl, heteroaryl, and substituted heteroaryl, and R' and R 2 together with the WO 99/06437 PCT/US98/16070 18 nitrogen atom bound to R 2 and the SO 2 group bound to R' can form a heterocyclic or a substituted heterocyclic group;

R

3 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, 5 heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic, and R 2 and R 3 together with the nitrogen atom bound to R 2 and the carbon atom bound to R 3 can form a saturated heterocyclic group or a saturated substituted heterocyclic group with the proviso that when monosubstituted, the substituent on said saturated substituted heterocyclic group is not 10 carboxyl; Ar is aryl, heteroaryl, substituted aryl or substituted heteroaryl; x is an integer of from 1 to 4;

R

6 is selected from the group consisting of 2,4-dioxo-tetrahydrofuran 3-yl (3,4-enol), amino, alkoxy, substituted alkoxy, cycloalkoxy, substituted 15 cycloalkoxy, -O-(N-succinimidyl), -NH-adamantyl, -O-cholest-5-en-3-p-yl, -NHOY where Y is hydrogen, alkyl, substituted alkyl, aryl, and substituted aryl, -NH(CH 2 )pCOOY where p is an integer of from 1 to 8 and Y is as defined above, -OCH,NR 9

R

l o where R 9 is selected from the group consisting of-C(O)-aryl and -C(O)-substituted aryl and R"o is selected from the group 20 consisting of hydrogen and -CHCOOR" where R" is alkyl, and -NHSO 2 Z" where Z" is alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic or substituted heterocyclic; Q is -C(X)NR 7 - wherein R 7 is selected from the group consisting of 25 hydrogen and alkyl; X is selected from the group consisting of oxygen and sulfur;

R

5 is -CH 2 X where X is selected from the group consisting of hydrogen, hydroxyl, acylamino, alkyl, alkoxy, aryloxy, aryl, aryloxyaryl, carboxyl, carboxylalkyl, carboxyl-substituted alkyl, carboxyl-cycloalkyl, 30 carboxyl-substituted cycloalkyl, carboxylaryl, carboxyl-substituted aryl, carboxylheteroaryl, carboxyl-substituted heteroaryl, carboxylheterocyclic, WO 99/06437 PCT/US98/16070 19 carboxyl-substituted heterocyclic, cycloalkyl, substituted alkyl, substituted alkoxy, substituted aryl, substituted aryloxy, substituted aryloxyaryl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic; 5 with the further provisos that: A. R' is not selected from the group consisting of -(CH 2 )n-aryl and -(CH 2 )n-heteroaryl where n is an integer equal to 1 to 4 when R 2 and R 3 together with the nitrogen atom bound to R 2 and the carbon atom bound to R 3 form a saturated heterocyclic group or a saturated substituted heterocyclic 10 group; B. R 5 is not -(CH2)x-Ar-R 5 ' where R 5 ' is selected from the group consisting of -O-Z-NR'R 8 ' and -O-Z-R 12 wherein R 8 and R 8 ' are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclic, and 15 substituted heterocyclic, and where R 8 and R 8' are joined to form a heterocycle or a substituted heterocycle; R1 2 is selected from the group consisting of heterocycles and substituted heterocycles, and Z is selected from the group consisting of-C(O)- and -SO 2 -, Ar is aryl, heteroaryl, substituted aryl or substituted heteroaryl, 20 x is an integer of from 1 to 4; C. R 5 is not -(CH 2 )x-Ar-R 5 ' where R 5 is selected from the group consisting of-NR 2 4 C(Z')NR'R' and -NR 24

C(Z')R

1 3 wherein Z' is selected from the group consisting of oxygen, sulfur and NR 2 4 , R 24 is selected from the group consisting of hydrogen, alkyl and aryl, R 8 and R 8 ' are 25 independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocyclic, heteroaryl and substituted heteroaryl provided that when Z' is oxygen, at least one of R 8 and R 8 ' is substituted alkyl, cycloalkyl, substituted cycloalkyl, saturated heterocyclic other than 30 morpholino and thiomorpholino, and substituted heterocyclic, or R 8 and R 8 ' can be joined to form a saturated heterocycle other than morpholino or WO 99/06437 PCT/US98/16070 20 thiomorpholino, a saturated substituted heterocycle or a saturated/unsaturated heterocycle having an amino group substituted with an alkoxycarbonyl substituent, and further provided that when Z' is sulfur, at least one of R 8 and

R

8 ' is a group other than aryl, substituted aryl, heteroaryl or substituted 5 heteroaryl, R" 3 is selected from the group consisting of substituted heterocyles and saturated heterocycles other than morpholino and thiomorpholino, Ar is aryl, substituted aryl, heteroaryl or substituted heteroaryl, x is an integer of from 1 to 4; 10 D. R 5 is not -ALK-X where ALK is an alkyl group of from 1 to 10 carbon atoms attached via a methylene group (-CH 2 -) to the carbon atom to which it is attached; X is selected from the group consisting of substituted alkylcarbonylamino, substituted alkenylcarbonylamino, substituted alkynylcarbonylamino, heterocyclylcarbonylamino, substituted 15 heterocyclylcarbonylamino, acyl, acyloxy, aminocarbonyloxy, acylamino, oxycarbonylamino, alkoxycarbonyl, substituted alkoxycarbonyl, aryloxycarbonyl, substituted aryloxycarbonyl, cycloalkoxycarbonyl, substituted cycloalkoxycarbonyl, heteroaryloxycarbonyl, substituted heteroaryloxycarbonyl, heterocyclyloxycarbonyl, substituted 20 heterocyclyloxycarbonyl, cycloalkyl, substituted cycloalkyl, saturated heterocyclic, substituted saturated heterocyclic, substituted alkoxy, substituted alkenoxy, substituted alkynoxy, heterocyclyloxy, substituted heterocycloxy, substituted thioalkyl, substituted thioalkenyl, substituted thioalkynyl, aminocarbonylamino, aminothiocarbonylamino, guanidino, 25 amidino, alkylamidino, thioamidino, halogen, cyano, nitro, -OS(O) 2 -alkyl,

-OS(O)

2 -substituted alkyl, -OS(O),-cycloalkyl, -OS(O) 2 -substituted cycloalkyl, -OS(O) 2 -aryl, -OS(O) 2 -substituted aryl, -OS(O) 2 -heteroaryl,

-OS(O)

2 -substituted heteroaryl, -OS(O) 2 -heterocyclic, -OS(O) 2 -substituted heterocyclic, -OSO 2 -NRR, -NRS(O) 2 -alkyl, -NRS(O) 2 -substituted alkyl, 30 -NRS(O) 2 -cycloalkyl, -NRS(O) 2 -substituted cycloalkyl, -NRS(O) 2 -aryl, WO 99/06437 PCT/US98/16070 21

-NRS(O)

2 -substituted aryl, -NRS(O) 2 -heteroaryl, -NRS(O) 2 -substituted heteroaryl, -NRS(O) 2 -heterocyclic, -NRS(O) 2 -substituted heterocyclic,

-NRS(O)

2 -NR-alkyl, -NRS(O) 2 -NR-substituted alkyl, -NRS(O) 2

-NR

cycloalkyl, -NRS(O) 2 -NR-substituted cycloalkyl, -NRS(O) 2 -NR-aryl, 5 -NRS(O) 2 -NR-substituted aryl, -NRS(O) 2 -NR-heteroaryl, -NRS(O) 2

-NR

substituted heteroaryl, -NRS(O) 2 -NR-heterocyclic, -NRS(O) 2 -NR-substituted heterocyclic where R is hydrogen or alkyl, -S(O) 2 -alkyl, -S(O) 2 -substituted alkyl, -S(O) 2 -aryl, -S(O) 2 -substituted aryl, -S(O) 2 -substituted heteroaryl,

-S(O)

2 -substituted heteroaryl, -S(O) 2 -heterocyclic, -S(O) 2 -substituted 10 heterocyclic, mono- and di-(substituted alkyl)amino, N,N-(alkyl, substituted alkyl)amino, N,N-(aryl, substituted alkyl)amino, N,N-(substituted aryl, substituted alkyl)amino, N,N-(heteroaryl, substituted alkyl)amino, N,N (substituted heteroaryl, substituted alkyl)amino, N,N-(heterocyclic, substituted alkyl)amino, N,N-N,N-(substituted heterocyclic, substituted 15 alkyl)amino, mono- and di-(heterocyclic)amino, mono- and di-(substituted heterocyclic)amino, N,N-(alkyl, heterocyclic)amino, N,N-(alkyl, substituted heterocyclic)amino, N,N-(aryl, heterocyclic)amino, N,N-(substituted aryl, heterocyclic)amino, N,N-(aryl, substituted heterocyclic)amino, N,N (substituted aryl, substituted heterocyclic)amino, N,N-(heteroaryl, 20 heterocyclic)amino, N,N-(heteroaryl, substituted heterocyclic)amino, N,N (substituted heteroaryl, heterocyclic)amino, and N,N-(substituted heteroaryl, substituted heterocyclic)amino; and E. R 5 is not -(CH 2 )x-Ar-R" where R 5 " is a substituent selected from the group consisting of: 25 (a) substituted alkylcarbonylamino with the proviso that at least one of the substituents on the substituted alkyl moiety is selected from the group consisting of alkoxy, substituted alkoxy, acyl, acylamino, thiocarbonylamino, acyloxy, alkenyl, amino, amidino, alkyl amidino, thioamidino, aminoacyl, aminocarbonylamino, aminothiocarbonylamino, 30 aminocarbonyloxy, aryloxy, substituted aryloxy, cyano, nitro, halogen, hydroxyl, carboxyl, carboxylalkyl, carboxyl-substituted alkyl, carboxyl- WO 99/06437 PCT/US98/16070 22 cycloalkyl, carboxyl-substituted cycloalkyl, carboxylaryl, carboxyl substituted aryl, carboxylheteroaryl, carboxyl-substituted heteroaryl, carboxylheterocyclic, carboxyl-substituted heterocyclic, cycloalkyl, substituted cycloalkyl, guanidino, guanidinosulfone, thiol, thioalkyl, 5 substituted thioalkyl, thioaryl, substituted thioaryl, thiocycloalkyl, substituted thiocycloalkyl, thioheteroaryl, substituted thioheteroaryl, thioheterocyclic, substituted thioheterocyclic, heterocyclic, substituted heterocyclic, cycloalkoxy, substituted cycloalkyoxy, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy, 10 oxycarbonylamino, oxythiocarbonylamino,

-OS(O)

2 -alkyl, -OS(O) 2 substituted alkyl, -OS(O) 2 -aryl, -OS(O) 2 -substituted aryl, -OS(O) 2 -heteroaryl,

-OS(O)

2 -substituted heteroaryl, -OS(O) 2 -heterocyclic, -OS(O),-substituted heterocyclic, -OSO, 2 -NRR, -NRS(O),-alkyl, -NRS(O)2-substituted alkyl, -NRS(O)2,-aryl, -NRS(O) 2 -substituted aryl, -NRS(O) 2 -heteroaryl, -NRS(O) 2 15 substituted heteroaryl, -NRS(O) 2 -heterocyclic, -NRS(O) 2 -substituted heterocyclic, -NRS(O) 2 -NR-alkyl, -NRS(O),-NR-substituted alkyl, NRS(O) 2 -NR-aryl, -NRS(O) 2 -NR-substituted aryl, -NRS(O) 2 -NR-heteroaryl, -NRS(O)2-NR-substituted heteroaryl, -NRS(O),-NR-heterocyclic,

-NRS(O)

2 NR-substituted heterocyclic, mono- and di-alkylamino, mono- and di 20 (substituted alkyl)amino, mono- and di-arylamino, mono- and di-(substituted aryl)amino, mono- and di-heteroarylamino, mono- and di-(substituted heteroaryl)amino, mono- and di-heterocyclic amino, mono- and di (substituted heterocyclic) amino, unsymmetric di-substituted amines having different substituents selected from the group consisting of alkyl, substituted 25 alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic, substituted alkyl groups having amino groups blocked by conventional blocking groups (such as Boc, Cbz, formyl, and the like) and alkyl/substituted alkyl groups substituted with -SO,-alkyl, -SO 2 substituted alkyl, -SO,-alkenyl, -SO,-substituted alkenyl, -SO 2 -cycloalkyl, 30 -SO,-substituted cycloalkyl, -SO,-aryl, -SO,-substituted aryl, -SO,2- WO 99/06437 PCT/US98/16070 23 heteroaryl, -SO2-substituted heteroaryl, -SO,-heterocyclic, -SO2-substituted heterocyclic or -SO 2 NRR, where R is hydrogen or alkyl; (b) alkoxyaryl substituted on the alkoxy moiety with a substituent selected from the group consisting of carboxyl and -COOR 23 where R 23 is 5 alkyl, substituted alkyl, cycloalkyl, aryl, heteroaryl or heterocyclic; (c) aryl and heteroaryl; (d) -NR'R' wherein each R' is independently selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclic and 10 substituted heterocyclic with the proviso that at least one of R' is substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclic or substituted heterocyclic and with the further proviso that when R' is substituted alkyl at least one of the substituents on the substituted alkyl moiety is selected from the group consisting of alkoxy, substituted alkoxy, acyl, acylamino, 15 thiocarbonylamino, acyloxy, alkenyl, amino, amidino, alkyl amidino, thioamidino, aminoacyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aryloxy, substituted aryloxy, cyano, nitro, halogen, hydroxyl, carboxyl, carboxylalkyl, carboxyl-substituted alkyl, carboxyl cycloalkyl, carboxyl-substituted cycloalkyl, carboxylaryl, carboxyl 20 substituted aryl, carboxylheteroaryl, carboxyl-substituted heteroaryl, carboxylheterocyclic, carboxyl-substituted heterocyclic, cycloalkyl, substituted cycloalkyl, guanidino, guanidinosulfone, thiol, thioalkyl, substituted thioalkyl, thioaryl, substituted thioaryl, thiocycloalkyl, substituted thiocycloalkyl, thioheteroaryl, substituted thioheteroaryl, 25 thioheterocyclic, substituted thioheterocyclic, heterocyclic, substituted heterocyclic, cycloalkoxy, substituted cycloalkyoxy, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy, oxycarbonylamino, oxythiocarbonylamino,

-OS(O)

2 -alkyl, -OS(O) 2 substituted alkyl, -OS(O) 2 -aryl, -OS(O) 2 -substituted aryl, -OS(O) 2 -heteroaryl, 30 -OS(O) 2 -substituted heteroaryl, -OS(O) 2 -heterocyclic, -OS(O) 2 -substituted heterocyclic, -OSO 2 -NRR, -NRS(O) 2 -alkyl, -NRS(O) 2 -substituted alkyl, WO 99/06437 PCT/US98/16070 24

-NRS(O)

2 -aryl, -NRS(O) 2 -substituted aryl, -NRS(O) 2 -heteroaryl, -NRS(O) 2 substituted heteroaryl, -NRS(O) 2 -heterocyclic, -NRS(O),-substituted heterocyclic, -NRS(O) 2 -NR-alkyl, -NRS(O) 2 -NR-substituted alkyl,

-NRS(O)

2 -NR-aryl, -NRS(O) 2 -NR-substituted aryl, -NRS(O) 2

-NR

5 heteroaryl, -NRS(O) 2 -NR-substituted heteroaryl, -NRS(O) 2 -NR-heterocyclic,

-NRS(O)

2 -NR-substituted heterocyclic, mono- and di-alkylamino, mono- and di-(substituted alkyl)amino, mono- and di-arylamino, mono- and di (substituted aryl)amino, mono- and di-heteroarylamino, mono- and di (substituted heteroaryl)amino, mono- and di-heterocyclic amino, mono- and 10 di-(substituted heterocyclic) amino, unsymmetric di-substituted amines having different substituents selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic, substituted alkyl groups having amino groups blocked by conventional blocking groups (such as Boc, Cbz, 15 formyl, and the like) and alkyl/substituted alkyl groups substituted with SO,-alkyl, -SO2-substituted alkyl, -SO 2 -alkenyl, -SO, -substituted alkenyl, SO 2 -cycloalkyl, -SO,-substituted cycloalkyl, -SO,-aryl, -SO,-substituted aryl,

-SO,

2 -heteroaryl, -SO,-substituted heteroaryl, -SO,-heterocyclic, -SO 2 substituted heterocyclic or -SO 2 NRR, where R is hydrogen or alkyl; 20 (e) -alkoxy-NR"R" wherein each R" is independently selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic with the proviso that when each R" is substituted alkyl then at least one of the substituents on the substituted 25 alkyl moiety is selected from the group consisting of alkoxy, substituted alkoxy, acyl, acylamino, thiocarbonylamino, acyloxy, alkenyl, amino, amidino, alkyl amidino, thioamidino, aminoacyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aryloxy, substituted aryloxy, cyano, nitro, halogen, hydroxyl, carboxyl, carboxylalkyl, carboxyl 30 substituted alkyl, carboxyl-cycloalkyl, carboxyl-substituted cycloalkyl, carboxylaryl, carboxyl-substituted aryl, carboxylheteroaryl, carboxyl- WO 99/06437 PCT/US98/16070 25 substituted heteroaryl, carboxylheterocyclic, carboxyl-substituted heterocyclic, cycloalkyl, substituted cycloalkyl, guanidino, guanidinosulfone, thiol, thioalkyl, substituted thioalkyl, thioaryl, substituted thioaryl, thiocycloalkyl, substituted thiocycloalkyl, thioheteroaryl, substituted 5 thioheteroaryl, thioheterocyclic, substituted thioheterocyclic, heterocyclic, substituted heterocyclic, cycloalkoxy, substituted cycloalkyoxy, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy, oxycarbonylamino, oxythiocarbonylamino, -OS(O) 2 -alkyl, OS(O),-substituted alkyl, -OS(O) 2 -aryl, -OS(O),-substituted aryl, -OS(O) 2 10 heteroaryl, -OS(O) 2 -substituted heteroaryl, -OS(O) 2 -heterocyclic, -OS(O) 2 substituted heterocyclic, -OSO 2 -NRR, -NRS(O) 2 -alkyl, -NRS(O) 2 -substituted alkyl, -NRS(O) 2 -aryl, -NRS(O) 2 -substituted aryl, -NRS(O)2,-heteroaryl, NRS(0)2-substituted heteroaryl, -NRS(O) 2 -heterocyclic, -NRS(O) 2 substituted heterocyclic, -NRS(O) 2 -NR-alkyl, -NRS(O) 2 -NR-substituted 15 alkyl, -NRS(O) 2 -NR-aryl, -NRS(O) 2 -NR-substituted aryl, -NRS(O)2-NR heteroaryl, -NRS(O) 2 -NR-substituted heteroaryl, -NRS(O)2-NR-heterocyclic,

-NRS(O)

2 -NR-substituted heterocyclic, mono- and di-alkylamino, mono- and di-(substituted alkyl)amino, mono- and di-arylamino, mono- and di (substituted aryl)amino, mono- and di-heteroarylamino, mono- and di 20 (substituted heteroaryl)amino, mono- and di-heterocyclic amino, mono- and di-(substituted heterocyclic) amino, and unsymmetric di-substituted amines having different substituents selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic, substituted alkyl groups having 25 amino groups blocked by conventional blocking groups (such as Boc, Cbz, formyl, and the like) and alkyl/substituted alkyl groups substituted with SO,-alkyl, -SO 2 -substituted alkyl, -SO, 2 -alkenyl, -SO, 2 -substituted alkenyl, SO 2 -cycloalkyl, -SO,-substituted cycloalkyl, -SO,-aryl, -SO,-substituted aryl, -SO,-heteroaryl, -SO,-substituted heteroaryl, -SO,-heterocyclic, -SO 2 30 substituted heterocyclic or -SO 2 NRR, where R is hydrogen or alkyl; WO 99/06437 PCT/US98/16070 26 (f) substituted alkenyl or substituted alkynyl with the proviso that at least one of the substituents on the substituted alkenyl/alkynyl moiety is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted 5 heteroaryl, heterocyclic, and substituted heterocyclic with the proviso that when substituted with substituted alkyl then at least one of the substituents on the substituted alkyl moiety is selected from the group consisting of alkoxy, substituted alkoxy, acyl, acylamino, thiocarbonylamino, acyloxy, alkenyl, amino, amidino, alkyl amidino, thioamidino, aminoacyl, 10 aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aryloxy, substituted aryloxy, cyano, nitro, halogen, hydroxyl, carboxyl, carboxylalkyl, carboxyl-substituted alkyl, carboxyl-cycloalkyl, carboxyl-substituted cycloalkyl, carboxylaryl, carboxyl-substituted aryl, carboxylheteroaryl, carboxyl-substituted heteroaryl, carboxylheterocyclic, carboxyl-substituted 15 heterocyclic, cycloalkyl, substituted cycloalkyl, guanidino, guanidinosulfone, thiol, thioalkyl, substituted thioalkyl, thioaryl, substituted thioaryl, thiocycloalkyl, substituted thiocycloalkyl, thioheteroaryl, substituted thioheteroaryl, thioheterocyclic, substituted thioheterocyclic, heterocyclic, substituted heterocyclic, cycloalkoxy, substituted cycloalkyoxy, 20 heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy, oxycarbonylamino, oxythiocarbonylamino, -OS(O)2,-alkyl, OS(O)2-substituted alkyl, -OS(O)2-aryl, -OS(O) 2 -substituted aryl, -OS(O) 2 heteroaryl, -OS(O) 2 -substituted heteroaryl, -OS(O)2-heterocyclic,

-OS(O)

2 substituted heterocyclic, -OSO,-NRR, -NRS(O),-alkyl, -NRS(O) 2 -substituted 25 alkyl, -NRS(O),-aryl, -NRS(O)2-substituted aryl, -NRS(O)2,-heteroaryl, NRS(O) 2 -substituted heteroaryl, -NRS(O) 2 -heterocyclic, -NRS(O)z substituted heterocyclic, -NRS(O) 2 -NR-alkyl, -NRS(O) 2 -NR-substituted alkyl, -NRS(O) 2 -NR-aryl, -NRS(O) 2 -NR-substituted aryl, -NRS(O) 2

-NR

heteroaryl, -NRS(O) 2 -NR-substituted heteroaryl, -NRS(O) 2 -NR-heterocyclic, 30 -NRS(O),-NR-substituted heterocyclic, mono- and di-alkylamino, mono- and di-(substituted alkyl)amino, mono- and di-arylamino, mono- and di- WO 99/06437 PCT/US98/16070 27 (substituted aryl)amino, mono- and di-heteroarylamino, mono- and di (substituted heteroaryl)amino, mono- and di-heterocyclic amino, mono- and di-(substituted heterocyclic) amino, unsymmetric di-substituted amines having different substituents selected from the group consisting of alkyl, 5 substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic, substituted alkyl groups having amino groups blocked by conventional blocking groups (such as Boc, Cbz, formyl, and the like) and alkyl/substituted alkyl groups substituted with SO,-alkyl, -SO,-substituted alkyl, -SO 2 -alkenyl, -SO2-substituted alkenyl, 10 SO 2 -cycloalkyl, -SO2-substituted cycloalkyl, -SO, 2 -aryl, -SO 2 -substituted aryl, -SO,-heteroaryl, -SO 2 -substituted heteroaryl, -SO, 2 -heterocyclic, -SO2 substituted heterocyclic or -SO,NRR, where R is hydrogen or alkyl; (g) substituted aryloxy and substituted heteroaryloxy with the proviso that at least one substituent on the substituted aryloxy/heteroaryloxy is other 15 than halogen, hydroxyl, amino, nitro, trifluoromethyl, trifluoromethoxy, alkyl, alkenyl, alkynyl, 1,2-dioxymethylene, 1,2-dioxyethylene, alkoxy, alkenoxy, alkynoxy, alkylamino, alkenylamino, alkynylamino, alkylcarbonyloxy, acyl, alkylcarbonylamino, alkoxycarbonylamino, alkylsulfonylamino, N-alkyl or N,N-dialkylurea; 20 (h) -alkoxy-saturated heterocyclic, -alkoxy-saturated substituted heterocyclic, -substituted alkoxy-heterocyclic and -substituted alkoxy substituted saturated heterocyclic; (i) -O-heterocyclic and -O-substituted heterocyclic; (j) tetrazolyl; 25 (k) -NR-S0 2 -substituted alkyl where R is hydrogen, alkyl or aryl, with the proviso that at least one substituent on the alkyl moiety of the substituted alkylsulfonylamino is other than halogen, hydroxyl, amino, nitro, trifluoromethyl, trifluoromethoxy, alkyl, alkenyl, alkynyl, 1,2 dioxymethylene, 1,2-dioxyethylene, alkoxy, alkenoxy, alkynoxy, 30 alkylamino, alkenylamino, alkynylamino, alkylcarbonyloxy, acyl, WO 99/06437 PCT/US98/16070 28 alkylcarbonylamino, alkoxycarbonylamino, alkylsulfonylamino, N-alkyl or N,N-dialkylurea; (1) alkenylsulfonylamino, alkynylsulfonylamino, substituted alkenylsulfonylamino and substituted alkynylsulfonylamino; 5 (min) substituted alkoxy with the proviso that the substitution on the alkyl moiety of said substituted alkoxy does not include alkoxy-NR"R" as defined above, unsaturated heterocyclic, alkyloxy, aryloxy, heteroaryloxy, aryl, heteroaryl or aryl/heteroaryl substituted with halogen, hydroxyl, amino, nitro, trifluoromethyl, trifluoromethoxy, alkyl, alkenyl, alkynyl, 1,2 10 dioxymethylene, 1,2-dioxyethylene, alkoxy, alkenoxy, alkynoxy, alkylamino, alkenylamino, alkynylamino, alkylcarbonyloxy, acyl, alkylcarbonylamino, alkoxycarbonylamino, alkylsulfonylamino, N-alkyl or N,N-dialkylurea; (n) amidine and amidine substituted with from I to 3 substituents 15 independently selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, heteroaryl and heterocyclic; (o) -C(O)NR"R'" where each R"' is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted 20 cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic with the proviso that when one R'" is unsaturated heterocyclic, aryl, heteroaryl or aryl/heteroaryl substituted with halogen, hydroxyl, amino, nitro, trifluoromethyl, trifluoromethoxy, alkyl, alkenyl, 25 alkynyl, 1,2-dioxymethylene, 1,2-dioxyethylene, alkoxy, alkenoxy, alkynoxy, alkylamino, alkenylamino, alkynylamino, alkylcarbonyloxy, acyl, alkylcarbonylamino, alkoxycarbonylamino, alkylsulfonylamino, N-alkyl or N,N-dialkylurea, then the other R'" is alkyl, substituted alkyl (other than unsaturated heterocyclyl substituted-alkyl), cycloalkyl, substituted 30 cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, heterocyclic or substituted heterocyclic; WO 99/06437 PCT/US98/16070 29 (p) -NR 2 2

C(O)-R

18 where R 1 8 is selected from the group consisting of alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic, and R 2 2 is alkyl, substituted alkyl, aryl, substituted aryl, 5 cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic or substituted heterocyclic; (q) -SO 2 -aryl, -SO2-substituted aryl, -SO,-heteroaryl, -SO 2 -substituted heteroaryl or -SO 2 -alkyl; (r) -NR'C(0)NR 9

R

9 wherein R' is selected from the group 10 consisting of alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic and each R 19 is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, 15 heterocyclic and substituted heterocyclic: (s) -NR'C(0)OR 9 wherein R' is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic and R 19 is selected from the group consisting of hydrogen, alkyl, 20 substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic; (t) -aminocarbonyl-(N-formylheterocylcyl); and (u) -alkyl-C(0)NH-heterocyclyl and -alkyl-C(0)NH-substituted heterocyclyl; 25 and pharmaceutically acceptable salts thereof; with the following additional proviso: when R 1 is p-methylphenyl, R 2 and R 3 together with their pendent nitrogen and carbon atoms form a pyrrolidinyl ring, R 5 is p-[-OCH 2

CH

2 -(4,5 dihydroimidizol-2-yl), Q is -C(0)NH-, then R 6 is not -O-methyl. 30 WO 99/06437 PCT/US98/16070 30 Preferred compounds within the scope of formulas I and IA above include by way of example the following: N-(Toluene- 4 -sulfonyl)-L-prolyl-4-(a-methylbenzyloxy)-L-phenylalanine 5 N-(Toluene-4-sulfonyl)-L-prolyl-L-tyrosine N-(Toluene-4-sulfonyl)-L-prolyl-4-carboxyphenylalanine N-(Toluene-4-sulfonyl)-L-prolyl-3-(carboxy)phenylalanine 10 N-(Toluene- 4 -sulfonyl)-L-prolyl-4-(2-carboxyphenoxy)-L-phenylalanine N-(Toluene-4-sulfonyl)-L-prolyl-O-(benzyl)-L-tyrosine 15 N-(Toluene-4-sulfonyl)-L-prolyl-4-(iodo)-L-phenylalanine N-(Toluene-4-sulfonyl)-L-prolyl-L-4-(methoxy)-phenylalanine N-(Toluene-4-sulfonyl)-L-prolyl-4-nitro-L-phenylalanine 20 N-(Toluene-4-sulfonyl)-L-prolyl-4-(O-tert-butyl)-L-tyrosine N-(Toluene-4-sulfonyl)-L-prolyl-L-(3,5-diiodo)-tyrosine 25 N-(Toluene- 4 -sulfonyl)-L-prolyl-L-4-(aminobenzoyl)-phenylalanine N-(Toluene-4-sulfonyl)-L-prolyl-L-(3-iodo-4-hydroxy)-phenylalanine N-(Toluene-4-sulfonyl)-L-prolyl-L-(4-chloro)phenylalanine 30 N-(Toluene-4-sulfonyl)-L-prolyl-L-leucine N-(Toluene-4-sulfonyl)-L-prolyl-L-alanine 35 N-(Toluene-4-sulfonyl)-L-prolyl-L-4-(acetamido)-phenylalanine N-(Toluene-4-sulfonyl)-L-prolyl-L-isoleucine N-(Toluene-4-sulfonyl)-L-prolyl-L-aspartic acid 40 N-(Toluene-4-sulfonyl)-L-prolyl-L-lysine N-(Toluene-4-sulfonyl)-L-prolyl-L-glutamic acid WO 99/06437 PCT/US98/16070 31 N-(Toluene- 4 -sulfonyl)-L-prolyl-L-(4-dibenzylamino)-phenylalanine methyl ester N-(Toluene-4-sulfonyl)-L-prolyl-L-(N-benzyl)-histidine 5 N-(Toluene- 4 -sulfonyl)-L-prolyl-L-(4-dibenzylamino)-phenylalanine N-(Toluene-4-sulfonyl)-L-prolyl-L-methionine 10 N-(Toluene-4-sulfonyl)-L-prolyl-L-serine N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)thiaprolylL-(N-benzyl)-histidine N-(Toluene-4-sulfonyl)-L-prolyl-L-(1-methyl)histidine 15 N-(Toluene-4-sulfonyl)-L-prolyl-D-(N-benzyl)histidine N-(Toluene-4-sulfonyl)-L-glutamyl-L-tyrosine 20 N-(Toluene-4-sulfonyl)-L-prolyl-L-(N-3-methyl)histidine N-(Toluene-4-sulfonyl)-L-prolyl-a-amino-2,3-dihydro-(1,4-benzodioxin)-6 propanoic acid 25 N-(Toluene-4-sulfonyl)-L-prolyl-a-amino-1,3-benzodioxole-5-propanoic acid N-(Toluene-4-sulfonyl)-L-prolyl-L-valine 30 N-(Toluene- 4 -sulfonyl)-L-prolyl-L-(4-iodo)-phenylalanine methyl ester N-(Toluene- 4 -sulfonyl)-L-prolyl-L-4-(aminobenzoyl)phenylalanine methyl ester 35 N-(Toluene- 4 -sulfonyl)-L-prolyl-L-(4-chloro)phenylalanine methyl ester N-(Toluene-4-sulfonyl)-L-prolyl-L-(4-amino)phenylalanine methyl ester N-(Toluene-4-sulfonyl)-L-prolyl-L-(4-acetamido)phenylalanine methyl ester 40 N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)thiaprolyl-L-(N-benzyl)-histidine methyl ester AN-(Toluene-4-sulfonyl)-L-prolyl-4-(3-3'-tolylureido)-L-phenylalanine 45 WO 99/06437 PCT/US98/16070 32 N-(Toluene-4-sulfonyl-L-prolyl-4-[(2,3,3a,7a-tetrahydro- I H-indole-2 carbonyl)-amino]-L-phenylalanine N-(Toluene- 4 -sulfonyl)-L-prolyl-L-(4-pentylamino)phenylalanine methyl 5 ester N-(Toluene-4-sulfonyl)-L-prolyl-L-O-(2-dibenzylamino-ethyl)-tyrosine methyl ester 10 N-(Toluene-4-sulfonyl)-L-prolyl-L-O-[2-(dibenzylamino)ethyl]-tyrosine N-(Toluene- 4 -sulfonyl)-L-prolyl-L-(4-pentylamino)phenylalanine N-(Toluene- 4 -sulfonyl)-L-prolyl-L-4-(4-chlorobenzylamino)-phenylalanine 15 methyl ester N-(Toluene-4-sulfonyl)-L-prolyl-L-4-[3-(4-cyanophenyl)-ureido]-phenyl alanine methyl ester 20 N-(Toluene-4-sulfonyl)-L-prolyl-L-4-[3-(4-cyanophenyl)-ureido]-phenyl alanine N-(Toluene- 4 -sulfonyl)-L-prolyl-L-O-(tert-butoxycarbonylmethyl)-tyrosine methyl ester 25 N-(Toluene- 4 -sulfonyl)-L-prolyl-L-O-(tert-butoxycarbonylmethyl)-tyrosine N-(Toluene-4-sulfonyl)-L-prolyl-L-4-[(3S)-3,4-dihydro-isoquinolin-3-yl aminocarbonyl]-phenylalanine 30 N-(Toluene-4-sulfonyl)-L-prolyl-4-[3-(3-methoxy-phenyl)-ureido]-L phenylalanine methyl ester N-(Toluene-4-sulfonyl)-L-prolyl-4-[3-(3-methoxy-phenyl)-ureido]-L 35 phenylalanine N-(Toluene-4-sulfonyl)-L-prolyl-L-O-(4,5-dihydro- 1 H-imidazol-2-yl methyl)-tyrosine 40 N-(Toluene-4-sulfonyl)-L-prolyl-L-4-(3-propyl-ureido)-phenylalanine A-(Toluene-4-sulfonyl)-L-prolyl-L-(4-benzylamino)phenylalanine N-(Toluene-4-sulfonyl)-L-prolyl-L-(4-benzylamino)phenylalanine methyl 45 ester WO 99/06437 PCT/US98/16070 33 N-(Toluene- 4 -sulfonyl)-L-prolyl-L-4-(4-chlorobenzylamino)-phenylalanine N-(Toluene- 4 -sulfonyl)-L-prolyl)-L-(4-chloromethanesulfonylamino) phenylalanine 5 N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)-thiaprolyl-L-4 (aminobenzoyl)phenylalanine methyl ester N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)-thiaprolyl-L-4 10 (benzamido)phenylalanine N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)-thiaprolyl-L-tyrosine ethyl ester N-(Toluene-4-Sulfonyl)-L-(5,5-dimethyl)-thiaprolyl-L-tyrosine 15 N-(Toluene-4-sulfonyl)-L-prolyl-L-4-[(pyridin-4 yl)methylamino]phenylanine N-(Toluene-4-sulfonyl)-L-prolyl-L-4-[(pyridin-4 20 yl)methylamino]phenylanine methyl ester N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)-thiaprolyl-L-4-(pyridin-3 carboxamido)phenylalanine methyl ester 25 N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)-thiaprolyl-L-4-(pyridine-3 carboxamido)phenylalanine N-(Toluene-4-sulfonyl)-L-prolyl-L-4-[(pyridin-3 ylmethyl)amino]phenylalanine 30 N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)-thiaprolyl-L-4-nitrophenylalanine methyl ester N-(Toluene-4-sulfonyl)-L-prolyl-L-4-nitrophenylalanine ethyl ester 35 N-(Toluene- 4 -sulfonyl)-L-prolyl-L-4-(2-methoxybenzamido)phenylalanine ethyl ester N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)-thiaprolyl-L-(4-nitro)phenylalanine 40 ethyl ester N-(Toluene- 4 -sulfonyl)-L-prolyl-L-4-(2-bromobenzamido)phenylalanine ethyl ester 45 N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)-thiamorphyl-L-4 aminophenylalanine ethyl ester WO 99/06437 PCT/US98/16070 34 N-(Toluene- 4 -sulfonyl)-L-prolyl-L-4-acetamidophenylalanine ethyl ester N-(Toluene- 4 -sulfonyl)-L-prolyl-L-4-(2-methoxybenzamido)phenylalanine 5 N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)-thiaprolyl-L-4 acetamidophenylalanine ethyl ester N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)-thiaprolyl-L-4 acetamidophenylalanine 10 N-(Toluene- 4 -sulfonyl)-L-prolyl-L-4-acetamidophenylalanine isopropyl ester N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)-L-4-(isonicotinamido) phenylalanine ethyl ester 15 N-(Toluene- 4 -sulfonyl)-L-prolyl-L-4-(isonicotinamido)phenylalanine ethyl ester N-(Toluene-4-sulfonyl)-L-prolyl-L-(x-toluene-4-sulfonyl)histidine methyl 20 ester N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)-thiaprolyl-L-4 (nicotinamido)phenylalanine ethyl ester 25 N-(Toluene-4-sulfonyl)-L-prolyl-L-(O-methyl)tyrosine ethyl ester N-(ca-Toluenesulfonyl)-L-prolyl-L-4-(isonicotinamido)phenylalanine ethyl ester 30 N-(Toluene- 4 -sulfonyl)-L-prolyl-L-4-(2-bromobenzamido)phenylalanine N-(a-Toluenesulfonyl)-L-prolyl-L-4-(isonicotinamido)phenylalanine N-(Toluene-4-sulfonyl)-L-(1,1-dioxo)thiamorpholyl-L-4-(2 35 bromobenzamido))phenylalanine ethyl ester N-(Toluene-4-sulfonyl)-L-(1,1-dioxo)thiamorpholyl-L-4-(2 bromobenzamido)phenylalanine 40 N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)-L-4 (isonicotinamido)phenylalanine N-(a-Toluenesulfonyl)-L-prolyl-L-4-(2-bromobenzamido)phenylalanine ethyl ester 45 WO 99/06437 PCT/US98/16070 35 N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)-thiaprolyl-L-tyrosine isopropyl ester N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)-thiaprolyl-L-tyrosine tert-butyl 5 ester N-(Toluene-4-sulfonyl)-L-prolyl-L-tyrosine tert-butyl ester N-(Toluene-4-sulfonyl)-L-prolyl-L-4-(2 10 trifluoromethylbenzamido)phenylalanine ethyl ester N-(Toluene- 4 -sulfonyl)-L-prolyl-L-4-(2-methylbenzamido)phenylalanine ethyl ester 15 N-(Toluene-4-sulfonyl)-L-prolyl-L-4-(2-trifluoromethylbenzamido) phenylalanine

N-(

4 -Fluorobenzenesulfonyl)-L-thiaprolyl-L-tyrosine tert-butyl Ester 20 N-(4-Fluorobenzenesulfonyl)-L-(5,5-dimethyl)-thiaprolyl-L-tyrosine tert butyl ester N-(Toluene- 4 -sulfonyl)-L-prolyl-4-(dimethylamino)-L-phenylalanine 25 N-(Toluene-4-sulfonyl)-L-prolyl-4-[(2-bromo)benzamido]-L-phenylalanine ethyl ester N-(Toluene-4-sulfonyl)-L-prolyl-4-[(pyrazin-2-yl)C(O)NH]-L-phenylalanine methyl ester 30 N-(Toluene-4-sulfonyl)-L-prolyl-4-(4-nitrobenzoyl)-L-phenylalanine ethyl ester N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)thiaprolyl-4-(2-bromobenzamido) 35 L-phenylalanine t-butyl ester N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)thiaprolyl-4-(2-bromobenzamido) L-phenylalanine t-butyl ester 40 N-(Toluene-4-sulfonyl)-L-prolyl-4-(1-H-2-oxo-3 methyltetrahydropyrimidin-1-yl)-L-phenylalanine t-butyl ester N-(Toluene-4-sulfonyl)-L-prolyl-4-(1-H-2-oxo-3 methyltetrahydropyrimidin- 1 -yl)-L-phenylalanine 45 WO 99/06437 PCT/US98/16070 36 N-(Toluene-4-sulfonyl)-L-prolyl-3-chloro-4-(t-butoxy)-L-phenylalanine t butyl ester N-(Toluene- 4 -sulfonyl)-L-prolyl-3-chloro-4-(hydroxy)-L-phenylalanine t 5 butyl ester N-(Toluene- 4 -sulfonyl)-L-prolyl-4-(N,N-dimethylureido)-L-phenylalanine t butyl ester 10 N-(4-Fluorobenzenesulfonyl)-L-(5,5-dimethyl)thiaprolyl-3-chloro-4 (hydroxy)-L-phenylalanine t-butyl ester N-(4-fluorobenzenesulfonyl)-L-(5,5-dimethyl)thiaprolyl-3-chloro-4 (hydroxy)-L-phenylalanine isopropyl ester 15 N-(Toluene- 4 -sulfonyl)-L-prolyl-4-(2-methoxyphenyl)-L-phenylalanine t butyl ester N-(Toluene- 4 -sulfonyl)-L-prolyl-4-(2-methoxyphenyl)-L-phenylalanine 20 N-(Toluene-4-sulfonyl)-L-prolyl-[(5-N,N-dimethyl ureido)-pyridin-2-yl] alanine N-(Toluene-4-sulfonyl)-L-prolyl-4-(N,N-dimethylsulfamyl)-L-phenylalanine 25 N-(Toluene-4-sulfonyl)-L-prolyl-4-(N 1

',N',N

2 -trimethylsulfamyl)-L phenylalanine N-(Toluene-4-sulfonyl)-L-prolyl-(1-t-butoxycarbonylmethylimidazol-4-yl) 30 L-alanine methyl ester N-(Toluene-4-sulfonyl)-L-prolyl-[N,N dimethylaminocarbonylmethylimidazol-4-yl]-L-alanine methyl ester 35 N-[4-(dimethyl ureylenyl)-benzenesulfonyl]-L-prolyl-4-hydroxy-L phenylalanine isopropyl ester N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)thiaprolyl-3 -chloro-4-hydroxy-L phenylalanine isopropyl ester 40 N-(Toluene-4-sulfonyl)-L-prolyl-3-chloro-4-hydroxy-L-phenylalanine isopropyl ester N-(Toluene- 4 -sulfonyl)-L-prolyl-4-(carboxymethyl)-L-phenylalanine methyl 45 ester WO 99/06437 PCT/US98/16070 37 N-(Toluene- 4 -sulfonyl)-L-prolyl-4-(2-methylbenzamido)-L-phenylalanine methyl ester N-(Toluene- 4 -sulfonyl)-L-prolyl-4-(N,N-dimethylaminocarbonylmethyl)-L 5 phenylalanine N-(1-methylimidazol-4-sulfonyl)-L-prolyl-4-hydroxy-L-phenylalanine isopropyl ester 10 N-(Toluene-4-sulfonyl)-L-prolyl-4-(2,4,5-trioxo-3 phenyltetrahydroimidazol-l1-yl)-L-phenylalanine isopropyl ester N-(4-Fluorobenzenesulfonyl)-L-(5,5-dimethyl)thiaprolyl-3-fluoro-4 hydroxy-L-phenylalanine isopropyl ester 15 N-(4-Fluorobenzenesulfonyl)-L-(5,5-dimethyl)thiaprolyl-3-chloro-4-t butoxy-L-phenylalanine t-butyl ester N- {N-[(1 S)-2,10-camphorsultamyl]acetyl }-L-tyrosine t-butyl ester 20 N- {N-[(1 S)-2,10-camphorsultamyl]acetyl }-3-chlorotyrosine isopropyl ester

N-(

4 -Fluorobenzenesulfonyl)-L-thiaprolyl-4-hydroxy-L-phenylalanine t butyl ester 25 N-(Toluene- 4 -sulfonyl)-L-prolyl-4-(N,N-dimethylaminocarbonylmethyl)-L phenylalanine t-butyl ester

N-(

4 -Nitrobenzenesulfonyl)-L-prolyl-4-(hydroxy)-L-phenylalanine t-butyl 30 ester N-(4-Fluorobenzenesulfonyl)-L-(5,5-dimethyl)thiaprolyl-4-hydroxy-L phenylalanine isopropyl ester 35 N-( 4 -Fluorobenzenesulfonyl)-L-prolyl-4-hydroxy-L-phenylalanine t-butyl ester N-(pyridin-3-sulfonyl)-L-prolyl-4-hydroxy-L-phenylalanine t-butyl ester 40 N-(Toluene- 4 -sulfonyl)-L-prolyl-4-(methanesulfonamido)-L-phenylalanine N-(Toluene-4-sulfonyl)-L-prolyl-4-(2,4,5-trioxo-3-(3-chlorophenyl) tetrahydroimidazol-1-yl)-L-phenylalanine benzyl ester 45 N-(1 -methylimidazol-4-sulfonyl)-L-(5,5-dimethyl)thiaprolyl-3-chloro-4 hydroxy-L-phenylalanine ethyl ester.

WO 99/06437 PCT/US98/16070 38 N-(4-Fluorobenzenesulfonyl)-L-(5,5-dimethyl) thiaprolyl-L-3-chloro 4-tert-butoxy-phenylalanine tert-Butyl Ester N-[2-(N-2,10-camphorsultamyl) acetyl]-L-3-chloro-4-hydroxyphenylalanine 5 Isopropyl Ester Preferably, in the compounds of formula I and IA above, R 1 is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heterocyclic, substituted heterocylic, heteroaryl and 10 substituted heteroaryl. Even more preferably, R' is selected from the group consisting of 4-methylphenyl, methyl, benzyl, n-butyl, 4-chlorophenyl, 1 naphthyl, 2-naphthyl, 4-methoxyphenyl, phenyl, 2,4,6-trimethylphenyl, 2-(methoxycarbonyl)phenyl, 2-carboxyphenyl, 3,5-dichlorophenyl, 4-trifluoromethylphenyl, 3,4-dichlorophenyl, 3,4-dimethoxyphenyl, 15 4-(CH 3 C(O)NH-)phenyl, 4-trifluoromethoxyphenyl, 4-cyanophenyl, isopropyl, 3,5-di-(trifluoromethyl)phenyl, 4-t-butylphenyl, 4-t-butoxyphenyl, 4-nitrophenyl, 2-thienyl, 1-N-methyl-3-methyl-5-chloropyrazol-4-yl, phenethyl, 1-N-methylimidazol-4-yl, 4-bromophenyl, 4-amidinophenyl, 4-methylamidinophenyl, 4-[CH 3 SC(=NH)]phenyl, 5-chloro-2-thienyl, 2,5 20 dichloro-4-thienyl, 1-N-methyl-4-pyrazolyl, 2-thiazolyl, 5-methyl-1,3,4 thiadiazol-2-yl, 4-[H 2 NC(S)]phenyl, 4-aminophenyl, 4-fluorophenyl, 2-fluorophenyl, 3-fluorophenyl, 3,5-difluorophenyl, pyridin-3-yl, pyrimidin 2-yl, 4-(3'-dimethylamino-n-propoxy)-phenyl, and 1-methylpyrazol-4-yl. 25 Preferably, in the compounds of formula I and IA above, R 2 is hydrogen, methyl, phenyl, benzyl, -(CH2)2-2-thienyl, and -(CH 2

)

2 -. In one embodiment, R' and R 2 together with the nitrogen atom bound to R 2 and the SO 2 group bound to R 1 are joined to form a heterocyclic group 30 or substituted heterocyclic group. Preferred heterocyclic and substituted heterocyclic groups include those having from 5 to 7 ring atoms and having 2 to 3 heteroatoms in the ring selected from the group consisting of nitrogen, oxygen and sulfur, which ring is optionally fused to another ring such as a WO 99/06437 PCT/US98/16070 39 phenyl or cyclohexyl ring to provide for a fused ring heterocycle of from 10 to 14 ring atoms and having 2 to 4 heteroatoms in the ring selected from the group consisting of nitrogen, oxygen and sulfur. Specifically preferred R'/R 2 joined groups include, by way of example, benzisothiazolinyl (saccharin-2 5 yl). Preferably, in the compounds of formula I and IA above, R 3 includes all of the isomers arising by substitution with methyl, phenyl, benzyl, diphenylmethyl, -CH 2

CH

2 -COOH, -CH 2 -COOH, 2-amidoethyl, iso-butyl, 10 t-butyl, -CH 2 0-benzyl and hydroxymethyl. In another preferred embodiment, R 2 and R 3 together with the nitrogen atom bound to R 2 and the carbon atom bound to R 3 form a saturated heterocyclic group or a saturated substituted heterocyclic group with the 15 proviso that when monosubstituted, the substituent on said saturated substituted heterocyclic group is not carboxyl. Q is preferably -C(O)NH- or -C(S)NH-. 20

R

5 is preferably selected from the group consisting of all possible isomers arising by substitution with the following groups: p-[-OCH(CH 3

)]

benzyl, 4-hydroxybenzyl, 2-carboxybenzyl, 3-carboxybenzyl, 4-carboxybenzyl, 4-(2-carboxyphenoxy)benzyl, 4-(benzyloxy)benzyl, 25 4-iodobenzyl, 4-methoxybenzyl, 4-nitrobenzyl, 4-(tert-butoxy)benzyl, 3,5 diiodo-4-hydroxybenzyl, 4-(benzamido)benzyl, benzyl, 4-hydroxy-3 iodobenzyl, 4-chlorobenzyl, isobutyl, methyl, 4-(acetamido)benzyl, n-butyl, carboxymethyl, 4-aminobutyl, 2-carboxyethyl, 4-(N,N-dibenzylamino) benzyl, (N-benzylimidazol-4-yl)methyl, 2-thiomethoxyethyl, hydroxymethyl, 30 (N-methylimidazol-4-yl)methyl, 4-(isopropyl-C(O)NH-) butyl, 4-(benzamido)butyl, 4-(benzyl-C(O)NH-)butyl, (N-methylimidazol-5 yl)methyl, 4-(pyridin-2-yl-C(O)NH-)butyl, 4-(6-methylpyridin-3-yl- WO 99/06437 PCT/US98/16070 40 C(O)NH-) butyl, 4-(3-methylthien-2-yl-C(O)NH-)butyl, 4-(pyrrol-2-yl C(O)NH-)butyl, 4-(furan-2-yl-C(O)NH)-butyl, isopropyl, 4-aminobenzyl, 4 (4-phenylbutoxy)benzyl, 4-(1-methylindol-3-yl-C(O)NH-)butyl, 4-(4 methanesulfonylphenyl-C(O)NH-)butyl, 4-(4-acetylphenyl-C(O)NH-)butyl, 5 4-(4-fluorophenyl-C(O)NH-)butyl, 4-[2-(pyridin-2-yl)ethynyl]benzyl, 4-[2-(3-hydroxyphenyl)ethynyl]benzyl, 4-(pyridin-4-yl-C(O)NH-)benzyl, 4-(pyridin-3-yl-C(O)NH-)benzyl, 4-(3-methylphenyl-NHC(O)NH-)benzyl, 4-(2,3-dihydroindol-2-yl-C(O)NH-)benzyl, 4-(NN-dipentylamino)benzyl, 4-(N-pentylamino)benzyl, 4-[ 2 -(NN-dibenzylamino)ethoxy]benzyl, 10 3-hydroxybenzyl, 4 -(N-n-butyl-N-n-pentylamino)benzyl, 4-(N-4 chlorophenylamino)benzyl, 4-(4-cyanophenyl-NHC(O)NH-)benzyl, 4-(carboxymethoxy)benzyl, 4 -(tert-butoxycarbonylmethoxy)benzyl, 4-(5-fluoroindol-2-yl-C(O)NH-)benzyl, 4-(1,2,3,4-tetrahydroisoquinolin-3 yl-C(O)NH-)benzyl, 4-(3-methoxyphenyl-NHC(O)NH-)benzyl, 4-[2-(indol 15 3-yl)ethoxy]benzyl, 4-(4,5-dihydroimidazol-2-ylmethoxy)benzyl, 4-(n propyl-NHC(O)NH-)benzyl, 4-(N-benzylamino)benzyl, 3-methoxybenzyl, 4 (pyridin-2-yl-C(O)NH-)benzyl, 4-(N-4-chlorobenzylamino)benzyl, 4-(2 chloromethylsulfonylamino)benzyl, 4-(NN-dimethylamino)benzyl, 3-aminobenzyl, 4-(benzyl)benzyl, 2-hydroxyethyl, 4-nitrobenzyl, 4-(phenyl 20 NHC(S)NH-)benzyl, 4-(pyridin-3-yl-NHC(S)NH-)benzyl, 4-(pyridin-4 ylmethylamino)benzyl, 4-[4CH 2 0CH,(Boc-H-N)CHC(O)NH-]benzyl, 4-(pyridin-3-yl-C(O)NH-)butyl, 4-(pyridin-4-vl-C(O)NH-)butyl, 4-(pyridin 3-yl-C(O)NH-)benzyl, 4-(pyridin-4-yl-C(O)NH-)benzyl, 4-(N toluenesulfonylpyrrolidin-2-yl-C(O)NH-)butyl, 4-(piperidin-4-yl-C(O)NH-) 25 butyl, 4-(2-Boc-1,2,3,4-tetrahydroisoquinolin-3-yl-NHCH,-)benzyl, 4-(2 Boc-1,2,3,4-tetrahydroisoquinolin-3-yl-C(O)NH-)benzyl, 4-(pyridin-3 ylmethylamino)benzyl, 4-[#CH 2 O(O)C(CbzNH)CHCHCHC(O)NH-] benzyl, 4-(2-methoxybenzamido)benzyl, 4-(2-bromobenzamido)benzyl, 4-(pyrazin-2-yl-C(O)NH-)benzyl, (1 -toluenesulfonylimidizol-4-yl)methyl, 30 [1 -(NN-dimethylaminosulfonyl)imidizol-4-yl]methyl, 4-(trifluoromethyl) benzyl, 4-(3 ,3-dimethylureido)benzyl, 4-(methoxycarbonylamino)benzyl, 4- WO 99/06437 PCT/US98/16070 41 (1,3,3-trimethylureido)benzyl, 4-(methoxycarbonyl-N-methylamino)benzyl, 4-cyanobenzyl, 4-(2-formyl-1,2,3,4-tetrahydroisoquinolin-3-yl C(O)NH)benzyl, phenyl, 4-(aminomethyl)benzyl, 4-(1-Boc-piperidin-4-yl

C(O)NHCH

2 -)benzyl, 4-(1-Boc-piperidin-4-yl-C(O)O-)benzyl, 4-(piperidin 5 4-yl-C(O)NHCH 2 -)benzyl, 4-[(1-methylpiperidin-4-yl)-O-]benzyl, 4 (1,2,3,4-tetrahydroquinolin-2-yl-C(O)NH-)benzyl, a-methylbenzyl, 4-(trimethylacetamido)benzyl, 4-(2-methylpropionamido)benzyl, 4 (morpholin-4-yl-C(O)NH-)benzyl, 4-(3,3-diethylureido)benzyl, 4-(2 trifluoromethylbenzamido)benzyl, 4-(2-methylbenzamido)benzyl, 4 10 hydroxy-3-nitrobenzyl, 3-hydroxy-4-(4-OC(O)NH-)benzyl, 4 (thiomorpholino-4-yl-C(O)NH-)benzyl, 4-(1,1 -dioxothiomorpholino-4-yl C(O)NH-)benzyl, 3 -nitro-4-(methoxycarbonylmethoxy)benzyl, (2 benzoxazolinon-6-yl)methyl, (2H-1,4-benzoxazin-3(4H)-one-7-yl)methyl, 4 [N,N-dimethyaminosulfonyl-(N-methyl)amino]benzyl, 4-[(2 15 methylpyrrolidin-1-yl)-C(O)NH-]benzyl, (pyridin-4-yl)methyl, 4-(1 methylpiperidin-4-yl-C(O)NH-)benzyl, 4-[bis(N,N dimethylaminothiocarbonyl)amino]benzyl, 4-(N,N-dimethylaminosulfonyl) benzyl, 4-(imidazolid-2-one-1-yl)benzyl, 3,4-(ethylenedioxy)benzyl-, 3,4 (methylenedioxy)benzyl- and 4-(3-formylimidazolid-2-one-1-yl)benzyl. 20 In the compounds of formula IA, R 6 is preferably 2,4-dioxo tetrahydrofuran-3-yl (3,4-enol), methoxy, ethoxy, iso-propoxy, n-butoxy, t-butoxy, cyclopentoxy, neo-pentoxy, 2-a-iso-propyl-4-p methylcyclohexoxy, 2 -p-isopropyl-4-p-methylcyclohexoxy,

-NH

2 , 25 benzyloxy, -NHCH 2 COOH, -NHCH,CH 2 COOH, -NH-adamantyl, NHCH 2

CH

2

COOCH

2

CH

3 , -NHSO 2 -p-CH 3 -4, -NHOR' where R 8 is hydrogen, methyl, iso-propyl or benzyl, O-(N-succinimidyl), -O-cholest-5 en-3-p-yl, -OCH,-OC(O)C(CH 3

)

3 , -O(CH 2 )zNHC(O)W where z is 1 or 2 and W is selected from the group consisting of pyrid-3-yl, N-methylpyridyl, and 30 N-methyl-1,4-dihydro-pyrid-3-yl, -NR"C(O)-R' where R' is aryl, heteroaryl or heterocyclic and R" is hydrogen or -CH,C(O)OCH,CH 3

.

WO 99/06437 PCT/US98/16070 42 This invention also provides methods for binding VLA-4 in a biological sample which method comprises contacting the biological sample with a compound of formula I or IA above under conditions wherein said compound binds to VLA-4. 5 Certain of the compounds of formula I and IA above are also useful in reducing VLA-4 mediated inflammation in vivo. This invention also provides pharmaceutical compositions 10 comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of one or more of the compounds of formula I or IA above with the exception that R 3 and R 5 are derived from L-amino acids or other similarly configured starting materials. Alternatively, racemic mixtures can be used. 15 The pharmaceutical compositions may be used to treat VLA-4 mediated disease conditions. Such disease conditions include, by way of example, asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes (including acute juvenile onset diabetis), inflammatory bowel 20 disease (including ulcerative colitis and Crohn's disease), multiple sclerosis, rheumatoid arthritis, tissue transplantation, tumor metastasis, meningitis, encephalitis, stroke, and other cerebral traumas, nephritis, retinitis, atopic dermatitis, psoriasis, myocardial ischemia and acute leukocyte-mediated lung injury such as that which occurs in adult respiratory distress syndrome. 25 Accordingly, this invention also provides methods for the treatment of an inflammatory disease in a patient mediated by VLA-4 which methods comprise administering to the patient the pharmaceutical compositions described above. 30 WO 99/06437 PCT/US98/16070 43 Preferred compounds of formula I and IA above include those set forth in Tables IA and IB below.

WO 99/06437 PCT/US98/1 6070 44 z u -94 of2 E E E E - > q> .s Q 0. u uIo' I U~Z~ Q 'Z' "'~' u z a 11 0 WO 99/06437 PCT/US98/1 6070 45 z 5' 0 0 0 0 0 0 0 -a -6 N 6 u ~ 0 m zn 6 WO 99/06437 PCTIUS98/1 6070 46 z y 11 9 O0 0 E o z .0u E E -. E - EE -9 .92 u2_ cc7 co mz 6 C a" WO 99/06437 PCTIUS98/1 6070 47 u ,- _ ICI 9 9 9 9 u ; S d m S -. - > C7U N C E WO 99/06437 PCT/US98/16070 48 z II X x x & 0 0 0 0 0 0 0 0 I E . .. .. O, 5O zz S s '- "- ' s .3: E, E- - E5 N '20. I 0 I I a m 0eo e m o- e a m lae-o =E. =5 =6E = o u a a5 o 5 m e I - I E WO 99/06437 PCT/US98/16070 49 z Y II 7 0 0 0 0 0 a - Z Z "7-O z z a 'a a u )E "" .- -=" . , = , - I r =e -n xU WO 99/06437 PCTIUS98/1 6070 50 z y= x _ N z z 5' 5' C.) C.. E 5' , 6' u u' E E EE u . co -5 , m En1 nc -4 x 4 ' WO 99/06437 PCT/US98/1 6070 51 z Y zz z cn E u 0 z N & WO 99/06437 PCT/US98/1 6070 52 z 2 N In In CA Eo E U Z ocu uc. ocu WO 99/06437 PCTIUS98/1 6070 53 z C C - N N z -n z - z 0 C Q L Nn Qn MZ n _ u u WO 99/06437 PCT/US98/16070 54 N N u N I >1 m 7: >1 >1> 1> 1 o~u -u u u u u u u 2 4. M m I e a x £ E £ E x 0 9 0 a a 09

U

WO 99/06437 PCT/US98/1 6070 55 E K N0 2 z EQ 5 E 2 -n en onMC z WO 99/06437 PCT/US98/1 6070 56 00 9 9 o z E2 E 5

E.

WO 99/06437 PCT/US98/1 6070 57 - --- - - _ Y z 22E E E Uq Ul "aUU X km.

WO 99/06437 PCT/US98/16070 58 Ii z z z U, X- i Z x u C z Q Cq "a M- C a c*' Cn en -n - n -u I- - WO 99/06437 PCT/US98/1 6070 59 x- II 9-2 E E E 11l 00 ZO 2 z Z Ox O s u a . 04 4 .E> CE= o E> -a u IIIIUn e n o E - u U .

II me> Ii e~ II a a 8 a C 0 _a a U U U U U U WO 99/06437 PCTIUS98/1 6070 60 - - - Y 11 ~4. z CI'4 - N 9. -E a m ; U z' co ME O X Edi 0 0 0n n ~u WO 99/06437 PCT/US98/16070 61 ii Q cc > 'n cn E N WO 99/06437 PCT/US98/1 6070 62 Y! 74 :z YE IIz 9 0i E E E ci ,A CN .I I I , mp- en en :~E -u u0* u WO 99/06437 PCT/US98/16070 63 o II i0 N N 9 a 5 I-IN Z . Z - E 2 62 E 0.. z E2. .9E E E0 E U : 2 c m U a a A A A A A WO 99/06437 PCT/US98/1 6070 64 CY 0 u~ cd uc cc 0 w0" Q _ E CC~4 uU . 4. r4.

WO 99/06437 PCTIUS98/16070 65 o II , 0 99 .o F N N Ye a uC E E Eh - '- - .- .- o .. 0 . . 0 , . - , + + ,I.

WO 99/06437 PCT/US98/16070 66 II 6E '9 9 9 9 C 0 . .n C- - . o a o o o o Ye + + + + + + WO 99/06437 PCT/US98/16070 67 II 9 0 O 0 A i I 112 YC u p 0 0 0 so r..° . . cc I " .o 0 2 E,., . ~~~~ C; .

WO 99/06437 PCTIUS98/1 6070 68 * E uc 9 EE u E 19u E 0 x* WO 99/06437 PCT/US98/1 6070 69 4. U a a~ y Em: zn ( CV) z 0x WO 99/06437 PCT/US98/16070 70 O

-

z E E E -=_.- = ' Z 5o o o " S0 S U> co O mUaum uc U U o U 2 o - * o E t>--, 2 F " F ( - Qu, 0 .~~' U'- 'Z' 0 '~ .,...n " u u WO 99/06437 PCT/US98/16070 71 II :z x ex9 Eii O O , 0 ax C4 6 E 2.E . cn 0 M C.. a c o c o ..... a .. 0 . C x S I III 9z ? F ?9 ?Q 0 2 ou00 0 a e A A2 A A~ A QQC09 WO 99/06437 PCTIUS98/16070 72 IIz 3:3, x x WO 99/06437 PCT/US98/16070 73 o 11 CY II -i C N z U .

Q u .- ~S9 o U2'~ 0 UI 0 d~ zI , I I WO 99/06437 PCTIUS98/1 6070 74 t)t 0 WO 99/06437 PCT/US98/1 6070 75 z - - -~ - - 0 0 >4 >4 >4 >4 N N - N N ~ >4 - -~ >4 >4 0 >4 0 -~ C -~ - >4 0 2 -r >4 0 0 >4 -t = - ' _______ 4 _______ ______ 1. ______ _______ ______ ~ 2I~22 ~ Q ~ Q 4 ~ - I - I - I - t - - ________________________________ WO 99/06437 PCT/US98/1 6070 76 z 9t 9t -6i s c 95 1- 9- WO 99/06437 PCTIUS98/1 6070 77 z 00 2:2 31z E 3 ~ u~'~y WO 99/06437 PCT/US98/1 6070 78 o .2 rnj WO 99/06437 PCTIUS98/1 6070 79 z 0, 2 - -73 Q -3 "C ce .N odU N _ WO 99/06437 PCTIUS98/1 6070 80 z 00 75 if if 0.if 7 WO 99/06437 PCTIUS98/16070 81 z a

-

- c o7 75-- WO 99/06437 PCT/US98/1 6070 82 z 0' = " WO 99/06437 PCTIUS98/1 6070 83 z > i WO 99/06437 PCTIUS98/1 6070 84 z aI Q3 S -U S0 z 7:3 tz WO 99/06437 PCTIUS98/1 6070 85 z U 0 ~0 Q S 0 C U U C .~ ~ '~ ~*.=C>I ~ U - U - U S ~~0 0 -' - . i - - - WO 99/06437 PCTIUS98/1 6070 86 zt 03' Q - 4 75 C 5 7 WO 99/06437 PCT/US98/16070 87 z o' -1 >, u - -7, u . 0E 1 -4 o 1.7, u - - = - -- . . G - - WO 99/06437 PCT/US98/1 6070 88 z I' CY 31 WO 99/06437 PCT/US98/1 6070 89 z a WO 99/06437 PCTIUS98/1 6070 90 W4 o *o -1 a)-) 0 - I3 u u u u WO 99/06437 PCT/US98/16070 91 II ,0. 0 0 0 0 0 o .e.

° s o E E 999 aau - II I WO 99/06437 PCT/US98/16070 92

I

C) 0 C c t ZE II CV o o L) 00 9 0 2 , o , o ~ , oo II * II O " o .- ' so , a o u uo u o'T - "- ) 0 0 0 - 0) -& z WO 99/06437 PCT/US98/16070 93 z II CVL o~ o, 9 I, 9 9 99 d 5, I N Nd 0' ** -- -- 0 o= -- 10 10 o a o Nx ZZ a , I c 2 II O 0 e- + E~ oS ~ o Im-A- 0 6 ,g, _ _ _ _ _ zz WO 99/06437 PCT/US98/1 6070 94 'IL N N 0 -0 N >1 >1 III N N N C~ C u- 0 -~ ..Dg:4 WO 99/06437 PCT/US98/16070 95 DETAILED DESCRIPTION OF THE INVENTION As above, this invention relates to compounds which inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA 4. However, prior to describing this invention in further detail, the following 5 terms will first be defined. Definitions As used herein, "alkyl" refers to alkyl groups preferably having from 1 to 10 carbon atoms and more preferably 1 to 6 carbon atoms. This term is 10 exemplified by groups such as methyl, t-butyl, n-heptyl, octyl and the like. "Substituted alkyl" refers to an alkyl group, preferably of from 1 to 10 carbon atoms, having from 1 to 5 substituents selected from the group consisting of alkoxy, substituted alkoxy, acyl, acylamino, 15 thiocarbonylamino, acyloxy, amino, amidino, alkyl amidino,thioamidino, aminoacyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aryl, substituted aryl, aryloxy, substituted aryloxy, aryloxylaryl, substituted aryloxyaryl, cyano, halogen, hydroxyl, nitro, carboxyl, carboxylalkyl, carboxyl-substituted alkyl, carboxyl-cycloalkyl, 20 carboxyl-substituted cycloalkyl, carboxylaryl, carboxyl-substituted aryl, carboxylheteroaryl, carboxyl-substituted heteroaryl, carboxylheterocyclic, carboxyl-substituted heterocyclic, cycloalkyl, substituted cycloalkyl, guanidino, guanidinosulfone, thiol, thioalkyl, substituted thioalkyl, thioaryl, substituted thioaryl, thiocycloalkyl, substituted thiocycloalkyl, 25 thioheteroaryl, substituted thioheteroaryl, thioheterocyclic, substituted thioheterocyclic, heteroaryl, substituted aryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkoxy, substituted cycloalkoxy, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy, oxycarbonylamino, oxythiocarbonylamino, WO 99/06437 PCT/US98/16070 96

-OS(O)

2 -alkyl, -OS(O) 2 -substituted alkyl, -OS(O) 2 -aryl, -OS(O) 2 -substituted aryl, -OS(O) 2 -heteroaryl, -OS(O) 2 -substituted heteroaryl, -OS(O) 2 heterocyclic, -OS(O) 2 -substituted heterocyclic, -OSO2-NRR,

-NRS(O)

2 -alkyl, -NRS(O) 2 -substituted alkyl, -NRS(O) 2 -aryl, -NRS(O) 2 5 substituted aryl, -NRS(O) 2 -heteroaryl, -NRS(O) 2 -substituted heteroaryl,

-NRS(O)

2 -heterocyclic, -NRS(O) 2 -substituted heterocyclic, -NRS(O) 2

-NR

alkyl, -NRS(O) 2 -NR-substituted alkyl, -NRS(O) 2 -NR-aryl, -NRS(O) 2

-NR

substituted aryl, -NRS(O) 2 -NR-heteroaryl, -NRS(O) 2 -NR-substituted heteroaryl, -NRS(O) 2 -NR-heterocyclic, -NRS(O) 2 -NR-substituted 10 heterocyclic, mono- and di-alkylamino, mono- and di-(substituted alkyl)amino, mono- and di-arylamino, mono- and di-(substituted aryl)amino, mono- and di-heteroarylamino, mono- and di-(substituted heteroaryl)amino, mono- and di-heterocyclic amino, mono- and di-(substituted heterocyclic) amino, unsymmetric di-substituted amines having different substituents 15 selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic; substituted alkyl groups having amino groups blocked by conventional blocking groups (such as Boc, Cbz, formyl, and the like) and alkyl/substituted alkyl groups substituted with -SO,-alkyl, -SO2 20 substituted alkyl, -SO,-alkenyl, -SO,-substituted alkenyl, -SO,-cycloalkyl, -SO2-substituted cycloalkyl, -SO,-aryl, -SO,-substituted aryl, -SO 2 heteroaryl, -SO2-substituted heteroaryl, -SO, 2 -heterocyclic, -SO,-substituted heterocyclic or -SO 2 NRR, where R is hydrogen or alkyl. 25 "Alkoxy" refers to the group "alkyl-O-" which includes, by way of example, methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, 1,2-dimethylbutoxy, and the like. "Substituted alkoxy" refers to the group "substituted alkyl-O-". 30 WO 99/06437 PCT/US98/16070 97 "Acyl" refers to the groups H-C(O)-, alkyl-C(O)-, substituted alkyl C(O)-, alkenyl-C(O)-, substituted alkenyl-C(O)-, alkynyl-C(O)-, substituted alkynyl-C(O)- cycloalkyl-C(O)-, substituted cycloalkyl-C(O)-, aryl-C(O)-, substituted aryl-C(O)-, heteroaryl-C(O)-, substituted heteroaryl-C(O), 5 heterocyclic-C(O)-, and substituted heterocyclic-C(O)- wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic are as defined herein. 10 "Acylamino" refers to the group -C(O)NRR where each R is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, 15 substituted heteroaryl, heterocyclic, and substituted heterocyclic; and where each R can be joined to form, together with the nitrogen atom, a heterocyclic or substituted heterocyclic ring wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, 20 heterocyclic and substituted heterocyclic are as defined herein. "Thiocarbonylamino" refers to the group -C(S)NRR where each R is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, 25 aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic, and where each R can be joined to form, together with the nitrogen atom, a heterocyclic or substituted heterocyclic ring wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted WO 99/06437 PCT/US98/16070 98 cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic are as defined herein. "Acyloxy" refers to the groups alkyl-C(O)O-, substituted alkyl 5 C(O)O-, alkenyl-C(O)O-, substituted alkenyl-C(O)O-, alkynyl-C(O)O-, substituted alkynyl-C(O)O-, aryl-C(O)O-, substituted aryl-C(O)O-, cycloalkyl-C(O)O-, substituted cycloalkyl-C(O)O-, heteroaryl-C(O)O-, substituted heteroaryl-C(O)O-, heterocyclic-C(O)O-, and substituted heterocyclic-C(O)O- wherein alkyl, substituted alkyl, alkenyl, substituted 10 alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic are as defined herein. "Alkenyl" refers to alkenyl group preferably having from 2 to 10 15 carbon atoms and more preferably 2 to 6 carbon atoms and having at least 1 and preferably from 1-2 sites of alkenyl unsaturation. "Substituted alkenyl" refers to alkenyl groups having from 1 to 5 substituents selected from the group consisting of alkoxy, substituted alkoxy, 20 acyl, acylamino, thiocarbonylamino, acyloxy, amino, amidino, alkylamidino, thioamidino, aminoacyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aryl, substituted aryl, aryloxy, substituted aryloxy, aryloxyaryl, substituted aryloxyaryl, halogen, hydroxyl, cyano, nitro, carboxyl, carboxylalkyl, carboxyl-substituted alkyl, carboxyl-cycloalkyl, 25 carboxyl-substituted cycloalkyl, carboxylaryl, carboxyl-substituted aryl, carboxylheteroaryl, carboxyl-substituted heteroaryl, carboxylheterocyclic, carboxyl-substituted heterocyclic, cycloalkyl, substituted cycloalkyl, guanidino, guanidinosulfone, thiol, thioalkyl, substituted thioalkyl, thioaryl, substituted thioaryl, thiocycloalkyl, substituted thiocycloalkyl, 30 thioheteroaryl, substituted thioheteroaryl, thioheterocyclic, substituted WO 99/06437 PCT/US98/16070 99 thioheterocyclic, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkoxy, substituted cycloalkoxy, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy, oxycarbonylamino, oxythiocarbonylamino, -OS(O)2,-alkyl, -OS(O) 2 5 substituted alkyl, -OS(O) 2 -aryl, -OS(O) 2 -substituted aryl, -OS(O) 2 -heteroaryl,

-OS(O)

2 -substituted heteroaryl, -OS(O) 2 -heterocyclic, -OS(O) 2 -substituted heterocyclic, -OSO,-NRR, -NRS(O) 2 -alkyl, -NRS(O) 2 -substituted alkyl,

-NRS(O)

2 -aryl, -NRS(O) 2 -substituted aryl, -NRS(O) 2 -heteroaryl, -NRS(O)2 substituted heteroaryl, -NRS(O)2-heterocyclic, -NRS(O) 2 -substituted 10 heterocyclic, -NRS(O) 2 -NR-alkyl, -NRS(O) 2 -NR-substituted alkyl, -NRS(O)2,-NR-aryl, -NRS(O),-NR-substituted aryl, -NRS(O) 2

-NR

heteroaryl, -NRS(O) 2 -NR-substituted heteroaryl, -NRS(O),-NR-heterocyclic, -NRS(O),-NR-substituted heterocyclic; mono- and di-alkylamino, mono- and di-(substituted alkyl)amino, mono- and di-arylamino, mono- and di 15 (substituted aryl)amino, mono- and di-heteroarylamino, mono- and di (substituted heteroaryl)amino, mono- and di-heterocyclic amino, mono- and di-(substituted heterocyclic) amino, unsymmetric di-substituted amines having different substituents selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, 20 heterocyclic and substituted heterocyclic and substituted alkenyl groups having amino groups blocked by conventional blocking groups (such as Boc, Cbz, formyl, and the like) and alkenyl/substituted alkenyl groups substituted with -SO,-alkyl, -SO2-substituted alkyl, -SO,-alkenyl, -SO,-substituted alkenyl, -SO,-cycloalkyl, -SO,-substituted cycloalkyl, -SO,-aryl, -SO2 25 substituted aryl, -SO 2 -heteroaryl, -S0 2 -substituted heteroaryl, -SO 2 heterocyclic, -SO,-substituted heterocyclic or -SO 2 NRR, where R is hydrogen or alkyl.

WO 99/06437 PCT/US98/16070 100 "Alkynyl" refers to alkynyl group preferably having from 2 to 10 carbon atoms and more preferably 3 to 6 carbon atoms and having at least 1 and preferably from 1-2 sites of alkynyl unsaturation. 5 "Substituted alkynyl" refers to alkynyl groups having from 1 to 5 substituents selected from the group consisting of alkoxy, substituted alkoxy, acyl, acylamino, thiocarbonylamino, acyloxy, amino, amidino, alkylamidino, thioamidino, aminoacyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aryl, substituted aryl, aryloxy, substituted aryloxy, 10 aryloxyaryl, substituted aryloxyaryl, halogen, hydroxyl, cyano, nitro, carboxyl, carboxylalkyl, carboxyl-substituted alkyl, carboxyl-cycloalkyl, carboxyl-substituted cycloalkyl, carboxylaryl, carboxyl-substituted aryl, carboxylheteroaryl, carboxyl-substituted heteroaryl, carboxylheterocyclic, carboxyl-substituted heterocyclic, cycloalkyl, substituted cycloalkyl, 15 guanidino, guanidinosulfone, thiol, thioalkyl, substituted thioalkyl, thioaryl, substituted thioaryl, thiocycloalkyl, substituted thiocycloalkyl, thioheteroaryl, substituted thioheteroaryl, thioheterocyclic, substituted thioheterocyclic, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkoxy, substituted cycloalkoxy, heteroaryloxy, 20 substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy, oxycarbonylamino, oxythiocarbonylamino,

-OS(O)

2 -substituted heteroaryl, -OS(O) 2 -heterocyclic, -OS(O) 2 -substituted heterocyclic, -OSO, 2 -NRR, -NRS(O) 2 -alkyl, -NRS(O)2,-substituted alkyl, 25 -NRS(O),-aryl, -NRS(O) 2 -substituted aryl, -NRS(O) 2 -heteroaryl, -NRS(O) 2 substituted heteroaryl, -NRS(O) 2 -heterocyclic, -NRS(O) 2 -substituted heterocyclic, -NRS(O) 2 -NR-alkyl, -NRS(O) 2 -NR-substituted alkyl, -NRS(O),-NR-aryl, -NRS(O) 2 -NR-substituted aryl, -NRS(O) 2

-NR

heteroaryl, -NRS(O) 2 -NR-substituted heteroaryl, -NRS(O) 2 -NR-heterocyclic, 30 -NRS(O),-NR-substituted heterocyclic, mono- and di-alkylamino, mono- and WO 99/06437 PCT/US98/16070 101 di-(substituted alkyl)amino, mono- and di-arylamino, mono- and di (substituted aryl)amino, mono- and di-heteroarylamino, mono- and di (substituted heteroaryl)amino, mono- and di-heterocyclic amino, mono- and di-(substituted heterocyclic) amino, unsymmetric di-substituted amines 5 having different substituents selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic; substituted alkynyl groups having amino groups blocked by conventional blocking groups (such as Boc, Cbz, formyl, and the like), and alkynyl/substituted alkynyl groups substituted with 10 -SO2-alkyl, -SO2-substituted alkyl, -SO 2 -alkenyl, -SO,-substituted alkenyl, -SO2-cycloalkyl, -SO,-substituted cycloalkyl, -SO 2 -aryl, -SO2-substituted aryl, -SO 2 -heteroaryl, -SO2-substituted heteroaryl, -SO,-heterocyclic, -SO,2 substituted heterocyclic or -SO2NRR, where R is hydrogen or alkyl. 15 "Amidino" refers to the group H 2 NC- and the term "alkylamidino" 11 NH refers to compounds having 1 to 3 alkyl groups (e.g., alkylHNC-). 20 NH "Thioamidino" refers to the group RSC- where R is hydrogen or 11 25 NH alkyl. "Aminoacyl" refers to the groups -NRC(0)alkyl, -NRC(O)substituted alkyl, -NRC(0)cycloalkyl, -NRC(0)substituted 30 cycloalkyl, -NRC(0)alkenyl, -NRC(0)substituted alkenyl, -NRC(0)alkynyl, -NRC(0)substituted alkynyl, -NRC(O)aryl, -NRC(0)substituted aryl, -NRC(O)heteroaryl, -NRC(0)substituted heteroaryl, -NRC(O)heterocyclic, and -NRC(0)substituted heterocyclic, WO 99/06437 PCT/US98/16070 102 where R is hydrogen or alkyl and wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic are as defined herein. 5 "Aminocarbonyloxy" refers to the groups -NRC(O)O-alkyl, -NRC(O)O-substituted alkyl, -NRC(O)O-alkenyl, -NRC(O)O-substituted alkenyl, -NRC(O)O-alkynyl, -NRC(O)O-substituted alkynyl, -NRC(O)O cycloalkyl, -NRC(O)O-substituted cycloalkyl, -NRC(O)O-aryl, -NRC(O)O 10 substituted aryl, -NRC(O)O-heteroaryl, -NRC(O)O-substituted heteroaryl, -NRC(O)O-heterocyclic, and -NRC(O)O-substituted heterocyclic where R is hydrogen or alkyl and wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and 15 substituted heterocyclic are as defined herein. "Oxycarbonylamino" refers to the groups -OC(O)NRR, -OC(O)NR-alkyl, -OC(O)NR-substituted alkyl, -OC(O)NR-alkenyl, -OC(O)NR-substituted alkenyl, -OC(O)NR-alkynyl, -OC(O)NR-substituted 20 alkynyl, -OC(O)NR-cycloalkyl, -OC(O)NR-substituted cycloalkyl, -OC(O)NR-aryl, -OC(O)NR-substituted aryl, -OC(O)NR-heteroaryl, -OC(O)NR-substituted heteroaryl,- OC(O)NR-heterocyclic, and -OC(O)NR-substituted heterocyclic where R is hydrogen or alkyl, and where each R can be joined to form, together with the nitrogen atom, a heterocyclic 25 or substituted heterocyclic ring and wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic are as defined herein. 30 "Oxythiocarbonylamino" refers to the groups -OC(S)NRR, WO 99/06437 PCT/US98/16070 103 -OC(S)NR-alkyl, -OC(S)NR-substituted alkyl, -OC(S)NR-alkenyl, -OC(S)NR-substituted alkenyl, -OC(S)NR-alkynyl, -OC(S)NR-substituted alkynyl, -OC(S)NR-cycloalkyl, -OC(S)NR-substituted cycloalkyl, -OC(S)NR-aryl, -OC(S)NR-substituted aryl, -OC(S)NR-heteroaryl, 5 -OC(S)NR-substituted heteroaryl, -OC(S)NR-heterocyclic, and -OC(S)NR substituted heterocyclic where R is hydrogen or alkyl, or where each R can be joined to form, together with the nitrogen atom, a heterocyclic or substituted heterocyclic ring and wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted 10 cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic are as defined herein. "Aminocarbonylamino" refers to the groups -NRC(O)NRR, -NRC(O)NR-alkyl, -NRC(O)NR-substituted alkyl, -NRC(O)NR-alkenyl, 15 -NRC(O)NR-substituted alkenyl, -NRC(O)NR-alkynyl, -NRC(O)NR substituted alkynyl, -NRC(O)NR-aryl, -NRC(O)NR-substituted aryl, -NRC(O)NR-cycloalkyl, -NRC(O)NR-substituted cycloalkyl, -NRC(O)NR heteroaryl, -NRC(O)NR-substituted heteroaryl, -NRC(O)NR-heterocyclic, and -NRC(O)NR-substituted heterocyclic where each R is independently 20 hydrogen, alkyl, and where each R can be joined to form, together with the nitrogen atom, a heterocyclic or substituted heterocyclic ring as well as where one of the amino groups is blocked by conventional blocking groups (such as Boc, Cbz, formyl, and the like) and wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, 25 substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic are as defined herein. "Aminothiocarbonylamino" refers to the groups -NRC(S)NRR, -NRC(S)NR-alkyl, -NRC(S)NR-substituted alkyl, -NRC(S)NR-alkenyl, WO 99/06437 PCT/US98/16070 104 -NRC(S)NR-substituted alkenyl, -NRC(S)NR-alkynyl, -NRC(S)NR substituted alkynyl, -NRC(S)NR-aryl, -NRC(S)NR-substituted aryl, -NRC(S)NR-cycloalkyl, -NRC(S)NR-substituted cycloalkyl, -NRC(S)NR heteroaryl, and -NRC(S)NR-substituted heteroaryl, -NRC(S)NR 5 heterocyclic, and -NRC(S)NR-substituted heterocyclic where each R is independently hydrogen, alkyl, and where each R can be joined to form, together with the nitrogen atom, a heterocyclic or substituted heterocyclic ring as well as where one of the amino groups is blocked by conventional blocking groups (such as Boc, Cbz, formyl, and the like) and wherein alkyl, 10 substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic are as defined herein. 15 "Aryl" or "Ar" refers to an unsaturated aromatic carbocyclic group of from 6 to 14 carbon atoms having a single ring (e.g., phenyl) or multiple condensed rings (e.g., naphthyl or anthryl) which condensed rings may or may not be aromatic (e.g., 2-benzoxazolinone, 2H-1,4-benzoxazin-3(4H) one-7-yl, and the like). Preferred aryls include phenyl and naphthyl. 20 Substituted aryl refers to aryl groups which are substituted with from 1 to 3 substituents selected from the group consisting of hydroxy, acyl, acylamino, thiocarbonylamino, acyloxy, alkyl, substituted alkyl, alkoxy, substituted alkoxy, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, 25 amidino, alkylamidino, thioamidino, amino, aminoacyl, aminocarbonyloxy, aminocarbonylamino, aminothiocarbonylamino, aryl, substituted aryl, aryloxy, substituted aryloxy, cycloalkoxy, substituted cycloalkoxy, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy, carboxyl, carboxylalkyl, carboxyl-substituted alkyl, 30 carboxyl-cycloalkyl, carboxyl-substituted cycloalkyl, carboxylaryl, carboxyl- WO 99/06437 PCT/US98/16070 105 substituted aryl, carboxylheteroaryl, carboxyl-substituted heteroaryl, carboxylheterocyclic, carboxyl-substituted heterocyclic, carboxylamido, cyano, thiol, thioalkyl, substituted thioalkyl, thioaryl, substituted thioaryl, thioheteroaryl, substituted thioheteroaryl, thiocycloalkyl, substituted 5 thiocycloalkyl, thioheterocyclic, substituted thioheterocyclic, cycloalkyl, substituted cycloalkyl, guanidino, guanidinosulfone, halo, nitro, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkoxy, substituted cycloalkoxy, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy, oxycarbonylamino, 10 oxythiocarbonylamino, -S(O) 2 -alkyl, -S(O) 2 -substituted alkyl, -S(O) 2 cycloalkyl, -S(O) 2 -substituted cycloalkyl, -S(O) 2 -alkenyl, -S(O) 2 -substituted alkenyl, -S(O) 2 -aryl, -S(O) 2 -substituted aryl, -S(O) 2 -heteroaryl, -S(O) 2 substituted heteroaryl, -S(O) 2 -heterocyclic, -S(O) 2 -substituted heterocyclic,

-OS(O)

2 -alkyl, -OS(O) 2 -substituted alkyl, -OS(O) 2 -aryl, -OS(O) 2 -substituted 15 aryl, -OS(O) 2 -heteroaryl, -OS(O) 2 -substituted heteroaryl, -OS(O) 2 heterocyclic, -OS(O) 2 -substituted heterocyclic, -OSO,-NRR, -NRS(O) 2 alkyl, -NRS(O)2-substituted alkyl, -NRS(O) 2 -aryl, -NRS(O),-substituted aryl,

-NRS(O)

2 -heteroaryl, -NRS(O) 2 -substituted heteroaryl, -NRS(O) 2 heterocyclic, -NRS(O) 2 -substituted heterocyclic, -NRS(O) 2 -NR-alkyl, 20 -NRS(O) 2 -NR-substituted alkyl, -NRS(O) 2 -NR-aryl, -NRS(O) 2

-NR

substituted aryl, -NRS(O) 2 -NR-heteroaryl, -NRS(O)2-NR-substituted heteroaryl, -NRS(O) 2 -NR-heterocyclic, -NRS(O) 2 -NR-substituted heterocyclic, mono- and di-alkylamino, mono- and di-(substituted alkyl)amino, mono- and di-arylamino, mono- and di-(substituted aryl)amino, 25 mono- and di-heteroarylamino, mono- and di-(substituted heteroaryl)amino, mono- and di-heterocyclic amino, mono- and di-(substituted heterocyclic) amino, unsymmetric di-substituted amines having different substituents selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted 30 heterocyclic, amino groups on the substituted aryl blocked by conventional WO 99/06437 PCT/US98/16070 106 blocking groups (such as Boc, Cbz, formyl, and the like), and -SO 2 NRR, where R is hydrogen or alkyl. "Aryloxy" refers to the group aryl-O- which includes, by way of 5 example, phenoxy, naphthoxy, and the like. "Substituted aryloxy" refers to substituted aryl-O- groups. "Aryloxyaryl" refers to the group -aryl-O-aryl. 10 "Substituted aryloxyaryl" refers to aryloxyaryl groups substituted with from 1 to 3 substituents on either or both aryl rings selected from the group consisting of hydroxy, acyl, acylamino, thiocarbonylamino, acyloxy, alkyl, substituted alkyl, alkoxy, substituted alkoxy, alkenyl, substituted 15 alkenyl, alkynyl, substituted alkynyl, amidino, alkylamidino, thioamidino, amino, aminoacyl, aminocarbonyloxy, aminocarbonylamino, aminothiocarbonylamino, aryl, substituted aryl, aryloxy, substituted aryloxy, cycloalkoxy, substituted cycloalkoxy, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy, carboxyl, 20 carboxylalkyl, carboxyl-substituted alkyl, carboxyl-cycloalkyl, carboxyl substituted cycloalkyl, carboxylaryl, carboxyl-substituted aryl, carboxylheteroaryl, carboxyl-substituted heteroaryl, carboxylheterocyclic, carboxyl-substituted heterocyclic, carboxylamido, cyano, thiol, thioalkyl, substituted thioalkyl, thioaryl, substituted thioaryl, thioheteroaryl, substituted 25 thioheteroaryl, thiocycloalkyl, substituted thiocycloalkyl, thioheterocyclic, substituted thioheterocyclic, cycloalkyl, substituted cycloalkyl, guanidino, guanidinosulfone, halo, nitro, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkoxy, substituted cycloalkoxy, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, substituted 30 heterocyclyloxy, oxycarbonylamino, oxythiocarbonylamino, WO 99/06437 PCT/US98/16070 107

-S(O)

2 -alkyl, -S(O) 2 -substituted alkyl, -S(O) 2 -cycloalkyl, -S(O) 2 -substituted cycloalkyl, -S(O) 2 -alkenyl, -S(O) 2 -substituted alkenyl, -S(O) 2 -aryl, -S(O) 2 substituted aryl, -S(O) 2 -heteroaryl, -S(O) 2 -substituted heteroaryl, -S(O) 2 heterocyclic, -S(O) 2 -substituted heterocyclic, -OS(O) 2 -alkyl, -OS(O) 2 5 substituted alkyl, -OS(O) 2 -aryl, -OS(O) 2 -substituted aryl, -OS(O) 2 -heteroaryl,

-OS(O)

-NRS(O)

2 -aryl, -NRS(O) 2 -substituted aryl, -NRS(O) 2 -heteroaryl, -NRS(O) 2 substituted heteroaryl, -NRS(O) 2 -heterocyclic, -NRS(O) 2 -substituted 10 heterocyclic, -NRS(O) 2 -NR-alkyl, -NRS(O) 2 -NR-substituted alkyl,

-NRS(O)

2 -NR-aryl, -NRS(O),-NR-substituted aryl, -NRS(O) 2

-NR

heteroaryl, -NRS(O) 2 -NR-substituted heteroaryl, -NRS(O) 2 -NR-heterocyclic,

-NRS(O)

2 -NR-substituted heterocyclic, mono- and di-alkylamino, mono- and di-(substituted alkyl)amino, mono- and di-arylamino, mono- and di 15 (substituted aryl)amino, mono- and di-heteroarylamino, mono- and di (substituted heteroaryl)amino, mono- and di-heterocyclic amino, mono- and di-(substituted heterocyclic) amino, unsymmetric di-substituted amines having different substituents selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, 20 heterocyclic and substituted heterocyclic, amino groups on the substituted aryl blocked by conventional blocking groups (such as Boc, Cbz, formyl, and the like) and substituted with -SONRR, where R is hydrogen or alkyl. "Cycloalkyl" refers to cyclic alkyl groups of from 3 to 8 carbon atoms 25 having a single cyclic ring including, by way of example, cyclopropyl, cyclobutyl, cyclopentyl, cyclooctyl and the like. Excluded from this definition are multi-ring alkyl groups such as adamantanyl, etc. "Cycloalkenyl" refers to cyclic alkenyl groups of from 3 to 8 carbon 30 atoms having single or multiple unsaturation but which are not aromatic.

WO 99/06437 PCT/US98/16070 108 "Substituted cycloalkyl" and "substituted cycloalkenyl" refer to a cycloalkyl and cycloalkenyl groups, preferably of from 3 to 8 carbon atoms, having from 1 to 5 substituents selected from the group consisting of oxo (=O), thioxo (=S), alkoxy, substituted alkoxy, acyl, acylamino, 5 thiocarbonylamino, acyloxy, amino, amidino, alkylamidino, thioamidino, aminoacyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aryl, substituted aryl, aryloxy, substituted aryloxy, aryloxyaryl, substituted aryloxyaryl, halogen, hydroxyl, cyano, nitro, carboxyl, carboxylalkyl, carboxyl-substituted alkyl, carboxyl-cycloalkyl, 10 carboxyl-substituted cycloalkyl, carboxylaryl, carboxyl-substituted aryl, carboxylheteroaryl, carboxyl-substituted heteroaryl, carboxylheterocyclic, carboxyl-substituted heterocyclic, cycloalkyl, substituted cycloalkyl, guanidino, guanidinosulfone, thiol, thioalkyl, substituted thioalkyl, thioaryl, substituted thioaryl, thiocycloalkyl, substituted thiocycloalkyl, 15 thioheteroaryl, substituted thioheteroaryl, thioheterocyclic, substituted thioheterocyclic, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkoxy, substituted cycloalkoxy, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy, oxycarbonylamino, oxythiocarbonylamino, -OS(0),-alkyl, -OS(0) 2 20 substituted alkyl, -OS(0) 2 -aryl, -OS(0) 2 -substituted aryl, -OS(0) 2 -heteroaryl, -OS(0) 2 -substituted heteroaryl, -OS(0) 2 -heterocyclic, -OS(0) 2 -substituted heterocyclic, -OSO 2 -NRR, -NRS(0),-alkyl, -NRS(0),-substituted alkyl, -NRS(0)2-aryl, -NRS(0) 2 -substituted aryl, -NRS(O),-heteroaryl, -NRS(0) 2 substituted heteroaryl, -NRS(0)2-heterocyclic, -NRS(O) 2 -substituted 25 heterocyclic, -NRS(0),-NR-alkyl, -NRS(O),-NR-substituted alkyl, -NRS(0),-NR-aryl, -NRS(0) 2 -NR-substituted aryl, -NRS(0) 2

-NR

heteroaryl, -NRS(0) 2 -NR-substituted heteroaryl, -NRS(0) 2 -NR-heterocyclic, -NRS(0),-NR-substituted heterocyclic, mono- and di-alkylamino, mono- and di-(substituted alkyl)amino, mono- and di-arylamino, mono- and di 30 (substituted aryl)amino, mono- and di-heteroarylamino, mono- and di- WO 99/06437 PCT/US98/16070 109 (substituted heteroaryl)amino, mono- and di-heterocyclic amino, mono- and di-(substituted heterocyclic) amino, unsymmetric di-substituted amines having different substituents selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, 5 heterocyclic and substituted heterocyclic, substituted alkynyl groups having amino groups blocked by conventional blocking groups (such as Boc, Cbz, formyl, and the like) and alkynyl/substituted alkynyl groups substituted with

-SO

2 -alkyl, -SO2-substituted alkyl, -SO 2 -alkenyl, -SO0-substituted alkenyl, SO 2 -cycloalkyl, -SO 2 -substituted cycloalkyl, -SO 2 -aryl, -SO 2 -substituted aryl, 10 -SO 2 -heteroaryl, -S0 2 -substituted heteroaryl, -SO 2 -heterocyclic, -SO2 substituted heterocyclic or -SO 2 NRR, where R is hydrogen or alkyl. "Cycloalkoxy" refers to -O-cycloalkyl groups. 15 "Substituted cycloalkoxy" refers to -O-substituted cycloalkyl groups. "Guanidino" refers to the groups -NRC(=NR)NRR, -NRC(=NR)NR-alkyl, -NRC(=NR)NR-substituted alkyl, -NRC(=NR)NR-alkenyl, -NRC(=NR)NR-substituted alkenyl, 20 -NRC(=NR)NR-alkynyl, -NRC(=NR)NR-substituted alkynyl, -NRC(=NR)NR-aryl, -NRC(=NR)NR-substituted aryl, -NRC(=NR)NR cycloalkyl, -NRC(=NR)NR-substituted cycloalkyl,-NRC(=NR)NR heteroaryl, -NRC(=NR)NR-substituted heteroaryl, -NRC(=NR)NR heterocyclic, and -NRC(=NR)NR-substituted heterocyclic where each R is 25 independently hydrogen and alkyl as well as where one of the amino groups is blocked by conventional blocking groups (such as Boc, Cbz, formyl, and the like) and wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and 30 substituted heterocyclic are as defined herein.

WO 99/06437 PCT/US98/16070 110 "Guanidinosulfone" refers to the groups -NRC(=NR)NRSO 2 -alkyl,

-NRC(=NR)NRSO

2 -substituted alkyl, -NRC(=NR)NRSO 2 -alkenyl,

-NRC(=NR)NRSO

2 -substituted alkenyl, -NRC(=NR)NRSO,-alkynyl,

-NRC(=NR)NRSO

2 -substituted alkynyl, -NRC(=NR)NRSO 2 -aryl, 5 -NRC(=NR)NRSO 2 -substituted aryl, -NRC(=NR)NRSO,-cycloalkyl,

-NRC(=NR)NRSO

2 -substituted cycloalkyl, -NRC(=NR)NRSO 2 -heteroaryl, and -NRC(=NR)NRSO 2 -substituted heteroaryl, -NRC(=NR)NRSO 2 heterocyclic, and -NRC(=NR)NRSO 2 -substituted heterocyclic where each R is independently hydrogen or alkyl and wherein alkyl, substituted alkyl, 10 alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic are as defined herein. "Halo" or "halogen" refers to fluoro, chloro, bromo and iodo and 15 preferably is either chloro or bromo. "Heteroaryl" refers to an aromatic carbocyclic group of from 2 to 10 carbon atoms and 1 to 4 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur within the ring. Such heteroaryl groups can have 20 a single ring (e.g., pyridyl or furyl) or multiple condensed rings (e.g., indolizinyl or benzothienyl). Preferred heteroaryls include pyridyl, pyrrolyl, indolyl and furyl. "Substituted heteroaryl" refers to heteroaryl groups which are 25 substituted with from 1 to 3 substituents selected from the group consisting of hydroxy, acyl, acylamino, thiocarbonylamino, acyloxy, alkyl, substituted alkyl, alkoxy, substituted alkoxy, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amidino, alkylamidino, thioamidino, amino, aminoacyl, aminocarbonyloxy, aminocarbonylamino, aminothiocarbonylamino, aryl, 30 substituted aryl, aryloxy, substituted aryloxy, cycloalkoxy, substituted WO 99/06437 PCT/US98/16070 111 cycloalkoxy, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy, carboxyl, carboxylalkyl, carboxyl-substituted alkyl, carboxyl-cycloalkyl, carboxyl-substituted cycloalkyl, carboxylaryl, carboxyl-substituted aryl, carboxylheteroaryl, carboxyl-substituted 5 heteroaryl, carboxylheterocyclic, carboxyl-substituted heterocyclic, carboxylamido, cyano, thiol, thioalkyl, substituted thioalkyl, thioaryl, substituted thioaryl, thioheteroaryl, substituted thioheteroaryl, thiocycloalkyl, substituted thiocycloalkyl, thioheterocyclic, substituted thioheterocyclic, cycloalkyl, substituted cycloalkyl, guanidino, guanidinosulfone, halo, nitro, 10 heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkoxy, substituted cycloalkoxy, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy, oxycarbonylamino, oxythiocarbonylamino, -S(O) 2 -alkyl, -S(O) 2 -substituted alkyl, -S(O) 2 -cycloalkyl, -S(O) 2 -substituted cycloalkyl, -S(O),-alkenyl, 15 -S(O)2-substituted alkenyl, -S(O) 2 -aryl, -S(O) 2 -substituted aryl, -S(O) 2 heteroaryl, -S(O) 2 -substituted heteroaryl, -S(O) 2 -heterocyclic, -S(O) 2 substituted heterocyclic, -OS(O) 2 -alkyl, -OS(O) 2 -substituted alkyl, -OS(O) 2 aryl, -OS(O) 2 -substituted aryl, -OS(O) 2 -heteroaryl, -OS(O) 2 -substituted heteroaryl, -OS(O)2-heterocyclic,

-OS(O)

2 -substituted heterocyclic, -OSO 2 20 NRR, -NRS(O),-alkyl, -NRS(O) 2 -substituted alkyl, -NRS(O) 2 -aryl, -NRS(O)2,-substituted aryl, -NRS(O),-heteroaryl, -NRS(O) 2 -substituted heteroaryl, -NRS(O) 2 -heterocyclic, -NRS(O) 2 -substituted heterocyclic, -NRS(O),-NR-alkyl, -NRS(O) 2 -NR-substituted alkyl, -NRS(O) 2 -NR-aryl, -NRS(O),-NR-substituted aryl, -NRS(O) 2 -NR-heteroaryl, -NRS(O)2,-NR 25 substituted heteroaryl, -NRS(O) 2 -NR-heterocyclic, -NRS(O) 2 -NR-substituted heterocyclic, mono- and di-alkylamino, mono- and di-(substituted alkyl)amino, mono- and di-arylamino, mono- and di-(substituted aryl)amino, mono- and di-heteroarylamino, mono- and di-(substituted heteroaryl)amino, mono- and di-heterocyclic amino, mono- and di-(substituted heterocyclic) 30 amino, unsymmetric di-substituted amines having different substituents WO 99/06437 PCT/US98/16070 112 selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic, amino groups on the substituted aryl blocked by conventional blocking groups (such as Boc, Cbz, formyl, and the like), and 5 -SO 2 NRR, where R is hydrogen or alkyl. "Heteroaryloxy" refers to the group -O-heteroaryl and "substituted heteroaryloxy" refers to the group -O-substituted heteroaryl. 10 "Heterocycle" or "heterocyclic" refers to a saturated or unsaturated group having a single ring or multiple condensed rings, from 1 to 10 carbon atoms and from 1 to 4 hetero atoms selected from the group consisting of nitrogen, sulfur or oxygen within the ring wherein, in fused ring systems, one or more the rings can be aryl or heteroaryl. 15 "Saturated heterocyclic" refers to heterocycles of single or multiple condensed rings lacking unsaturation in any ring (e.g., carbon to carbon unsaturation, carbon to nitrogen unsaturation, nitrogen to nitrogen unsaturation, and the like). 20 "Unsaturated heterocyclic" refers to non-aromatic heterocycles of single or multiple condensed rings having unsaturation in any ring (e.g., carbon to carbon unsaturation, carbon to nitrogen unsaturation, nitrogen to nitrogen unsaturation, and the like). 25 "Substituted heterocyclic" refers to heterocycle groups which are substituted with from 1 to 3 substituents selected from the group consisting of oxo (=0), thioxo (=S), alkoxy, substituted alkoxy, acyl, acylamino, thiocarbonylamino, acyloxy, amino, amidino, alkylamidino, thioamidino, 30 aminoacyl, aminocarbonylamino, aminothiocarbonylamino, WO 99/06437 PCT/US98/16070 113 aminocarbonyloxy, aryl, substituted aryl, aryloxy, substituted aryloxy, aryloxyaryl, substituted aryloxyaryl, halogen, hydroxyl, cyano, nitro, carboxyl, carboxylalkyl, carboxyl-substituted alkyl, carboxyl-cycloalkyl, carboxyl-substituted cycloalkyl, carboxylaryl, carboxyl-substituted aryl, 5 carboxylheteroaryl, carboxyl-substituted heteroaryl, carboxylheterocyclic, carboxyl-substituted heterocyclic, cycloalkyl, substituted cycloalkyl, guanidino, guanidinosulfone, thiol, thioalkyl, substituted thioalkyl, thioaryl, substituted thioaryl, thiocycloalkyl, substituted thiocycloalkyl, thioheteroaryl, substituted thioheteroaryl, thioheterocyclic, substituted 10 thioheterocyclic, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkoxy, substituted cycloalkoxy, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy, oxycarbonylamino, oxythiocarbonylamino,

-OS(O)

2 -alkyl, -OS(O) 2 substituted alkyl, -OS(O) 2 -aryl, -OS(O) 2 -substituted aryl, -OS(O) 2 -heteroaryl, 15 -OS(O) 2 -substituted heteroaryl, -OS(O) 2 -heterocyclic, -OS(O) 2 -substituted heterocyclic, -OSO,-NRR, -NRS(O) 2 -alkyl, -NRS(O) 2 -substituted alkyl,

-NRS(O)

2 -aryl, -NRS(O) 2 -substituted aryl, -NRS(O) 2 -heteroaryl, -NRS(O) 2 substituted heteroaryl, -NRS(O) 2 -heterocyclic, -NRS(O) 2 -substituted heterocyclic, -NRS(O) 2 -NR-alkyl, -NRS(O) 2 -NR-substituted alkyl, 20 -NRS(O) 2 -NR-aryl, -NRS(O) 2 -NR-substituted aryl, -NRS(O),-NR heteroaryl, -NRS(O) 2 -NR-substituted heteroaryl, -NRS(O) 2 -NR-heterocyclic,

-NRS(O)

2 -NR-substituted heterocyclic, mono- and di-alkylamino, mono- and di-(substituted alkyl)amino, mono- and di-arylamino, mono- and di (substituted aryl)amino, mono- and di-heteroarylamino, mono- and di 25 (substituted heteroaryl)amino, mono- and di-heterocyclic amino, mono- and di-(substituted heterocyclic) amino, unsymmetric di-substituted amines having different substituents selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic, substituted alkynyl groups having 30 amino groups blocked by conventional blocking groups (such as Boc, Cbz, WO 99/06437 PCT/US98/16070 114 formyl, and the like) and alkynyl/substituted alkynyl groups substituted with

-SO

2 -alkyl, -SO 2 -substituted alkyl, -SO 2 -alkenyl, -SO2-substituted alkenyl,

-SO

2 -cycloalkyl, -SO 2 -substituted cycloalkyl, -SO 2 -aryl, -SO 2 -substituted aryl, -SO 2 -heteroaryl, -SO2-substituted heteroaryl, -SO 2 -heterocyclic, -SO 2 5 substituted heterocyclic or -SO 2 NRR, where R is hydrogen or alkyl. Examples of heterocycles and heteroaryls include, but are not limited to, azetidine, pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole, indole, dihydroindole, indazole, purine, 10 quinolizine, isoquinoline, quinoline, phthalazine, naphthylpyridine, quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carboline, phenanthridine, acridine, phenanthroline, isothiazole, phenazine, isoxazole, phenoxazine, phenothiazine, imidazolidine, imidazoline, piperidine, piperazine, indoline, phthalimide, 1,2,3,4-tetrahydroisoquinoline, 4,5,6,7 15 tetrahydrobenzo[b]thiophene, thiazole, thiazolidine, thiophene, benzo[b]thiophene, morpholino, thiomorpholino, piperidinyl, pyrrolidine, tetrahydrofuranyl, and the like. "Saturated substituted heterocyclic" refers to substituted heterocycles 20 of single or multiple condensed rings lacking unsaturation in any ring (e.g., carbon to carbon unsaturation, carbon to nitrogen unsaturation, nitrogen to nitrogen unsaturation, and the like). "Unsaturated substituted heterocyclic" refers to non-aromatic 25 substituted heterocycles of single or multiple condensed rings having unsaturation in any ring (e.g., carbon to carbon unsaturation, carbon to nitrogen unsaturation, nitrogen to nitrogen unsaturation, and the like). "Heterocyclyloxy" refers to the group -O-heterocyclic and 30 "substituted heterocyclyloxy" refers to the group -O-substituted heterocyclic.

WO 99/06437 PCT/US98/16070 115 "Thiol" refers to the group -SH. "Thioalkyl" refers to the groups -S-alkyl. 5 "Substituted thioalkyl" refers to the group -S-substituted alkyl. "Thiocycloalkyl" refers to the groups -S-cycloalkyl. "Substituted thiocycloalkyl" refers to the group -S-substituted 10 cycloalkyl. "Thioaryl" refers to the group -S-aryl and "substituted thioaryl" refers to the group -S-substituted aryl. 15 "Thioheteroaryl" refers to the group -S-heteroaryl and "substituted thioheteroaryl" refers to the group -S-substituted heteroaryl. "Thioheterocyclic" refers to the group -S-heterocyclic and "substituted thioheterocyclic" refers to the group -S-substituted heterocyclic. 20 "Pharmaceutically acceptable salt" refers to pharmaceutically acceptable salts of a compound of Formula I or Formula IA, which salts are derived from a variety of organic and inorganic counter ions well known in the art and include, by way of example only, sodium, potassium, calcium, 25 magnesium, ammonium, tetraalkylammonium, and the like; and when the compound (of Formula I or IA) contains a basic functionality, salts of organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate and the like. 30 WO 99/06437 PCT/US98/16070 116 Compound Preparation The compounds of this invention can be prepared from readily available starting materials using the following general methods and procedures. It will be appreciated that where typical or preferred process 5 conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures. 10 Additionally, as will be apparent to those skilled in the art, conventional protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions. Suitable protecting groups for various functional groups as well as suitable conditions for 15 protecting and deprotecting particular functional groups are well known in the art. For example, numerous protecting groups are described in T. W. Greene and G. M. Wuts, Protecting Groups in Organic Synthesis, Second Edition, Wiley, New York, 1991, and references cited therein. 20 Furthermore, the compounds of this invention will typically contain one or more chiral centers. Accordingly, if desired, such compounds can be prepared or isolated as pure stereoisomers, i.e., as individual enantiomers or diastereomers, or as stereoisomer-enriched mixtures. All such stereoisomers (and enriched mixtures) are included within the scope of this invention, 25 unless otherwise indicated. Pure stereoisomers (or enriched mixtures) may be prepared using, for example, optically active starting materials or stereoselective reagents well-known in the art. Alternatively, racemic mixtures of such compounds can be separated using, for example, chiral column chromatography, chiral resolving agents and the like. 30 WO 99/06437 PCT/US98/16070 117 In a preferred method of synthesis, the compounds of formula I and IA wherein Q is -C(O)NR 7 - are prepared by first coupling an amino acid of formula II: 5

R

3

R

2 -NH-C-COOH II I H 10 wherein R 2 and R 3 are as defined above, with a sulfonyl chloride of formula III: R'-SO2-Cl III 15 wherein R' is as defined above, to provide an N-sulfonyl amino acid of formula IV:

R

3 20

R

1

-SO

2

-N(R

2 )-C-COOH IV I H 25 wherein R 1

-R

3 are as defined above. This reaction is typically conducted by contacting the amino acid of formula II with at least one equivalent, preferably about 1.1 to about 2 equivalents, of sulfonyl chloride III in an inert diluent such as 30 dichloromethane and the like. Generally, the reaction is conducted at a temperature ranging from about -70'C to about 40 0 C for about 1 to about 24 hours. Preferably, this reaction is conducted in the presence of a suitable WO 99/06437 PCT/US98/16070 118 base to scavenge the acid generated during the reaction. Suitable bases include, by way of example, tertiary amines, such as triethylamine, diisopropylethylamine, N-methylmorpholine and the like. Alternatively, the reaction can be conducted under Schotten-Baumann-type conditions using 5 aqueous alkali, such as sodium hydroxide and the like, as the base. Upon completion of the reaction, the resulting N-sulfonyl amino acid IV is recovered by conventional methods including neutralization, extraction, precipitation, chromatography, filtration, and the like. 10 The amino acids of formula II employed in the above reaction are either known compounds or compounds that can be prepared from known compounds by conventional synthetic procedures. Examples of suitable amino acids for use in this reaction include, but are not limited to, L-proline, trans-4-hydroxyl-L-proline, cis-4-hydroxyl-L-proline, trans-3-phenyl-L 15 proline, cis-3-phenyl-L-proline, L-(2-methyl)proline, L-pipecolinic acid, L azetidine-2-carboxylic acid,glycine, 2-tert-butylglycine, D,L-phenylglycine, L-alanine, a-methylalanine, N-methyl-L-phenylalanine, L-diphenylalanine, sarcosine, D,L-phenylsarcosine, L-aspartic acid P-tert-butyl ester, L-glutamic acid y-tert-butyl ester, L-(O-benzyl)serine, 1-aminocyclopropanecarboxylic 20 acid, 1-aminocyclobutanecarboxylic acid, 1 -aminocyclopentanecarboxylic acid (cycloleucine) 1-aminocyclo-hexanecarboxylic acid, L-serine and the like. If desired, the corresponding carboxylic acid esters of the amino acids of formula II, such as the methyl esters, ethyl esters and the like, can be employed in the above reaction with the sulfonyl chloride III. Subsequent 25 hydrolysis of the ester group to the carboxylic acid using conventional reagents and conditions, i.e., treatment with an alkali metal hydroxide in an inert diluent such as methanol/water, then provides the N-sulfonyl amino acid IV.

WO 99/06437 PCT/US98/16070 119 Similarly, the sulfonyl chlorides of formula III employed in the above reaction are either known compounds or compounds that can be prepared from known compounds by conventional synthetic procedures. Such compounds are typically prepared from the corresponding sulfonic acid, i.e., 5 from compounds of the formula R'-SO 3 H where R' is as defined above, using phosphorous trichloride and phosphorous pentachloride. This reaction is generally conducted by contacting the sulfonic acid with about 2 to 5 molar equivalents of phosphorous trichloride and phosphorous pentachloride, either neat or in an inert solvent, such as dichloromethane, at temperature in 10 the range of about 0OC to about 80 0 C for about 1 to about 48 hours to afford the sulfonyl chloride. Alternatively, the sulfonyl chlorides of formula III can be prepared from the corresponding thiol compound, i.e., from compounds of the formula R'-SH where R' is as defined above, by treating the thiol with chlorine (Cl 2 ) and water under conventional reaction conditions. 15 Examples of sulfonyl chlorides suitable for use in this invention include, but are not limited to, methanesulfonyl chloride, 2-propanesulfonyl chloride, 1-butanesulfonyl chloride, benzenesulfonyl chloride, 1-naphthalenesulfonyl chloride, 2-naphthalenesulfonyl chloride, 20 p-toluenesulfonyl chloride, x-toluenesulfonyl chloride, 4-acetamidobenzenesulfonyl chloride, 4-amidinobenzenesulfonyl chloride, 4-tert-butylbenzenesulfonyl chloride, 4-bromobenzenesulfonyl chloride, 2-carboxybenzenesulfonyl chloride, 4-cyanobenzenesulfonyl chloride, 3,4 dichlorobenzenesulfonyl chloride, 3,5-dichlorobenzenesulfonyl chloride, 3,4 25 dimethoxybenzenesulfonyl chloride, 3,5-ditrifluoromethylbenzenesulfonyl chloride, 4-fluorobenzenesulfonyl chloride, 4-methoxybenzenesulfonyl chloride, 2-methoxycarbonylbenzenesulfonyl chloride, 4-methylamidobenzenesulfonyl chloride, 4-nitrobenzenesulfonyl chloride, 4-thioamidobenzenesulfonyl chloride, 4-trifluoromethylbenzenesulfonyl 30 chloride, 4 -trifluoromethoxybenzenesulfonyl chloride, 2,4,6- WO 99/06437 PCT/US98/16070 120 trimethylbenzenesulfonyl chloride, 2-phenylethanesulfonyl chloride, 2-thiophenesulfonyl chloride, 5-chloro-2-thiophenesulfonyl chloride, 2,5 dichloro-4-thiophenesulfonyl chloride, 2-thiazolesulfonyl chloride, 2-methyl 4-thiazolesulfonyl chloride, 1-methyl-4-imidazolesulfonyl chloride, 5 1-methyl-4-pyrazolesulfonyl chloride, 5-chloro-1,3-dimethyl-4 pyrazolesulfonyl chloride, 3-pyridinesulfonyl chloride, 2-pyrimidinesulfonyl chloride, and the like. If desired, a sulfonyl fluoride, sulfonyl bromide or sulfonic acid anhydride may be used in place of the sulfonyl chloride in the above reaction to form the N-sulfonyl amino acids of formula IV. 10 The intermediate N-sulfonyl amino acids of formula IV, wherein R 3 is hydrogen, can also be prepared by reacting a sulfonamide of formula V:

R'-SO

2

-NH-R

2 V 15 wherein R' and R 2 are as defined above, with a carboxylic acid derivative of the formula L(R 3 )CHCOOR where L is a leaving group, such as chloro, bromo, iodo, mesylate, tosylate and the like, R 3 is as defined above and R is hydrogen or an alkyl group. This reaction is typically conducted by 20 contacting the sulfonamide V with at least one equivalent, preferably 1.1 to 2 equivalents, of the carboxylic acid derivative in the presence of a suitable base, such as triethylamine, in an inert diluent, such as DMF, at a temperature ranging from about 24oC to about 37 0 C for about 0.5 to about 4 hours. This reaction is further described in Zuckermann et al., J. Am. Chem. 25 Soc., 1992, 114, 10646-10647. Preferred carboxylic acid derivatives for use in this reaction are a-chloro and a-bromocarboxylic acid esters such as tert butyl bromoacetate, and the like. When an carboxylic acid ester is employed in this reaction, the ester group is subsequently hydrolyzed using conventional procedures to afford an N-sulfonyl amino acid of formula IV. 30 WO 99/06437 PCT/US98/16070 121 The compounds of formula I and IA are then prepared by coupling the intermediate N-sulfonyl amino acid of formula IV with an amino acid derivative of formula VI: 5 O

R

7

-NH-CH-C-R

6 VI I

R

5 10 wherein R 5

-R

7 are as defined above. This coupling reaction is typically conducted using well-known coupling reagents such as carbodiimides, BOP reagent (benzotriazol- 1 -yloxy-tris(dimethylamino)phosphonium hexafluorophosphonate) and the like. Suitable carbodiimides include, by 15 way of example, dicyclohexylcarbodiimide (DCC), 1-(3 dimethylaminopropyl)-3-ethylcarbodiimide (EDC) and the like. If desired, polymer supported forms of carbodiimide coupling reagents may also be used including, for example, those described in Tetrahedron Letters, 34(48), 7685 (1993). Additionally, well-known coupling promoters, such as N 20 hydroxysuccinimide, 1-hydroxybenzotriazole and the like, may be used to facilitate the coupling reaction. This coupling reaction is typically conducted by contacting the N sulfonylamino acid IV with about 1 to about 2 equivalents of the coupling 25 reagent and at least one equivalent, preferably about 1 to about 1.2 equivalents, of amino acid derivative VI in an inert diluent, such as dichloromethane, chloroform, acetonitrile, tetrahydrofuran, N,N dimethylformamide and the like. Generally, this reaction is conducted at a temperature ranging from about O'C to about 37oC for about 12 to about 24 30 hours. Upon completion of the reaction, the compound of formula I is WO 99/06437 PCT/US98/16070 122 recovered by conventional methods including neutralization, extraction, precipitation, chromatography, filtration, and the like. Alternatively, the N-sulfonyl amino acid IV can be converted into an 5 acid halide and the acid halide coupled with amino acid derivative VI to provide compounds of formula I. The acid halide of VI can be prepared by contacting VI with an inorganic acid halide, such as thionyl chloride, phosphorous trichloride, phosphorous tribromide or phosphorous pentachloride, or preferably, with oxalyl chloride under conventional 10 conditions. Generally, this reaction is conducted using about 1 to 5 molar equivalents of the inorganic acid halide or oxalyl chloride, either neat or in an inert solvent, such as dichloromethane or carbon tetrachloride, at a temperature in the range of about 0 0 C to about 80'C for about 1 to about 48 hours. A catalyst, such as N,N-dimethylformamide, may also be used in this 15 reaction. The acid halide of N-sulfonyl amino acid IV is then contacted with at least one equivalent, preferably about 1.1 to about 1.5 equivalents, of amino acid derivative VI in an inert diluent, such as dichloromethane, at a 20 temperature ranging from about -70oC to about 40'C for about 1 to about 24 hours. Preferably, this reaction is conducted in the presence of a suitable base to scavenge the acid generated during the reaction. Suitable bases include, by way of example, tertiary amines, such as triethylamine, diisopropylethylamine, N-methylmorpholine and the like. Alternatively, the 25 reaction can be conducted under Schotten-Baumann-type conditions using aqueous alkali, such as sodium hydroxide and the like. Upon completion of the reaction, the compound of formula I is recovered by conventional methods including neutralization, extraction, precipitation, chromatography, filtration, and the like. 30 WO 99/06437 PCT/US98/16070 123 Alternatively, the compounds of formula I can be prepared by first forming a diamino acid derivative of formula VII:

R

3

R

7 O 5 1 1

R

2 -NH-C-C(0)N-CH-C-R 6 VII I I H

R

5 10 wherein R 2 , R 3 , R 5 , R 6 , and R 7 are as defined above. The diamino acid derivatives of formula VII can be readily prepared by coupling an amino acid of formula II with an amino acid derivative of formula VI using conventional amino acid coupling techniques and reagents, such carbodiimides, BOP reagent and the like, as described above. Diamino acid VII can then be 15 sulfonated using a sulfonyl chloride of formula III and using the synthetic procedures described above to provide a compound of formula I. The amino acid derivatives of formula VI employed in the above reactions are either known compounds or compounds that can be prepared 20 from known compounds by conventional synthetic procedures. For example, amino acid derivatives of formula VI can be prepared by C-alkylating commercially available diethyl 2-acetamidomalonate (Aldrich, Milwaukee, Wisconsin, USA) with an alkyl or substituted alkyl halide. This reaction is typically conducted by treating the diethyl 2-acetamidomalonate with at least 25 one equivalent of sodium ethoxide and at least one equivalent of an alkyl or substituted alkyl halide in refluxing ethanol for about 6 to about 12 hours. The resulting C-alkylated malonate is then deacetylated, hydrolyzed and decarboxylated by heating in aqueous hydrochloric acid at reflux for about 6 to about 12 hours to provide the amino acid, typically as the hydrochloride 30 salt.

WO 99/06437 PCT/US98/16070 124 Examples of amino acid derivatives of formula VI suitable for use in the above reactions include, but are not limited to, L-alanine methyl ester, L isoleucine methyl ester, L-leucine methyl ester, L-valine methyl ester, P-tert butyl-L-aspartic acid methyl ester, L-asparagine tert-butyl ester, E-Boc-L 5 lysine methyl ester, e-Cbz-L-lysine methyl ester, y-tert-butyl-L-glutamic acid methyl ester, L-glutamine tert-butyl ester, L-(N-methyl)histidine methyl ester, L-(N-benzyl)histidine methyl ester, L-methionine methyl ester, L-(O benzyl)serine methyl ester, L-tryptophan methyl ester, L-phenylalanine methyl ester, L-phenylalanine isopropyl ester, L-phenylalanine benzyl ester, 10 L-phenylalaninamide, N-methyl-L-phenylalanine benzyl ester, 3-carboxy D,L-phenylalanine methyl ester, 4-carboxy-D,L-phenylalanine methyl ester, L-4-chlorophenylalanine methyl ester, L-4-(3 dimethylaminopropyloxy)phenylalanine methyl ester, L-4-iodophenylalanine methyl ester, L-3,4-methylenedioxyphenylalanine methyl ester, L-3,4 15 ethylenedioxyphenylalanine methyl ester, L-4-nitrophenylalanine methyl ester, L-tyrosine methyl ester, D,L-homophenylalanine methyl ester, L-(O methyl)tyrosine methyl ester, L-(O-tert-butyl)tyrosine methyl ester, L-(O benzyl)tyrosine methyl ester, L-3,5-diiodotyrosine methyl ester, L-3 iodotyrosine methyl ester, [-(1-naphthyl)-L-alanine methyl ester, P3-(2 20 naphthyl)-L-alanine methyl ester, P-(2-thienyl)-L-alanine methyl ester, P cyclohexyl-L-alanine methyl ester, P-(2-pyridyl)-L-alanine methyl ester, 3 (3-pyridyl)-L-alanine methyl ester, P-(4-pyridyl)-L-alanine methyl ester, P3 (2-thiazolyl)-D,L-alanine methyl ester, P3-(1,2,4-triazol-3-yl)-D,L-alanine methyl ester, and the like. If desired, of course, other esters or amides of the 25 above-described compounds may also be employed. For ease of synthesis, the compounds of formula I are typically prepared as an ester, i.e., where R 6 is an alkoxy or substituted alkoxy group and the like. If desired, the ester group can be hydrolysed using conventional 30 conditions and reagents to provide the corresponding carboxylic acid.

WO 99/06437 PCT/US98/16070 125 Typically, this reaction is conducted by treating the ester with at least one equivalent of an alkali metal hydroxide, such as lithium, sodium or potassium hydroxide, in an inert diluent, such as methanol or mixtures of methanol and water, at a temperature ranging about O'C to about 24oC for 5 about 1 to about 12 hours. Alternatively, benzyl esters may be removed by hydrogenolysis using a palladium catalyst, such as palladium on carbon. The resulting carboxylic acids may be coupled, if desired, to amines such as P-alanine ethyl ester, hydroxyamines such as hydroxylamine and N-hydroxysuccinimide, alkoxyamines and substituted alkoxyamines such as 10 O-methylhydroxylamine and O-benzylhydroxylamine, and the like, using conventional coupling reagents and conditions as described above. As will be apparent to those skilled in the art, other functional groups present on any of the substituents of the compounds of formula I can be 15 readily modified or derivatized either before or after the above-described coupling reactions using well-known synthetic procedures. For example, a nitro group present on a substituent of a compound of formula I or an intermediate thereof may be readily reduced by hydrogenation in the presence of a palladium catalyst, such as palladium on carbon, to provide the 20 corresponding amino group. This reaction is typically conducted at a temperature of from about 20 0 C to about 50 0 C for about 6 to about 24 hours in an inert diluent, such as methanol. Compounds having a nitro group on the R 5 substituent can be prepared, for example, by using a 4 nitrophenylalanine derivative and the like in the above-described coupling 25 reactions. Similarly, a pyridyl group can be hydrogenated in the presence of a platinum catalyst, such as platinum oxide, in an acidic diluent to provide the corresponding piperidinyl analogue. Generally, this reaction is conducted by 30 treating the pyridine compound with hydrogen at a pressure ranging from WO 99/06437 PCT/US98/16070 126 about 20 psi to about 60 psi, preferably about 40 psi, in the presence of the catalyst at a temperature of about 20 0 C to about 50 0 C for about 2 to about 24 hours in an acidic diluent, such as a mixture of methanol and aqueous hydrochloric acid. Compounds having a pyridyl group can be readily 5 prepared by using, for example, P-(2-pyridyl)-, P-(3-pyridyl)- or P-(4 pyridyl)-L-alanine derivatives in the above-described coupling reactions. Additionally, when the R 5 substituent of a compound of formula I or an intermediate thereof contains a primary or secondary amino group, such 10 amino groups can be further derivatized either before or after the above coupling reactions to provide, by way of example, amides, sulfonamides, ureas, thioureas, carbamates, secondary or tertiary amines and the like. Compounds having a primary amino group on the R 5 substituent may be prepared, for example, by reduction of the corresponding nitro compound as 15 described above. Alternatively, such compounds can be prepared by using an amino acid derivative of formula VI derived from lysine, 4-aminophenylalanine and the like in the above-described coupling reactions. By way of illustration, a compound of formula I or an intermediate 20 thereof having a substituent containing a primary or secondary amino group, such as where R 5 is a (4-aminophenyl)methyl group, can be readily N-acylated using conventional acylating reagents and conditions to provide the corresponding amide. This acylation reaction is typically conducted by treating the amino compound with at least one equivalent, preferably about 25 1.1 to about 1.2 equivalents, of a carboxylic acid in the presence of a coupling reagent such as a carbodiimide, BOP reagent (benzotriazol-1-yl oxy-tris(dimethylamino)phosphonium hexafluorophosphonate) and the like, in an inert diluent, such as dichloromethane, chloroform, acetonitrile, tetrahydrofuran, N,N-dimethylformamide and the like, at a temperature 30 ranging from about 0 0 C to about 37 0 C for about 4 to about 24 hours.

WO 99/06437 PCT/US98/16070 127 Preferably, a promoter, such as N-hydroxysuccinimide, 1-hydroxy benzotriazole and the like, is used to facilitate the acylation reaction. Examples of carboxylic acids suitable for use in this reaction include, but are not limited to, N-tert-butyloxycarbonylglycine, N-tert-butyloxycarbonyl-L 5 phenylalanine, N-tert-butyloxycarbonyl-L-aspartic acid benzyl ester, benzoic acid, N-tert-butyloxycarbonylisonipecotic acid, N-methylisonipecotic acid, N-tert-butyloxycarbonylnipecotic acid, N-tert-butyloxycarbonyl-L tetrahydroisoquinoline-3-carboxylic acid, N-(toluene-4-sulfonyl)-L-proline and the like. 10 Alternatively, a compound of formula I or an intermediate thereof containing a primary or secondary amino group can be N-acylated using an acyl halide or a carboxylic acid anhydride to form the corresponding amide. This reaction is typically conducted by contacting the amino compound with 15 at least one equivalent, preferably about 1.1 to about 1.2 equivalents, of the acyl halide or carboxylic acid anhydride in an inert diluent, such as dichloromethane, at a temperature ranging from about of about -70 0 C to about 40oC for about 1 to about 24 hours. If desired, an acylation catalyst such as 4-(N,N-dimethylamino)pyridine may be used to promote the 20 acylation reaction. The acylation reaction is preferably conducted in the presence of a suitable base to scavenge the acid generated during the reaction. Suitable bases include, by way of example, tertiary amines, such as triethylamine, diisopropylethylamine, N-methylmorpholine and the like. Alternatively, the reaction can be conducted under Schotten-Baumann-type 25 conditions using aqueous alkali, such as sodium hydroxide and the like. Examples of acyl halides and carboxylic acid anhydrides suitable for use in this reaction include, but are not limited to, 2-methylpropionyl chloride, trimethylacetyl chloride, phenylacetyl chloride, benzoyl chloride, 2 30 bromobenzoyl chloride, 2-methylbenzoyl chloride, 2-trifluoro- WO 99/06437 PCT/US98/16070 128 methylbenzoyl chloride, isonicotinoyl chloride, nicotinoyl chloride, picolinoyl chloride, acetic anhydride, succinic anhydride, and the like. Carbamyl chlorides, such as N,N-dimethylcarbamyl chloride, N,N diethylcarbamyl chloride and the like, can also be used in this reaction to 5 provide ureas. Similarly, dicarbonates, such as di-tert-butyl dicarbonate, may be employed to provide carbamates. In a similar manner, a compound of formula I or an intermediate thereof containing a primary or secondary amino group may be N-sulfonated 10 to form a sulfonamide using a sulfonyl halide or a sulfonic acid anhydride. Sulfonyl halides and sulfonic acid anhydrides suitable for use in this reaction include, but are not limited to, methanesulfonyl chloride, chloromethanesulfonyl chloride, p-toluenesulfonyl chloride, trifluoromethanesulfonic anhydride, and the like. Similarly, sulfamoyl 15 chlorides, such as dimethylsulfamoyl chloride, can be used to provide sulfamides (e.g., >N-SO,-N<). Additionally, a primary and secondary amino group present on a substituent of a compound of formula I or an intermediate thereof can be 20 reacted with an isocyanate or a thioisocyanate to give a urea or thiourea, respectively. This reaction is typically conducted by contacting the amino compound with at least one equivalent, preferably about 1.1 to about 1.2 equivalents, of the isocyanate or thioisocyanate in an inert diluent, such as toluene and the like, at a temperature ranging from about 24 C to about 25 37 0 C for about 12 to about 24 hours. The isocyanates and thioisocyanates used in this reaction are commercially available or can be prepared from commercially available compounds using well-known synthetic procedures. For example, isocyanates and thioisocyanates are readily prepared by reacting the appropriate amine with phosgene or thiophosgene. Examples of 30 isocyanates and thioisocyanates suitable for use in this reaction include, but WO 99/06437 PCT/US98/16070 129 are not limited to, ethyl isocyanate, n-propyl isocyanate, 4-cyanophenyl isocyanate, 3-methoxyphenyl isocyanate, 2-phenylethyl isocyanate, methyl thioisocyanate, ethyl thioisocyanate, 2-phenylethyl thioisocyanate, 3 phenylpropyl thioisocyanate, 3-(NVN-diethylamino)propyl thioisocyanate, 5 phenyl thioisocyanate, benzyl thioisocyanate, 3-pyridyl thioisocyanate, fluorescein isothiocyanate (isomer I) and the like. Furthermore, when a compound of formula I or IA, or an intermediate thereof, contains a primary or secondary amino group, the 10 amino group can be reductively alkylated using aldehydes or ketones to form a secondary or tertiary amino group. This reaction is typically conducted by contacting the amino compound with at least one equivalent, preferably about 1.1 to about 1.5 equivalents, of an aldehyde or ketone and at least one equivalent based on the amino compound of a metal hydride reducing agent, 15 such as sodium cyanoborohydride, in an inert diluent, such as methanol, tetrahydrofuran, mixtures thereof and the like, at a temperature ranging from about 0 0 C to about 50oC for about 1 to about 72 hours. Aldehydes and ketones suitable for use in this reaction include, by way of example, benzaldehyde, 4-chlorobenzaldehyde, valeraldehyde and the like. 20 In a similar manner, when a compound of formula I or an intermediate thereof has a substituent containing a hydroxyl group, the hydroxyl group can be further modified or derivatized either before or after the above coupling reactions to provide, by way of example, ethers, 25 carbamates and the like. Compounds having a hydroxyl group on the R 5 substituent, for example, can be prepared using an amino acid derivative of formula VI derived from tyrosine and the like in the above-described reactions.

WO 99/06437 PCT/US98/16070 130 By way of example, a compound of formula I or an intermediate thereof having a substituent containing a hydroxyl group, such as where R 5 is a (4-hydroxyphenyl)methyl group, can be readily O-alkylated to form ethers. This O-alkylation reaction is typically conducted by contacting the hydroxy 5 compound with a suitable alkali or alkaline earth metal base, such as potassium carbonate, in an inert diluent, such as acetone, 2-butanone and the like, to form the alkali or alkaline earth metal salt of the hydroxyl group. This salt is generally not isolated, but is reacted in situ with at least one equivalent of an alkyl or substituted alkyl halide or sulfonate, such as an 10 alkyl chloride, bromide, iodide, mesylate or tosylate, to afford the ether. Generally, this reaction is conducted at a temperature ranging from about 60 0 C to about 150 0 C for about 24 to about 72 hours. Preferably, a catalytic amount of sodium or potassium iodide is added to the reaction mixture when an alkyl chloride or bromide is employed in the reaction. 15 Examples of alkyl or substituted alkyl halides and sulfonates suitable for use in this reaction include, but are not limited to, tert-butyl bromoacetate, N-tert-butyl chloroacetamide, 1-bromoethylbenzene, ethyl ce bromophenylacetate, 2-(N-ethyl-N-phenylamino)ethyl chloride, 2-(N,N 20 ethylamino)ethyl chloride, 2-(N,N-diisopropylamino)ethyl chloride, 2-(N,N dibenzylamino)ethyl chloride, 3-(N,N-ethylamino)propyl chloride, 3-(N benzyl-N-methylamino)propyl chloride, N-(2-chloroethyl)morpholine, 2 (hexamethyleneimino)ethyl chloride, 3-(N-methylpiperazine)propyl chloride, 1-( 3 -chlorophenyl)-4-(3-chloropropyl)piperazine, 2-(4-hydroxy-4 25 phenylpiperidine)ethyl chloride, N-tert-butyloxycarbonyl-3-piperidinemethyl tosylate, and the like. Alternatively, a hydroxyl group present on a substituent of a compound of formula I or an intermediate thereof can be O-alkylating using 30 the Mitsunobu reaction. In this reaction, an alcohol, such as 3-(N,N- WO 99/06437 PCT/US98/16070 131 dimethylamino)-l-propanol and the like, is reacted with about 1.0 to about 1.3 equivalents of triphenylphosphine and about 1.0 to about 1.3 equivalents of diethyl azodicarboxylate in an inert diluent, such as tetrahydrofuran, at a temperature ranging from about -10oC to about 5 C for about 0.25 to about 5 1 hour. About 1.0 to about 1.3 equivalents of a hydroxy compound, such as N-tert-butyltyrosine methyl ester, is then added and the reaction mixture is stirred at a temperature of about 0 0 C to about 30'C for about 2 to about 48 hours to provide the O-alkylated product. 10 In a similar manner, a compound of formula I or an intermediate thereof containing a aryl hydroxy group can be reacted with an aryl iodide to provide a diaryl ether. Generally, this reaction is conducted by forming the alkali metal salt of the hydroxyl group using a suitable base, such as sodium hydride, in an inert diluent such as xylenes at a temperature of about -25 0 C 15 to about 100 C. The salt is then treated with about 1.1 to about 1.5 equivalents of cuprous bromide dimethyl sulfide complex at a temperature ranging from about 10 0 C to about 30 0 C for about 0.5 to about 2.0 hours, followed by about 1.1 to about 1.5 equivalents of an aryl iodide, such as sodium 2-iodobenzoate and the like. The reaction is then heated to about 20 70 0 C to about 150 0 C for about 2 to about 24 hours to provide the diaryl ether. Additionally, a hydroxy-containing compound can also be readily derivatized to form a carbamate. In one method for preparing such 25 carbamates, a hydroxy compound of formula I or an intermediate thereof is contacted with about 1.0 to about 1.2 equivalents of 4-nitrophenyl chloroformate in an inert diluent, such as dichloromethane, at a temperature ranging from about -25oC to about 0 0 C for about 0.5 to about 2.0 hours. Treatment of the resulting carbonate with an excess, preferably about 2 to 30 about 5 equivalents, of a trialkylamine, such as triethylamine, for about 0.5 WO 99/06437 PCT/US98/16070 132 to 2 hours, followed by about 1.0 to about 1.5 equivalents of a primary or secondary amine provides the carbamate. Examples of amines suitable for using in this reaction include, but are not limited to, piperazine, 1 methylpiperazine, 1-acetylpiperazine, morpholine, thiomorpholine, 5 pyrrolidine, piperidine and the like. Alternatively, in another method for preparing carbamates, a hydroxy-containing compound is contacted with about 1.0 to about 1.5 equivalents of a carbamyl chloride in an inert diluent, such as 10 dichloromethane, at a temperature ranging from about 25 C to about 70 0 C for about 2 to about 72 hours. Typically, this reaction is conducted in the presence of a suitable base to scavenge the acid generated during the reaction. Suitable bases include, by way of example, tertiary amines, such as triethylamine, diisopropylethylamine, N-methylmorpholine and the like. 15 Additionally, at least one equivalent (based on the hydroxy compound) of 4 (N,N-dimethylamino)pyridine is preferably added to the reaction mixture to facilitate the reaction. Examples of carbamyl chlorides suitable for use in this reaction include, by way of example, dimethylcarbamyl chloride, diethylcarbamyl chloride and the like. 20 Likewise, when a compound of formula I or an intermediate thereof contains a primary or secondary hydroxyl group, such hydroxyl groups can be readily converted into a leaving group and displaced to form, for example, amines, sulfides and fluorides. For example, derivatives of 4-hydroxy-L 25 proline can be converted into the corresponding 4-amino, 4-thio or 4-fluoro L-proline derivatives via nucleophilic displacement of the derivatized hydroxyl group. Generally, when a chiral compound is employed in these reactions, the stereochemistry at the carbon atom attached to the derivatized hydroxyl group is inverted. 30 WO 99/06437 PCT/US98/16070 133 These reactions are typically conducted by first converting the hydroxyl group into a leaving group, such as a tosylate, by treatment of the hydroxy compound with at least one equivalent of a sulfonyl halide, such as p-toluenesulfonyl chloride and the like, in pyridine. This reaction is 5 generally conducted at a temperature of from about 0 0 C to about 70'C for about 1 to about 48 hours. The resulting tosylate can then be readily displaced with sodium azide, for example, by contacting the tosylate with at least one equivalent of sodium azide in an inert diluent, such as a mixture of N,N-dimethylformamide and water, at a temperature ranging from about 0 0 C 10 to about 370 C for about I to about 12 hours to provide the corresponding azido compound. The azido group can then be reduced by, for example, hydrogenation using a palladium on carbon catalyst to provide the amino (

NH

2 ) compound. 15 Similarly, a tosylate group can be readily displaced by a thiol to form a sulfide. This reaction is typically conducted by contacting the tosylate with at least one equivalent of a thiol, such as thiophenol, in the presence of a suitable base, such as 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), in an inert diluent, such as N,N-dimethylformamide, at a temperature of from about 0 C 20 to about 37'C for about 1 to about 12 hours to provide the sulfide. Additionally, treatment of a tosylate with morpholinosulfur trifluoride in an inert diluent, such as dichloromethane, at a temperature ranging from about 0 0 C to about 37 0 C for about 12 to about 24 hours affords the corresponding fluoro compound. 25 Furthermore, a compound of formula I or IA or an intermediate thereof having a substituent containing an iodoaryl group, for example, when

R

5 is a (4-iodophenyl)methyl group, can be readily converted either before or after the above coupling reactions into a biaryl compound. Typically, this 30 reaction is conducted by treating the iodoaryl compound with about 1.1 to WO 99/06437 PCT/US98/16070 134 about 2 equivalents of an arylzinc iodide, such as 2-(methoxycarbonyl) phenylzinc iodide, in the presence of a palladium catalyst, such as palladium tetra(triphenylphosphine), in an inert diluent, such as tetrahydrofuran, at a temperature ranging from about 24 0 C to about 30 0 C until reaction 5 completion. This reaction is further described, for example, in Rieke, J Org. Chem. 1991, 56, 1445. In some cases, the compounds of formula I or IA or intermediates thereof may contain substituents having one or more sulfur atoms. Such 10 sulfur atoms will be present, for example, when the amino acid of formula II employed in the above reactions is derived from L-thiazolidine-4-carboxylic acid, L-(5,5-dimethyl)thiazolidine-4-carboxylic acid, L-thiamorpholine-3 carboxylic acid and the like. When present, such sulfur atoms can be oxidized either before or after the above coupling reactions to provide a 15 sulfoxide or sulfone compound using conventional reagents and reaction conditions. Suitable reagents for oxidizing a sulfide compound to a sulfoxide include, by way of example, hydrogen peroxide, 3-chloroperoxybenzoic acid (MCPBA), sodium periodate and the like. The oxidation reaction is typically conducted by contacting the sulfide compound 20 with about 0.95 to about 1.1 equivalents of the oxidizing reagent in an inert diluent, such as dichloromethane, at a temperature ranging from about -50'C to about 75 0 C for about 1 to about 24 hours. The resulting sulfoxide can then be further oxidized to the corresponding sulfone by contacting the sulfoxide with at least one additional equivalent of an oxidizing reagent, such 25 as hydrogen peroxide, MCPBA, potassium permanganate and the like. Alternatively, the sulfone can be prepared directly by contacting the sulfide with at least two equivalents, and preferably an excess, of the oxidizing reagent. Such reactions are described further in March, "Advanced Organic Chemistry", 4th Ed., pp. 1201-1202, Wiley Publisher, 1992. 30 WO 99/06437 PCT/US98/16070 135 As described above, the compounds of formula I having an R 2 substituent other an hydrogen can be prepared using an N-substituted amino acid of formula II, such as sarcosine, N-methyl-L-phenylalanine and the like, in the above-described coupling reactions. Alternatively, such compounds 5 can be prepared by N-alkylation of a sulfonamide of formula I or IV (where

R

2 is hydrogen) using conventional synthetic procedures. Typically, this N alkylation reaction is conducted by contacting the sulfonamide with at least one equivalent, preferably 1.1 to 2 equivalents, of an alkyl or substituted alkyl halide in the presence of a suitable base, such as potassium carbonate, 10 in an inert diluent, such as acetone, 2-butanone and the like, at a temperature ranging from about 25 'C to about 70'C for about 2 to about 48 hours. Examples of alkyl or substituted alkyl halides suitable for use in this reaction include, but are not limited to, methyl iodide, and the like. 15 Additionally, the sulfonamides of formula I or IV wherein R 2 is hydrogen and R' is a 2-alkoxycarbonylaryl group can be intramolecularly cyclized to form 1,2-benzisothiazol-3-one derivatives or analogues thereof. This reaction is typically conducted by treating a sulfonamide, such as N-(2 methoxycarbonylphenylsulfonyl)glycine-L-phenylalanine benzyl ester, with 20 about 1.0 to 1.5 equivalents of a suitable base, such as an alkali metal hydride, in a inert diluent, such as tetrahydrofuran, at a temperature ranging from about 0 0 C to about 30 0 C for about 2 to about 48 hours to afford the cyclized 1,2-benzisothiazol-3-one derivative. 25 Lastly, the compounds of formula I where Q is -C(S)NR 7 - can be prepared by using an amino thionoacid derivative in place of amino acid II in the above described synthetic procedures. Such amino thionoacid derivatives can be prepared by the procedures described in Shalaky, et al., J. Org. Chem., 61:9045-9048 (1996) and Brain, et al., J. Org. Chem., 62:3808-3809 30 (1997) and references cited therein.

WO 99/06437 PCT/US98/16070 136 Pharmaceutical Formulations When employed as pharmaceuticals, the compounds of formula I and IA are usually administered in the form of pharmaceutical compositions. These compounds can be administered by a variety of routes including oral, 5 rectal, transdermal, subcutaneous, intravenous, intramuscular, and intranasal. These compounds are effective as both injectable and oral compositions. Such compositions are prepared in a manner well known in the pharmaceutical art and include at least one active compound. 10 This invention also includes pharmaceutical compositions which contain, as the active ingredient, one or more of the compounds of formula I and IA above associated with pharmaceutically acceptable carriers. In making the compositions of this invention, the active ingredient is usually mixed with an excipient, diluted by an excipient or enclosed within such a 15 carrier which can be in the form of a capsule, sachet, paper or other container. When the excipient serves as a diluent, it can be a solid, semi solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, 20 solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders. 25 In preparing a formulation, it may be necessary to mill the active compound to provide the appropriate particle size prior to combining with the other ingredients. If the active compound is substantially insoluble, it ordinarily is milled to a particle size of less than 200 mesh. If the active compound is substantially water soluble, the particle size is normally WO 99/06437 PCT/US98/16070 137 adjusted by milling to provide a substantially uniform distribution in the formulation, e.g. about 40 mesh. Some examples of suitable excipients include lactose, dextrose, 5 sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose. The formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and 10 suspending agents; preserving agents such as methyl- and propylhydroxy benzoates; sweetening agents; and flavoring agents. The compositions of the invention can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art. 15 The compositions are preferably formulated in a unit dosage form, each dosage containing from about 5 to about 100 mg, more usually about 10 to about 30 mg, of the active ingredient. The term "unit dosage forms" refers to physically discrete units suitable as unitary dosages for human subjects 20 and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient. The active compound is effective over a wide dosage range and is 25 generally administered in a pharmaceutically effective amount. It, will be understood, however, that the amount of the compound actually administered will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the 30 individual patient, the severity of the patient's symptoms, and the like.

WO 99/06437 PCT/US98/16070 138 For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention. When referring to these preformulation 5 compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation is then subdivided into unit dosage forms of the type described above containing from, for example, 0.1 10 to about 500 mg of the active ingredient of the present invention. The tablets or pills of the present invention may be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can include an inner dosage 15 and an outer dosage component, the latter being in the form of an envelope over the former. The two components can separated by an enteric layer which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such 20 materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate. The liquid forms in which the compositions of the present invention may be incorporated for administration orally or by injection include 25 aqueous solutions suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles.

WO 99/06437 PCT/US98/16070 139 Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra. 5 Preferably the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions in preferably pharmaceutically acceptable solvents may be nebulized by use of inert gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device may be attached to a face mask tent, or intermittent 10 positive pressure breathing machine. Solution, suspension, or powder compositions may be administered, preferably orally or nasally, from devices which deliver the formulation in an appropriate manner. The following formulation examples illustrate the pharmaceutical 15 compositions of the present invention. Formulation Example 1 Hard gelatin capsules containing the following ingredients are prepared: 20 Quantity Ingredient (mg/capsule) Active Ingredient 30.0 Starch 305.0 25 Magnesium stearate 5.0 The above ingredients are mixed and filled into hard gelatin capsules in 340 mg quantities. 30 WO 99/06437 PCT/US98/16070 140 Formulation Example 2 A tablet formula is prepared using the ingredients below: Quantity Ingredient (mg/tablet) 5 Active Ingredient 25.0 Cellulose, microcrystalline 200.0 Colloidal silicon dioxide 10.0 Stearic acid 5.0 10 The components are blended and compressed to form tablets, each weighing 240 mg. Formulation Example 3 A dry powder inhaler formulation is prepared containing the 15 following components: Ingredient Weight % Active Ingredient 5 Lactose 95 20 The active mixture is mixed with the lactose and the mixture is added to a dry powder inhaling appliance. 25 Formulation Example 4 Tablets, each containing 30 mg of active ingredient, are prepared as follows: Quantity Ingredient (mg/tablet) 30 Active Ingredient 30.0 mg Starch 45.0 mg Microcrystalline cellulose 35.0 mg Polyvinylpyrrolidone (as 10% solution in water) 4.0 mg 35 Sodium carboxymethyl starch 4.5 mg Magnesium stearate 0.5 mg Talc 1.0 mg Total 120 mg WO 99/06437 PCT/US98/16070 141 The active ingredient, starch and cellulose are passed through a No. 20 mesh U.S. sieve and mixed thoroughly. The solution of polyvinyl pyrrolidone is mixed with the resultant powders, which are then passed through a 16 mesh U.S. sieve. The granules so produced are dried at 500 to 5 60 0 C and passed through a 16 mesh U.S. sieve. The sodium carboxymethyl starch, magnesium stearate, and talc, previously passed through a No. 30 mesh U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets each weighing 150 mg. 10 Formulation Example 5 Capsules, each containing 40 mg of medicament are made as follows: Quantity Ingredient (mg/capsule) 15 Active Ingredient 40.0 mg Starch 109.0 mg Magnesium stearate 1.0 mg Total 150.0 mg 20 The active ingredient, cellulose, starch, an magnesium stearate are blended, passed through a No. 20 mesh U.S. sieve, and filled into hard gelatin capsules in 150 mg quantities. 25 Formulation Example 6 Suppositories, each containing 25 mg of active ingredient are made as follows: 30 Ingredient Amount Active Ingredient 25 mg Saturated fatty acid glycerides to 2,000 mg 35 WO 99/06437 PCT/US98/16070 142 The active ingredient is passed through a No. 60 mesh U.S. sieve and suspended in the saturated fatty acid glycerides previously melted using the minimum heat necessary. The mixture is then poured into a suppository mold of nominal 2.0 g capacity and allowed to cool. 5 Formulation Example 7 Suspensions, each containing 50 mg of medicament per 5.0 ml dose are made as follows: Ingredient Amount 10 Active Ingredient 50.00mg Xanthan gum 4.00mg Sodium carboxymethyl cellulose (11%) Microcrystalline cellulose (89%) 50.00mg 15 Sucrose 1.75 g Sodium benzoate 10.00mg Flavor and Color q.v. Purified water to 5.00ml 20 The medicament, sucrose and xanthan gum are blended, passed through a No. 10 mesh U.S. sieve, and then mixed with a previously made solution of the microcrystalline cellulose and sodium carboxymethyl cellulose in water. The sodium benzoate, flavor, and color are diluted with 25 some of the water and added with stirring. Sufficient water is then added to produce the required volume. Formulation Example 8 Quantity 30 Ingredient (mg/capsule) Active Ingredient 15.0 mg Starch 407.0 mg Magnesium stearate 3.0 mg 35 Total 425.0 mg WO 99/06437 PCT/US98/16070 143 The active ingredient, cellulose, starch, and magnesium stearate are blended, passed through a No. 20 mesh U.S. sieve, and filled into hard gelatin capsules in 560 mg quantities. 5 Formulation Example 9 An intravenous formulation may be prepared as follows: Ingredient Ouantity Active Ingredient 250.0 mg 10 Isotonic saline 1000.0 ml Formulation Example 10 A topical formulation may be prepared as follows: 15 Ingredient Quantity Active Ingredient 1-10 g Emulsifying Wax 30g Liquid Paraffin 20 g 20 White Soft Paraffin to 100 g The white soft paraffin is heated until molten. The liquid paraffin and emulsifying wax are incorporated and stirred until dissolved. The active 25 ingredient is added and stirring is continued until dispersed. The mixture is then cooled until solid. Another preferred formulation employed in the methods of the present invention employs transdermal delivery devices ("patches"). Such 30 transdermal patches may be used to provide continuous or discontinuous infusion of the compounds of the present invention in controlled amounts. The construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art. See. e.g., U.S. Patent 5,023,252, issued June 11, 1991, herein incorporated by reference. Such WO 99/06437 PCT/US98/16070 144 patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents. It may be desirable or necessary to introduce the pharmaceutical 5 composition to the brain, either directly or indirectly. Direct techniques usually involve placement of a drug delivery catheter into the host's ventricular system to bypass the blood-brain barrier. One such implantable delivery system used for the transport of biological factors to specific anatomical regions of the body is described in U.S. Patent 5,011,472 which 10 is herein incorporated by reference. Indirect techniques, which are generally preferred, usually involve formulating the compositions to provide for drug latentiation by the conversion of hydrophilic drugs into lipid-soluble drugs. Latentiation is 15 generally achieved through blocking of the hydroxy, carbonyl, sulfate, and primary amine groups present on the drug to render the drug more lipid soluble and amenable to transportation across the blood-brain barrier. Alternatively, the delivery of hydrophilic drugs may be enhanced by intra-arterial infusion of hypertonic solutions which can transiently open the 20 blood-brain barrier. Utility The compounds of this invention can be employed to bind VLA-4 (a43 1 integrin) in biological samples and, accordingly have utility in, for 25 example, assaying such samples for VLA-4. In such assays, the compounds can be bound to a solid support and the VLA-4 sample added thereto. The amount of VLA-4 in the sample can be determined by conventional methods such as use of a sandwich ELISA assay. Alternatively, labeled VLA-4 can be used in a competitive assay to measure for the presence of VLA-4 in the 30 sample. Other suitable assays are well known in the art.

WO 99/06437 PCT/US98/16070 145 In addition, certain of the compounds of this invention inhibit, in vivo, adhesion of leukocytes to endothelial cells mediated by VLA-4 and, accordingly, can be used in the treatment of diseases mediated by VLA-4. Such diseases include inflammatory diseases in mammalian patients 5 such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes (including acute juvenile onset diabetes), inflammatory bowel disease (including ulcerative colitis and Crohn's disease), multiple sclerosis, rheumatoid arthritis, tissue transplantation, tumor metastasis, meningitis, encephalitis, stroke, and other cerebral traumas, nephritis, retinitis, atopic 10 dermatitis, psoriasis, myocardial ischemia and acute leukocyte-mediated lung injury such as that which occurs in adult respiratory distress syndrome. The biological activity of the compounds identified above may be assayed in a variety of systems. For example, a compound can be 15 immobilized on a solid surface and adhesion of cells expressing VLA-4 can be measured. Using such formats, large numbers of compounds can be screened. Cells suitable for this assay include any leukocytes known to express VLA-4 such as T cells, B cells, monocytes, eosinophils, and basophils. A number of leukocyte cell lines can also be used, examples 20 include Jurkat and U937. The test compounds can also be tested for the ability to competitively inhibit binding between VLA-4 and VCAM-1, or between VLA-4 and a labeled compound known to bind VLA-4 such as a compound of this 25 invention or antibodies to VLA-4. In these assays, the VCAM-1 can be immobilized on a solid surface. VCAM-1 may also be expressed as a recombinant fusion protein having an Ig tail (e.g., IgG) so that binding to VLA-4 may be detected in an immunoassay. Alternatively, VCAM-19 expressing cells, such as activated endothelial cells or VCAM-1 I transfected 30 fibroblasts can be used. For assays to measure the ability to block adhesion WO 99/06437 PCT/US98/16070 146 to brain endothelial cells, the assays described in International Patent Application Publication No. WO 91/05038 are particularly preferred. This application is incorporated herein by reference in its entirety. 5 Many assay formats employ labelled assay components. The labelling systems can be in a variety of forms. The label may be coupled directly or indirectly to the desired component of the assay according to methods well known in the art. A wide variety of labels may be used. The component may be labelled by any one of several methods. The most 10 common method of detection is the use of autoradiography with 3 H, 125, 35S, 14C, or 3 2 P labelled compounds and the like. Non-radioactive labels include ligands which bind to labelled antibodies, fluorophores, chemiluminescent agents, enzymes and antibodies which can serve as specific binding pair members for a labelled ligand. The choice of label depends on sensitivity 15 required, ease of conjugation with the compound, stability requirements, and available instrumentation. Appropriate in vivo models for demonstrating efficacy in treating inflammatory responses include EAE (experimental autoimmune 20 encephalomyelitis) in mice, rats, guinea pigs or primates, as well as other inflammatory models dependent upon a4 integrins. Compounds having the desired biological activity may be modified as necessary to provide desired properties such as improved pharmacological 25 properties (e.g., in vivo stability, bio-availability), or the ability to be detected in diagnostic applications. For instance, inclusion of one or more D-amino acids in the sulfonamides of this invention typically increases in vivo stability. Stability can be assayed in a variety of ways such as by measuring the half-life of the proteins during incubation with peptidases or 30 human plasma or serum. A number of such protein stability assays have WO 99/06437 PCT/US98/16070 147 been described (see, e.g., Verhoef et al., Eur. J. Drug Metab. Pharmacokinet., 1990, 15.():83-93). For diagnostic purposes, a wide variety of labels may be linked to the 5 compounds, which may provide, directly or indirectly, a detectable signal. Thus, the compounds of the subject invention may be modified in a variety of ways for a variety of end purposes while still retaining biological activity. In addition, various reactive sites may be introduced at the terminus for linking to particles, solid substrates, macromolecules, and the like. 10 Labeled compounds can be used in a variety of in vivo or in vitro applications. A wide variety of labels may be employed, such as radionuclides (e.g., gamma-emitting radioisotopes such as technetium-99 or indium-1 11), fluorescers (e.g., fluorescein), enzymes, enzyme substrates, 15 enzyme cofactors, enzyme inhibitors, chemiluminescent compounds, bioluminescent compounds, and the like. Those of ordinary skill in the art will know of other suitable labels for binding to the complexes, or will be able to ascertain such using routine experimentation. The binding of these labels is achieved using standard techniques common to those of ordinary 20 skill in the art. In vitro uses include diagnostic applications such as monitoring inflammatory responses by detecting the presence of leukocytes expressing VLA-4. The compounds of this invention can also be used for isolating or 25 labeling such cells. In addition, as mentioned above, the compounds of the invention can be used to assay for potential inhibitors of VLA-4/VCAM-1 interactions. For in vivo diagnostic imaging to identify, e.g., sites of inflammation, 30 radioisotopes are typically used in accordance with well known techniques.

WO 99/06437 PCT/US98/16070 148 The radioisotopes may be bound to the peptide either directly or indirectly using intermediate functional groups. For instance, chelating agents such as diethylenetriaminepentacetic acid (DTPA) and ethylenediaminetetraacetic acid (EDTA) and similar molecules have been used to bind proteins to 5 metallic ion radioisotopes. The complexes can also be labeled with a paramagnetic isotope for purposes of in vivo diagnosis, as in magnetic resonance imaging (MRI) or electron spin resonance (ESR), both of which are well known. In general, 10 any conventional method for visualizing diagnostic images can be used. Usually gamma- and positron-emitting radioisotopes are used for camera imaging and paramagnetic isotopes are used for MRI. Thus, the compounds can be used to monitor the course of amelioration of an inflammatory response in an individual. By measuring the increase or decrease in 15 lymphocytes expressing VLA-4 it is possible to determine whether a particular therapeutic regimen aimed at ameliorating the disease is effective. The pharmaceutical compositions of the present invention can be used to block or inhibit cellular adhesion associated with a number of 20 diseases and disorders, or to treat diseases in a mammalian patient which are mediated by a 9 1 . For instance, a number of inflammatory disorders are associated with integrins or leukocytes. Treatable disorders include, e.g., transplantation rejection (e.g., allograft rejection), Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes (including acute juvenile onset 25 diabetes), retinitis, cancer metastases, rheumatoid arthritis, acute leukocyte-mediated lung injury (e.g., adult respiratory distress syndrome), asthma, nephritis, and acute and chronic inflammation, including atopic dermatitis, psoriasis, myocardial ischemia, and inflammatory bowel disease (including Crohn's disease and ulcerative colitis). In preferred embodiments WO 99/06437 PCT/US98/16070 149 the pharmaceutical compositions are used to treat inflammatory brain disorders, such as multiple sclerosis (MS), viral meningitis and encephalitis. Inflammatory bowel disease is a collective term for two similar 5 diseases referred to as Crohn's disease and ulcerative colitis. Crohn's disease is an idiopathic, chronic ulceroconstrictive inflammatory disease characterized by sharply delimited and typically transmural involvement of all layers of the bowel wall by a granulomatous inflammatory reaction. Any segment of the gastrointestinal tract, from the mouth to the anus, may be 10 involved, although the disease most commonly affects the terminal ileum and/or colon. Ulcerative colitis is an inflammatory response limited largely to the colonic mucosa and submucosa. Lymphocytes and macrophages are numerous in lesions of inflammatory bowel disease and may contribute to inflammatory injury. 15 Asthma is a disease characterized by increased responsiveness of the tracheobronchial tree to various stimuli potentiating paroxysmal constriction of the bronchial airways. The stimuli cause release of various mediators of inflammation from IgE-coated mast cells including histamine, eosinophilic 20 and neutrophilic chemotactic factors, leukotrines, prostaglandin and platelet activating factor. Release of these factors recruits basophils, eosinophils and neutrophils, which cause inflammatory injury. Atherosclerosis is a disease of arteries (e.g., coronary, carotid, aorta 25 and iliac). The basic lesion, the atheroma, consists of a raised focal plaque within the intima, having a core of lipid and a covering fibrous cap. Atheromas compromise arterial blood flow and weaken affected arteries. Myocardial and cerebral infarcts are a major consequence of this disease. Macrophages and leukocytes are recruited to atheromas and contribute to 30 inflammatory injury.

WO 99/06437 PCT/US98/16070 150 Rheumatoid arthritis is a chronic, relapsing inflammatory disease that primarily causes impairment and destruction of joints. Rheumatoid arthritis usually first affects the small joints of the hands and feet but then may involve the wrists, elbows, ankles and knees. The arthritis results from 5 interaction of synovial cells with leukocytes that infiltrate from the circulation into the synovial lining of the joints. See e.g., Paul, Immunology (3d ed., Raven Press, 1993). Another indication for the compounds of this invention is in 10 treatment of organ or graft rejection mediated by VLA-4. Over recent years there has been a considerable improvement in the efficiency of surgical techniques for transplanting tissues and organs such as skin, kidney, liver, heart, lung, pancreas and bone marrow. Perhaps the principal outstanding problem is the lack of satisfactory agents for inducing immunotolerance in 15 the recipient to the transplanted allograft or organ. When allogenetic cells or organs are transplanted into a host (i.e., the donor and donee are different individuals from the same species), the host immune system is likely to mount an immune response to foreign antigens in the transplant (host-versus graft disease) leading to destruction of the transplanted tissue. CD8' cells, 20 CD4 cells and monocytes are all involved in the rejection of transplant tissues. Compounds of this invention which bind to alpha-4 integrin are useful, inter alia, to block alloantigen-induced immune responses in the donee thereby preventing such cells from participating in the destruction of the transplanted tissue or organ. See, e.g., Paul et al., Transplant 25 International 9, 420-425 (1996); Georczynski et al., Immunology 87, 573 580 (1996); Georcyznski et al., Transplant. Immunol. 3, 55-61 (1995); Yang et al., Transplantation 60, 71-76 (1995); Anderson et al., APMIS 102, 23-27 (1994).

WO 99/06437 PCT/US98/16070 151 A related use for compounds of this invention which bind to VLA-4 is in modulating the immune response involved in "graft versus host" disease (GVHD). See e.g., Schlegel et al., J. Immunol. 155, 3856-3865 (1995). GVHD is a potentially fatal disease that occurs when immunologically 5 competent cells are transferred to an allogenetic recipient. In this situation, the donor's immunocompetent cells may attack tissues in the recipient. Tissues of the skin, gut epithelia and liver are frequent targets and may be destroyed during the course of GVHD. The disease presents an especially severe problem when immune tissue is being transplanted, such as in bone 10 marrow transplantation; but less severe GVHD has also been reported in other cases as well, including heart and liver transplants. The therapeutic agents of the present invention are used, inter alia, to block activation of the donor T-cells thereby interfering with their ability to lyse target cells in the host. 15 A further use of the compounds of this invention is inhibiting tumor metastasis. Several tumor cells have been reported to express VLA-4 and compounds which bind VLA-4 block adhesion of such cells to endothelial cells. Steinback et al., Urol. Res. 23, 175-83 (1995); Orosz et al., Int. J 20 Cancer 60, 867-71 (1995); Freedman et al., Leuk. Lymphoma 13, 47-52 (1994); Okahara et al., Cancer Res. 54, 3233-6 (1994). A further use of the compounds of this invention is in treating multiple sclerosis. Multiple sclerosis is a progressive neurological 25 autoimmune disease that affects an estimated 250,000 to 350,000 people in the United States. Multiple sclerosis is thought to be the result of a specific autoimmune reaction in which certain leukocytes attack and initiate the destruction of myelin, the insulating sheath covering nerve fibers. In an animal model for multiple sclerosis, murine monoclonal antibodies directed 30 against VLA-4 have been shown to block the adhesion of leukocytes to the WO 99/06437 PCT/US98/16070 152 endothelium, and thus prevent inflammation of the central nervous system and subsequent paralysis in the animals 6 . Pharmaceutical compositions of the invention are suitable for use in a 5 variety of drug delivery systems. Suitable formulations for use in the present invention are found in Remington's Pharmaceutical Sciences, Mace Publishing Company, Philadelphia, PA, 17th ed. (1985). In order to enhance serum half-life, the compounds may be 10 encapsulated, introduced into the lumen of liposomes, prepared as a colloid, or other conventional techniques may be employed which provide an extended serum half-life of the compounds. A variety of methods are available for preparing liposomes, as described in, e.g., Szoka, et al., U.S. Patent Nos. 4,235,871, 4,501,728 and 4,837,028 each of which is 15 incorporated herein by reference. The amount administered to the patient will vary depending upon what is being administered, the purpose of the administration, such as prophylaxis or therapy, the state of the patient, the manner of administration, 20 and the like. In therapeutic applications, compositions are administered to a patient already suffering from a disease in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications. An amount adequate to accomplish this is defined as "therapeutically effective dose." Amounts effective for this use will depend on the disease condition 25 being treated as well as by the judgment of the attending clinician depending upon factors such as the severity of the inflammation, the age, weight and general condition of the patient, and the like. The compositions administered to a patient are in the form of 30 pharmaceutical compositions described above. These compositions may be WO 99/06437 PCT/US98/16070 153 sterilized by conventional sterilization techniques, or may be sterile filtered. The resulting aqueous solutions may be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration. The pH of the compound 5 preparations typically will be between 3 and 11, more preferably from 5 to 9 and most preferably from 7 to 8. It will be understood that use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of pharmaceutical salts. 10 The therapeutic dosage of the compounds of the present invention will vary according to, for example, the particular use for which the treatment is made, the manner of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician. For example, for intravenous administration, the dose will typically be in the 15 range of about 20 /g to about 500 jg per kilogram body weight, preferably about 100 gg to about 300 gg per kilogram body weight. Suitable dosage ranges for intranasal administration are generally about 0.1 pg to 1 mg per kilogram body weight. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems. 20 The following synthetic and biological examples are offered to illustrate this invention and are not to be construed in any way as limiting the scope of this invention. Unless otherwise stated, all temperatures are in degrees Celsius. 25 EXAMPLES In the examples below, the following abbreviations have the following meanings. If an abbreviation is not defined, it has its generally accepted meaning. 30 aq or aq. = aqueous WO 99/06437 PCT/US98/16070 154 AcOH = acetic acid bd = broad doublet bm = broad multiplet bs = broad singlet 5 Bn = benzyl Boc = N-tert-butoxylcarbonyl Boc 2 0 = di-tert-butyl dicarbonate BOP = benzotriazol- 1 -yloxy tris(dimethylamino)phosphonium 10 hexafluorophosphate Cbz = carbobenzyloxy CHC1 3 = chloroform

CH

2 Cl 2 = dichloromethane (COC1) 2 oxalyl chloride 15 d = doublet dd = doublet of doublets dt = doublet of triplets DBU - 1,8-diazabicyclo[5.4.0]undec-7-ene DCC - 1,3-dicyclohexylcarbodiimide 20 DMAP = 4-N,N-dimethylaminopyridine DME = ethylene glycol dimethyl ether DMF = N,N-dimethylformamide DMSO - dimethylsulfoxide EDC - 1-(3-dimethylaminopropyl)-3 25 ethylcarbodiimide hydrochloride Et 3 N - triethylamine Et 2 ,O = diethyl ether EtOAc = ethyl acetate EtOH = ethanol 30 eq or eq. = equivalent Fmoc = N-(9-fluorenylmethoxycarbonyl) FmocONSu = N-(9-fluorenylmethoxycarbonyl) succinimide g = grams 35 h = hour

H

2 0, = water HBr = hydrobromic acid HCI - hydrochloric acid HOBT = 1-hydroxybenzotriazole hydrate 40 hr = hour

K

2

CO

3 = potassium carbonate L = liter m = multiplet MeOH = methanol WO 99/06437 PCT/US98/16070 155 mg = milligram MgSO 4 magnesium sulfate mL = milliliter mm = millimeter 5 mM = millimolar mmol = millimol mp = melting point N = normal NaCl = sodium chloride 10 Na 2

CO

3 = sodium carbonate NaHCO 3 = sodium bicarbonate NaOEt = sodium ethoxide NaOH = sodium hydroxide

NH

4 C1 ammonium chloride 15 NMM = N-methylmorpholine Phe = L-phenylalanine Pro = L-proline psi = pounds per square inch PtO 2 platinum oxide 20 q = quartet quint. = quintet rt = room temperature s = singlet sat = saturated 25 t = triplet t-BuOH = tert-butanol TFA = trifluoroacetic acid THF = tetrahydrofuran TLC or tlc = thin layer chromatography 30 Ts = tosyl TsCl = tosyl chloride TsOH = tosylate L = microliter 35 In the examples below, all temperatures are in degrees Celcius (unless otherwise indicated). The following Methods were used to prepare the compounds set forth below as indicated.

WO 99/06437 PCT/US98/16070 156 Method 1 N-Tosylation Procedure N-Tosylation of the appropriate amino acid was conducted via the method of Cupps, Boutin and Rapoport J. Org. Chem. 1985, 50, 3972. 5 Method 2 Methyl Ester Preparation Procedure Amino acid methyl esters were prepared using the method of Brenner and Huber Helv. Chim. Acta 1953, 36, 1109. 10 Method 3 BOP Coupling Procedure The desired dipeptide esters were prepared by the reaction of a suitable N-protected amino acid (1 equivalent) with the appropriate amino 15 acid ester or amino acid ester hydrochloride (1 equivalent), benzotriazol-1 yloxy-tris(dimethylamino)phosphonium hexafluorophosphate [BOP] (2.0 equivalent), triethylamine (1.1 equivalent), and DMF. The reaction mixture was stirred at room temperature overnight. The crude product was purified flash chromatography to afford the dipeptide ester. 20 Method 4 Hydrogenation Procedure I Hydrogenation was performed using 10% palladium on carbon (10% by weight) in methanol at 30 psi overnight. The reaction mixtures were 25 filtered through a pad of Celite and the filtrate concentrated to yield the desired amino compounds.

WO 99/06437 PCT/US98/16070 157 Method 5 Hydrolysis Procedure I To a chilled (00C) THF/H 2 0 solution (2:1, 5 - 10 mL) of the appropriate ester was added LiOH (or NaOH) (0.95 equivalents). The 5 temperature was maintained at O'C and the reaction was complete in 1 to 3 hours. The reaction mixture was extracted with ethyl acetate and the aqueous phase was lyophilized resulting in the desired carboxylate salt. Method 6 10 Ester Hydrolysis Procedure II To a chilled (0oC) THF/HO 2 0 solution (2:1, 5 - 10 mL) of the appropriate ester was added LiOH (1.1 equivalents). The temperature was maintained at 0 0 C and the reaction was complete in 1 to 3 hours. The reaction mixture was concentrated and the residue was taken up into H 2 0 and 15 the pH adjusted to 2 to 3 with aqueous HC1. The product was extracted with ethyl acetate and the combined organic phase was washed with brine, dried over MgSO 4 , filtered and concentrated to yield the desired acid. Method 7 20 Ester Hydrolysis Procedure III The appropriate ester was dissolved in dioxane/H 2 0 (1:1) and 0.9 equivalents of 0.5 N NaOH was added. The reaction was stirred for 3 to 16 hours and then concentrated. The resulting residue was dissolved in H 2 0 and extracted with ethyl acetate. The aqueous phase was lyophilized to yield the 25 desired carboxylate sodium salt. Method 8 Sulfonvlation Procedure I To the appropriately protected amino acid analog (11.2 mmol), 30 dissolved in methylene chloride (25ml) and cooled to -78 0 C was added the WO 99/06437 PCT/US98/16070 158 desired sulfonyl chloride (12 mmol) followed by dropwise addition of pyridine (2 mL). The solution was allowed to warm to room temperature and was stirred for 48 hr. The reaction solution was transferred to a 250 mL separatory funnel with methylene chloride (100 mL) and extracted with IN 5 HCI (50 mL x 3), brine (50 mL), and water (100 mL). The organic phase was dried (MgSO 4 ) and the solvent concentrated to yield the desired product. Method 9 Reductive Amination Procedure 10 Reductive amination of Tos-Pro-p-NH 2 -Phe with the appropriate aldehyde was conducted using acetic acid, sodium triacetoxyborohydride, methylene chloride and the combined mixture was stirred at room temperature overnight. The crude product was purified by flash chromatography. 15 Method 10 BOC Removal Procedure Anhydrous hydrochloride (HC1) gas was bubbled through a methanolic solution of the appropriate Boc-amino acid ester at 0oC for 15 20 minutes and the reaction mixture was stirred for three hours. The solution was concentrated to a syrup and dissolved in Et,O and reconcentrated. This procedure was repeated and the resulting solid was placed under high vacuum overnight. 25 Method 11 Tert-Butyl Ester Hydrolysis Procedure I The tert-butyl ester was dissolved in CH 2 C1, and treated with TFA. The reaction was complete in 1-3 hr at which time the reaction mixture was concentrated and the residue dissolved in H0,O and lyophilized to yield the 30 desired acid.

WO 99/06437 PCT/US98/16070 159 Method 12 EDC Coupling Procedure I To a CH 2 Cl 2 solution (5-20 mL) of N-(toluene-4-sulfonyl)-L-proline (1 equivalent), the appropriate amino acid ester hydrochloride (1 equivalent), 5 N-methylmorpholine (1.1-2.2 equivalents) and 1-hydroxybenzotriazole (2 equivalents) were mixed, placed in an ice bath and 1-(3 dimethylaminopropyl)-3-ethyl carbodiimide (1.1 equivalents) was added. The reaction was allowed to rise to room temperature and stirred overnight. The reaction mixture was poured into HO 2 0 and the organic phase was washed 10 with sat. NaHCO 3 , brine, dried (MgSO 4 or Na 2

SO

4 ), filtered and concentrated. The crude product was purified by column chromatography. Method 13 EDC Coupling Procedure II 15 To a DMF solution (5-20 mL) of the appropriate N-protected amino acid (1 equivalent), the appropriated amino acid ester hydrochloride (1 equivalent), Et 3 N (1.1 equivalents) and 1-hydroxybenzotriazole (2 equivalents) were mixed, placed in an ice bath and 1-(3 dimethylaminopropyl)-3-ethyl carbodiimide (1.1 equivalents) was added. 20 The reaction was allowed to rise to room temperature and stirred overnight. The reaction mixture was partitioned between EtOAc and HO and the organic phase washed with 0.2 N citric acid, H 2 0, sat. NaHCO 3 , and brine, then dried (MgSO 4 or Na 2

SO

4 ), filtered and concentrated. The crude product was purified by column chromatography or preparative TLC. 25 Method 14 Sulfonylation Procedure II The appropriate sulfonyl chloride was dissolved in CH 2 C12 and placed in an ice bath. L-Pro-L-Phe-OMe * HCI (1 equivalent) and Et 3

N

WO 99/06437 PCT/US98/16070 160 (1.1 equivalent) was added and the reaction allowed to warm to room temperature and stirred overnight under an atmosphere of nitrogen. The reaction mixture was concentrated and the residue partitioned between EtOAc and H 2 0 and the organic phase washed with sat. NaHCO 3 , brine, 5 dried (MgSO 4 or NaSO 4 ), filtered and concentrated. The crude product was purified by column chromatography or preparative TLC. Method 15 Sulfonylation Procedure III 10 To a solution of L-Pro-L-4-(3-dimethylaminopropyloxy)-Phe-OMe [prepared using the procedure described in Method 10] (1 equivalent) in

CH

2 C12 was added Et 3 N (5 equivalents) followed by the appropriate sulfonyl chloride (1.1 equivalent). The reaction was allowed to warm to room temperature and stirred overnite under an atmosphere of nitrogen. The 15 mixture was concentrated, dissolved in EtOAc, washed with sat. NaHCO 3 and 0.2 N citric acid. The aqueous phase was made basic with solid NaHCO 3 and the product extracted with EtOAc. The organic phase was washed with brine, dried (MgSO 4 or Na 2

SO

4 ), filtered and concentrated. The crude methyl ester was purified by preparative TLC. The corresponding acid 20 was prepared using the procedure described in Method 7. Method 16 Hydrogenation Procedure II To a methanol (10 -15 mL) solution of the azlactone was added 25 NaOAc (1 equivalent) and 10% Pd/C. This mixture was placed on the hydrogenator at 40 psi H 2 . After 8 - 16 hours, the reaction mixture was filtered through a pad of Celite and the filtrate concentrated to yield the dehydrodipeptide methyl ester. The ester was dissolved in dioxane/HO 2 0 (5 10 mL), to which was added 0.5 N NaOH (1.05 equivalents). After stirring 30 for 1- 3 hours, the reaction mixture was concentrated and the residue was WO 99/06437 PCT/US98/16070 161 redissolved in H 2 0 and washed with EtOAc. The aqueous phase was made acidic with 0.2 N HCI and the product was extracted with EtOAc. The combined organic phase was washed with brine (1 x 5 mL), dried (MgSO 4 or Na 2

SO

4 ), filtered and concentrated to yield the acid as approximately a 1:1 5 mixture of diastereomers. Method 17 Tert-Butvl Ester Hydrolysis Procedure II The tert-butyl ester was dissolved in CHC1 2 (5 mL) and treated with 10 TFA (5 mL). The reaction was complete in 1-3 hours at which time the reaction mixture was concentrated and the residue dissolved in H 2 0 and concentrated. The residue was redissolved in H 2 0 and lyophilized to yield the desired product. Example 1 15 Synthesis of N-(Toluene- 4 -sulfonyl)-L-prolyl-4-((x-methylbenzyloxy)-L-phenylalanine N-(Toluene-4-sulfonyl)-L-prolyl-L-tyrosine methyl ester (see Example 2 (3)) (785 mg, 1.89 mmol) was dissolved in DMF (20 mL) at room 20 temperature. To this was added K 2

CO

3 (1.1 eq, 281 rmg) and 1-bromoethyl benzene (1.1 eq, 284 ptL). The reaction was stirred for 12 hours at room temperature. Ethyl acetate (100 mL) was added, and the organic layer washed several times with brine (5 x 50 mL). The organic layer was dried over MgSO 4 . Upon filtration and evaporation of the solvents under reduced 25 pressure, an oil was isolated. The crude material was purified by elution on silica gel (EtOAc/hexanes (1:4)). The desired material was isolated in 32% yield (330 mg, 0.6 mmol). The methyl ester (330 mg. 0.6 mmol) was then converted to the corresponding acid upon treatment with NaOH (1.1 eq, 27 mg), in MeOH:HO 2 0 (1:1) (15 mL), for 4 hours at room temperature. EtOAc 30 was added as well as water. The aqueous layer was collected and acidified with IN HCI to pH 2.5, and reextracted with EtOAc. The organic layer was WO 99/06437 PCT/US98/16070 162 dried over MgSO 4 . Upon filtration and evaporation of the solvents under reduced pressure, a foam was isolated in quantitative yields. NMR data was as follows: 'H NMR (300 MHz, CDC1 3 ): 6 = 7.71 (bd, 2H), 7.34 (mn, 7H), 7.20 5 (in, 1H), 7.01 (min, 2H), 6.80 (d, 2H, J= 8.37 Hz), 5.27 (m, 1H), 4.75 (mn, 1H), 4.04 (min, 1H), 3.23-2.93 (min, 4H), 2.42 (s, 3H), 1.85 (min, 1H), 1.60 (d, 3H, J= 6.09 Hz), 1.36-1.26 (min, 3H). 13C NMR (75 MHz, CDC1 3 ): 8 = 174.74, 172.22, 157.53, 145.00, 143.77, 133.42, 130.76, 130.58, 129.14, 128.60, 128.48, 127.94, 126.15, 10 116.57, 76.39, 62.73, 53.90, 50.09, 37.09, 25.07, 24.52, 22.17. Mass Spectroscopy: (FAB) 537 (M+H). Example 2 Synthesis of 15 N-(Toluene-4-sulfonyl)-L-prolyl-L-tyrosine N-toluene-4-sulfonyl)-L-proline (1.56 g, 6.93 mmol) was dissolved in 50 mL of DMF, with L-tyrosine methyl ester (1.1 eq, 1.76g), Et 3 N (2.2 eq, 2.0 mL), and BOP reagent (1.1 eq, 3.36 g). The ester was isolated in 75% yield (2.14 g, 5.16 mmol). The ester (120 mg, 0.27 mmol) was taken up in a 20 1:1 mixture of MeOH:H20 (5 mL) with 1.1 eq. of NaOH. The title acid was isolated in quantitative yield as an oil. NMR data was as follows: 'H NMR (300 MHz, CD 3 OD): 8 = 7.46 (d, 2H, J= 8.25 Hz), 7.12 (d, 2H, J= 7.83 Hz), 6.77 (d, 2H, J= 8.35 Hz), 6.49 (d, 2H, J= 8.39 Hz), 4.46 25 (min, 1H), 3.80 (min, 1H), 3.11-2.70 (min, 4H), 2.19 (s, 3H), 1.66 (mn, 1H), 1.31 (min, 3H). 13C NMR (75 MHz, CD 3 OD): 6 = 177.36, 176.12, 160.30, 149.12, 137.29, 134.79, 134.50, 132.22, 131.50, 119.63, 66.67, 57.90, 54.02, 41.06, 34.57, 28.54, 25.79. 30 Mass Spectroscopy: (FAB) 417 (M+H).

WO 99/06437 PCT/US98/16070 163 Example 3 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-4-carboxyphenylalanine Diethyl 2-acetamidomalonate was treated with 4-cyanobenzyl 5 bromide and NaOEt in EtOH, to give after dilution with H 2 0, and isolation of the resulting precipitate, diethyl 2 -acetamido-2-(4-cyanobenzyl)malonate. This product was heated in HC1, and the mixture evaporated to give 4 carboxy-D,L-phenylalanine hydrochloride [D,L-Phe(4-CO 2 H)-OHHCI]. This product was treated with MeOH and HC1 gas to give after evaporation, 10 D,L-Phe(4-CO 2 Me)-OMeHCI. This product was treated with N-(toluene-4 sulfonyl)-L-Pro-OH, BOP, and NMM in DMF, to give after aqueous workup and flash chromatography, N-(toluene-4-sulfonyl)-L-Pro-D,L-Phe(4

CO

2 Me)-OMe. This product was treated with NaOH in dioxane and water, to give after acidification, extraction, drying with MgSO 4 , filtration and 15 evaporation the title compound as a clear oil. NMR data was as follows: 'H NMR (CD 3 OD, 300 MHz): 6 = 7.86 (d, J= 8.2, 1H), 7.83 (d, J= 8.2, 1H), 7.74 (d, J= 8.3, 1H), 7.73 (d, J= 8.3, 1H), 7.41 (d, J= 8.2, 2H), 7.31 (d, J= 8.2, 1H), 7.21 (d, J= 8.1, 1H), 4.53 (dd, J= 7.1, J= 4.7, 0.5H), 20 4.46 (dd, J= 5.9, 0.5H), 4.07-3.99 (min, 1H), 3.58-3.45 (m, 1H), 3.28-3.02 (inm, 3H), 2.43 (s, 3H), 1.83-1.43 (min, 4H). 1 3 C NMR (CD 3 OD w/ CD 3 ONa, 75 MHz): 6 = 179.12, 179.08, 177.5, 177.4, 173.1, 173.0, 145.83, 145.80, 139.6, 139.4, 137.8, 137.7, 134.77, 134.75, 131.0, 130.9, 130.5, 130.4, 129.44, 129.39, 129.1, 129.0, 25 63.61, 63.57, 57.0, 56.9, 50.74, 50.70, 38.7, 38.6, 31.71, 31.65, 25.2, 25.1, 21.50.21.49. Mass Spectroscopy: (+FAB, 3-nitrobenzyl alcohol) 461 (M+H).

WO 99/06437 PCT/US98/16070 164 Example 4 Synthesis of N-(Toluene- 4 -sulfonyl)-L-prolyl-3-(carboxy)phenylalanine Substitution of 3-cyanobenzyl bromide for 4-cyanobenzyl bromide, 5 and following the methods for preparation of Example 3, gave the title compound as a clear oil. NMR data was as follows: 'H NMR (CD 3 OD, 300 MHz): 6 = 7.82 (s, 0.5H), 7.77 (s, 0.5H), 7.73 (d, J= 8.2, 1H), 7.72 (d, J= 8.2, 1H), 7.40 (d, J= 8.2, 2H), 7.37-7.19 (m, 10 3H), 4.53 (dd, J= 7.5, J=4.9, 0.5H), 4.46 (t, J= 5.9, 0.5H), 4.05 (dd, J= 8.2, J= 3.5, 0.5H), 3.99 (dd, J= 8.8, J= 3.4, 0.5H), 3.48-3.42 (m, 0.5H), 3.36 2.99 (m, 3.5H), 2.42 (s, 3H), 1.88-1.38 (m, 4H). 1 3 C NMR (CD 3 OD w/ CD 3 ONa, 75 MHz): 8 = 179.18, 179.16, 177.6, 177.5, 173.04, 172.97, 145.82, 145.81, 139.5, 139.4, 137.81, 137.78, 15 134.77, 134.75, 132.33, 132.31, 131.03, 130.96, 130.7, 130.6, 129.87, 129.85, 129.4, 129.34, 128.96, 128.4, 63.6, 63.5, 57.0, 56.8, 50.77, 50.76, 38.72, 38.68, 31.7, 31.6, 25.4, 25.1, 21.50. 21.48. Mass Spectroscopy: (+FAB, 3-nitrobenzyl alcohol) 461 (M+H). 20 Example 5 Synthesis of N-(Toluene- 4 -sulfonyl)-L-prolyl-4-(2-carboxyphenoxy)-L-phenylalanine N-(Toluene-4-sulfonyl)-L-prolyl-L-tyrosine methyl ester (2.14 g, 5.16 mmol) was added to a suspension of sodium hydride, 60% in oil (1.1 25 eq., 228 mg) in xylenes (50 mL) at 0OC. The reaction mixture was stirred for 5 minutes and cuprous bromidedimethyl sulfide complex (1.4 eq., 1.48 g) was added. The reaction mixture was stirred at 23 C for 0.5 hr. To this was added sodium 2-iodobenzoate (1.5 eq., 8.06 mmol), and the reaction mixture was refluxed for 12 hours. EtOAc (100 mL) was added, and the organic 30 layer washed with NH 4 C1, 10% HC1, and brine, then dried over MgSO 4 . The WO 99/06437 PCT/US98/16070 165 crude material was eluted on column chromatography (silica gel), with CHCl 3 :MeOH (9:1), and isolated as an oil. The acid was prepared by treatment with NaOH (1.1 eq), in MeOH:H 2 0 (1:1) for 4 hours at room temperature. The diacid was isolated as a foam. 5 NMR data was as follows: 1 H NMR (300 MHz, CDC13): 6 = 7.71 (min, 2H), 7.29 (mn, 4H), 7.19 (min, 4H), 6.72 (min, 1H), 4.84 (min, 1H), 4.13 (min, 1H), 3.39 (m, 1H), 3.11 (inm, 3H), 2.43 (s, 3H), 1.89 (min, 1H), 1.48 (min, 3H). 13 C NMR (75 MHz, CDCl 3 ): 6 = 172.67, 157.84, 155.89, 155.04, 10 145.17, 133.61, 133.19, 133.08, 131.69, 131.02, 130.64, 128.42, 127.87, 124.24, 120.04, 119.61, 116.12, 62.81, 50.31, 37.28, 30.69, 24.81, 22.15. Mass Spectroscopy: (FAB) 553 (M+H). Example 6 15 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-O-(benzyl)-L-tyrosine N-(Toluene-4-sulfonyl)-L-Pro-OH was treated with (COC1) 2 and DMF in CH 2 C1, to give, after evaporation, N-(Toluene-4-sulfonyl)-L-Pro-Cl. This product was treated with L-Tyr(Bn)-OH and NaOH in THF and HO 2 0, to 20 give, after acidification, extraction, drying with MgSO 4 , and evaporation the title compound as a clear oil. NMR data was as follows: 1 H NMR (DMSO-d 6 , 300 MHz): 6 = 8.04 (d, J= 8.2, 1H), 7.70 (d, J= 8.1, 2H), 7.42-7.21 (m, 6H), 7.15 (d, J= 8.5, 2H), 6.90 (d, J= 8.5, 2H), 25 5.04 (s, 2H), 4.49-4.42 (min, 1H), 4.13-4.09 (min, 1H), 3.33-3.27 (m, 2H), 3.10 2.89 (m, 3H), 2.38 (s, 3H), 1.60-1.35 (m, 4H). 13C NMR (DMSO-d 6 , 75 MHz): 6 = 172.63, 170.8, 157.0, 143.6, 137.2, 133.8, 130.3, 129.8, 129.4, 128.9, 128.4, 127.6, 125.3, 114.4, 69.1, 61.3, 53.4, 49.0, 35.8, 30.4, 23.8, 21.0. 30 Mass Spectroscopy: (+FAB, 3-nitrobenzyl alcohol) 523 (M+H).

WO 99/06437 PCT/US98/16070 166 Example 7 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-4-(iodo)-L-phenylalanine Following the experimental procedure described for the synthesis of 5 Example 8, affords the title compound as a foam. NMR data was as follows: 1 H NMR (300 MHz, DMSO-d 6 ): 8 = 8.30 (d, 1H, J= 8.40 Hz), 7.87 (d, 2H, J= 8.50 Hz), 7.78 (d, 2H, J= 8.50 Hz), 7.55 (d, 2H, J= 8.30 Hz), 7.25 (d, 2H, J= 8.30 Hz), 4.63 (m, 1H), 4.26 (m, 1H), 3.20 (m, 4H), 2.53 (s, 10 3H), 1.75 (m, 4H). Mass Spectroscopy: (FAB) 543 (M+H). Example 8 Synthesis of 15 N-(Toluene- 4 -sulfonyl)-L-prolyl-L-4-(methoxy)-phenylalanine Following the experimental procedure described for Example 1, N (toluene-4-sulfonyl)-L-proline (861 mg, 3.2 mmol) was dissolved in 20 mL of DMF, with Et 3 N (2.0 eq, 981 ptL), BOP (1.1 eq, 1.55 g), and O-methyl-L tyrosine methyl esterHCI salt (1.1 eq). The methyl ester was isolated in 25% 20 yield (370 mg, 0.80 mmol). It was then hydrolyzed in a 1:1 solution of MeOH: H,O (5 mL), with NaOH (1.1 eq, 35 mg). The acid was isolated as a foam, in 60% yield (216 mg, 0.48 mmol). NMR data was as follows: 1 H NMR (300 MHz, CDCl 3 ): 6 =7.72 (d, 2H, J= 7.80 Hz), 7.46 (d, 25 1H, J= 6.30 Hz), 7.33 (d, 2H, J= 7.20 Hz), 7.26 (d, 2H, J= 7.80 Hz), 7.14 (d, 2H, J= 8.40 Hz), 5.65 (bs, 2H), 4.82 (m, 1H), 4.10 (m, 1H), 3.75 (s, 3H), 3.35-3.01 (m, 4H), 2.42 (s, 3H), 1.97 (m, 1H), 1.48 (m, 3H).

WO 99/06437 PCT/US98/16070 167 1 3 C NMR (75 MHz, CDC1 3 ): 6 = 174.57, 172.25, 159.18, 145.07, 133.40, 130.97, 130.59, 128.66, 128.44, 114.53, 62.78, 55.84, 54.09, 50.20, 37.09, 30.48, 24.68, 22.15. Mass Spectroscopy: (FAB) 447 (M+H). 5 Example 9 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-4-nitro-L-phenylalanine N-(toluene-4-sulfonyl)-L-proline (955 mg, 3.4 mmol) was dissolved 10 in dry DMF (50 mL) with L-(4-nitro)-phenylalanine methyl ester (1.1 eq, 777 mg), Et 3 N (2.2 eq, 1.04 mL), and BOP reagent (1.1 eq, 1.65 g). The desired methyl ester was isolated in 40% yield (500 mg, 1.05 mmol). The ester was hydrolyzed in a 1:1 solution of MeOH:H 2 0,O (10 mL) with NaOH (1.1 eq, 42 mg). The title compound was isolated as an oil in 51% yield (246 15 mg, 0.53 mmol). NMR data was as follows: 1 H NMR (300 MHz, CDC1 3 ): 6 = 8.10 (d, 2H, J= 8.79 Hz), 7.81 (d, 1H, J= 8.25 Hz), 7.68 (d, 2H, J= 8.22 Hz), 7.42 (d, 2H, J= 8.79 Hz), 7.32 (d, 2H, J= 8.25 Hz), 4.93 (m, 1H), 4.09 (m, 1H), 3.44 (m, 2H), 3.24 (m, 1H), 20 3.04 (m, 1H), 2.38 (s, 3H), 1.83 (m, 1H), 1.38 (m, 3H). 1 3 C NMR (75 MHz, CDCl 3 ): 6 = 174.25, 173.00, 147.87, 145.34, 145.06, 133.06, 131.13, 130.73, 128.42, 124.18, 62.62, 53.29, 50.04, 37.48, 30.21, 24.35, 21.76. Mass Spectroscopy: (FAB) 462 (M+H). 25 Example 10 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-4-(O-tert-butyl)-L-tyrosine Following the experimental procedure described in Example 8, the 30 desired material was isolated as a solid, mp = dec >80 0

C.

WO 99/06437 PCT/US98/16070 168 NMR data was as follows: 1 H NMR (300 MHz, CDCl 3 ): 6 = 7.66 (d, 2H, J= 8.40 Hz), 7.32 (d, 2H, J= 8.01 Hz), 7.09 (d, 2H, J= 8.37 Hz), 6.91 (d, 2H, J= 7.86 Hz), 4.75 (m, 1H), 4.00 (m, 1H), 3.25 (m, 2H), 3.05 (m, 2H), 2.40 (s, 3H), 1.95 (m, 5 4H), 1.27 (s, 9H). Mass Spectroscopy: (FAB) 489 (M+H). Example 11 Synthesis of 10 N-(Toluene-4-sulfonyl)-L-prolyl-L-(3,5-diiodo)-tyrosine Following the experimental procedure described in Example 8 but substituting 3,5-diiodo-L-tyrisine methyl esterHCI salt for the O-methyl-L tyrosine provided for the title compound as a foam. NMR data was as follows: 15 'H NMR (300 MHz, CDCl 3 ): 8 = 7.74 (d, 2H, J= 8.19 Hz), 7.51 (s, 1H), 7.42 (m, 1H), 7.36 (d, 2H, J= 8.22 Hz), 7.26 (s, 1H), 4.75 (m, 1H), 4.12 (m, 1H), 3.55 (m, 1H), 3.24 (m, 2H), 3.05 (m, 1H), 2.44 (s, 3H), 1.62 (m, 4H). Mass Spectroscopy: (FAB) 685 (M+H), 713 (M+Na). 20 Example 12 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-L-4-(aminobenzoyl)-phenylalanine Following the experimental procedure described for Example 1, the 25 title compound was isolated as an oil in quantitative yields. NMR data was as follows: 'H NMR (300 MHz, CD30D): 8 = 7.70 (d, 2H, J= 8.50 Hz), 7.62 (d, 2H, J= 8.50 Hz), 7.44-7.17 (m, 5H), 7.20 (d, 2H, J= 8.25 Hz), 7.06 (d, 2H, J = 8.52 Hz), 4.47 (m, 1H), 3.89 (m, 1H), 3.18 (m, 1H), 3.05-2.83 (m, 3H), 30 2.20 (s, 3H), 1.60-1.39 (m, 4H).

WO 99/06437 PCT/US98/16070 169 1 3 C NMR (75 MHz, CD 3 OD): 6 = 177.08, 171.91,148.83,141.80, 139.37, 138.10, 137.48, 136.92, 134.12, 132.72, 132.37, 131.69, 125.32, 66.34, 58.09, 53.70, 40.85, 34.78, 28.47, 24.61. Mass Spectroscopy: (FAB) 537 (M+H). 5 Preparative Example A Synthesis of N-(Toluene-4-sulfonyl)-D-prolyl-D-phenylalanine Boc-D-Pro-OH and D-Phe-OBnHCI were treated with BOP and 10 NMM in DMF, to give after aqueous workup and flash chromatography, Boc-D-Pro-D-Phe-OBn. This product was treated with TFA and anisole, and the mixture was evaporated. The residue was dissolved in Et20 and washed with saturated aqueuos NaHCO 3 and saturated aqueous NaC1. The EtO layers were dried with MgSO 4 , filtered, and evaporated to give D-Pro-D-Phe 15 OBn. This product was treated with CH 3

SO

2 C1 and Et 3 N in CH 2 C1 2 , to give after aqueous workup and flash chromatography, N-(CH 3

SO

2 )-D-Pro-D-Phe OBn. This product was treated with 10% Pd on C in THF, and the mixture was shaken under 50 psi H 2 . The mixture was filtered through Celite, and evaporated to give the title compound as a solid, mp = 71-75'C. 20 NMR data was as follows: 'H NMR (CDC1 3 , 300 MHz): 6 = 1.24-1.54 (m, 3H), 1.95 (m, 1H), 2.43 (s, 3H), 3.10 (m, 2H), 3.32 (m, 2H), 4.09 (m, 1H), 4.82 (m, 1H), 7.10 7.40 (m, 7H), 7.69 (d, 2H, J= 8.0 Hz). 13C NMR (CDCl 3 , 75 MHz): 6 = 22.1, 25.8, 32.2, 38.8, 55.4, 63.8, 25 128.5, 129.5, 130.0, 131.1, 131.6, 135.5, 138.7, 146.3, 174.58, 174.63. Mass Spectroscopy: (FAB+) 417 (M+H).

WO 99/06437 PCT/US98/16070 170 Example 13 Synthesis of N-(Toluene- 4 -sulfonyl)-L-prolyl-L-(3-iodo-4-hydroxy)-phenylalanine The title compound was prepared according to the procedure 5 described for the synthesis described in Example 8. The corresponding material was isolated as a film. NMR data was as follows: 1H NMR (300 MHz, DMSO-d 6 ): 6 = 7.72 (d, 2H, J= 8.50 Hz), 7.42 (s, 1H), 7.43 (d, 2H, J= 8.50 Hz), 7.08 (d, 1H, J= 8.05 Hz), 6.75 (d, 1H, J 10 8.05 Hz), 4.81 (m, 1H), 4.11 (m, 1H), 3.45 (m, 1H), 3.20 (m, 2H), 2.98 (m, 1H), 2.62 (m, 1H), 2.44 (s, 3H), 1.96 (m, 2H). Example 14 Synthesis of 15 N-(Toluene- 4 -sulfonyl)-L-prolyl-L-(4-chloro)phenylalanine The title compound was prepared from the product of Example 37 using the procedure described in Method 7, mp = >200 0 C Example 15 20 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-L-leucine N-(Toluene-4-sulfonyl)-L-proline hydrate was coupled to L-leucine methyl ester hydrochloride using the procedure described in Method 3. The title compound was prepared via hydrolysis of the methyl ester using LiOH 25 in THF/water. NMR data was as follows: 'H NMR (CDCl 3 ): 8 = 9.80 (bs, 1H), 7.72 (d, 2H, J= 8.0 Hz), 7.47 (d, 1H, J= 8.0 Hz), 7.32 (d, 2H, J= 8.0 Hz), 4.56 (m, 1H), 4.16 (m, 1H), 3.51 (m, 1H), 3.17 (m, IH), 2.38 (s, 3H), 2.12 (m, 1H), 1.73-1.54 (6H), 0.91 30 (d, 3H, J= 6.5 Hz), 0.89 (d, 3H, J= 6.0 Hz).

WO 99/06437 PCT/US98/16070 171 1 3 C NMR (CDC13): 8 = 176.2, 172.5, 145.0, 133.4, 130.6 128.4, 62.7, 51.7, 50.3, 41.4, 30.5, 25.5, 23.4, 22.4, 22.1. Mass Spectroscopy: FAB m/e 383 (M+H). 5 Example 16 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-L-alanine N-(Toluene-4-sulfonyl)-L-proline hydrate was coupled to L-alanine methyl ester hydrochloride using the procedure described in Method 3. The 10 resulting methyl ester was deesterified via hydrolysis using LiOH in THF/water to provide the title compound as a solid, mp = 160.5-162.5 0 C. NMR data was as follows: 'H NMR (CDCl 3 ): 6 = 7.76 (d, 2H, J= 8.2 Hz), 7.52 (d, 1H, J= 6.7 Hz), 7.37 (d, 2H, J= 8.0 Hz), 4.56 (p, 1H, J= 7.1 Hz), 4.14 (dd, 1H, J= 2.6, 15 8.5 Hz), 3.56 (m, 1H), 3.21 (dt, 1H, J= 6.6, 9.7 Hz), 2.45 (s, 3H), 2.21 (m, 1H), 1.78 (m, 1H), 1.62 (m, 2H), 1.52 (d, 3H, J= 7.1 Hz). 13C NMR (CDC 3 ): 68 = 176.4, 172.3,145.1, 133.3, 130.6,128.5, 62.7, 50.4, 49.1, 30.5, 25.0, 22.2, 18.5. Mass Spectroscopy: FAB m/e 341 (M+H). 20 Example 17 Synthesis of N-(Toluene- 4 -sulfonyl)-L-prolyl-L-4-(acetamido)-phenylalanine The title compound was prepared from the product of Example 39 25 using the procedure described in Method 6. NMR data was as follows: 'H NMR (300 MHz, CD 3 OD): 6 = 7.50 (d. 2H, J= 8.25 Hz), 7.28 (d, 2H, J= 8.37 Hz), 7.17 (d, 2H, J= 8.20 Hz), 6.99 (d, 2H, J= 8.37 Hz), 4.50 (m, 1H), 3.92 (m, 1H), 3.17 (m, 1H), 3.04 (m, 2H), 2.81 (m, 1H), 2.19 (s, 30 3H), 1.87 (s, 3H), 1.56 (m, 1H), 1.40 (m, 3H).

WO 99/06437 PCT/US98/16070 172 1 3 C NMR (75 MHz, CD 3 OD): 6 = 174.61,172.14, 146.30, 139.29, 135.47, 134.38, 131.64, 131.48, 129.54, 121.71, 63.82, 55.36, 51.20, 38.27, 32.26, 25.93, 24.50, 22.19. Mass Spectroscopy: (FAB) 474 (M+H). 5 Example 18 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-L-isoleucine N-(Toluene-4-sulfonyl)-L-proline hydrate was coupled to L 10 isoleucine methyl ester hydrochloride using the procedure described in Method 3. The title compound was prepared via hydrolysis of the methyl ester using LiOH in THF/water. NMR data was as follows: 'H NMR (CDC1 3 ): 6 = 7.72 (d, 2H, J= 8.3 Hz), 7.46 (d, 1H, J= 7.5 15 Hz), 7.36 (d, 2H, J= 8.1 Hz), 4.54 (dt, 1H, J= 5.4, 7.6 Hz), 4.16 (dd, 1H, J 2.6, 8.7 Hz), 3.54 (m, 1H), 3.21 (m, 1H), 2.44 (s, 3H), 2.20 (m, 1H), 1.97 (m, 1H), 1.33-1.57 (4H), 1.35 (m, 4H), 0.90 (d, 3H, J= 7.0 Hz). 1 3 C NMR (CDCl 3 ): 6 = 176.2, 172.2, 145.1, 133.4, 130.6, 128.5, 62.8, 53.3, 50.4, 32.1, 30.4, 28.0, 25.1, 22.8, 22.2, 14.5. 20 Mass Spectroscopy: FAB m/e 383 (M+H). Example 19 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-L-aspartic acid 25 N-(Toluene-4-sulfonyl)-L-proline hydrate was coupled to L-4-(1,1 dimethylethyl)-aspartic acid methyl ester hydrochloride using the procedure described in Method 3. The methyl ester was hydrolyzed using LiOH in THF/water to provide a solid, mp = 153-155'C. The title compound was prepared, via cleavage of the t-butyl ester using trifluoroacetic acid in 30 CH 2 C12, as a solid, mp = 174-176 0

C.

WO 99/06437 PCT/US98/16070 173 NMR data was as follows: 1 H NMR (DMSO-d 6 ): 8 = 8.27 (d, 1H, J= 8.0 Hz), 7.75 (d, 2H, J= 8.2 Hz), 7.44 (d, 2H, J= 8.2 Hz), 4.54 (m, 1H), 4.16 (m, 1H), 3.38 (m, 1H), 3.13 (m, 1H), 2.74 (dd, 1H, J= 5.9, 16.7 Hz), 2.63 (dd, 1H, J= 6.3, 16.7 Hz), 5 2.41 (s, 3H), 1.75 (m, 2H), 1.51 (m, 2H). 1 3 C NMR (DMSO-d 6 ): 6 = 172.5, 172.2, 171.3, 144.0, 134.3, 130.2, 127.9, 61.7, 49.3, 48.9, 36.2, 30.9, 24.3, 21.4. Mass Spectroscopy: FAB m/e 385 (M+H). 10 Example 20 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-L-lysine N-(Toluene-4-sulfonyl)-L-proline hydrate was coupled to L-E-Cbz lysine methyl ester hydrochloride using the procedure described in Method 3. 15 The methyl ester was hydrolyzed using LiOH in THF/water. The title compound was prepared using the procedure described in Method 4 as a solid, mp = >200oC. Example 21 20 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-L-glutamic acid N-(Toluene-4-sulfonyl)-L-proline hydrate was coupled to L-5-(1,1 dimethylethyl)-glutamic acid methyl ester hydrochloride using the procedure described in Method 3. The methyl ester was hydrolyzed using LiOH in 25 THF/water to provide a solid, mp = 164-166 0 C. The title compound was prepared, via cleavage of the t-butyl ester using trifluoroacetic acid in

CH

2

CI

2 l, as a solid, mp = >200'C.

WO 99/06437 PCT/US98/16070 174 Example 22 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-L (4-dibenzylamino)-phenylalanine methyl ester 5 The title compound was prepared using the procedure described in Method 9. The crude product was purified by flash chromatography (silica, 1:1 EtOAc:hexane) to afford the methyl ester as a white solid, mp = 60 65 0 C. 10 Example 23 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-L-(N-benzyl)-histidine N-(Toluene-4-sulfonyl)-L-proline hydrate was coupled to L-(N benzyl)-histidine methyl ester dihydrochloride using the procedure described 15 in Method 3. The title compound was prepared via hydrolysis of the methyl ester using LiOH in THF/water. NMR data was as follows: 'H NMR (DMSO-d 6 ): 8 = 8.15 (2, 1H, J= 7.8 Hz), 7.72 (mn, 3H), 7.42 (d, 2H, J= 8.0 Hz), 7.37-7.21 (6H), 6.96 (s, 1H), 5.11 (s, 2H), 4.42 (inm, 20 1H), 4.09 (min, 1H), 3.29 (min, 1H), 3.04 (min, 1H), 2.90 (mn, 3H), 2.40 (s, 3H), 1.65-1.39 (4H).

"

3 C NMR (DMSO-d 6 ): 6 = 173.1, 171.0, 144.0, 138.0, 137.7, 137.1, 134.2, 130.2, 129.0, 128.9, 128.0, 127.9, 117.3, 61.8, 52.5, 49.9, 49.3, 30.7, 30.1, 24.1, 21.4. 25 Mass Spectroscopy: FAB m/e 497 (M+H). Example 24 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-L-(4-dibenzylamino)-phenylalanine 30 The methyl ester was prepared using the procedure described in Example 22. The crude product was purified by flash chromatography WO 99/06437 PCT/US98/16070 175 (silica, 1:1 EtOAc:hexane) to afford the methyl ester as a white solid, mp = 60-65 C. The title compound was then prepared using the procedure de scribed in Method 5. NMR data was as follows: 5 'H NMR (DMSO-d 6 , 400 MHz): 6 = 7.72 (d, 2H, J= 8.34Hz); 7.55 (d, 1H, J= 5.71Hz); 7.4 (d, 2H, J= 7.9Hz); 7.24 (mn, 4H); 7.18 (m, 6H); 6.76 (d, 2H, J = 8.56Hz); 6.44 (d, 2H, J= 8.56Hz); 4.58 (d, 4H, J= 3.07Hz); 3.89 (dd, 1H, J= 2.74, 8.89Hz); 3.76 (min, 1H); 2.92 (min, 4H); 2.39 (s, 3H); 1.61 (mn, 1H); 1.05-1.34 (min, 3H). 10 IR (KBr, cm-' ) 3400, 1655, 1620, 1520, 1405, 1300, 1160. Mass Spectroscopy: ((+) FAB, m/e (%)) 634 (20 [M+ Li]+); 612 (100 [M+H]+). Example 25 15 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-L-methionine N-(Toluene-4-sulfonyl)-L-proline hydrate was coupled to methionine methyl ester using the procedure described in Method 3. The title compound was prepared via hydrolysis of the methyl ester using LiOH in THF/water. 20 NMR data was as follows: 'H NMR (CDCl 3 ): 6 = 9.05 (bs, 1H), 7.76 (d. 2H, J= 8.2 Hz), 7.69 (d, 1H, J= 7.7 Hz), 7.37 (d, 2H, J= 7.9 Hz), 4.68 (min. 1H), 4.16 (m, 1H), 3.57 (min, 1H), 3.20 (min, 1H), 2.59 (t, 2H, J= 7.4 Hz), 2.45 (s, 1H), 2.21 (m 3H), 2.19 (s, 3H), 1.79 (min, 1H), 1.63 (m, 2H). 25 1 3 C NMR (CDCl 3 ): 6 = 174.5, 172.0, 144.5, 132.6, 130.0, 127.9, 62.2, 51.9, 49.8, 30.8, 30.0, 29.9, 24.5, 21.6, 15.4. Mass Spectroscopy: FAB m/e 401 (M+H).

WO 99/06437 PCT/US98/16070 176 Example 26 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-L-serine The title compound was prepared via hydrogenolysis of the 5 corresponding benzyl ether using 10% Pd/C in EtOH/HOAc (20:1). The reaction mixture was filtered through celite and the filtrate was evaporated in vacuo to give a residue which was lyophilized from water to give the title compound as a white solid. NMR data was as follows: 10 'H NMR (CDC1 3 ): 6 = 7.97 (d, 1H, J= 7.1 Hz), 7.74 (d, 2H, J= 8.0 Hz), 7.33 (d, 2H, J= 8.4 Hz), 4.62 (m 1H), 4.21-3.94 (2H), 3.60 (mn, 1H), 3.17 (min, 1H), 2.41 (s, 3H), 2.07 (min, 1H), 1.88-1.55 (3H). 1 3 C NMR (CDCl 3 ): 6 = 172.8, 144.4, 132.8, 130.0, 127.8, 62.3, 55.0, 49.8, 30.8, 30.2, 24.4, 21.5. 15 Mass Spectroscopy: FAB m/e 357 (M+H). Preparative Example B Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-D-aspartic acid 20 N-Benzyloxycarbonyl-D-4-(1,1-dimethylethyl)-aspartic acid was con verted to the methyl ester using the procedure described in Method 2. D-4 (1,1-dimethylethyl)-aspartic acid methyl ester was prepared from the product of the previous step utilizing the procedure described in Method 4. N (Toluene-4-sulfonyl)-L-proline hydrate was coupled to the resulting D-4 25 (1,1-dimethylethyl)-aspartic acid methyl ester utilizing the procedure described in Method 3. The methyl ester was hydrolyzed using the procedure described in Method 6. The product was isolated as a white solid, mp = 55 oC. The title compound was then prepared using the procedure described in Method 11. The product was isolated as a white solid, mp = 30 131-132°C.

WO 99/06437 PCT/US98/16070 177 NMR data was as follows: 'H NMR (DMSO-d 6 ,300 MHz): 6 = 8.19 (d, 1H, J= 8.0 Hz); 7.73 (d, 2H, J= 7.0 Hz); 7.43 (d, 2H, J= 8.0 Hz); 4.55, (m 1 H); 4.12, (m, 1H); 3.40 (m, 1H); 3.13 (m, 1H); 2.60 (m, 2H); 2.41 (s, 3H); 1.76 (m, 2H); 1.55 5 (m, 2H). 13C NMR (DMSO-d 6 ,75 MHz): 8 = 172.5, 172.2, 171.3, 144.0, 134.2, 130.2, 127.9, 61.8, 49.4, 48.8, 36.2, 30.9, 24.2, 21.4. Mass Spectroscopy: (PI-FAB) 385, (M+H)*. 10 Preparative Example C Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-D-glutamic acid N-Benzyloxycarbonyl-D-5-(1,1-dimethylethyl)-glutamic acid was converted to the methyl ester using the procedure described in Method 2. D 15 5-(1,1-dimethylethyl)-glutamic acid methyl ester was prepared from the product of the previous step utilizing the procedure described in Method 4. N-(Toluene-4-sulfonyl)-L-proline hydrate was coupled to the resulting D-5 (1,1-dimethylethyl)-glutamic acid methyl ester utilizing the procedure described in Method 3. The methyl ester was hydrolyzed using the 20 procedure described in Method 6. The product was isolated as a white solid, mp = 50'C. The title compound was then prepared using the procedure described in Method 11. The product was isolated as a white solid, mp = 60 0 C. NMR data was as follows: 25 'H NMR (DMSO-d 6 ,300 MHz): 8 = 8.12 (d, 1H, J= 4.0 Hz); 7.73 (m, 2H); 7.43, (m, 2H); 4.25 (m, 1 H); 4.05 (m, 1H); 3.43 (m, 1H); 3.15 (m, 1H); 2.40 (s, 3H), 2.45 (m, 2H); 2.02 (m, 2 H); 1.90 - 1.40 (bin, 4 H). 13C NMR (DMSO-d 6 ,75 MHz): 6 = 174.3, 173.3,171.6, 144.0, 134.1, 130.3, 127.8, 61.9, 51.4, 49.5, 31.2, 30.3, 26.3, 24.3, 21.4. 30 Mass Spectroscopy: (PI-FAB) 399, (M+H) .

WO 99/06437 PCT/US98/16070 178 Example 27 Synthesis of N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl) thiaprolyl-L-(N-benzyl)-histidine 5 N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)-thiazolidine-4-carboxylic acid was prepared from L-(5,5-dimethyl)-thiazolidine-4-carboxylic acid using the procedure described in Method 1. The title compound was then prepared using standard coupling procedures to provide a solid, mp = >200 0 C (dec.). 10 NMR data was as follows: 1 H NMR (DO 2 0, 300 MHz): 6 = 0.95 (s, 3H), 1.08 (s, 3H), 2.41 (s, 3H), 2.85-3.12 (m, 2H), 3.84 (s, 1H), 4.32 (m, 1H), 4.40 (s, 2H), 5.09 (s, 2H), 7.01 (s, 1H), 7.24-7.43 (m, 7H), 7.60-7.71 (m, 3H). 13C NMR (D 2 0, 75 MHz): 6 = 27.9, 30.2, 30.3, 35.6, 37.0, 57.7, 61.3, 15 61.7, 79.8, 124.9, 134.6, 135.06, 135.10, 135.8, 137.1, 138.9, 143.2, 143.4, 143.5, 152.6, 176.7, 184.1. Mass Spectroscopy: (FAB+) 565 (M+H). Example 28 20 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-L-(1-methyl)histidine The ester of the title compound was synthesized as described in Method 12. The ester was dissolved in dioxane/H 2 0 (8 mL) to which was added solid NaOH (1 eq.). After stirring overnight, the reaction mixture was 25 concentrated. The residue was redissolved in HO and loaded onto an ion exchange column (Dowex 50W-X8-100, H+ form). After washing the column with HO, the compound was eluted with 5% aqueous pyridine. Fractions containing the compound were pooled and concentrated and the residue was dissolved in HO 2 0 and lyophilized. The product was isolated as a 30 white solid, mp = 135-137 0 C. NMR data was as follows: WO 99/06437 PCT/US98/16070 179 1 H NMR(DMSO-d 6 , 300 MHz): 8 = 8.16 (d, 2H, J= 8.0 Hz); 7.72 (d, 2H, J= 8.0 Hz); 7.54 (s, 1H); 7.42 (d, 2H, J= 8.0 Hz); 6.91 (s, 1H); 5.10 (bs, 1 H); 4.41 (min, 1H); 4.11 (M, 1H); 3.57 (s, 3H), 3.34 (min, 1H); 3.10 (inm, 1H); 2.92 (min, 2 H); 2.39 (s, 3 H); 1.80-1.45 (bin, 4H). 5 13 C NMR(DMSO-d 6 ,75 MHz): 8 = 173.0,171.0,143.9,137.5,136.9, 134.3, 130.2, 127.8, 118.6, 61.8, 52.5, 49.3, 33.3, 30.8, 29.9, 24.2, 21.4. Mass Spectroscopy: (PI-FAB) 421, (M+H). Example 29 10 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-D-(N-benzyl)histidine A CH 2 Cl1 2 solution of Boc-D-(N-benzyl)histidine was chilled to -15 'C (dry ice/CH 3 CN bath) to which was added diethylisopropylamine (1.5 eq.), methanol (3.0 eq.) and BOP (1.1 eq) to form the methyl ester. The 15 reaction was allowed to warm to room temperature and stirred overnight. The reaction mixture was then poured into 0.1 M HCI and the organic phase washed with H 2 0, saturated NaHCO 3 , brine, dried (MgSO 4 ), filtered and concentrated. The crude methyl ester was purified by column chromatography. The Boc group was removed with TFA/CHC1 2 l. The crude 20 reaction mixture was taken-up in CHC1, and washed with 5% Na2CO 3 . The organic phase was washed with brine and dried (MgSO 4 ), filtered and concentrated to give the free amine. The coupling was performed using the procedure described in Method 12 and the ester hydrolyzed using the procedure described in Method 7. The product was isolated as a white solid, 25 mp = >200 0 C. NMR data was as follows: 1 H NMR (DMSO-d 6 ,300 MHz): 8 = 7.75 - 7.61 (mn, 3 H); 7.51 (s, 1H); 7.45-7.15 (bin, 7 H); 6.89 (s, 1H); 5.05 (min, 2H); 4.05 (min, 2H); 3.30 (inm, 1 H); 3.10 (mn, 1H); 2.95 (min, 1H); 2.75 (min, 1H); 2.38 (s, 3H); 1.67 (mn, 2H); 30 1.35 (inm, 2H).

WO 99/06437 PCT/US98/16070 180 1 3 C NMR (DMSO-d 6 , 75 MHz): 6 = 17403, 169.6, 143.9, 139.3, 138.3,136.5, 134.1,130.3, 128.9, 127.8, 127.7, 117.1, 62.4, 54.3, 49.8, 49.4, 31.8, 30.6, 24.2, 21.4. Mass Spectroscopy: (PI-FAB) 519, (M+H)*. 5 Example 30 Synthesis of N-(Toluene-4-sulfonyl)-L-glutamyl-L-tyrosine Cbz-L-5-(1,1-dimethylethyl)-glutamic acid was coupled with L 10 tyrosine t-butyl ester using the procedure described in Method 3. The Cbz group was removed using the procedure described in Method 4. The resulting ester was tosylated using the procedure described in Method 1. The title compound was prepared using the procedure outlined in Method 11 which provided a solid, mp= 173-175oC. 15 NMR data was as follows: 'H NMR (DMSO-d 6 , 300 MHz): 6 = 1.70-1.90 (m, 2H), 2.24-2.32 (m, 2H), 2.40 (s, 3H), 2.80-3.10 (m, 2H), 3.51 (m, 1H), 4.0-4.5 (C-H buried under large H 2 0 peak), 6.87 (d, 2H, J= 8.4 Hz), 7.18 (d, 2H, J= 8.2 Hz), 7.44 (d, 2H, J= 8.2 Hz), 7.70 (d, 2H, J= 8.2 Hz), 8.34 (bs, 1H). 20 13C NMR (DMSO-d 6 , 75 MHz): 6 = 21.5, 28.5, 31.1, 36.7, 52.9, 54.8, 121.9, 128.5, 130.6, 131.1, 131.9, 138.0, 146.1, 147.9, 170.7, 173.0, 174.7. Mass Spectroscopy: (FAB+) 465 (M+H). Example 31 25 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-L-(N-3-methyl)histidine Boc-L-(3-methyl)histidine was dissolved in MeOH and chilled in an ice bath. HCI gas was then bubbled through the reaction mixture for 15 minutes. After stirring overnight, the reaction mixture was concentrated to a 30 gummy solid. The dihydrochloride was coupled to Tos-Pro-OBn using the WO 99/06437 PCT/US98/16070 181 procedure described in Method 12 and hydrolyzed via Method 7. The product was isolated as a white solid, mp = >200 0 C. NMR data was as follows: 1H NMR (DMSO-d 6 , 300 MHz): 6 = 7.74 (m, 3H); 7.45 - 7.35 (bin, 5 3H); 6.56 (s, 1H); 4.10-3.93 (m, 2H); 3.51 (s, 3 H), 3.22 (m, 1H), 3.10 (m, 2H); 2.91 (m, 1H); 2.38 (s, 3 H); 1.70 (m, 1H); 1.45 (m, 3H). 1 3 C NMR (DMSO-d 6 , 75 MHz): 6 = 173.3, 170.1, 144.1, 137.5, 133.9, 130.3, 128.8, 128.1, 127.5, 62.4, 53.6, 49.1, 31.2, 30.6, 26.2, 24.1, 21.4. 10 Mass Spectroscopy: (PI-FAB) 443, (M+H) . Example 32 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-a-amino-2,3 15 dihydro-(1,4-benzodioxin)-6-propanoic acid The title compound was prepared using the procedure described in Method 16 and isolated as a white solid. NMR data was as follows: 'H NMR (CDCl 3 , 300 MHz): 6 = 7.73 (m, 2H); 7.32 (m, 2H); 6.87 20 6.26 (m, 2 H); 6.64 (m, 1H); 4.84 (m, 1 H); 4.21 (m, 4H), 4.10 (m, 1H); 3.55 3.40 (m, 1H); 3.30-2.95 (m, 3H); 2.43 (m, 3H); 2.06 (m, 1 H); 1.64 (m, 3H). 13C NMR (CDCl 3 , 75 MHz): 6 = 175.0, 174.5, 172.4, 172.3, 145.0, 144.9, 144.2, 143.9, 143.4, 143.2, 133.5, 133.4, 130.6, 129.6, 129.1, 128.5, 123.2, 122.69, 118.9, 118.7, 118.1, 117.9, 64.9, 63.1, 62.8, 53.9, 53.8, 50.4, 25 50.2, 37.3, 37.2, 30.9, 30.5, 24.8, 24.7, 22.2. Mass Spectroscopy: (PI-FAB) 475, (M+H) t

.

WO 99/06437 PCT/US98/16070 182 Example 33 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl a-amino-1,3-benzodioxole-5-propanoic acid 5 The title compound was prepared using the procedure described in Method 16 and isolated as a white solid. NMR data was as follows: 'H NMR (CDCl 3 , 300 MHz): 6 = 7.71 (m, 2H); 7.50 - 7.29 (bm, 3H); 7.81-7.60 (m, 3H); 5.90 (m, 2H); 4.80 (m, 1H); 4.15 (m, 1H); 3.43 (m, 1H); 10 3.30-3.00 (bm, 3H); 2.41 (s, 3H); 2.10 (m, 1H); 1.70 (m, 1H); 1.51 (m, 2H). 13C NMR (CDCl 3 , 75 MHz): 6 = 174.9, 174.5, 172.5, 172.3, 148.5, 148.2, 147.4, 147.2, 145.0, 133.4, 133.2, 130.6, 130.2, 129.5, 128.5, 128.5, 123.6, 123.1, 110.5, 110.2, 109.2, 108.8, 101.5, 63.1, 62.7, 54.0, 53.7, 50.4, 50.2, 37.8, 37.6, 31.0, 30.4, 24.8, 22.1. 15 Mass Spectroscopy: (PI-FAB) 461, (M+H)*. Example 34 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-L-valine 20 N-(Toluene-4-sulfonyl)-L-proline hydrate was coupled to L-valine methyl ester hydrochloride using the procedure described in Method 3. The title compound was prepared via hydrolysis of the methyl ester using LiOH in THF/water. NMR data was as follows: 25 'H NMR (CDCl 3 ): 6 = 8.20 (br s, 1H), 7.76 (d, 2H, J = 8. Hz), 7.49 (d, 1H, J = 8.3 Hz), 7.35 (d, 2H, J = 8.0 Hz), 4.50 (dd, 1H, J = 4.8, 8.3 Hz), 4.19 (m, 3H), 3.54 (m, 1H), 3.21 (m, 1H), 2.44 (s, 3H), 2.31-2.18 (2H), 1.70 1.56 (3H), 1.00 (d, 3H, J = 6.9 Hz), 0.99 (d, 2H, J = 6.9 Hz). 13C NMR (CDC1 3 ): 6 = 175.7, 172.3, 145.0, 133.5, 130.6, 128.5, 62.8, 30 58.1, 50.3, 31.6, 30.3, 25.1, 22.2, 19.7, 18.2. Mass Spectroscopy: FAB m/e 369 (M+H).

WO 99/06437 PCT/US98/16070 183 Example 35 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-L-(4-iodo)-phenylalanine methyl ester The procedure used for the preparation of Example 8 was utilized. 5 The title compound was isolated as a white foam. NMR data was as follows: 'H NMR (300 MHz, CDC13): 6 = 7.72 (d, 2H, J = 8.25 Hz), 7.64 (d, 2H, J = 8.25 Hz), 7.41 (d, 1H, J = 8.20 Hz), 7.36 (d, 2H, J = 8.10 Hz), 7.00 (d, 2H, J= 8.25 Hz), 4.82 (m, 1H), 4.08 (m, 1H), 3.71 (s, 3H), 3.35 (m,2H), 10 3.10 (m, 2H), 2.44 (s, 3H), 2.01 (m, 1H), 1.55 (m, 3H). Mass Spectroscopy: (FAB) 557 (M+H). Example 36 Synthesis of 15 N-(Toluene-4-sulfonyl)-L-prolyl L-4-(aminobenzoyl)phenylalanine methyl ester Followed the experimental section described for Example 1. N (Toluene- 4 -sulfonyl)-L-prolyl-L-p-amino-phenylalanine methyl ester (1.75 g, 3.93 mmol) was dissolved in dichloromethane (25 mL) with Et 3 N (1.1 eq, 20 600 mL) and benzoyl chloride (1.1 eq, 860 mL). The title material was isolated as a solid, in 90% yield (1.95 g, 3.55 mmol), mp = 191-193oC. NMR data was as follows: 'H NMR (300 MHz, CDCI 3 ): 6 = 7.94 (broad s, 1H), 7.67 (d, 2H, J 8.31 Hz), 7.71 (d, 2H, J = 8.22 Hz), 7.60 (d, 2H, J = 8.37 Hz), 7.45 (m, 5H), 25 7.34 (d, 2H, J = 8.34 Hz), 7.16 (d, 2H, J = 8.25 Hz), 4.82 (m, 1H), 4.40 (broad s, 1H), 4.05 (m, 1H), 3.77 (s, 3H), 3.40 (m, lH), 3.23 (m, 1H), 3.09 (m, 2H), 2.42 (s, 3H), 2.02 (m, 1HO, 1.56 (m, 3H). 1 3 C NMR (75 MHz, CDCl 3 ): 6 = 171.93, 171. 46, 144.93, 137.98, 135.45, 133.49, 132.78, 132.44, 130.55, 129.36, 128.43, 127.53, 120.80, 30 62.83, 54.02, 53.11, 50.29, 37.96, 30.31, 24.88, 22.16. Mass Spectroscopy: (FAB) 550 (M+H).

WO 99/06437 PCT/US98/16070 184 Example 37 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-L-(4-chloro)phenylalanine methyl ester N-(Toluene-4-sulfonyl)-L-proline (660 mg, 2.3 mmol) was added to 5 12 mL of DMF, at room temperature under N 2 . To this was added L-(4 chloro)phenylalanine methyl ester hydrochloride (1.1 eq. 493.3 mg), N methyl morpholine (3.5 eq., 890 mL) and BOP reagent (1.0 eq., 660 mg). The title compound was isolated as an oil in 31% yield (310 mg, 0.7 mmol). NMR data was as follows: 10 1 H NMR (300 MHz, CDC1 3 ): 6 = 7.70 (broad d, 2H), 7.35 (min, 2H), 7.25 (min, 2H), 7.11 (min, 2H), 4.82 (min, 1H), 4.05 (min, 1H), 3.78 (s, 3H), 3.35 (mn, 1H), 3.25 (m, 1H), 3.05 (m,2H), 2.45 (s,3H), 1.52 (mn, 3H). Mass Spectroscopy: (FAB) 433 (M+H). 15 Example 38 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-L-(4-amino)phenylalanine methyl ester N-(Toluene-4-sulfonyl)-L-prolyl-L-(4-nitro)phenylalanine methyl ester (2.00 g, 4.48 mmol) was dissolved in MeOH (10 mL) with a catalytic 20 amount of 10% Pd on C. The hydrogenation reaction was run at room temperature for 12 hours at 40 psi. Upon filtration of the reaction mixture over Celite, the solvent was evaporated under reduced pressure yielding the title compound as a pink foam in quantitative yields. NMR data was as follows: 25 'H NMR (300 MHz, CDCI 3 ): 8 = 7.68 (d, 2H, J = 8.25 Hz), 7.30 (d, 2H, J = 8.07 Hz), 6.88 (d, 2H, J = 8.25 Hz), 6.57 (d, 2H, J = 8.25 Hz), 4.74 (min, 1H), 4.04 (broad m, 3H), 3.70 (s, 3H), 3.36 (min, 1H), 3.11 (min, 2H), 2.92 (min, 1H), 2.39 (s, 3H), 1.97 (min, 1H), 1.48 (mn, 3H).

WO 99/06437 PCT/US98/16070 185 13C NMR (75 MHz, CDC13): 6 = 172.14, 171.31, 145.97, 144.86, 133.61, 130.65, 130.51, 128.43, 126.23, 115.79, 111.35, 62.83, 54.16, 52.96, 50.21, 37.68, 30.34, 24.76, 22.16, 14.7. Mass Spectroscopy: (FAB) 446 (M+H). 5 Example 39 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-L (4-acetamido)phenylalanine methyl ester 10 The title compound was prepared following the experimental proce dure described for Example 1 and was isolated as a foam in quantitative yields. NMR data was as follows: 1 H NMR (300 MHz, CDC13): 8 = 7.70 (d, 2H, J = 8.10 Hz), 7.65 (m, 15 2H), 7.33 (d, 2H, J = 8.40 Hz), 7.08 (d, 2H, J = 8.40 Hz), 4.79 (m, 1H), 4.05 (m, 1H), 3.75 (s, 3H), 3.37 (m, 1H), 3.11 (m, 3H), 2.42 (s, 3H), 2.22 (s, 3H), 2.02 (m, 1H), 1.48 (m, 3H). 1 3 C NMR (75 MHz, CDC13): 6 = 177.61, 171.92, 171.46, 169.07, 144.98, 137.69, 133.41, 132.25, 130.56, 130.32, 128.41, 120.40, 62.83, 20 54.00, 53.10, 50.28, 45.10, 37.89, 30.34, 25.13, 24.84, 22.17. Mass Spectroscopy: (FAB) 488 (M+H). Example 40 Synthesis of 25 N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)thiaprolyl-L (N-benzyl)-histidine methyl ester N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)thiazolidine-4-carboxylic acid was prepared from L-(5,5-dimethyl)thiazolidine-4-carboxylic acid using the procedure described in Method 1. The title compound was prepared 30 using standard coupling procedures to provide a solid, mp = 60-66oC. NMR data was as follows: WO 99/06437 PCT/US98/16070 186 1 H NMR (CDC1 3 , 300 MHz): 6 = 1.17 (s, 3H), 1.30 (s, 3H), 2.43 (s, 3H), 3.09 (m, 2H), 3.67 (s, 3H), 3.92 (s, 1H), 4.45 (d, 1H, J = 10.2 Hz), 4.62 (d, 1H, J = 10.1 Hz), 5.03 (s, 2H), 6.71 (s, 1H), 7.13 (d, 2H, J = 7.7 Hz), 7.29-7.38 (m, 5H), 7.46 (s, 1H), 7.76 (d, 2H, J = 8.1 Hz), 7.93 (d, 1H, J = 7.4 5 Hz). 13 C NMR (CDC1 3 ,75 MHz): 6 = 22.3, 24.9, 29.8, 30.3, 51.1, 51.5, 52.9, 53.0, 55.3, 74.0, 117.9, 128.0, 128.6, 128.9, 129.6, 130.5, 133.0, 136.5, 137.6, 137.9, 145.0, 169.1, 171.9. Mass Spectroscopy: (FAB+) 557 (M+H). 10 Example 4 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-4-(3-3'-tolylureido)-L-phenylalanine The methyl ester was prepared by the reaction of N-(toluene-4 15 sulfonyl)-L-prolyl-L-4-aminophenylalanine with 3-tolylisocyanate (triethylamine, toluene, reflux one hour). The resulting solid was removed by filtration and washed well with EtOAC/Hexane to give the methyl ester as a white solid. The methyl ester was hydrolyzed using 1IM LiOH in THF. The title compound was isolated following acid/base work-up as a white 20 solid, mp= 135-140 0 C. NMR data was as follows: 1 H NMR (DMSO-d 6 , 400 MHz): 6 = 12.79 (br s, 1H); 8.55 (s, 1H); 8.50 (s, 1H); 8.02 (d, 1H, J = 7.9Hz); 7.69 (d, 2H, J = 8.3Hz); 7.39 (d, 2H, J = 7.9Hz); 7.33 (d, 2H, J = 8.56Hz); 7.26 (s, 1H); 7.18 (d, 1H, J = 8.4Hz); 25 7.12 (m, 3H); 6.75 (d, 1H, J = 7.25Hz); 4.43 (m, 1H); 4.11 (dd, 1H, J = 3, 8.1Hz); 3.32 (m, 1H); 3.1 (m, 1H); 3.01 (dd,1 H, J = 5.05, 13.83Hz); 2.91 (dd, 1H, J= 8.45,13.73Hz);2.38 (s,3H); 1.4-1.63 (m, 4H). IR (KBr, cm-'): 3340, 3290, 3090, 2980, 1730, 1650, 1600, 1550, 1495, 1350, 1290, 1210, 1160, 660. 30 Mass Spectroscopy: ((+) FAB, m/e (%)) 565 (60 [M+H]+).

WO 99/06437 PCT/US98/16070 187 Example 42 Synthesis of N-(Toluene-4-sulfonyl-L-prolyl-4-[(2,3,3a,7a-tetrahydro 1H-indole-2-carbonyl)-amino]-L-phenylalanine 5 The N-Boc compound was prepared using the procedures described in Method 13 and Method 6. The title compound was then prepared using the procedure described in Method 10. NMR data was as follows: 1 H NMR (DMSO-d 6 ): 8 = 7.75 (d, 2H), 7.65 (m, 2H), 7.45 (d, 4H), 10 7.10 (m, 4H), 6.80 (d, 2H), 4.35 (m, 1H), 4.10 (b, 1H), 4.02 (m, 1H), 3.10 (m, 4H), 2.40 (s, 3H), 1.70 (b, 1H), 1.41 (m, 2H). Mass Spectroscopy: (+) FAB (M+H)* 579 Example 43 15 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-L

(

4 -pentylamino)phenylalanine methyl ester The methyl ester was prepared by reductive amination of N-(toluene 4 -sulfonyl)-L-prolyl-L-(4-amino)phenylalanine with valeraldehyde (acetic 20 acid, sodium triacetoxyborohydride, methylene chloride, which was stirred at room temperature for one hour). The crude product was purified by flash chromatography (silica, 1:1 EtOAc:hexane) to afford the methyl ester as a white solid, mp= >160 0 C. 25 Example 44 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-L-O (2-dibenzylamino-ethyl)-tyrosine methyl ester The title compound was prepared via O-alkylation of N-(toluene-4 30 sulfonyl)-L-prolyl-L-tyrosine methyl ester with N-(2 chloroethyl)dibenzylamine hydrochloride in refluxing 2-butanone in the presence of potassium carbonate and sodium iodide. The obtained mixture WO 99/06437 PCT/US98/16070 188 was chromatographed on SiO2 in 1% MeOH/CHC 3 (Rf = 0.75 using 10% MeOH/CHC1 3 ). NMR data was as follows: 'H NMR (DMSO-d 6 , 400 Mhz): 8 = 1.4-1.6 (4H, m); 2.38 (3H, s); 5 2.75 (2H, t, J=7,7Hz); 2.95 (2H, m); 3.1 (1H, dd, J=6,10,6Hz); 3.33 (1H, dd); 3.6 (3H, s); 3.65 (4H, s); 4.0 (2H, t, J=6,6Hz); 4.1 (1H, t, J=8,8Hz); 4.5 (1H, t, J=8,8Hz); 6.75 (2H, d, J=O10Hz); 7.08 (2H, d, J=10OHz); 7.2-7.35 (10H, m); 7.4 (2H, d, J=10Hz); 7.68 (2H, d, J=10Hz); 8.1 (1H, d, J=10Hz). MS: +FAB, m/z 670 ([MH]+, 45 %), 154 (100%). 10 Example 45 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-L-O-[2-(dibenzylamino)ethyl]-tyrosine The methyl ester was prepared via O-alkylation of N-(toluene-4 15 sulfonyl)-L-prolyl-L-tyrosine methyl ester with N-(2 chloroethyl)dibenzylamine hydrochloride in refluxing 2-butanone in the presence of potassium carbonate and sodium iodide. The title compound was prepared using the procedure described in Method 7, and was isolated as a solid, mp = 106-110 0 C. 20 NMR data was as follows: 'H NMR (DMSO-d 6 , 400 Mhz): 8 = 1.2-1.45 (3H, m); 1.75 (1H, m); 2.38 (3H, s); 2.75 (2H, t, J=6,6Hz); 2.95 (2H, m); 3.1 (1H, dd, J=7,6,7Hz); 3.38 (1H, bs); 3.62 (4H, s); 3.85 (1H, dd, J=6,4,6Hz); 3.95 (1H, t, J=4,4Hz); 3.97 (2H, t, J=8,8Hz); 6.62 (2H, d, J=10Hz); 6.95 (2H, d, J=O10Hz); 7.2-7.4 25 (10H, m); 7.41 (2H, d, J=10Hz); 7.62 (1H, d, J=4Hz); 7.75 (2H, d, J=10Hz). MS: +FAB, m/z 656 ([MH]+, 15 %), 154 (100%).

WO 99/06437 PCT/US98/16070 189 Example 46 Synthesis of N-(Toluene- 4 -sulfonyl)-L-prolyl-L-(4-pentylamino)phenylalanine The title compound was prepared from the product of Example 43 5 using the procedure described in Method 6. NMR data was as follows: 1 H NMR (DMSO-d 6 , 400 MHz): 8 = 7.73 (d, 2H, J = 8.1Hz); 7.57 (d, 1H, J = 5.7Hz); 7.39 (d, 2H, J = 7.9Hz); 6.76 (d, 2H, J = 8.3Hz); 6.32 (d, 2H, J = 8.5Hz); 5.14 (t, 1H, J = 5.6Hz); 3.94 (dd, 1H, J = .2,.007Hz); 3.77 (m, 10 1H); 3.18 (m, 2H); 2.90 (m, 4H); 2.38 (s, 3H); 1.73 (m, 1H); 1.41 (m, 5H); 1.29 (m, 4H); .85 (m, 3H). IR (KBr, cm-'): 3400, 2950, 2910, 2870, 1660, 1620, 1525, 1405, 1350, 1155,670, 600, 550. Mass Spectroscopy: ((+) FAB, m/e (%)) 508 (60 [M+ Li]+). 15 Example 47 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-L-4

(

4 -chlorobenzylamino)-phenylalanine methyl ester 20 The title compound was prepared by reductive amination of N (toluene- 4 -sulfonyl)-L-prolyl-L-(4-amino)-phenylalanine methyl ester with 4-chlorobenzaldehyde (acetic acid, sodium triacetoxyborohydride, methylene chloride, stirred at room temperature for 2.5 hours). The crude product was purified by flash chromatography (silica, 1:1 EtOAc:hexane) to afford the 25 title compound as a white solid.

WO 99/06437 PCT/US98/16070 190 Example 48 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-L-4-[3 (4-cyanophenyl)-ureido]-phenylalanine methyl ester 5 The title compound was prepared by the reaction of N-(toluene-4 sulfonyl)-L-prolyl-L-(4-amino)-phenylalanine methyl ester with 4 cyanophenylisocyanate (triethylamine, toluene, reflux 3.5 hours). The crude product was purified by flash chromatography (silica, 1:1 EtOAc:hexane) to give the methyl ester as a white solid, mp = 204-206 0 C. 10 Example 49 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-L-4-[3 (4-cyanophenyl)-ureido]-phenylalanine 15 The title compound was prepared from the product of Example 48 using the procedure described in Method 6 as a solid, mp = 163-165 0 C. NMR data was as follows: 'H NMR (DMSO-d 6 , 400 MHz): 8 = 12.8 (br s, 1H); 9.12 (s, 1H); 8.78 (s, 1H); 8.04 (d, 1H, J = 8.1Hz); 7.69 (m,4H); 7.6 (d, 2H, J = 9Hz); 7.39 20 (d, 2H, J = 8.1Hz); 7.35 (d, 2H, J= 8.5Hz); 7.15 (d, 2H, J = 8.5Hz); 7.12 (m, 3H); 4.43 (m, 1H); 4.11 (dd, 1H, J = 3.1, 8.2Hz); 3.29 (m, 1H); 3.06 (m, 2H); 2.92 (dd,1H, J = 8.4, 13.9Hz); 2.38 (s,3H); 1.38-1.63 (m, 4H). IR (KBr, cm-'): 3360, 2220, 1720, 1650, 1590, 1530, 1510, 1410, 1230, 1150,1090, 830, 670, 595, 550. 25 Mass Spectroscopy: ((-) FAB, m/z (%)) 574 (40 [M-H]-). Example 50 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-L-O-(tert 30 butoxycarbonylmethyl)-tyrosine methyl ester The title compound was prepared by reaction of N-(toluene-4 sulfonyl)-L-prolyl-L-tyrosine methyl ester with t-butyl bromoacetate WO 99/06437 PCT/US98/16070 191 (potasium carbonate, DMF, under Argon for 72 hrs). The product was purified by flash column chromatography (silica, 1:1 hexane:EtOAc) to afford the methyl ester as a white solid, mp = 55 oC. 5 Example 51 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-L-O (tert-butoxycarbonylmethyl)-tyrosine The title compound was prepared from the product of Example 50 10 using the procedure described in Method 6 and was isolated as a solid, mp = 69-70 C. NMR data was as follows: 'H NMR (DMSO-d 6 , 400 MHz): 6 = 12.2 (br s, 1H); 8.00 (d, 1H, J = 8.1Hz); 7.67 (d, 2H, J= 8.2Hz); 7.38 (d, 2H, J = 7.9Hz); 7.11 (d, 2H, J= 15 8.6Hz); 6.76 (d, 2H, J = 8.5Hz); 4.5 (s, 2H); 4.4 (m, 1H); 4.07 (m, 1H); 2.8 3.1 (m, 4H); 2.37 (s, 3H); 1.5 (m, 4H); 1.38 (s, 9H). IR (KBr, cm-'): 3400, 2950, 1750, 1660, 1510, 1340, 1225, 1160, 1075,660, 575,525. Mass Spectroscopy: (ESI, m/e (%)) 545 (100, (M-H)). 20 Example 52 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-L-4-[(3S)-3, 4 -dihydro-isoquinolin-3-yl-aminocarbonyl]-phenylalanine 25 N-(Toluene-4-sulfonyl)-L-prolyl-L-(4-amino)phenylalanine methyl ester (20 mmol) was taken into CHzC1 2 with HOBT, Boc-L-tetrahydro isoquinoline-3-carboxylic acid (20 mmol), and DCC (24.3 mmol). The mixture was stirred overnight at room temperature, filtered and concentrated in vacuo. The resulting residue was partitioned between 10% citric acid and 30 EtOAc. The organic layer was washed with H 2 0, saturated NaHCO 3 , and

H

2 0, dried over NaSO 4 and concentrated in vacuo to yield an amorphous WO 99/06437 PCT/US98/16070 192 solid. The resulting ester was converted to the acid using the procedure described in Method 6. The title compound was then prepared using the procedure described in Method 10 and was isolated as a solid, mp = 145 150 0 C. 5 NMR data was as follows: 'H NMR (DMSO-d 6 ): 8 = 8.12 (d, 1H), 7.70 (d, 2H), 7.55 (d, 2H), 7.40 (d, 2H), 7.25 (d, 6H), 4.45 (min, 1H), 4.38 (d, 1H), 4.28 (min, 1H), 4.10 (d, 1H), 3.10 (m, 2H), 2.40 (s, 3H), 1.60 (inm, 4H). Mass Spectroscopy: (FAB) (M+H)* 591 (M + Na) + 613. 10 Example 53 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-4-[3 (3-methoxy-phenyl)-ureido]-L-phenylalanine methyl ester 15 The title compound was prepared by the reaction of N-(toluene-4 sulfonyl)-L-prolyl-L-(4-amino)-phenylalanine methyl ester with 3-methoxy phenylisocyanate (triethylamine, toluene, reflux one hour). The resulting solid was removed by filtration and washed with EtOAc/hexane to give the methyl ester as a white solid, mp = 206-209'C. 20 Example 54 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-4-[3 (3-methoxy-phenyl)-ureido]-L-phenylalanine 25 The title compound was prepared from the product of Example 53 using the procedure described in Method 6. NMR data was as follows: 1 H NMR (DMSO-d 6 , 400 MHz): 8 = 12.80 (br s, 1H); 8.6 (d, 2H. J= 13.8); 8.03 (d, 1H, J = 7.9Hz); 7.69 (d, 2H, J = 8.1Hz); 7.39 (d, 2H, J = 30 8.1Hz); 7.33 (d, 2H, J = 8.56Hz); 7.14 (min, 1H); 6.9 (dd, 1H, J = 1.53,7.9Hz); 6.52 (dd, 1H, J = 2.19, 8.12Hz); 4.42 (min, 1H); 4.11 (dd, 1H, J = 2.96, WO 99/06437 PCT/US98/16070 193 8.45Hz); 3.7 (s, 3H); 3.35 (min, 1H); 3.09 (min, 1H); 3.01 (dd,1H, J = 4.83, 13.6Hz); 2.91 (dd, 1H, J= 8.34,13.8Hz);2.48 (s,3H); 1.41-1.63 (mn, 4H). IR (KBr, cm-'): 3390, 2940, 1655, 1595, 1545, 1500, 1450, 1345, 1320, 1210, 1160, 660, 580, 545. 5 Mass Spectroscopy: ((+) FAB, m/e (%)) 603(30[M+Na]+); 581 (10 [M+H]+). Example 55 Synthesis of 10 N-(Toluene-4-sulfonyl)-L-prolyl-L-O--(4,5 dihydro-1 H-imidazol-2-yl-methyl)-tyrosine The methyl ester was prepared by reaction of N-(toluene-4-sulfonyl) L-prolyl)-L-O-cyanomethyl-tyrosine methyl ester with ethylene diamine (in refluxing methanol under Argon overnight). The product was purified by 15 flash column chromatography (silica, 5% methanol in chloroform) to afford the methyl ester as a white foam. The title compound was prepared using the procedure described in Method 6 and was isolated as a solid, mp = 147 1490C. NMR data was as follows: 20 1 H NMR (DMSO-d 6 , 400 MHz): 6 = 7.74 (d, 2H. J = 8.4Hz); 7.61 (d, 1H, J = 5.7Hz); 7.40 (d, 2H, J = 8.2Hz); 6.97 (d, 2H, J = 8.6Hz); 6.75 (m, 2H); 6.51 (br s, 1H); 4.49 (s, 2H); 3.96 (dd, 1H; J = 2.5, 6Hz); 3.82 (dd, 1H, J = 5.1, 9.6Hz); 3.59 (t, 1H, J = 9.7Hz); 3.21 (t, 1H, J =9.6Hz); 3.04 (m, 4H); 2.39 (s, 3H); 1.70 (m, 1H); 1.35 (min, 3H). 25 IR (KBr, cm'): 3400, 2900, 1650, 1610, 1510, 1400, 1315, 1245, 1150, 1075, 1040, 700, 600, 550. Mass Spectroscopy: (ESI, m/e (%)) 515 (100, (M+H)+).

WO 99/06437 PCT/US98/16070 194 Example 56 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-L-4-(3-propyl-ureido)-phenylalanine The methyl ester was prepared by the reaction of N-(toluene-4 5 sulfonyl)-L-prolyl-L-(4-amino)-phenylalanine methyl ester with propyl isocyanate (triethylamine, toluene, reflux 1.25 hours). The crude product was purified by flash chromatography (silica, 1:1 EtOAc:hexane) to give the methyl ester as a white foam. The title compound was prepared using the procedure described in Method 6. 10 NMR data was as follows: 'H NMR (DMSO-d 6 , 400 MHz): 6 = 12.78 (br s, 1H); 8.29 (s, 1H); 7.99 (d, 1H, J = 8.1Hz); 7.68 (d, 2H, J = 8.1Hz); 7.39 (d, 2H, J= 8.1Hz); 7.26 (d, 2H, J = 8.5Hz); 7.06 (d, 2H, J = 8.5Hz); 6.04 (t, 1H, J = 5.7Hz); 4.39 (mn, 1H); 4.1 (dd, 1H, J = 2.9, 8.2Hz); 3.3 (min, 1H); 3.09 (mn, 1H); 2.99 (inm, 15 3H); 2.87 (dd, 1H, J = 8.34, 13.83Hz); 2.38 (s,3H); 1.49-1.64 (mn, 3H); 1.40 (min, 3H); 0.84 (t, 3H, J = 7.46Hz). IR (KBr, cm'): 3590, 3350, 3220, 3050, 2960, 2930, 2860, 1750, 1660, 1630, 1590, 1560, 1540, 1345, 1320, 1160, 660, 590. Mass Spectroscopy: ((+) FAB, m/e (%)) 539 (40, [M + Na] ); 517 20 (20 [M+H]+). Example 57 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-L-(4-benzylamino)phenylalanine 25 The title compound was prepared from the product of Example 58 using the procedure described in Method 6. NMR data was as follows: 1 H NMR (DMSO-d 6 , 400 MHz): 6 7.72 (d, 2H, J = 8.3 Hz); 7.54 (d, 1H, J = 5.49 Hz); 7.4 (d, 2H, J = 7.9 Hz); 7.27 (min, 4H); 717 (min, 1H); 6.72 (d, 30 2H, J = 8.56 Hz); 6.34 (d, 2H, J = 8.56 Hz); 5.91 (t, 1H, J = 6.15 Hz); 4.17 WO 99/06437 PCT/US98/16070 195 (d, 2H, J = 6.15 Hz); 3.91 (dd, 1H, J = 2.74, 8.89 Hz); 3.75 (m, 1H); 2.95 (m, 2H); 2.88 (m, 2H); 2.38 (s, 3H); 1.66 (m, 1H); 1.18-1.42 (m, 3H). 1R (KBr, cm - 1) 3400, 1655, 1620, 1525, 1410, 1340, 1160, 670. MS ((+) FAB, m/e (%)) 528 (100 [M + Li]+); 522 (15 [M+H]+). 5 Anal. Calc'd for C 28

H

3 0

N

3 0 5 S Li 1.5 H 2 0; C, 60.64; H, 5.90; N, 7.57. Found: C, 60.60; H, 5.61; N, 7.45. Example 58 Synthesis of 10 N-(Toluene-4-sulfonyl)-L-prolyl L-(4-benzylamino)phenylalanine methyl ester The title compound was prepared by reductive amination of N (toluene-4-sulfonyl)-L-prolyl-L-4-aminophenylalanine methyl ester with benzaldehyde (acetic acid, sodium triacetoxyborohydride, methylene 15 chloride, stirred at room temperature overnight). The crude product was purified by flash chromatography (silica, 1:1 EtOAc:hexane) to afford the title compound as a white solid, mp = 53-56 0 C (0.501 g, 41%). NMR data was as follows: 'H NMR (DMSO-d 6 , 400 MHz): 6 8.09 (d, 1H, J = 7.90 Hz); 7.68 (d, 20 2H, J = 8.34 Hz); 7.39 (d, 2H, J = 7.90 Hz); 7.28 (m. 4H); 717 (m, 1H); 6.87 (d, 2H, J= 8.34 Hz); 6.46 (d, 2H, J = 8.56 Hz); 6.12 (t, 1H, J = 6.15 Hz); 4.38 (m, 1H); 4.20 (d, 2H, J = 5.71 Hz); 4.07 (m, 1H); 3.58 (s, 3H); 3.27 (m, 1H); 3.06 (m, 1H); 2.82 (m, 2H); 2.39 (s, 3H); 1.53 (m, 3H); 1.36 (m, 1H). IR (KBr, cm-') 3400, 2950, 1745, 1675, 1610, 1525, 1450, 1350, 25 1210, 1100, 680, 595,550. MS ((+) FAB, m/e (%)) 536 (70 [M+H]+). Anal. Calc'd for C 29

H

3 3

N

3 0 5 S: C, 65.03: H, 6.21; N, 7.84. Found: C, 64.57; H, 6.10; N, 7.58. 30 WO 99/06437 PCT/US98/16070 196 Example 59 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-L-4 (4-chlorobenzylamino)-phenylalanine 5 The methyl ester was prepared by reductive amination of N-(toluene 4-sulfonyl)-L-prolyl-L-(4-amino)-phenylalanine methyl ester with 4 chlorobenzaldehyde (acetic acid, sodium triacetoxyborohydride, methylene chloride, stirred at room temperature for 2.5 hours). The crude product was purified by flash chromatography (silica, 1:1 EtOAc:hexane) to afford the 10 methyl ester as a white solid. The title compound was prepared using the procedure described in Method 6. NMR data was as follows: 1 H NMR (DMSO-d 6 , 400 MHz): 6 = 7.72 (d, 2H, J = 8.3Hz); 7.53 (d, 1H, J = 5.7Hz); 7.4 (d, 2H, J = 7.9Hz); 7.3 (s, 4H); 6.72 (d, 2H, J = 8.3Hz); 15 6.31 (d, 2H, J = 8.5Hz); 6.0 (m, 1H); 4.16 (d, 2H, J = 6.1Hz); 3.92 (dd, 1H, J = 9, 2.85Hz); 3.75 (m, 1H); 2.91 (m, 4H); 2.38 (s, 3H); 1.65 (m, 1H); 1.35 (m, 1H); 1.18 (m, 2H). IR (KBr, cm-'): 3400, 1620, 1525, 1410, 1340, 670. Mass Spectroscopy: ((+) FAB, m/e (%)) 578 (95, [M + Na] ); 562 20 (50, [M+ Li]+); 556 (40 [M+H]+). Example 60 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl)-L 25 (4-chloromethanesulfonylamino)-phenylalanine N-(Toluene-4-sulfonyl)-L-prolyl-L-(4-amino)-phenylalanine methyl ester (1.00g, 2.2 mmol) was dissolved in methylene chloride (2.5 mL) and cooled to -78 0 C. With stirring, chloromethane sulfonyl chloride (0.34g, 2.2 mmol) was added followed by dropwise addition of pyridine (182 mL, 2.2 30 mmol). The clear solution became yellow, then orange, then finally red upon the chloromethanesulfonyl chloride addition. The solution was allowed to WO 99/06437 PCT/US98/16070 197 warm to room temperature and was stirred for 16 hr. The reaction solution was transferred to a 250 mL separatory funnel with CH 2 Cl 2 (50 mL) and extracted with IN HCI (50 mL x 2), brine (50 mL x 2), and water (50 mL). The organic phase was dried (MgSO 4 ) and the solvent removed to give a red 5 solid which was flash chromatographed (SiO 2 , 3:1 CH 2 Cl,:CH 3 CN) to yield a white solid. The title compound was prepared using the procedure described in Method 6 and was isolated as a solid, mp = 163-170'C. NMR data was as follows: 'H NMR (DMSO-d 6 , 400 Mhz): 6 = 8.08 (d, 1H, J = 7.7Hz); 7.71 10 (dd, 4H, J = 14.7Hz, 8.3Hz); 7.51 (d, 1H, J = 5.9Hz); 7.41-7.39 (mn, 4H); 6.84-6.82 (min, 2H); 6.78-6.72 (min, 4H); 6.68 (d, 2H, J = 7.5Hz); 4.40 (q, 1H, J = 7.7Hz); 4.18 (s, 3H); 4.19-4.08 (min, 1H); 3.95-3.89 (mn, 2H); 3.60 (s, 2H); 3.11-3.04 (min, 2H); 2.95-2.83 (min, 3H); 2.39 (s, 3H); 1.78-1.65 (min, 1H); 1.61 1.56 (min, 3H); 1.42-1.37 (min, 4H). 15 IR (KBr, cm-1): 3400, broad; 2960; 2850; 1749; 1650; 1510; 1450; 1400; 1350; 1300; 1260; 1160; 1100; 1000; 840; 800; 650; 600; 550. Mass Spectroscopy: (-) ESI: 542.1 (M-H); 483.8; 442.2; 341.6; 273.8; 202.1; 144.9. 20 Example 61 Synthesis of N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl) thiaprolyl-L-4-(aminobenzoyl)phenylalanine methyl ester The title compound was prepared following the procedure outlined 25 for the preparation of Example 36. NMR data was as follows: 'H NMR (CDCl 3 ): 6 = 7.89-7.85 (min, 3H), 7.74 (d, 2H), 7.60-7.47 (inm, 5H), 7.29 (d, 2H), 7.21 (d, 2H), 7.02 (d, 1H), 4.89 (min, 1H), 4.56 (d, 1H), 4.37 (d, 1H), 3.85 (s, 1H), 3.75 (s, 3H), 3.12 (min, 2H), 2.44 (s, 3H), 1.18 (s, 3H), 30 1.08 (s, 3H).

WO 99/06437 PCT/US98/16070 198

"

3 C NMR (CDC1 3 ): 6 = 171.8, 169.1, 166.3,145.4, 137.6, 135.8, 133.3, 132.7, 132.5, 130.7, 130.6, 129.4, 128.7, 127.6, 120.7, 74.1, 55.2, 53.9, 53.1, 51.1, 38.4, 29.8, 24.6, 22.3. 5 Example 62 Synthesis of N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl) thiaprolyl-L-4-(benzamido)phenylalanine The title compound was prepared from the product of Example 61 10 using the procedure described in Method 7. NMR data was as follows: 'H NMR (CDCl 3 ): 6 = 8.43 (s, 1H), 7.84 (d, 2H), 7.72 (d, 2H), 7.61 (d, 2H), 7.49-7.20 (m, 7H), 4.93 (q, 1H), 4.55 (d, 1H), 4.37, (d, 1H), 3.92 (s, 1H), 3.15 (m, 2H), 2.42 (s, 3H), 1.19 (s, 3H), 1.08 (s, 3H). 15 1 3 C NMR (CDCl 3 ): 6 = 177.62,174.35, 169.69, 145.53, 137.73, 135.51, 133.19, 132.44, 132.39, 130.79, 130.63, 129.23, 128.63, 127.82, 121.1, 73.94, 55.13, 53.97, 51.08, 38.02, 29.79, 24.62, 22.24. Example 63 20 Synthesis of N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl) thiaprolyl-L-tyrosine ethyl ester The title compound was prepared following the procedure outlined for the preparation of Example 36. 25 NMR data was as follows: 1 H NMR (CDCl 3 ): 6 = 7.73 (d, 2H), 7.33 (d, 2H), 7.08-7.04 (m, 3H), 6.73 (d, 2H), 6.51 (s, 1H), 4.88 (e, 1H), 4.54 (d, 2H), 4.33 (d, 2H),1.28 (t, 3H), 4.23 (q, 2H), 3.83 (s, 1H), 3.14-2.93 (m, 2H), 2.43 (s, 3H), 1.03 (s, 3H), 1.02 (s, 3H).

WO 99/06437 PCT/US98/16070 199 1 3 C NMR (CDCl 3 ): 6 = 171.56, 169.44, 155.87, 145.40, 133.16, 131.16, 130.59, 128.66, 127.97, 116.00, 74.01, 62.35, 55.11, 54.16, 51.04, 38.33, 29.79, 24.26, 22.24, 14.67. 5 Example 64 Synthesis of N-(Toluene-4-Sulfonyl)-L-(5,5-dimethyl)-thiaprolyl-L-tyrosine The title compound was prepared from the product of Example 63 using the procedure described in Method 7. 10 NMR data was as follows: 'H NMR (CDCl 3 ): 6 = 7.96 (d, 1H), 7.49 (d, 2H), 7.17 (d, 2H), 6.91 (d, 2H), 6.49 (d, 2H), 4.40 (m, 1H), 4.38-4.27 (dd, 2H), 3.83 (s, 1H), 2.95 2.70 (m, 2H), 2.23 (s, 3H), 0.94 (s, 3H), 0.92 (s, 3H). 15 Example 65 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl L-4-[(pyridin-4-yl)methylamino] phenylanine The title compound was prepared from the product of Example 66 20 using the procedure described in Method 6. NMR data was as follows: 'H NMR (DMSO-d 6 , 400 MHz): 6 = 8.42 (d, 2H, J = 5.93Hz); 7.72 (d, 2H, J = 8.34Hz); 7.53 (d, 1H, J = 5.71Hz); 7.39 (d, 2H, J = 7.90Hz); 7.28 (d, 2H, J = 5.93Hz); 6.74 (d, 2H, J = 8.56Hz); 6.31 (d, 2H, J = 8.34Hz); 6.07 25 (t, 1H, J = 6.26Hz); 4.22 (d, 2H, J = 6.15Hz); 3.91 (dd, 1H, J = 2.85, 8.78Hz); 3.77 (dd, 1H J = 5.38, 9.99 Hz); 2.95 (m, 2H); 2.89 (m, 2H); 2.38 (s, 3H); 1.66 (m, 1H); 1.19-1.38 (m, 3H). IR (KBr, cm-') 3400, 1650, 1610, 1520, 1420, 1340, 1155. MS ((-) ESI, m/e (%)) 521 (100[M-H]-) 30 Anal. Calc'd for C 2 7

H

29

N

4 0 5 S Li 2.5 HO 2 0: C, 56.47; H, 5.97; N, 9.7.6. Found: C, 56.32; H, 5.61; N, 9.64.

WO 99/06437 PCT/US98/16070 200 Example 66 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-L-4 [(pyridin-4-yl)methylamino]phenylanine methyl ester 5 Substituting 4-pyridinecarboxaldehyde for benzaldehyde, and following the method for the preparation of Example 58, gave the title compound. NMR data was as follows: 'H NMR (DMSO-d 6 , 400 MHz) 8 = 8.43 (d, 2H, J = 6.15Hz); 8.10 (d, 10 1H, J = 7.90 Hz); 7.67 (d, 2H, J = 8.12Hz); 7.39 (d, (2H, J=7.90Hz); 7.28 (d, 2H, J = 6.15Hz); 6.89 (d, 2H, J = 8.56 Hz); 6.43 (d, 2H, J = 8.56); 6.26 (t, 1H, J = 6.26 Hz); 4.38 (m, 1H); 4.26 (d, 2H), J = 6.37Hz); 4.06 (m, 1H); 3.58 (s, 3H); 3.28 (m, 1H); 3.06 (m, 1H); 2.84 (m, 2H); 2.39 (s, 3H), 1.51 (m, 3H); 1.34 (m, 1H). 15 IR (KBr, cm-' ) 3400, 2930, 1745, 1675, 1615, 1600, 1520, 1345, 1160, 1090, 1000, 770, 720, 600, 550. MS ((+) FAB, m/e (%)) 537 (75[m+H] ). Example 67 20 Synthesis of N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)-thiaprolyl-L-4 (pyridin-3-carboxamido)phenylalanine methyl ester The title compound was prepared following the procedure outlined for the preparation of Example 36. 25 NMR data was as follows: 'H NMR (CDCl 3 ): 8 = 9.01 (d, 1H), 8.74 (m, 1H), 8.23 (m, 2H), 7.73 (d, 2H), 7.59 (d, 2H), 7.43 (m, 1H), 7.33 (d, 2H), 7.27 (m, 1H), 7.20 (d, 2H), 4.84 (m, 1H), 4.40-4.32 (dd, 2H), 3.86 (s, 1H), 3.74 (s, 3H), 3.15-3.10 (m, 2H), 2.44 (s, 3H), 1.19 (s, 3H), 1.05 (s, 3H).

WO 99/06437 PCT/US98/16070 201 13 C NMR (CDCI 3 ): 8 = 171.8,169.2,164.3,152.9,148.5,145.4, 137.2, 136.1, 133.3, 133.2, 131.3, 130.8, 130.6, 128.6, 124.3, 121.0, 74.1, 55.1, 54.1, 53.0, 51.1, 38.2, 29.8, 24.6, 22.2. 5 Example 68 Synthesis of N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl) thiaprolyl-L-4-(pyridine-3-carboxamido)phenylalanine The title compound was prepared from the product of Example 67 10 using the procedure described in Method 7. NMR data was as follows: 'H NMR (CD 3

)

2 SO): 8 = 9.10 (s, 1H), 8.73 (d, 1H), 8.33 (d, 1H), 7.78 (d, 2H), 7.73 (d, 1H), 7.62 (d, 2H), 7.53 (m, 1H), 7.41 (d, 2H), 7.20 (d, 2H), 4.51 (dd, 2H), 4.08-4.03 (m, 2H), 3.00 (m, 2H), 2.39 (s, 3H), 1.19 (s, 3H), 15 1.10 (s, 3H). 13 C NMR (CD 3

)

2 SO): 8 = 173.1, 167.1, 164.1, 152.3, 149.1, 144.3, 137.0, 135.8, 135.2, 134.2, 131.1, 130.3, 130.2, 128.3, 123.8, 120.1, 73.0, 55.9, 54.9, 50.6, 37.5, 29.9, 25.0, 21.4. 20 Example 69 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-L 4-[(pyridin-3-ylmethyl)amino]phenylalanine Substituting 3-pyridinecarboxaldehyde for benzaldehyde, and 25 following the method for the preparation of Example 58, gave the title compound. NMR data was as follows: 1 H NMR (DMSO-d 6 ,400 MHz) 6 = 8.51 (s, 1H); 8.38 (m, 1H); 7.72 (d, 2H, J=8.13Hz); 7.68 (m, 1H); 7.54 (d, 1H, J=5.71Hz); 7.40 (d, 2H, 30 J=7.90Hz); 7.28 (m, 1H); 6.75 (d, 2H, J=8.56 Hz); 6.36 (d, 2H, J=8.56Hz); WO 99/06437 PCT/US98/16070 202 5.98 (t, 1H, J=5.27, 9.88Hz); 2.96 (m, 2H); 2.89 (m, 2H); 2.39 (s, 3H); 1.65 (m, 1H); 1.16-1.43 (m, 3H). IR (KBr, cm

-

'

) 3400, 1670, 1620, 1520, 1400, 1345, 1160, 675, 600. MS ((+) FAB, m/e (%)) 523 (25[M+H]+); 529 (100[M + Li] ). 5 Anal. Calc'd for C2 7

H

2 9

N

4 0 5 S Li 2.5 H 2 0: C,56.47; H, 5.97; N, 9.76. Found: C, 56.62; H, 5.57; N, 9.69. Example 70 Synthesis of 10 N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl) thiaprolyl-L-4-nitrophenylalanine methyl ester The title compound was prepared following the procedure outlined for the preparation of Example 36. NMR data was as follows: 15 'H NMR (CDCI 3 ): 6 = 8.14 (d, 2H), 7.74 (d, 2H), 7.41 (d, 2H), 7.35 (d, 2H), 7.10 (d, 1H), 4.94 (m, 1H), 4.58 (d, 1H), 4.33 (d, 1H), 3.82 (s, 1H), 3.76 (s, 3H), 3.25 (m, 2H), 2.44 (s, 3H), 1.11 (s, 3H), 1.02 (s, 3H). 13C NMR (CDCl 3 ): 6 = 171.3, 169.3, 147.7, 145.6, 144.6, 133.0, 131.0, 130.6, 128.6, 124.2, 74.0, 54.9, 53.6, 53.3, 51.1, 38.7, 29.8, 24.5, 22.3. 20 Example 71 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-L-4-nitrophenylalanine ethyl ester The title compound was prepared following the procedure outlined 25 for the preparation of Example 36. NMR data was as follows: 'H NMR (CDCl 3 ): 6 = 8.16 (d, 2H), 7.71 (d, 2H), 7.48 (d, 1H), 7.40 7.31 (m, 4H), 4.87 (q, 1H), 4.24 (q, 2H), 4.07 (m, 1H), 3.44-3.35 (m, 2H), 3.23-3.05 (m, 2H), 2.44 (s, 3H), 2.04 (m, 1H), 1.62-1.44 (m, 3H), 1.30 (t, 30 3H).

WO 99/06437 PCT/US98/16070 203 13C NMR (CDC1 3 ): 8 = 171.5, 170.9, 147.6, 145.1, 144.7, 133.2, 130.9, 130.6, 128.4, 124.2, 62.7, 62.6, 53.7, 50.8, 38.4, 30.1, 25.0, 22.2, 14.7. Example 72 5 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-L-4-(2 methoxybenzamido)phenylalanine ethyl ester The title compound was prepared following the procedure outlined for the preparation of Example 36. 10 NMR data was as follows: 'H NMR (CDC1 3 ): 8 = 9.81 (s, 1H), 8.27(d, 1H), 7.71 (d, 2H), 7.60 (d, 2H), 7.49 (t, 1H), 7.37-7.28 (m, 3H), 7.18-7.10 (m, 3H), 7.03 (d, 1H), 4.82 (m, 2H), 4.22 (q, 2H), 4.10-4.04 (m, 4H), 3.40 (m, 1H), 3.30-3.02 (m, 3H), 2.42 (s, 3H), 2.03 (m, 1H), 1.53 (m, 3H), 1.30 (t, 3H). 15 1 3 C NMR (CDC1 3 ): 6 =171.4, 163.7, 157.8, 144.9, 137.9, 133.9, 133.6, 133.1 ,132.4, 130.5, 128.5, 122.3, 120.9, 112.1, 62.9, 62.3, 56.8, 54.1, 50.3, 38.0, 30.5, 24.9, 22.2, 14.7. Example 73 20 Synthesis of N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl) thiaprolyl-L-(4-nitro)phenylalanine ethyl ester The title compound was prepared following the procedure outlined for the preparation of Example 36. 25 NMR data was as follows: 'H NMR (CDCl 3 ): 6 = 8.12 (d, 2H), 7.73 (d, 2H), 7.42 (d, 2H), 7.34 (d, 2H), 7.12 (d, 1H), 4.92 (m, 1H), 4.57 (d, 1H), 4.33 (d, 1H), 4.20 (q, 2H), 3.83 (s, 1H), 3.33-3.15 (m, 2H), 2.43 (s, 3H), 1.25 (t, 3H), 1.11 (s, 3H), 1.01 (s, 3H).

WO 99/06437 PCT/US98/16070 204

'

3 C NMR (CDC13): 8 = 170.8, 169.3, 147.6, 145.5, 144.7, 133.0, 131.1, 130.6, 128.6, 124.2, 74.0, 62.6, 54.9, 53.6, 51.0, 38.8, 29.8, 24.5, 22.2, 14.7. 5 Example 74 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-L-4

(

2 -bromobenzamido)phenylalanine ethyl ester The title compound was prepared following the procedure outlined 10 for the preparation of Example 36. NMR data was as follows: 1 H NMR (CDCl 3 ): 8 = 7.78 (s, 1H), 7.70 (d, 2H), 7.65-7.55 (m, 4H), 7.42-7.29 (m, 5H), 7.16 (d, 2H), 4.81 (m, 1H), 4.23 (q, 2H), 4.06 (m, 1H), 3.43-3.00 (m, 4H), 2.43 (s, 3H), 2.08-1.99 (m, 1H), 1.60-1.45 (m, 3H), 1.30 15 (t, 3H). 13 C NMR (CDCl 3 ): 6 =171.5, 171.3, 166.1,144.9, 138.3, 137.1, 134.1, 133.5, 133.3, 132.3, 130.6, 130.5, 130.3, 128.5, 128.3, 120.6, 119.8, 62.9, 62.3, 51.0, 50.3, 38.0, 30.4, 24.9, 22.2, 14.7. 20 Example 75 Synthesis of N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl) thiamorphyl-L-4-aminophenylalanine ethyl ester The title compound was prepared following the procedure outlined 25 for the preparation of Example 38. NMR data was as follows: 1 H NMR (CDCl 3 ): 6 = 7.74 (d, 2H), 7.33 (d, 2H), 6.96 (m, 3H), 6.59 (d, 2H), 4.81 (m, 1H), 4.53 (d, 1H), 4.38 (d, 1H), 4.19 (q, 2H), 3.85 (s, 1H), 3.61 (br s, 2H), 2.98 (m, 2H), 2.44 (s, 3H), 1.26 (t, 3H), 1.17 (s, 3H), 1.10 (s, 30 3H).

WO 99/06437 PCT/US98/16070 205

"

3 C NMR (CDC13): 8 = 171.5, 168.8, 125.9, 145.3, 133.4, 130.9, 130.5, 128.7, 126.3, 115.8, 74.1, 62.1, 55.3, 54.1, 38.2, 29.8, 24.6, 22.2, 14.7. Example 76 5 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl L-4-acetamidophenylalanine ethyl ester The title compound was prepared following the procedure outlined for the preparation of Example 39. 10 NMR data was as follows: 1 H NMR (CDC13): 6 = 7.69 (d, 2H), 7.52 (s, 1H), 7.42 (d, 2H), 7.38 7.30 (m, 3H), 7.09 (d, 2H), 4.78 (m, 1H), 4.21 (q, 2H), 4.04 (m, 1H), 3.38 (m, 1H), 3.25-2.97 (m, 3H), 2.43 (s, 3H), 2.13 (s, 3H), 2.02 (m, 1H), 1.58 1.44 (m, 3H), 1.28 (t, 3H). 15 13C NMR (CDCl 3 ): 6 = 171.4, 169.0, 144.9, 137.6, 133.4, 132.4, 130.6, 130.4, 128.4, 120.4, 62.9, 62.3, 54.0, 50.3, 37.9, 30.4, 25.2, 24.9, 22.2, 14.7. Example 77 20 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl L-4-(2-methoxybenzamido)phenylalanine The title compound was prepared from the product of Example 72 using the procedure described in Method 7. 25 NMR data was as follows: 'H NMR (CD 3 OD): 6 = 7.82 (d, 1H), 7.67 (d, 1H), 7.51 (d, 2H), 7.41 (d, 2H), 7.31 (t, 1H), 7.19 (d, 2H), 7.05 (d, 2H), 6.97 (d, 1H), 6.89 (t, 1H), 4.49 (m, 1H), 3.91 (m, 1H), 3.78 (s, 3H), 3.23-2.83 (m, 3H), 2.21 (S, 3H), 1.68-1.28 (m, 4H). 30 WO 99/06437 PCT/US98/16070 206 Example 78 Synthesis of N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl) thiaprolyl-L-4-acetamidophenylalanine ethyl ester 5 The title compound was prepared following the procedure outlined for the preparation of Example 39. NMR data was as follows: 'H NMR (CDCl 3 ): 8 = 7.73 (d, 2H), 7.50 (brs, 1H), 7.42 (d, 2H), 7.33 (d, 2H), 7.15 (d, 2H), 7.02 (d, 1H), 4.84 (m, 1H), 4.53 (d, 1H), 4.35 (d, 1H), 10 4.18 (q, 2H), 3.84 (s, 1H), 3.08 (m, 2H), 2.43 (s, 3H), 2.15 (s, 3H), 1.25 (t, 3H), 1.13 (s, 3H), 1.06 (s, 3H). 1 3 C NMR (CDC 3 ): 8 = 171.3, 169.1, 163.0, 145.4, 137.6, 133.3, 132.4, 130.6, 128.7, 120.4, 112.0, 74.1, 62.3, 55.1, 54.0, 41.1, 38.4, 29.8, 25.2, 24.5, 22.2, 14.7. 15 Example 79 Synthesis of N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl) thiaprolyl-L-4-acetamidophenylalanine 20 The title compound was prepared from the product of Example 78 using the procedure described in Method 7. NMR data was as follows: 'H NMR (CDCl 3 ): 8 = 8.19 (s, 1H), 7.73 (d, 2H), 7.40 (d, 2H), 7.32 (d, 2H), 7.23 (d, 1H), 7.15 (d, 2H), 4.86 (m, 1H), 4.55 (d, 1H), 4.36 (d, 1H), 25 3.92 (s, 1H), 3.10 (m, 2H), 2.42 (s, 3H), 2.10 (s, 3H), 1.19 (s, 3H), 1.07 (s, 3H).

WO 99/06437 PCT/US98/16070 207 Example 80 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl L-4-acetamidophenylalanine Isopropyl Ester 5 The title compound was prepared following the procedure outlined for the preparation of Example 39. NMR data was as follows: 'H NMR (CDCl 3 ): 6 = 7.70 (d, 2H), 7.42 (d, 2H), 7.33 (d, 2H), 7.10 (d, 2H), 5.11-5.03 (m, 1H11), 4.80-4.73 (m, 1H), 4.06 (dd, 1H), 3.41-3.36 (m, 10 1H), 3.20 (dd, 1H), 3.12-3.09 (m, 1H), 3.02 (dd, 1H), 2.44 (s, 3H), 2.15 (s, 3H), 2.05-2.01 (m, 1H), 1.58-1.44 (m, 3H), 1.27 (d, 3H). 13C NMR (CDCl 3 ): 6 = 170.7, 170.2, 168.3, 144.3, 136.9, 132.9, 131.9, 129.9, 129.9, 127.8, 119.7, 69.5, 62.3, 53.5, 49.7, 37.3, 29.8, 24.6, 24.2, 21.7, 21.7, 21.6. 15 Example 81 Synthesis of N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)

L-

4 -(isonicotinamido)phenylalanine ethyl ester 20 The title compound was prepared following the procedure outlined for the preparation of Example 36. NMR data was as follows: 'H NMR (CDCl 3 ): 6 = 8.75 (d, 2H), 8.27 (s, 1H), 7.74-7.68 (m, 4H), 7.59 (d, 2H), 7.33 (d, 2H), 7.22 (d, 2H), 7.08 (d, 1H), 4.86 (m, 1H), 4.54 (d, 25 1H), 4.34 (d, 1H), 4.18 (q, 2H), 3.84 (s, 1H), 3.18-3.03 (m, 2H), 2.43 (s, 3H), 1.26 (t, 3H), 1.26 (t, 3H), 1.15 (s, 3H), 1.04 (s, 3H). 1 3 C NMR (CDCl 3 ): 6 =171.3,169.1,164.3, 151.2, 145.4, 142.6, 137.0, 133.4, 133.2, 130.8, 130.6, 128.6, 121.6, 121.0, 74.1, 62.4, 55.1, 54.0, 51.1, 38.4, 29.8, 24.6, 22.2, 14.7. 30 WO 99/06437 PCT/US98/16070 208 Example 82 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-L-4 (isonicotinamido)phenylalanine ethyl ester 5 The title compound was prepared following the procedure outlined for the preparation of Example 36. NMR data was as follows: 'H NMR (CDCl 3 ): 6 = 8.76 (d, 2H), 8.34 (s, 1H), 7.72 (d, 2H), 7.68 (d, 2H), 7.59 (d, 2H), 7.40 (d, 1H), 7.32 (d, 2H), 7.16 (d, 2H), 4.80 (m, 1H), 10 4.21 (q, 2H), 4.04 (m, 1H), 3.40 (m, 1H), 3.28-3.02 (m, 3H), 2.43 (s, 3H), 2.03 (m, 1H), 1.60-1.42 (m, 3H), 1.29 (t, 3H).

"

3 C NMR (CDC1 3 ): 8 = 171.4, 171.3, 164.3, 151.2, 145.0, 142.6, 137.0, 133.5, 133.4, 130.6, 130.6, 128.4, 121.6, 121.0, 62.9, 62.3, 54.1, 52.3, 38.0, 30.3, 24.9, 22.2, 14.7. 15 Example 83 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl L-(x-toluene-4-sulfonyl)histidine methyl ester 20 L-Prolyl-L-histidine methyl ester was treated with CH 3 SOzC1 and Et 3 N in CHzC1 2 to give the title compound. NMR data was as follows: 'H NMR (CDC1 3 ): 8 = 7.93 (s, 1H), 7.81 (d. 2H), 7.77 (d, 1H), 7.73 (d, 2H), 7.34 (d, 4H), 7.09 (s, 1H), 4.82 (m, 1H), 4.76-4.09 (dd, 1H), 3.68 (s, 25 3H), 3.51-3.44 (m, 1H), 3.18-3.08 (m, 3H), 2.45 (s, 3H), 2.41 (s, 3H), 2.10 2.05 (m, 1H), 1.68-1.53 (m, 3H). 1 3 C NMR (CDCl 3 ): 6 = 171.1, 171.0, 146.2, 144.2, 140.0, 136.5, 134.8, 133.2, 130.4, 129.9, 127.8, 127.4, 114.8, 62.2, 52.5, 51.9, 49.5, 30.1, 29.9, 24.3, 21.7, 21.6. 30 WO 99/06437 PCT/US98/16070 209 Example 84 Synthesis of N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)-thiaprolyl-L 4-(nicotinamido)phenylalanine ethyl ester 5 The title compound was prepared following the procedure outlined for the preparation of Example 36. NMR data was as follows: 1 H NMR (CDC1 3 ): 8 = 9.06 (s, 1H), 8.76 (d, 1H), 8.22 (d, 1H), 8.14 (s, 1H), 7.73 (d, 2H), 7.59 (d, 2H), 7.45 (t, 1H), 7.33 (d, 2H), 7.23 (d, 2H), 10 7.18 (d, 1H), 4.86 (m, 1H), 4.52 (d, 1H), 4.34 (d, 1H), 4.20 (q, 2H), 3.06 2.20 (m, 2H), 2.43 (s, 3H), 1.27 (t, 3H), 1.20 (s, 3H), 1.08 (s, 3H). 1 3 C NMR (CDC13): a = 171.3, 169.1, 152.9, 148.4, 145.4, 137.1, 136.1, 133.4, 130.8, 130.6, 128.7, 124.3, 120.9, 74.1, 62.3, 55.1, 54.0, 51.1, 38.7, 29.8, 24.6, 22.3, 14.7. 15 Example 85 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-L-(O-methyl)tyrosine ethyl ester The title compound was prepared following the procedure outlined 20 for the preparation of Example 36. NMR data was as follows: 1 H NMR (CDCl 3 ): 8 = 7.71 (d, 2H), 7.32 (m, 3H), 7.06 (d, 2H), 6.80 (d, 2H), 4.77 (m, 1H), 4.21 (q, 1H), 4.18-4.06 (m, 1H), 3.77 (s, 3H), 3.37 3.34 (m, 1H), 3.20-3.09 (m, 2H), 3.00 (dd, 3H), 2.43 (s, 3H), 1.55-1.46 (m, 25 3H), 1.28 (t, 3H). 1 3 C NMR (CDC13): 6 = 171.5, 171.3, 159.2, 144.9, 133.6, 130.9, 130.5, 128.7, 128.4, 114.4, 62.8, 62.2, 55.8, 54.1, 50.2, 37.7, 30.3, 24.8, 22.3, 14.7.

WO 99/06437 PCT/US98/16070 210 Example 86 Synthesis of N-(a-Toluenesulfonyl)-L-prolyl

L-

4 -(isonicotinamido)phenylalanine ethyl ester 5 The title compound was prepared following the procedure outlined for the preparation of Example 36. NMR data was as follows: 1 H NMR (CDCl 3 ): 6 = 8.72 (d, 2H), 8.45 (s, 1H), 7.69 (d, 2H), 7.55 (d, 2H), 7.45-7.30 (m, 5H), 7.13 (d, 2H), 6.99 (d, 1H), 4.78 (m, 1H), 4.28 (s, 10 2H), 4.18 (q, 2H), 4.03 (m, 1H), 3.23-2.98 (m, 4H), 2.10-1.62 (m, 4H), 1.27 (t, 3H). 1 3 C NMR (CDCl 3 ): 6 = 171.6, 174.5, 164.4, 151.1, 142.6, 137.1, 133.3, 131.4, 130.6, 129.5, 129.4, 129.0, 121.6, 121.1, 62.9, 62.4, 57.3, 53.9, 50.1, 37.9, 31.0, 25.5, 14.7. 15 Example 87 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl L-4-(2-bromobenzamido)phenylalanine 20 The title compound was prepared from the product of Example 74 using the procedure described in Method 7. NMR data was as follows: 'H NMR (CD 3 OD): 6 = 8.01 (brd, 1H), 7.75-7.58 (m, 4H), 7.50-7.33 (m, 4H), 7.24 (d, 2H), 4.70 (m, 1H), 3.50-3.00 (m, 5H), 2.43 (s, 3H), 1.85 25 1.48 (m, 4H). Example 88 Synthesis of N-(a-Toluenesulfonyl)-L-prolyl 30 L-4-(isonicotinamido)phenylalanine The title compound was prepared from the product of Example 86 using the procedure described in Method 7.

WO 99/06437 PCT/US98/16070 211 NMR data was as follows: 'H NMR (D 2 0): 6 = 8.45 (d, 2H), 7.50 (d, 2H), 7.26 (d, 2H), 7.18 (s, 5H), 7.05 (d, 2H), 4.29 (m, 1H), 4.10 (m, 2H), 3.83 (m, 1H), 3.20-2.97 (m, 3H), 2.76 (m, 1H), 1.94 (m, 1H), 1.70-1.43 (m, 3H). 5 Example 89 Synthesis of N-(Toluene-4-sulfonyl)-L-(1,1-dioxo)thiamorpholyl

L-

4

-(

2 -bromobenzamido))phenylalanine ethyl ester 10 The title compound was prepared following the procedure outlined for the preparation of Example 36 and the procedure described by Larsson et al., Acta Chemica Scan., 1994, 48, 522. NMR data was as follows: 'H NMR (CDCl 3 ): 6 = 8.19 (d, 1H), 7.70 (d, 1H), 7.61-7.50 (m, 5H), 15 7.36-7.23 (m, 3H), 7.09-7.04 (m, 2H), 6.84 (d, 1/2H), 6.74 (d, 1/2H), 5.10 (d, 1/2H), 4.97 (d, 1/2H), 4.81 (m, 1/2H), 4.66 (m, 1/2H) 4.14 (m, 3H), 3.87 (m, 1H), 3.23-3.74 (m, 6H), 2.41 (s, 3H), 1.22 (t, 3H). 1 3 C NMR (CDCl 3 ): 6 = 170.9, 170.7, 166.0, 165.8, 165.1, 164.8, 145.6, 145.5, 137.9, 136.9, 136.7, 135.1, 135.0, 133.4, 132.0, 131.9, 131.5, 20 130.7, 130.6, 130.0, 130.1, 129.5, 129.4, 127.6, 127.4, 127.2, 120.7, 120.2, 61.8, 55.9, 55.8, 53.5, 53.3, 49.3, 49.2, 48.7, 48.6, 41.8, 41.7, 36.8, 36.3, 21.5, 13.9. Example 90 25 Synthesis of N-(Toluene-4-sulfonyl)-L-(1,1-dioxo)thiamorpholyl

L-

4

-(

2 -bromobenzamido)phenylalanine The title compound was prepared from the product of Example 89 using the procedure described in Method 7. 30 NMR data was as follows: WO 99/06437 PCT/US98/16070 212 'H NMR (CD 3 OD): 6 = 8.12 (d, 0.5H), 7.97 (d, 0.5H), 7.76-7.59 (m, 5.5H), 7.60-7.18 (m, 7H), 5.12 (m, 1H), 4.64 (m, 1H), 4.07 (m, 1H), 3.62 (m, 1H), 3.35 (m, 6H), 2.40 (s, 3H), 2.32-2.14 (m, 3H). 13 C NMR (CD 3 OD): 6 = 174.1, 169.7, 169.6, 169.2, 169.1, 146.4, 5 146.2, 140.3, 140.3, 138.7, 138.6, 137.4, 137.2, 134.9, 134.6, 134.3, 132.5, 131.6, 131.5, 131.2, 131.1, 130.0, 129.9, 128.9, 128.7, 128.6, 122.1, 121.8, 120.6, 56.9, 56.8, 54.9, 54.5, 50.8, 50.3, 40.8, 10.4, 37.8, 37.4, 21.6. Example 91 10 Synthesis of N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl) L-4-(isonicotinamido)phenylalanine The title compound was prepared from the product of Example 81 using the procedure described in Method 7. 15 Physical data was as follows: M.p. >200 0 C; MS(FAB+) 583(M+H). Example 92 20 Synthesis of N-(a-Toluenesulfonyl)-L-prolyl-L-4 (2-bromobenzamido)phenylalanine ethyl ester The title compound was prepared following the procedure outlined for the preparation of Example 36. 25 NMR data was as follows: 'H NMR (CDC1 3 ): 6 = 7.37 (s, 1H, 7.68-7.30 (m, 1 1H), 7.16 (d, 2H), 6.93 (d, 1H), 4.83 (m, 1H, 4.32 (s, 2H, 4.23 (q, 2H), 4.10 (m, 1H), 3.27-3.03 (m, 5H), 2.10-1.62 (m, 4H), 1.29 (t, 3H). 13C NMR (CDC1 3 ): 6 = 166.7, 161.2, 133.4, 132.2, 129.2, 128.1, 30 127.3, 126.4, 125.7, 125.4, 125.6, 124.5, 124.1, 123.4, 115.7, 114.9, 57.8, 57.3, 55.9, 52.4, 48.7, 45.1, 32.8, 26.0, 20.4, 9.6.

WO 99/06437 PCT/US98/16070 213 Example 93 Synthesis of N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl) 5 thiaprolyl-L-tyrosine Isoropyl Ester The title compound was prepared following the procedure outlined for the preparation of Example 36. NMR data was as follows: 'H NMR (CDCl 3 ): 8 = 7.73 (d, 2H), 7.33 (d, 2H), 7.10 (br d, 1H), 10 7.08 (d, 2H), 6.75 (d, 2H), 5.06 (m, 1H), 4.86 (m, 1H), 4.54 (d, 1H), 4.33 (d, 1H), 3.84 (s, 1H), 3.09-2.97 (m, 2H), 2.43 (s, 3H), 1.23 (dd, 6H), 1.05 (s, 3H), 1.02 (s, 3H). 13C NMR (CDCl 3 ): 6 = 170.6, 169.0, 155.3, 144.9, 132.6, 130.6, 130.0, 128.1, 127.2, 115.4, 73.3, 69.6, 65.8, 54.4, 53.6, 50.3, 37.6, 29.0, 23.5, 15 21.5,21.5. Example 94 Synthesis of N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl) 20 thiaprolyl-L-tyrosine tert-Butyl Ester The title compound was prepared following the procedure outlined for the preparation of Example 36. NMR data was as follows: 'H NMR (CDCl 3 ): 8 = 7.75 (d, 2H), 7.34 (d, 2H), 7.11 (d, 2H), 7.07 25 (d, 1H), 6.76 (d, 2H), 6.62 (br s, 1H), 4.79 (m, 1H), 4.56 (d, 1H), 4.35 (d, 1H), 3.84 (s, 1H), 3.07-2.96 (m, 2H), 2.45 (s, 3H), 1.46 (s, 9H), 1.05 (s, 3H), 1.03 (s, 3H). 13C NMR (CDC1 3 ): a = 170.1, 168.8, 155.3, 144.9, 132.6, 130.7, 130.0. 128.1, 127.6, 115.3, 82.7, 73.3, 54.5, 54.1, 50.4, 37.8, 29.1, 27.8, 23.5, 30 21.5.

WO 99/06437 PCT/US98/16070 214 Example 95 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-L-tyrosine tert-Butyl Ester The title compound was prepared following the procedure outlined 5 for the preparation of Example 36. NMR data was as follows: 'H NMR (CDCl 3 ): 8 = 7.62 (d, 2H), 7.35 (d, 1H), 7.25 (d, 2H), 6.96 (d, 2H), 6.71 (d, 2H), 4.65 (min, 1H), 4.07 (min, 1H), 3.30 (mn, 1H), 3.15-2.83 (min, 3H), 2.35 (s, 3H), 1.84 (min, 1H), 1.52-1.34 (min, 13H). 10 13C NMR (CDCl 3 ): 6 = 171.5, 170.0, 155.8, 144.5, 132.8, 130.4, 130.0, 127.8 ,127.1, 115.3, 82.5, 62.2, 54.1, 49.5, 37.0, 29.8, 27.7, 23.9, 21.3, 14.0. Example 96 15 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-L-4 (2-trifluoromethylbenzamido)phenylalanine ethyl ester The title compound was prepared following the procedure outlined for the preparation of Example 36. 20 NMR data was as follows: 'H NMR (CDC13): 8 = 7.81 (s, 1H), 7.50 - 7.38 (min, 8H), 7.38 (d, 1H), 7.33 (d, 2H), 7.14 (d, 2H), 4.80 (min, 1H), 4.22 (q, 2H), 4.03 (min, 1H), 3.37 (inm, 1H), 3.30 - 3.20 (min, 1H), 3.14 - 2.98 (min, 2H), 2.43 (s, 3H), 1.95 (min, 1H), 1.57 - 1.40 (m, 3H), 1.30 (t, 3H). 25 1 3 H NMR (CDC1 3 ): 6 = 171.2, 170.9, 165.8, 144.4, 136.6, 135.7, 132.9, 132.8, 132.2, 130.7, 130.2, 130.0, 130.0, 128.5, 127.9, 126.5, 120.2, 62.1, 61.7, 53.3, 49.6, 37.2, 29.7, 24.0, 21.4, 13.9.

WO 99/06437 PCT/US98/16070 215 Example 97 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl

L-

4

-(

2 -methylbenzamido)phenylalanine ethyl ester 5 The title compound was prepared following the procedure outlined for the preparation of Example 36. NMR data was as follows: 'H NMR (CDCl 3 ): 8 = 7.72 (d, 2H), 7.58-7.43 (m, 4H), 7.40-7.20 (m, 7H), 7.15 (d, 2H), 4.82 (m, 1H), 4.24 (q, 2H), 4.08 (m, 1H), 3.43 (m, 1H), 10 3.29-3.03 (m, 3H), 2.50 (s, 3H), 2.44 (s, 3H), 2.05 (m, 1H), 1.55 (m, 3H), 1.31 (t, 3H). 13C NMR (CDC 3 ): 6 = 170.9,170.9,144.4,137.0, 136.5, 133.0, 132.4, 131.3, 130.3, 130.1, 130.0, 127.9, 126.6, 125.9, 119.8, 62.2, 61.6, 53.4, 49.6, 37.3, 29.6, 24.2, 21.4, 19.7, 14.0. 15 Example 98 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl

L-

4

-(

2 -trifluoromethylbenzamido)phenylalanine 20 The title compound was prepared from the product of Example 96 using the procedure described in Method 7. NMR data was as follows: 'H NMR (CDCl 3 ): 6 = 8.28 (s, 1H), 7.68-7.40 (m, 9H), 7.33 (d, 2H), 7.17 (d, 2H), 4.84 (m, 1H), 4.05 (m, 1H), 3.44-3.04 (m, 4H), 2.43 (s, 3H), 25 1.90 (m, 1H), 1.49 (m, 3H). Example 99 Synthesis of

N-(

4 -Fluorobenzenesulfonyl)-L-thiaprolyl-L-tyrosine tert-Butyl Ester 30 The title compound was prepared following the procedure outlined for the preparation of Example 36.

WO 99/06437 PCT/US98/16070 216 NMR data was as follows: 1 H NMR (CDCl 3 ): 8 = 7.87 (m, 2H), 7.23 (m, 3H), 7.03 (d, 2H), 6.73 (d, 2H), 6.29 (s, 1H), 4.68 (m, 1H), 4.56 (m, 2H), 4.10 (d, 1H), 3.29-2.93 (m, 3H), 2.61 (m, 1H), 1.49 (s, 9H). 5 13C NMR (CDC 3 ): 8 = 169.9, 168.2, 155.4, 132.5, 130.9, 130.7, 127.3, 117.1, 116.8, 115.4, 82.9, 65.0, 54.1, 51.5, 36.8, 33.3, 27.9. Example 100 Synthesis of 10 N-(4-Fluorobenzenesulfonyl)-L-(5,5-dimethyl) thiaprolyl-L-tyrosine tert-Butyl Ester The title compound was prepared following the procedure described for the preparation of Example 36. NMR data was as follows: 15 'H NMR (CDC1 3 ): 8 = 7.90 (m, 2H), 7.23 (m, 2H), 7.09 (d, 2H), 6.98 (d, 1H), 6.76 (d, 2H), 4.77 (m, 1H), 4.55 (d, 1H), 4.37 (d, 1H), 3.83 (s, 1H), 3.01 (m, 1H), 1.44 (s, 9H), 1.10 (s, 3H),1.05 (s, 3H). 13C NMR (CDCl 3 ): 8 = 170.1, 168.6, 155.3, 132.0, 131.0, 130.8, 127.7, 116.9, 116.6, 115.3, 82.8, 73.4, 54.6, 54.0, 50.4, 37.8, 29.1, 27.8, 23.5. 20 Example 203 Synthesis of N-(Toluene- 4 -sulfonyl)-L-prolyl-L-4-(4-nitro-phenoxycarbonyloxy) phenylalanine ethyl ester 25 In a nitrogen atmosphere, Tos-Pro-Tyr ethyl ester was dissolved in

CH

2 C1, at RT, the flask cooled to 0OC and 4-nitrophenylchloroformate added in one portion. Next, Et 3 N was added dropwise slowly, stirred at 0OC for 30 minutes and then at RT for 30 minutes. The reaction mixture was again cooled to 0oC and N,N-dimethylethanolamine was added dropwise. The ice 30 bath was taken away after 10 minutes and the reaction mixture stirred at RT for 3 hours. The reaction mixture was diluted with Et,O and washed with WO 99/06437 PCT/US98/16070 217 10% K 2

CO

3 until all yellow color disappeared. Flash chromatography (SiO 2 ) eluting with 40% EtOAc/hex yielded a white foam in 30% yield. Example 204 5 Synthesis of N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl) thiaprolyl-4-(2-bromobenzamido)-D-phenylalanine t-butyl ester The starting (2R)-3-(4-amino-phenyl)-2- { [(4R)-5,5-dimethyl-3 (toluene-4-sulfonyl)-thiazolidine-4-carbonyl]-amino }-propionic acid tert-butyl ester (230 mg), 2-bromobenzoic acid (100 mg), and 10 4-methylmorpholine (0.19 mL) were dissolved in DMF (5 mL) at 0OC in an ice bath. BOP (229 mg) was added to the solution. The ice bath was removed after 10 minutes. The reaction mixture was stirred at room temperature for 18 hours. Ethyl acetate (20 mL) was added. The mixture was washed with citric acid (5%, 20 mL, 2x) and saturated NaHCO 3 solution 15 (20 mL, 2x), then washed with brine. The solution was dried with MgSO 4 . The solvent was evaporated in vacuo and the residue was purified using HPLC (reverse phase, 65-95% CH 3 OH/water). The retention time was 13 minutes. The desired product was freeze dried to give 181 mg of a white solid. MP: 92-93oC 20 Example 205 Synthesis of N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)thiaprolyl-4

(

2 -bromobenzamido)-L-phenylalanine t-butyl ester The starting (2S)-3-(4-amino-phenyl)-2- { [(4R)-5,5-dimethyl-3 25 (toluene- 4 -sulfonyl)-thiazolidine-4-carbonyl]-amino } -propionic acid tert-butyl ester (230 mg), 2-bromobenzoic acid (100 mg), and 4-methylmorpholine (0.19 mL) were dissolved in DMF (5 mL) at 0OC in an ice bath. BOP (229 mg) was added to the solution. The ice bath was removed after 10 minutes. The reaction mixture was stirred at room 30 temperature for 18 hours. Ethyl acetate (20 mL) was added. The mixture WO 99/06437 PCT/US98/16070 218 was washed with citric acid (5%, 20 mL, 2x) and saturated NaHCO 3 solution (20 mL, 2x), then washed with brine. The solution was dried with MgSO 4 . The solvent was evaporated in vacuo and the residue was purified using HPLC (reverse phase, 65-95% CH 3 OH/water). The retention time was 13.5 5 minutes. The desired product was freeze dried to give 27 mg of the title compound as a white solid. MP: 92-93 0 C Example 207 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-4-(1-H, 10 2 -oxo-3-methyltetrahydropyrimidin-1-yl)-L-phenylalanine The title compound was prepared from the corresponding t-butyl ester using the procedure described in Method 11. NMR data was as follows: 1 H NMR (CDC13): 8 = 7.73 (d, 2H), 7.58 (d, 1H), 7.34 (d, 2H), 7.21 15 (d, 2H), 7.17 (d, 2H), 4.79 (q, 1H1), 4.15 - 4.11 (min, 1H), 3.68 - 3.63 (mn, 2H), 3.48- 3.39 (min, 3H), 3.27 (dd, 1H), 3.17 (dd, 1H), 3.15 - 3.07 (mn, 1H), 2.99 (s, 3H), 2.43 (s, 3H), 2.16 -2.08 (min, 2H), 2.00 - 1.98 (min, 1H). 1 3 C NMR (CDCl 3 ):6 = 173.4, 172.2, 164.2, 156.4, 144.4, 142.5, 134.1, 133.0, 130.2, 130.0, 127.9, 126.2, 62.1, 53.4, 49.5, 48.9, 47.9, 36.5, 35.9, 30.2, 24.2, 20 22.0, 21.4. Example 212 N-(4-Fluorobenzenesulfonyl)-L-(5,5-dimethyl) thiaprolyl-L-3-chloro-4 hydroxyphenylalanine Isopropyl Ester 25 The compound was prepared following the procedure described for the preparation of Example 36 employing N-(4-fluorobenzenesulfonyl)-L (5,5-dimethyl, thiaproline (prepared according to Method 8and 3-chloro-L- WO 99/06437 PCT/US98/16070 219 tyrosine isopropyl ester (prepared from commercially available 3-chloro-L tryosine and isopropyl alcohol in the presence of anhydrous HCI). MS:(-) ESI [M-H]-557 HPLC: 96.8% 5 Example 214 Synthesis of N-(Toluene- 4 -sulfonyl)-L-prolyl-4-(2-methoxyphenyl)-L-phenylalanine The title compound was prepared from the corresponding t-butyl 10 ester using the procedure described in Method 11. NMR data was as follows: 1 H NMR (CD 3 OD):6 = 7.70 (m, 2H), 7.36 (m, 4H), 7.22 (m, 4H), 6.98 (m, 2H), 4.75 (m, 1H), 4.10 (m, 1H), 3.71 (s, 3H), 3.29 (m, 2H), 3.11 (m, 2H), 2.39 (s, 3H), 1.75 (m, 1H), 1.53 (m, 3H). 15 1 3 C NMR (CD 3 OD):6 = 174.4, 174.2, 158.1, 145.9, 138.9, 136.7, 135.1, 131.2, 130.9, 130.8, 130.2, 129.9, 129.1, 122.0, 112.6, 63.3, 55.9, 54.6, 50.5, 37.9, 31.5, 25.2, 21.4. Example 215 20 Synthesis of N-(Toluene- 4 -sulfonyl)-L-prolyl-4-(2-methoxyphenyl)-L-phenylalanine The title compound was prepared from the corresponding t-butyl ester using the procedure described in Method 11. NMR data was as follows: 25 'H NMR (CDC1 3 ): 6 8.41 (d, 1H), 8.21 (s, 1H), 8.03 (d, 1H), 7.98 (s, 1H), 7.74 (d, 2H), 7.39 (d, 1H), 7.33 (d, 2H), 4.72-4.68 (m, 1H), 4.17-4.13 (m, 1H), 3.54-3.34 (m, 3H), 3.20-3.12 (m, 1H), 2.82 (s, 6H)m 2.43 (s, 3H), 2.09-2.04 (m, 1H), 1.79-1.59 (m, 3H).

WO 99/06437 PCT/US98/16070 220

"

3 C NMR (CDC1 3 ):8 = 173.7, 171.8, 154.5, 147.2,144.4,137.8, 135.5, 133.2, 130.1, 127.9, 126.4, 62.2, 53.0, 49.5, 38.5, 36.0, 30.3, 24.4, 21.4. 5 Example 216 N-(Toluene-4-sulfonyl)-L-prolyl-4-(N,N-dimethylsulfamyl) L-phenylalanine The title compound was prepared from the corresponding tert-butyl ester using the procedure described in Method 11. 10 NMR data was as follows: 'H NMR (CDCl 3 ):6 = 7.71 (d, 2H), 7.58 (d, 1H), 7.49 (bs, 1H), 7.34 (d, 2H), 7.16 (d, 2H), 7.12 (d, 2H), 4.90 - 4.83 (m, 1H), 4.13 - 4.09 (m, 1H), 3.46 - 3.40 (m, 1H), 3.28 (dd, 1H), 3.15 - 3.04 (m, 2H), 2.77 (s, 6H), 2.43 (s, 3H), 1.93 - 1.88 (m, 1H), 1.54 - 1.45 (m, 3H). 15 3 C NMR (CDC 3 ):8 = 173.7, 172.0, 144.7, 136.6, 132.6, 132.1, 130.4, 130.2, 127.9, 120.3, 62.2, 53.3, 49.7, 38.0, 36.8, 29.9, 24.1, 21.4. Example 217 Synthesis of 20 N-(Toluene-4-sulfonyl)-L-prolyl-(N1,N1,N2-trimethylsulfamyl) L-phenylalanine The title compound was prepared from the corresponding tert-butyl ester using the procedure described in Method 11. NMR data was as follows: 25 'H NMR (CDCl 3 ):8 = 7.71 (d, 2H), 7.49 (d, 1H), 7.35 (d, 4H), 7.24 (d, 2H), 4.89 - 4.82 (m, 1H), 4.10 - 4.07 (m, 1H), 3.41 - 3.31 (m, 2H), 3.22 (s, 3H), 3.16 - 3.06 (m, 2H), 2.76 (s, 6H), 2.44 (s, 3H), 1.98 - 1.95 (m, 1H), 1.55 - 1.38 (m, 3H). 13C NMR (CDC1 3 ):8 = 173.7, 171.8, 144.6, 141.7, 135.1, 132.7, 30 130.2, 103.1, 127.9, 126.6, 62.2, 53.2, 49.6, 39.4, 38.2, 36.7, 29.6, 24.1, 21.5.

WO 99/06437 PCT/US98/16070 221 Example 220 Synthesis of

N-[

4

-(

3

,

3 -Dimethyl-ureido)-benzenesulfonyl]-L-prolyl-(4-hydroxy) L-phenylalanine isopropyl ester 5 The reaction vessel was flushed with N 2 , Pd/C was added to the flask and wet with iso-PrOH. Next, the nitro compound was added to the flask in iso- PrOH and a balloon filled with H 2 was attached to the flask. The N 2 was vacuumed out, H 2 added, evacuated, and H 2 added again. The reaction was complete in 2 hours; diluted with iso-PrOH and filtered through Celite and 10 evaporated to dryness. Flash chromatography (SiO 2 ) diluting with 1% MeOH/CH 2 C1, yielded a white solid in 62% yield of the lower Rf from the separation. Example 225 15 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-4-(N,N-dimethylaminocarbonylmethyl) L-phenylalanine The title compound was prepared from the product of Example 233 using the procedure described in Method 11. 20 NMR data was as follows: H NMR (CD 3 OD): 6 = 8.04 (d, 1H), 7.70 (d, 2H), 7.40 (d, 2H), 7.20 (m, 4H), 4.99 (bs, 1H), 4.70 (m, 1H), 4.10 (m, 1H), 3.69 (s, 2H), 3.40 (m, 1H), 3.20 (m, 1H), 3.04 (m, 2H), 3.01 (s, 3H), 2.92 (s, 3H), 2.41 (s, 3H), 1.80 (m, 1H), 1.62 (m, 3H). 25 1 3 C NMR (CD 3 OD):8 = 174.2, 174.1, 1.73.9, 145.8, 136.8, 135.0, 131.2, 131.0, 130.0, 129.1, 63.2, 54.7, 54.6, 50.5, 41.0, 38.3, 37.7, 35.9, 31.6, 25.2, 21.5.

WO 99/06437 PCT/US98/16070 222 Example 226 Synthesis of N-(1-Methylimidazol-4-sulfonyl)-L-prolyl-(4-hydroxyl)-L.-phenylalanine isopropyl ester 5 The compound was prepared by BOP coupling of 1-methylimidazole-4-sulfonyl-Pro with Tyr-isopropyl ester. The crude product was purified by flash chromatography (silica, 95:3:2 EtOAc:EtOH:Et 3 N) to afford a white solid, m.p. = 159-162 0 C. (2.03g, 65%). MS((+)ESI, m/z (%)) 465 (100 [M+H]+). 10 Example 227 Synthesis of N-(Toluene- 4 -sulfonyl)-L-prolyl-4-(2,4,5-trioxo-3-phenyltetrahydro imidazol-1-yl)-L-phenylalanine isopropyl ester 15 The compound was prepared by treatment of N-(toluene-4-sulfonyl) L-prolyl-4-[(phenyl ureido)-tetrahydroimidazol-1-yl]-L-phenylalanine isopropyl ester with oxalyl chloride in methylene chloride. The crude product was purified by flash chromatography (silica, 3:2 Hex:EtOAc) to afford a white solid. (0.490g, 49%). 20 MS((+)ESI, m/z (%)) 647 (15 [M+H]+); 664 (100[M+NH 4 ]+. Example 229 N-(4-Fluorobenzenesulfonyl)-L-(5,5-dimethyl) thiaprolyl-L-3-chloro 4-tert-butoxy-phenylalanine tert-Butyl Ester 25 The compound was prepared according to the procedure described in Example 36. The required 3-chloro-O-tert-butyl-L-tyrosine tert-butyl ester was prepared from 3-chloro-L-tyrosine and iso-butylene in the presence of one equivalent of sulfuric acid and used without further purification. 30 MS-(+)ESI [M+H] 629 [M+NH 4

]

+

646.

WO 99/06437 PCT/US98/16070 223 Example 231 N-[2-(N-2,10-camphorsultamyl) acetyl] -L-3-chloro-4-hydroxyphenylalanine Isopropyl Ester 5 The above compound was prepared by the following steps: Step 1: Preparation of N-(tert-butoxycarbonylmethyl) camphorsultam Camphorsultam (3g, 14 mmole) in DMF (25 mol) was mixed with NaH (1.1 equiv.) for 15 minutes, then tert-butyl bromoacetate (2.5 ml) was 10 added and the reaction mixture was stirred overnight. The solvent was evaporated to dryness and the residue was partitioned between aq-citric acid and EtoAc. The organic layer was washed with sat. aq. NaHCOQ, and water, dried and evaporated to give the ester. (3.5 g) 15 Step 2: Preparation of N-(carboxymethyl) camphorsultam The ester (3.3g) was converted to the acid according to Method 17. MS (-)ESI [M-HI- 272 Step 3: Preparation of N-[2-(N-2,10-camphorsultamyl) acetyl] 20 L-3-chloro-4-hydroxyphenylalanine Isopropyl Ester The titled compound was prepared by amide bond formation according to a method similar to Example 52. MS:(+)ESI [M+H]+513 HPLC: 99.4% 25 Example 236 Synthesis of

N-(

4 -Fluorobenzenesulfonyl)-L-prolyl-4-hydroxy-L-phenylalanine t-butyl ester 30 The compound was prepared using the procedure described in Method 12. The crude product was purified by flash column WO 99/06437 PCT/US98/16070 224 chromatography (silica, hexane:EtOAc 1:1) to give the title compound as a white foam (580 mg, 64%). MS (+)ESI, [M+H]+ @ m/z 493 [M+NH4]+ @ m/z 510 5 Example 237 Synthesis of

N-(

4 -Fluorobenzenesulfonyl)-L-prolyl-4-hydroxy-L-phenylalanine ispropyl ester The compound was prepared using the procedure described in 10 Method 12. The crude product was purified by flash column chromatography (silica, hexane:EtOAc 1:1) (380 mg, 43%). MS (+)ESI, [M+H]+ @ m/z 479 (100%) [M+NH4]+ @ m/z 496 Example 238 15 Synthesis of N-(1-Methylimidazol-4-sulfonyl)-L-prolyl-4-hydroxy-L-phenylalanine t-butyl ester The compound was prepared by BOP coupling of 1-methylimidazole-4-sulfonyl-Pro with Tyr-t-butyl ester. The crude product 20 was purified by flash chromatography (silica, 95:3:2 EtOAc: EtOH:Et 3 N) to afford a white solid. (1.21 g, 66%) MS ((+)ESI, m/z (%)) 479 (100 [M+H]+) Example 239 25 Synthesis of N-(Pyridine-3-sulfonyl)-L-prolyl-4-hydroxy-L phenylalanine t-butyl ester The compound was prepared by BOP coupling of 3-pyridinesulfonyl-Pro with Tyr-t-butyl ester. The crude product was purified by flash chromatography (silica, 95:3:2 EtOAc: EtOH:Et 3 N) to 30 afford a pale orange foam. (0.

9 30g, 95%) MS ((+)ESI, m/z (%)) 476 (100 [M+H]+) WO 99/06437 PCT/US98/16070 225 Example 240 Synthesis of N-(Toluene-4-sulfonyl)-L-prolyl-4-(methanesulfonamido) L-phenylalanine To a solution of 3

-(

4 -methanesulfonylamino-phenyl) 5 2- { [1 -(toluene-4-sulfonyl)- pyrrolidine-2-carbonyl]-amino } -propionic acid methyl ester (0.250 g, 0.477 mmol) in THF (1.0 mL) was added IN LiOH (955 mL, 0.955 mmol) and the clear solution was stirred at 25 0 C, under nitrogen, for 16 h. The reaction solution was then diluted with additional water (50mL) and washed with diethyl ether (25 mL). The aqueous layer was 10 lyophilized to afford a fluffy white solid (0.216 g, 87%). MS (-ESI): 508 [M - 1] Example 242 Synthesis of 15 N-(Toluene- 4 -sulfonyl)-L-prolyl-4-(2,4,5-trioxo-3-(3-chlorophenyl)-tetra hydroimidazol-1-yl)-L-phenylalanine benzyl ester The compound was prepared by treatment of N-(toluene-4-sulfonyl) L-prolyl-4-[(3-chlorophenyl ureido)-tetrahydroimidazol-1-yl]-L phenylalanine isopropyl ester with oxalyl chloride in methylene chloride. 20 The crude product was purified by flash chromatography (silica, 3:2 Hex: EtOAc) to afford a white solid. (0.410g, 50%). MS ((+)ESI, m/z (%) 746 (100[M+H]+) (746/748 1Cl) Certain of the above exemplified compounds as well as certain other 25 compounds which can be prepared by the methods described above include those set forth in Tables IA and IB above.

WO 99/06437 PCT/US98/16070 226 Example 244 In vitro Assay For Determining Binding of Candidate Compounds to VLA-4 An in vitro assay was used to assess binding of candidate compounds 5 to a43 1 integrin. Compounds which bind in this assay can be used to assess VCAM-1 levels in biological samples by conventional assays (e.g., competitive binding assays). This assay is sensitive to IC 50 values as low as about InM. 10 The activity of a4 P 1 integrin was measured by the interaction of soluble VCAM-1 with Jurkat cells (e.g., American Type Culture Collection Nos. TIB 152, TIB 153, and CRL 8163), a human T-cell line which expresses high levels of a4P 1 integrin. VCAM-1 interacts with the cell surface in an a4 1 integrin-dependent fashion (Yednock, et al. J. Biol. Chem., 15 1995, 270:28740). Recombinant soluble VCAM-1 was expressed as a chimeric fusion protein containing the seven extracellular domains of VCAM-1 on the N terminus and the human IgGi heavy chain constant region on the C-terminus. 20 The VCAM-1 fusion protein was made and purified by the manner described by Yednock, supra. Jurkat cells were grown in RPMI 1640 supplemented with 10% fetal bovine serum, penicillin, streptomycin and glutamine as described by 25 Yednock, supra. Jurkat cells were incubated with 1.5 mM MnCl, and 5 pg/mL 15/7 antibody for 30 minutes on ice. Mn +2 activates the receptor to enhance ligand binding, and 15/7 is a monoclonal antibody that recognizes an 30 activated/ligand occupied conformation of a 4

P

1 integrin and locks the WO 99/06437 PCT/US98/16070 227 molecule into this conformation thereby stabilizing the VCAM-1/ 4

P

1 integrin interaction. Yednock, et al., supra. Antibodies similar to the 15/7 antibody have been prepared by other investigators (Luque, et al, 1996, J. Biol. Chem. 271:11067) and may be used in this assay. 5 Cells were then incubated for 30 minutes at room temperature with candidate compounds, in various concentrations ranging from 66 pM to 0.01 pM using a standard 5-point serial dilution. 15 tL soluble recombinant VCAM-1 fusion protein was then added to Jurkat cells and incubated for 30 10 minutes on ice. (Yednock et al., supra.). Cells were then washed two times and resuspended in PE-conjugated goat F(ab')2, anti-mouse IgG Fc (Immunotech, Westbrook, ME) at 1:200 and incubated on ice, in the dark, for 30 minutes. Cells were washed twice and 15 analyzed with a standard fluorescence activated cell sorter ("FACS") analysis as described in Yednock, et al., supra. Compounds having an IC 50 of less than about 15pM possess a suitable binding affinity to cX 4 1I* 20 When tested in this assay, each of the compounds in Examples 1-243 has an IC 5 0 of 15 4M or less. Example 245 25 In vitro Saturation Assay For Determining Binding of Candidate Compounds to cX43 1 The following describes an in vitro assay to determine the plasma levels needed for a compound to be active in the Experimental Autoimmune Encephalomyelitis ("EAE") model, described in the next example, or in other 30 in vivo models.

WO 99/06437 PCT/US98/16070 228 Log-growth Jurkat cells are washed and resuspended in normal animal plasma containing 20 pg/ml of the 15/7 antibody (described in the above example). 5 The Jurkat cells are diluted two-fold into either normal plasma samples containing known candidate compound amounts in various concentrations ranging from 66 pM to 0.01 pM, using a standard 12 point serial dilution for a standard curve, or into plasma samples obtained from the peripheral blood of candidate compound-treated animals. 10 Cells are then incubated for 30 minutes at room temperature, washed twice with phosphate-buffered saline ("PBS") containing 2% fetal bovine serum and 1mM each of calcium chloride and magnesium chloride (assay medium) to remove unbound 15/7 antibody. 15 The cells are then exposed to phycoerythrin-conjugated goat F(ab'), anti-mouse IgG Fc (Immunotech, Westbrook, ME), which has been adsorbed for any non-specific cross-reactivity by co-incubation with 5% serum from the animal species being studied, at 1:200 and incubated in the dark at 4 0 C 20 for 30 minutes. Cells are washed twice with assay medium and resuspended in the same. They are then analyzed with a standard fluorescence activated cell sorter ("FACS") analysis as described in Yednock et al. J. Biol. Chem., 1995, 25 270:28740. The data is then graphed as fluorescence versus dose, e.g., in a normal dose-response fashion. The dose levels that result in the upper plateau of the curve represent the levels needed to obtain efficacy in an in 30 vivo model.

WO 99/06437 PCT/US98/16070 229 This assay may also be used to determine the plasma levels needed to saturate the binding sites of other integrins, such as the a 91 I integrin, which is the integrin most closely related a 4 3 1 (Palmer et al, 1993, J. Cell Bio., 123:1289). Such binding is predictive of in vivo utility for inflammatory 5 conditions mediated by a9pl integrin, including by way of example, airway hyper-responsiveness and occlusion that occurs with chronic asthma, smooth muscle cell proliferation in atherosclerosis, vascular occlusion following angioplasty, fibrosis and glomerular scarring as a result of renal disease, aortic stenosis, hypertrophy of synovial membranes in rheumatoid arthritis, 10 and inflammation and scarring that occur with the progression of ulcerative colitis and Crohn's disease. Accordingly, the above-described assay may be performed with a human colon carcinoma cell line, SW 480 (ATTC #CCL228) transfected 15 with cDNA encoding a 9 integrin (Yokosaki et al., 1994, J. Biol. Chem., 269:26691), in place of the Jurkat cells, to measure the binding of the a9 1 I integrin. As a control, SW 480 cells which express other a and 3, subunits may be used. 20 Using a conventional oral formulation, compounds of this invention would be active in this model. Example 246 In vivo Evaluation 25 The standard multiple sclerosis model, Experimental Autoimmune (or Allergic) Encephalomyelitis ("EAE"), was used to determine the effect of candidate compounds to reduce motor impairment in rats or guinea pigs. Reduction in motor impairment is based on blocking adhesion between leukocytes and the endothelium and correlates with anti-inflammatory 30 activity in the candidate compound. This model has been previously WO 99/06437 PCT/US98/16070 230 described by Keszthelyi et al., Neurology, 1996, 47:1053-1059, and measures the delay of onset of disease. Brains and spinal cords of adult Hartley guinea pigs were 5 homogenized in an equal volume of phosphate-buffered saline. An equal volume of Freund's complete adjuvant (100 mg mycobacterium tuberculosis plus 10 ml Freund's incomplete adjuvant) was added to the homogenate. The mixture was emulsified by circulating it repeatedly through a 20 ml syringe with a peristaltic pump for about 20 minutes. 10 Female Lewis rats (2-3 months old, 170-220 g) or Hartley guinea pigs (20 day old, 180-200 g) were anesthetized with isoflurane and three injections of the emulsion, 0.1 ml each, were made in each flank. Motor impairment onset is seen in approximately 9 days. 15 Candidate compound treatment began on Day 8, just before onset of symptoms. Compounds were administered subcutaneously ("SC"), orally ("PO") or intraperitoneally ("IP"). Doses were given in a range of 10mg/kg to 200 mg/kg, bid, for five days, with typical dosing of 10 to 100 mg/kg SC, 20 10 to 50 mg/kg PO, and 10 to 100 mg/kg IP. Antibody GG5/3 against a4 integrin (Keszthelyi et al., Neurology, 1996, 47:1053-1059), which delays the onset of symptoms, was used as a positive control and was injected subcutaneously at 3 mg/kg on Day 8 and 25 11. Body weight and motor impairment were measured daily. Motor impairment was rated with the following clinical score: 30 WO 99/06437 PCT/US98/16070 231 0 no change 1 tail weakness or paralysis 2 hindlimb weakness 3 hindlimb paralysis 5 4 moribund or dead A candidate compound was considered active if it delayed the onset of symptoms, e.g., produced clinical scores no greater than 2 or slowed body 10 weight loss as compared to the control. When tested in this in vivo assay, the compounds of Examples 10 and 27 were active. 15 Example 247 In vivo Evaluation - Asthma Inflammatory conditions mediated by o 4 f3 1 integrin include, for example, airway hyper-responsiveness and occlusion that occurs with chronic asthma. The following describes an asthma model which can be 20 used to study the in vivo effects of the compounds of this invention for use in treating asthma. Following the procedures described by Abraham et al, J. Clin. Invest. 93:776-787 (1994) and Abraham et al, Am J. Respir Crit Care Med. 156:696 25 703 (1997), both of which are incorporated by reference in their entirety, compounds of this invention are formulated into an aerosol and administered to sheep which are hypersensitive to Ascaris suum antigen. Compounds which decrease the early antigen-induced bronchial response and/or block the late-phase airway response, e.g., have a protective effect against antigen 30 induced late responses and airway hyper-responsiveness ("AHR"), are considered to be active in this model.

WO 99/06437 PCT/US98/16070 232 Allergic sheep which are shown to develop both early and late bronchial responses to inhaled Ascaris suum antigen are used to study the airway effects of the candidate compounds. Following topical anesthesia of the nasal passages with 2% lidocaine, a balloon catheter is advanced through 5 one nostril into the lower esophagus. The animals are then intubated with a cuffed endotracheal tube through the other nostril with a flexible fiberoptic bronchoscope as a guide. Pleural pressure is estimated according to Abraham (1994). Aerosols 10 (see formulation below) are generated using a disposable medical nebulizer that provides an aerosol with a mass median aerodynamic diameter of 3.2 tm as determined with an Andersen cascade impactor. The nebulizer is connected to a dosimeter system consisting of a solenoid valve and a source of compressed air (20 psi). The output of the nebulizer is directed into a 15 plastic T-piece, one end of which is connected to the inspiratory port of a piston respirator. The solenoid valve is activated for 1 second at the beginning of the inspiratory cycle of the respirator. Aerosols are delivered at VT of 500 ml and a rate of 20 breaths/minute. A 0.5% sodium bicarbonate solution only is used as a control. 20 To assess bronchial responsiveness, cumulative concentration response curves to carbachol can be generated according to Abraham (1994). Bronchial biopsies can be taken prior to and following the initiation of treatment and 24 hours after antigen challenge. Bronchial biopsies can be 25 preformed according to Abraham (1994). An in vitro adhesion study of alveolar macrophages can also be performed according to Abraham (1994), and a percentage of adherent cells is calculated. 30 WO 99/06437 PCT/US98/16070 233 Aerosol Formulation A solution of the candidate compound in 0.5% sodium bicarbonate/saline (w/v) at a concentration of 30.0 mg/mL is prepared using the following procedure: 5 A. Preparation of 100.0 mL of 0.5% Sodium Bicarbonate / Saline Stock Solution Ingredient Gram / 100.0 mL Final Concentration 10 Sodium Bicarbonate 0.5 g 0.5% Saline q.s. ad 100.0 mL q.s. ad 100% Procedure: 1. Add 0.5g sodium bicarbonate into a 100 mL volumetric flask. 15 2. Add approximately 90.0 mL saline and sonicate until dissolved. 3. Q.S. to 100.0 mL with saline and mix thoroughly. B. Preparation of 30.0 mg/mL Candidate Compound: 10.0 mL 20 Ingredient Gram / 10.0 mL Final Concentration Candidate Compound 0.300 g 30.0 mg/mL 0.5% Sodium Bicarbonate / q.s. ad 10.0 mL q.s ad 100% Saline Stock Solution 25 Procedure: 1. Add 0.300 g of the candidate compound into a 10.0 mL volumetric flask. 2. Add approximately 9.7 mL of 0.5% sodium bicarbonate / 30 saline stock solution.

WO 99/06437 PCT/US98/16070 234 3. Sonicate until the candidate compound is completely dissolved. 4. Q.S. to 10.0 mL with 0.5% sodium bicarbonate / saline stock solution and mix thoroughly. 5 Using a conventional oral formulation, compounds of this invention would be active in this model.

Claims

1. A compound of formula I: R 3 0 5 R'-SO, 2 -N(R 2 )-C-Q-CH-C-OH I I H R 5 10 where R' is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocylic, heteroaryl and substituted heteroaryl; R 2 is selected from the group consisting of hydrogen, alkyl, 15 substituted alkyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heterocyclic, substituted heterocyclic, aryl, substituted aryl, heteroaryl, and substituted heteroaryl, and R 1 and R 2 together with the nitrogen atom bound to R 2 and the SO 2 group bound to R' can form a heterocyclic or a substituted heterocyclic group; 20 R 3 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic and R 2 and R 3 together with the nitrogen atom bound to R 2 and the carbon atom bound to R 3 can form a saturated heterocyclic group or a saturated 25 substituted heterocyclic group with the proviso that when monosubstituted, the substituent on said saturated substituted heterocyclic group is not carboxyl; Ar is aryl, heteroaryl, substituted aryl or substituted heteroaryl; x is an integer of from 1 to 4; 30 Q is -C(X)NR 7 - wherein R 7 is selected from the group consisting of hydrogen and alkyl; X is selected from the group consisting of oxygen and sulfur; WO 99/06437 PCT/US98/16070 236 R 5 is -CH 2 X where X is selected from the group consisting of hydrogen, hydroxyl, acylamino, alkyl, alkoxy, aryloxy, aryl, aryloxyaryl, carboxyl, carboxylalkyl, carboxyl-substituted alkyl, carboxyl-cycloalkyl, carboxyl-substituted cycloalkyl, carboxylaryl, carboxyl-substituted aryl, 5 carboxylheteroaryl, carboxyl-substituted heteroaryl, carboxylheterocyclic, carboxyl-substituted heterocyclic, cycloalkyl, substituted alkyl, substituted alkoxy, substituted aryl, substituted aryloxy, substituted aryloxyaryl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic, 10 with the further provisos that: A. R 5 is not selected from the group consisting of -(CH 2 )n-aryl and -(CH2)n-heteroaryl where n is an integer equal to 1 to 4 when R 2 and R 3 together with the nitrogen atom bound to R 2 and the carbon atom bound to R 3 form a saturated heterocyclic group or a saturated substituted heterocyclic 15 group; B. R 5 is not -(CH 2 )x-Ar-R 5 ' where R 5 ' is-O-Z-NR'R 8 or -O-Z-R 1 2, wherein R 8 and R" ' are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocyclic, and where R 8 and R 8 ' are joined to 20 form a heterocycle or a substituted heterocycle, R' 2 is selected from the group consisting of heterocycles and substituted heterocycles, and Z is selected from the group consisting of-C(O)- and -SO 2 -, Ar is aryl, heteroaryl, substituted aryl or substituted heteroaryl, x is an integer of from 1 to 4; 25 C. R 5 is not -(CH 2 )x-Ar-R 5 ' where R' is selected from the group consisting of-NR 24 C(Z')NR'R' and -NR 24 C(Z')R 1 3 wherein Z' is selected from the group consisting of oxygen, sulfur and NR 2 4 , R 24 is selected from the group consisting of hydrogen, alkyl and aryl, R 8 and R 8 ' are independently selected from the group consisting of hydrogen, alkyl, 30 substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, WO 99/06437 PCT/US98/16070 237 heterocyclic, substituted heterocyclic, heteroaryl and substituted heteroaryl provided that when Z' is oxygen, at least one of R 8 and R 8 ' is sustituted alkyl, cycloalkyl, substituted cycloalkyl, saturated heterocyclic other than morpholino and thiomorpholino, substituted heterocyclic or R 8 and R 8 ' can 5 be joined to form a saturated heterocycle other than morpholino or thiomorpholino, a saturated substituted heterocycle or a saturated/unsaturated heterocycle having an amino group substituted with an alkoxycarbonyl substituent, and further provided that when Z' is sulfur, at least one of R 8 and R 8 ' is a group other than aryl, substituted aryl, heteroaryl or substituted 10 heteroaryl, R 13 is selected from the group consisting of substituted heterocycles and saturated heterocycles other than morpholino and thiomorpholino, Ar is aryl, substituted aryl, heteroaryl or substituted heteroaryl, x is an integer of from 1 to 4; 15 D. R 5 is not -ALK-X where ALK is an alkyl group of from 1 to 10 carbon atoms attached via a methylene group (-CH,-) to the carbon atom to which it is attached; X is selected from the group consisting of substituted alkylcarbonylamino, substituted alkenylcarbonylamino, substituted alkynylcarbonylamino, heterocyclylcarbonylamino, substituted 20 heterocyclylcarbonylamino, acyl, acyloxy, aminocarbonyloxy, acylamino, oxycarbonylamino, alkoxycarbonyl, substituted alkoxycarbonyl, aryloxycarbonyl, substituted aryloxycarbonyl, cycloalkoxycarbonyl, substituted cycloalkoxycarbonyl, heteroaryloxycarbonyl, substituted heteroaryloxycarbonyl, heterocyclyloxycarbonyl, substituted 25 heterocyclyloxycarbonyl, cycloalkyl, substituted cycloalkyl, saturated heterocyclic, substituted saturated heterocyclic, substituted alkoxy, substituted alkenoxy, substituted alkynoxy, heterocyclyloxy, substituted heterocycloxy, substituted thioalkyl, substituted thioalkenyl, substituted thioalkynyl, aminocarbonylamino, aminothiocarbonylamino, guanidino, 30 amidino, alkylamidino, thioamidino, halogen, cyano, nitro, -OS(O),-alkyl, WO 99/06437 PCT/US98/16070 238 -OS(O)2,-substituted alkyl, -OS(O) 2 -cycloalkyl, -OS(O) 2 -substituted cycloalkyl, -OS(O) 2 -aryl, -OS(O) 2 -substituted aryl, -OS(O) 2 -heteroaryl, -OS(O) 2 -substituted heteroaryl, -OS(O) 2 -heterocyclic, -OS(O) 2 -substituted heterocyclic, -OSO 2 -NRR, -NRS(O) 2 -alkyl, -NRS(O) 2 -substituted alkyl, 5 -NRS(O) 2 -cycloalkyl, -NRS(O) 2 -substituted cycloalkyl, -NRS(O) 2 -aryl, -NRS(O) 2 -substituted aryl, -NRS(O) 2 -heteroaryl, -NRS(O) 2 -substituted heteroaryl, -NRS(O) 2 -heterocyclic, -NRS(O) 2 -substituted heterocyclic, -NRS(O) 2 -NR-alkyl, -NRS(O) 2 -NR-substituted alkyl, -NRS(O) 2 -NR cycloalkyl, -NRS(O) 2 -NR-substituted cycloalkyl, -NRS(O) 2 -NR-aryl, 10 -NRS(O),-NR-substituted aryl, -NRS(O),-NR-heteroaryl, -NRS(O) 2 -NR substituted heteroaryl, -NRS(O) 2 -NR-heterocyclic, -NRS(O) 2 -NR-substituted heterocyclic where R is hydrogen or alkyl, -S(O) 2 -alkyl, -S(O) 2 -substituted alkyl, -S(O) 2 -aryl, -S(O) 2 -substituted aryl, -S(O) 2 -substituted heteroaryl, S(O) 2 -substituted heteroaryl, -S(O) 2 -heterocyclic, -S(O) 2 -substituted 15 heterocyclic, mono- and di-(substituted alkyl)amino, N,N-(alkyl, substituted alkyl)amino, N,N-(aryl, substituted alkyl)amino, N,N-(substituted aryl, substituted alkyl)amino, N,N-(heteroaryl, substituted alkyl)amino, N,N (substituted heteroaryl, substituted alkyl)amino, N,N-(heterocyclic, substituted alkyl)amino, N,N-N,N-(substituted heterocyclic, substituted 20 alkyl)amino, mono- and di-(heterocyclic)amino, mono- and di-(substituted heterocyclic)amino, N,N-(alkyl, heterocyclic)amino, N,N-(alkyl, substituted heterocyclic)amino, N,N-(aryl, heterocyclic)amino, N,N-(substituted aryl, heterocyclic)amino, N,N-(aryl, substituted heterocyclic)amino, N,N (substituted aryl, substituted heterocyclic)amino, N,N-(heteroaryl, 25 heterocyclic)amino, N,N-(heteroaryl, substituted heterocyclic)amino, N,N (substituted heteroaryl, heterocyclic)amino, N,N-(substituted heteroaryl and substituted heterocyclic)amino; and E. R 5 is not -(CH 2 )x-Ar-R 5 " where R 5 " is a substituent selected from the group consisting of: WO 99/06437 PCT/US98/16070 239 (a) substituted alkylcarbonylamino with the proviso that at least one of the substituents on the substituted alkyl moiety is selected from the group consisting of alkoxy, substituted alkoxy, acyl, acylamino, thiocarbonylamino, acyloxy, alkenyl, amino, amidino, alkyl amidino, 5 thioamidino, aminoacyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aryloxy, substituted aryloxy, cyano, nitro, halogen, hydroxyl, carboxyl, carboxylalkyl, carboxyl-substituted alkyl, carboxyl cycloalkyl, carboxyl-substituted cycloalkyl, carboxylaryl, carboxyl substituted aryl, carboxylheteroaryl, carboxyl-substituted heteroaryl, 10 carboxylheterocyclic, carboxyl-substituted heterocyclic, cycloalkyl, substituted cycloalkyl, guanidino, guanidinosulfone, thiol, thioalkyl, substituted thioalkyl, thioaryl, substituted thioaryl, thiocycloalkyl, substituted thiocycloalkyl, thioheteroaryl, substituted thioheteroaryl, thioheterocyclic, substituted thioheterocyclic, heterocyclic, substituted 15 heterocyclic, cycloalkoxy, substituted cycloalkyoxy, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy, oxycarbonylamino, oxythiocarbonylamino, -OS(O),-alkyl, -OS(O) 2 substituted alkyl, -OS(O) 2 -aryl, -OS(O) 2 -substituted aryl, -OS(O) 2 -heteroaryl, -OS(O) 2 -substituted heteroaryl, -OS(O) 2 -heterocyclic, -OS(O)2-substituted 20 heterocyclic, -OSO 2 -NRR, -NRS(O),-alkyl, -NRS(O) 2 -substituted alkyl, NRS(O) 2 -aryl, -NRS(O) 2 -substituted aryl, -NRS(O) 2 -heteroaryl, -NRS(O) 2 substituted heteroaryl, -NRS(O),-heterocyclic, -NRS(O),-substituted heterocyclic, -NRS(O),-NR-alkyl, -NRS(O) 2 -NR substituted alkyl, -NRS(O) 2 -NR-aryl, -NRS(O) 2 -NR-substituted aryl, 25 -NRS(O) 2 -NR-heteroaryl, -NRS(O) 2 -NR-substituted heteroaryl, -NRS(O)2 NR-heterocyclic, -NRS(O) 2 -NR-substituted heterocyclic, mono- and di alkylamino, mono- and di-(substituted alkyl)amino, mono- and di-arylamino, mono- and di-(substituted aryl)amino, mono- and di-heteroarylamino, mono and di-(substituted heteroaryl)amino, mono- and di-heterocyclic amino, 30 mono- and di-(substituted heterocyclic) amino, unsymmetric di-substituted WO 99/06437 PCT/US98/16070 240 amines having different substituents selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic, substituted alkyl groups having amino groups blocked by conventional blocking groups and 5 alkyl/substituted alkyl groups substituted with -SO 2 -alkyl, -SO,-substituted alkyl, -SO 2 -alkenyl, -SO,-substituted alkenyl, -SO2-cycloalkyl, -SO 2 substituted cycloalkyl, -SO,-aryl, -SO,-substituted aryl, -SO,-heteroaryl, -SO,-substituted heteroaryl, -SO 2 -heterocyclic, -SO,-substituted heterocyclic or -SO,NRR, where R is hydrogen or alkyl; 10 (b) alkoxyaryl substituted on the alkoxy moiety with a substituent selected from the group consisting of carboxyl and -COOR 23 where R 23 is alkyl, substituted alkyl, cycloalkyl, aryl, heteroaryl or heterocyclic; (c) aryl and heteroaryl; (d) -NR'R' wherein each R' is independently selected from the group 15 consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclic and substituted heterocyclic with the proviso that at least one of R' is substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclic and substituted heterocyclic and with the further proviso that when R' is substituted alkyl at 20 least one of the substituents on the substituted alkyl moiety is selected from the group consisting of alkoxy, substituted alkoxy, acyl, acylamino, thiocarbonylamino, acyloxy, alkenyl, amino, amidino, alkyl amidino, thioamidino, aminoacyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aryloxy, substituted aryloxy, cyano, nitro, halogen, 25 hydroxyl, carboxyl, carboxylalkyl, carboxyl-substituted alkyl, carboxyl cycloalkyl, carboxyl-substituted cycloalkyl, carboxylaryl, carboxyl substituted aryl, carboxylheteroaryl, carboxyl-substituted heteroaryl, carboxylheterocyclic, carboxyl-substituted heterocyclic, cycloalkyl, substituted cycloalkyl, guanidino, guanidinosulfone, thiol, thioalkyl, 30 substituted thioalkyl, thioaryl, substituted thioaryl, thiocycloalkyl, WO 99/06437 PCT/US98/16070 241 substituted thiocycloalkyl, thioheteroaryl, substituted thioheteroaryl, thioheterocyclic, substituted thioheterocyclic, heterocyclic, substituted heterocyclic, cycloalkoxy, substituted cycloalkyoxy, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy, 5 oxycarbonylamino, oxythiocarbonylamino, -OS(O)2,-alkyl, -OS(O) 2 substituted alkyl, -OS(O) 2 -aryl, -OS(O) 2 -substituted aryl, -OS(O) 2 -heteroaryl, -OS(O) 2 -substituted heteroaryl, -OS(O) 2 -heterocyclic, -OS(O) 2 -substituted heterocyclic, -OSO,-NRR, -NRS(O) 2 -alkyl, -NRS(O) 2 -substituted alkyl, NRS(O) 2 -aryl, -NRS(O) 2 -substituted aryl, -NRS(O) 2 -heteroaryl, -NRS(O) 2 10 substituted heteroaryl, -NRS(O) 2 -heterocyclic, -NRS(O) 2 -substituted heterocyclic, -NRS(O) 2 -NR-alkyl, -NRS(O) 2 -NR substituted alkyl, -NRS(O) 2 -NR-aryl, -NRS(O) 2 -NR-substituted aryl, -NRS(O) 2 -NR-heteroaryl, -NRS(O) 2 -NR-substituted heteroaryl, -NRS(O) 2 NR-heterocyclic, -NRS(O)2,-NR-substituted heterocyclic, mono- and di 15 alkylamino, mono- and di-(substituted alkyl)amino, mono- and di-arylamino, mono- and di-(substituted aryl)amino, mono- and di-heteroarylamino, mono and di-(substituted heteroaryl)amino, mono- and di-heterocyclic amino, mono- and di-(substituted heterocyclic) amino, unsymmetric di-substituted amines having different substituents selected from the group consisting of 20 alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic, substituted alkyl groups having amino groups blocked by conventional blocking groups and alkyl/substituted alkyl groups substituted with -SO 2 -alkyl, -SO,-substituted alkyl, -SO,-alkenyl, -SO2-substituted alkenyl, -SO,-cycloalkyl, -SO 2 25 substituted cycloalkyl, -SO,-aryl, -SO,-substituted aryl, -SO,-heteroaryl, -SO, 2 -substituted heteroaryl, -SO,-heterocyclic, -SO,-substituted heterocyclic or -SO 2 NRR, where R is hydrogen or alkyl; (e) -alkoxy-NR"R" wherein each R" is independently selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, 30 cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, WO 99/06437 PCT/US98/16070 242 heterocyclic, and substituted heterocyclic with the proviso that when each R" is substituted alkyl then at least one of the substituents on the substituted alkyl moiety is selected from the group consisting of alkoxy, substituted alkoxy, acyl, acylamino, thiocarbonylamino, acyloxy, alkenyl, amino, 5 amidino, alkyl amidino, thioamidino, aminoacyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aryloxy, substituted aryloxy, cyano, nitro, halogen, hydroxyl, carboxyl, carboxylalkyl, carboxyl substituted alkyl, carboxyl-cycloalkyl, carboxyl-substituted cycloalkyl, carboxylaryl, carboxyl-substituted aryl, carboxylheteroaryl, carboxyl 10 substituted heteroaryl, carboxylheterocyclic, carboxyl-substituted heterocyclic, cycloalkyl, substituted cycloalkyl, guanidino, guanidinosulfone, thiol, thioalkyl, substituted thioalkyl, thioaryl, substituted thioaryl, thiocycloalkyl, substituted thiocycloalkyl, thioheteroaryl, substituted thioheteroaryl, thioheterocyclic, substituted thioheterocyclic, heterocyclic, 15 substituted heterocyclic, cycloalkoxy, substituted cycloalkyoxy, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy, oxycarbonylamino, oxythiocarbonylamino, -OS(O) 2 -alkyl, OS(O) 2 -substituted alkyl, -OS(O) 2 -aryl, -OS(O) 2 -substituted aryl, -OS(O) 2 heteroaryl, -OS(O) 2 -substituted heteroaryl, -OS(O) 2 -heterocyclic, -OS(O) 2 20 substituted heterocyclic, -OSO, 2 -NRR, -NRS(O) 2 -alkyl, -NRS(O)2,-substituted alkyl, -NRS(O) 2 -aryl, -NRS(O)2,-substituted aryl, -NRS(O) 2 -heteroaryl, NRS(O) 2 -substituted heteroaryl, -NRS(O) 2 -heterocyclic, -NRS(O) 2 -substituted heterocyclic, -NRS(O),-NR-alkyl, -NRS(O) 2 -NR substituted alkyl, -NRS(O),-NR-aryl, -NRS(O) 2 -NR-substituted aryl, 25 -NRS(O) 2 -NR-heteroaryl, -NRS(O) 2 -NR-substituted heteroaryl, -NRS(O) 2 NR-heterocyclic, -NRS(O) 2 -NR-substituted heterocyclic, mono- and di alkylamino, mono- and di-(substituted alkyl)amino, mono- and di-arylamino, mono- and di-(substituted aryl)amino, mono- and di-heteroarylamino, mono and di-(substituted heteroaryl)amino, mono- and di-heterocyclic amino, 30 mono- and di-(substituted heterocyclic) amino, unsymmetric di-substituted WO 99/06437 PCT/US98/16070 243 amines having different substituents selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic, substituted alkyl groups having amino groups blocked by conventional blocking groups and 5 alkyl/substituted alkyl groups substituted with -SO,-alkyl, -SO2-substituted alkyl, -SO 2 -alkenyl, -SO 2 -substituted alkenyl, -SO 2 -cycloalkyl, -SO 2 substituted cycloalkyl, -SO,-aryl, -SO, 2 -substituted aryl, -SO 2 -heteroaryl, -SO 2 -substituted heteroaryl, -SO 2 -heterocyclic, -SO 2 -substituted heterocyclic or -SO 2 NRR, where R is hydrogen or alkyl; 10 (f) substituted alkenyl or substituted alkynyl with the proviso that at least one of the substituents on the substituted alkenyl/alkynyl moiety is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic with the proviso that 15 when substituted with substituted alkyl then at least one of the substituents on the substituted alkyl moiety is selected from the group consisting of alkoxy, substituted alkoxy, acyl, acylamino, thiocarbonylamino, acyloxy, alkenyl, amino, amidino, alkyl amidino, thioamidino, aminoacyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aryloxy, 20 substituted aryloxy, cyano, nitro, halogen, hydroxyl, carboxyl, carboxylalkyl, carboxyl-substituted alkyl, carboxyl-cycloalkyl, carboxyl-substituted cycloalkyl, carboxylaryl, carboxyl-substituted aryl, carboxylheteroaryl, carboxyl-substituted heteroaryl, carboxylheterocyclic, carboxyl-substituted heterocyclic, cycloalkyl, substituted cycloalkyl, guanidino, guanidinosulfone, 25 thiol, thioalkyl, substituted thioalkyl, thioaryl, substituted thioaryl, thiocycloalkyl, substituted thiocycloalkyl, thioheteroaryl, substituted thioheteroaryl, thioheterocyclic, substituted thioheterocyclic, heterocyclic, substituted heterocyclic, cycloalkoxy, substituted cycloalkyoxy, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, substituted 30 heterocyclyloxy, oxycarbonylamino, oxythiocarbonylamino, -OS(O),-alkyl, - WO 99/06437 PCT/US98/16070 244 OS(O) 2 -substituted alkyl, -OS(O) 2 -aryl, -OS(O) 2 -substituted aryl, -OS(0)2 heteroaryl, -OS(O) 2 -substituted heteroaryl, -OS(O) 2 -heterocyclic, -OS(0)2 substituted heterocyclic, -OSO 2 -NRR, -NRS(0) 2 -alkyl, -NRS(O) 2 -substituted alkyl, -NRS(O) 2 -aryl, -NRS(0),-substituted aryl, -NRS(0) 2 -heteroaryl, 5 -NRS(O) 2 -substituted heteroaryl, -NRS(O) 2 -heterocyclic, -NRS(O) 2 -substituted heterocyclic, -NRS(O) 2 -NR-alkyl, -NRS(O) 2 -NR substituted alkyl, -NRS(0) 2 -NR-aryl, -NRS(O)2-NR-substituted aryl, -NRS(O) 2 -NR-heteroaryl, -NRS(O) 2 -NR-substituted heteroaryl, -NRS(O)2 NR-heterocyclic, -NRS(0) 2 -NR-substituted heterocyclic, mono- and di 10 alkylamino, mono- and di-(substituted alkyl)amino, mono- and di-arylamino, mono- and di-(substituted aryl)amino, mono- and di-heteroarylamino, mono and di-(substituted heteroaryl)amino, mono- and di-heterocyclic amino, mono- and di-(substituted heterocyclic) amino, unsymmetric di-substituted amines having different substituents selected from the group consisting of 15 alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic, and substituted alkyl groups having amino groups blocked by conventional blocking groups, and alkyl/substituted alkyl groups substituted with -S,0 2 -alkyl, -S,0 2 -substituted alkyl, -SO,-alkenyl, -SO, 2 -substituted alkenyl, -SO,-cycloalkyl, -SO2 20 substituted cycloalkyl, -SO,-aryl, -SO,-substituted aryl, -SO, 2 -heteroaryl, -SO, 2 -substituted heteroaryl, -SO,-heterocyclic, -SO, -substituted heterocyclic or -SONRR, where R is hydrogen or alkyl; (g) substituted aryloxy and substituted heteroaryloxy with the proviso that at least one substituent on the substituted aryloxy/heteroaryloxy is other 25 than halogen, hydroxyl, amino, nitro, trifluoromethyl, trifluoromethoxy, alkyl, alkenyl, alkynyl, 1,2-dioxymethylene, 1,2-dioxyethylene, alkoxy, alkenoxy, alkynoxy, alkylamino, alkenylamino, alkynylamino, alkylcarbonyloxy, acyl, alkylcarbonylamino, alkoxycarbonylamino, alkylsulfonylamino, N-alkyl or N,N-dialkylurea; WO 99/06437 PCT/US98/16070 245 (h) -alkoxy-saturated heterocyclic, -alkoxy-saturated substituted heterocyclic, -substituted alkoxy-heterocyclic and -substituted alkoxy substituted saturated heterocyclic; (i) -O-heterocyclic and -O-substituted heterocyclic; 5 (j) tetrazolyl; (k) -NR-SO,-substituted alkyl where R is hydrogen, alkyl or aryl, with the proviso that at least one substituent on the alkyl moiety of the substituted alkylsulfonylamino is other than halogen, hydroxyl, amino, nitro, trifluoromethyl, trifluoromethoxy, alkyl, alkenyl, alkynyl, 10 1,2-dioxymethylene, 1,2-dioxyethylene, alkoxy, alkenoxy, alkynoxy, alkylamino, alkenylamino, alkynylamino, alkylcarbonyloxy, acyl, alkylcarbonylamino, alkoxycarbonylamino, alkylsulfonylamino, N-alkyl or N,N-dialkylurea; (1) alkenylsulfonylamino, alkynylsulfonylamino, substituted 15 alkenylsulfonylamino and substituted alkynylsulfonylamino; (m) substituted alkoxy with the proviso that the substitution on the alkyl moiety of said substituted alkoxy does not include alkoxy-NR"R",as defined above, unsaturated heterocyclyl, alkyloxy, aryloxy, heteroaryloxy, aryl, heteroaryl and aryl/heteroaryl substituted with halogen, hydroxyl, 20 amino, nitro, trifluoromethyl, trifluoromethoxy, alkyl, alkenyl, alkynyl, 1,2 dioxymethylene, 1,2-dioxyethylene, alkoxy, alkenoxy, alkynoxy, alkylamino, alkenylamino, alkynylamino, alkylcarbonyloxy, acyl, alkylcarbonylamino, alkoxycarbonylamino, alkylsulfonylamino, N-alkyl or N,N-dialkylurea; 25 (n) amidine and amidine substituted with from 1 to 3 substituents independently selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, heteroaryl and heterocyclic; (o) -C(0)NR"'R"' where each R' is independently selected from the 30 group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted WO 99/06437 PCT/US98/16070 246 cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic with the proviso that when one R"' is unsaturated heterocyclic, aryl, heteroaryl or aryl/heteroaryl substituted with halogen, 5 hydroxyl, amino, nitro, trifluoromethyl, trifluoromethoxy, alkyl, alkenyl, alkynyl, 1,2-dioxymethylene, 1,2-dioxyethylene, alkoxy, alkenoxy, alkynoxy, alkylamino, alkenylamino, alkynylamino, alkylcarbonyloxy, acyl, alkylcarbonylamino, alkoxycarbonylamino, alkylsulfonylamino, N-alkyl or N,N-dialkylurea, then the other R'" is alkyl, substituted alkyl (other than 10 unsaturated heterocyclyl substituted-alkyl), cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, heterocyclic or substituted heterocyclic; (p) -NR 2 2 C(O)-R" 8 where R" 8 is selected from the group consisting of alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted 15 aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic, and R 22 is alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic or substituted heterocyclic; (q) -SO 2 -aryl, -SO,-substituted aryl, -SO,-heteroaryl, -SO, 2 -substituted 20 heteroaryl or -SO,-alkyl; (r) -NR'C(O)NR 9 R 9 wherein R' is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic and each R 19 is independently selected from the 25 group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic: (s) -NR'C(O)OR 9 wherein R' is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted 30 cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic and substituted WO 99/06437 PCT/US98/16070 247 heterocyclic, and R' 9 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic; 5 (t) -aminocarbonyl-(N-formylheterocylcyl); and (u) -alkyl-C(O)NH-heterocyclyl and -alkyl-C(O)NH-substituted heterocyclyl, and pharmaceutically acceptable salts thereof; and still further with the following provisos excluding the following 10 compounds: A. when R' is p-methylphenyl, R 2 and R 3 together with their pendent nitrogen and carbon atoms form a pyrrolidinyl ring and Q is -C(O)NH-, then R 5 is not -CH 2 COOH or -CH 2 CHCOOH; and B. when R' is p-methylphenyl, R 2 and R 3 together with their pendent 15 nitrogen and carbon atoms form a pyrrolidinyl ring and Q is -C(O)NH-, then R 5 is not 2,4,6-trimethylbenzyl.

2. A compound of the formula: 20 R 3 O I I i R 1 -S O 2 -N(R 2 )-C-Q-CH-C-R 6 IA H R 5 25 where R' is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocylic, heteroaryl and substituted heteroaryl; 30 R 2 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heterocyclic, substituted heterocyclic, aryl, substituted aryl, WO 99/06437 PCT/US98/16070 248 heteroaryl, substituted heteroaryl, and R' and R 2 together with the nitrogen atom bound to R 2 and the SO 2 group bound to R' can form a heterocyclic or a substituted heterocyclic group; R' is selected from the group consisting of hydrogen, alkyl, 5 substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic and R 2 and R 3 together with the nitrogen atom bound to R 2 and the carbon atom bound to R 3 can form a saturated heterocyclic group or a saturated substituted heterocyclic group with the proviso that when monosubstituted, 10 the substituent on said saturated substituted heterocyclic group is not carboxyl; Ar is aryl, heteroaryl, substituted aryl or substituted heteroaryl; x is an integer of from 1 to 4; R 6 is selected from the group consisting of 2,4-dioxo-tetrahydrofuran 15 3-yl (3,4-enol), amino, alkoxy, substituted alkoxy, cycloalkoxy, substituted cycloalkoxy, -O-(N-succinimidyl), -NH-adamantyl, -O-cholest-5-en-3-P-yl, -NHOY where Y is hydrogen, alkyl, substituted alkyl, aryl, and substituted aryl, -NH(CH2)pCOOY where p is an integer of from 1 to 8 and Y is as defined above, -OCHNR 9 R l o where R 9 is selected from the group consisting 20 of-C(O)-aryl and -C(O)-substituted aryl and R"o is selected from the group consisting of hydrogen and -CH 2 COOR" where R" is alkyl, and -NHSO 2 Z" where Z" is alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic or substituted heterocyclic; 25 Q is -C(X)NR 7 - wherein R 7 is selected from the group consisting of hydrogen and alkyl; X is selected from the group consisting of oxygen and sulfur; R 5 is-CH 2 X where X is selected from the group consisting of hydrogen, hydroxyl, acylamino, alkyl, alkoxy, aryloxy, aryl, aryloxyaryl, 30 carboxyl, carboxylalkyl, carboxyl-substituted alkyl, carboxyl-cycloalkyl, WO 99/06437 PCT/US98/16070 249 carboxyl-substituted cycloalkyl, carboxylaryl, carboxyl-substituted aryl, carboxylheteroaryl, carboxyl-substituted heteroaryl, carboxylheterocyclic, carboxyl-substituted heterocyclic, cycloalkyl, substituted alkyl, substituted alkoxy, substituted aryl, substituted aryloxy, substituted aryloxyaryl, 5 substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic; with the further provisos that: A. R 5 is not selected from the group consisting of -(CH 2 )n-aryl and -(CH 2 )n-heteroaryl where n is an integer equal to 1 to 4 when R 2 and R 3 10 together with the nitrogen atom bound to R 2 and the carbon atom bound to R 3 form a saturated heterocyclic group or a saturated substituted heterocyclic group; B. R 5 is not -(CH 2 )x-Ar-R 5 ' where R 5 ' is-O-Z-NRR 8 ' or -O-Z-R 1 2 , wherein R 8 and R 8 ' are independently selected from the group consisting of 15 hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocyclic, and where R 8 and R 8 ' " are joined to form a heterocycle or a substituted heterocycle, R1 2 is selected from the group consisting of heterocycles and substituted heterocycles, and Z is selected from the group consisting of-C(O)- and -SO 2 -, 20 Ar is aryl, heteroaryl, substituted aryl or substituted heteroaryl, x is an integer of from 1 to 4; C. R 5 is not -(CH,)x-Ar-R 5 ' where R 5 ' is selected from the group consisting of-NR 24 C(Z')NR'R' and -NR 24 C(Z')R 1 3 wherein Z' is selected from the group consisting of oxygen, sulfur and NR 24 , R 24 is selected from 25 the group consisting of hydrogen, alkyl and aryl, R 8 and R 8 ' are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocyclic, heteroaryl and substituted heteroaryl provided that when Z' is oxygen, at least one of R 8 and R 8 ' is sustituted alkyl, 30 cycloalkyl, substituted cycloalkyl, saturated heterocyclic other than WO 99/06437 PCT/US98/16070 250 morpholino and thiomorpholino, substituted heterocyclic or R 8 and R 8 ' can be joined to form a saturated heterocycle other than morpholino or thiomorpholino, a saturated substituted heterocycle or a saturated/unsaturated heterocycle having an amino group substituted with an alkoxycarbonyl 5 substituent, and further provided that when Z' is sulfur, at least one of R 8 and R 8 ' is a group other than aryl, substituted aryl, heteroaryl or substituted heteroaryl, R 13 is selected from the group consisting of substituted heterocycles and saturated heterocycles other than morpholino and thiomorpholino, 10 Ar is aryl, substituted aryl, heteroaryl or substituted heteroaryl, x is an integer of from 1 to 4; D. R 5 is not -ALK-X where ALK is an alkyl group of from 1 to 10 carbon atoms attached via a methylene group (-CH,-) to the carbon atom to which it is attached; X is selected from the group consisting of substituted 15 alkylcarbonylamino, substituted alkenylcarbonylamino, substituted alkynylcarbonylamino, heterocyclylcarbonylamino, substituted heterocyclylcarbonylamino, acyl, acyloxy, aminocarbonyloxy, acylamino, oxycarbonylamino, alkoxycarbonyl, substituted alkoxycarbonyl, aryloxycarbonyl, substituted aryloxycarbonyl, cycloalkoxycarbonyl, 20 substituted cycloalkoxycarbonyl, heteroaryloxycarbonyl, substituted heteroaryloxycarbonyl, heterocyclyloxycarbonyl, substituted heterocyclyloxycarbonyl, cycloalkyl, substituted cycloalkyl, saturated heterocyclic, substituted saturated heterocyclic, substituted alkoxy, substituted alkenoxy, substituted alkynoxy, heterocyclyloxy, substituted 25 heterocycloxy, substituted thioalkyl, substituted thioalkenyl, substituted thioalkynyl, aminocarbonylamino, aminothiocarbonylamino, guanidino, amidino, alkylamidino, thioamidino, halogen, cyano, nitro, -OS(O) 2 -alkyl, -OS(O) 2 -substituted alkyl, -OS(O),-cycloalkyl, -OS(O) 2 -substituted cycloalkyl, -OS(O) 2 -aryl, -OS(O) 2 -substituted aryl, -OS(O) 2 -heteroaryl, WO 99/06437 PCT/US98/16070 251 -OS(O) 2 -substituted heteroaryl, -OS(O) 2 -heterocyclic, -OS(O) 2 -substituted heterocyclic, -OS0 2 -NRR, -NRS(O) 2 -alkyl, -NRS(O) 2 -substituted alkyl, -NRS(O) 2 -cycloalkyl, -NRS(O) 2 -substituted cycloalkyl, -NRS(O) 2 -aryl, -NRS(O) 2 -substituted aryl, -NRS(O) 2 -heteroaryl, -NRS(O) 2 -substituted 5 heteroaryl, -NRS(O) 2 -heterocyclic, -NRS(O) 2 -substituted heterocyclic, -NRS(O) 2 -NR-alkyl, -NRS(O) 2 -NR-substituted alkyl, -NRS(O) 2 -NR cycloalkyl, -NRS(O) 2 -NR-substituted cycloalkyl, -NRS(O) 2 -NR-aryl, -NRS(O) 2 -NR-substituted aryl, -NRS(O) 2 -NR-heteroaryl, -NRS(O) 2 -NR substituted heteroaryl, -NRS(O) 2 -NR-heterocyclic, -NRS(O) 2 -NR-substituted 10 heterocyclic, -S(O) 2 -alkyl, -S(O) 2 -substituted alkyl, -S(O) 2 -aryl, -S(O) 2 -substituted aryl, -S(O) 2 -substituted heteroaryl, -S(O) 2 -substituted heteroaryl, -S(O) 2 -heterocyclic, -S(O) 2 -substituted heterocyclic, mono- and di-(substituted alkyl)amino, N,N-(alkyl, substituted alkyl)amino, N,N-(aryl, substituted alkyl)amino, N,N-(substituted aryl, substituted alkyl)amino, N,N 15 (heteroaryl, substituted alkyl)amino, N,N-(substituted heteroaryl, substituted alkyl)amino, N,N-(heterocyclic, substituted alkyl)amino, N,N-N,N (substituted heterocyclic, substituted alkyl)amino, mono- and di (heterocyclic)amino, mono- and di-(substituted heterocyclic)amino, N,N (alkyl, heterocyclic)amino, N,N-(alkyl, substituted heterocyclic)amino, N,N 20 (aryl, heterocyclic)amino, N,N-(substituted aryl, heterocyclic)amino, N,N (aryl, substituted heterocyclic)amino, N,N-(substituted aryl, substituted heterocyclic)amino, N,N-(heteroaryl, heterocyclic)amino, N,N-(heteroaryl, substituted heterocyclic)amino, N,N-(substituted heteroaryl, heterocyclic)amino, N,N-(substituted heteroaryl and substituted 25 heterocyclic)amino; and E. R 5 is not -(CH 2 )x-Ar-R" where R 5 " is a substituent selected from the group consisting of: (a) substituted alkylcarbonylamino with the proviso that at least one of the substituents on the substituted alkyl moiety is selected from the group 30 consisting of alkoxy, substituted alkoxy, acyl, acylamino, WO 99/06437 PCT/US98/16070 252 thiocarbonylamino, acyloxy, alkenyl, amino, amidino, alkyl amidino, thioamidino, aminoacyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aryloxy, substituted aryloxy, cyano, nitro, halogen, hydroxyl, carboxyl, carboxylalkyl, carboxyl-substituted alkyl, carboxyl 5 cycloalkyl, carboxyl-substituted cycloalkyl, carboxylaryl, carboxyl substituted aryl, carboxylheteroaryl, carboxyl-substituted heteroaryl, carboxylheterocyclic, carboxyl-substituted heterocyclic, cycloalkyl, substituted cycloalkyl, guanidino, guanidinosulfone, thiol, thioalkyl, substituted thioalkyl, thioaryl, substituted thioaryl, thiocycloalkyl, 10 substituted thiocycloalkyl, thioheteroaryl, substituted thioheteroaryl, thioheterocyclic, substituted thioheterocyclic, heterocyclic, substituted heterocyclic, cycloalkoxy, substituted cycloalkyoxy, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy, oxycarbonylamino, oxythiocarbonylamino, -OS(O) 2 -alkyl, -OS(O) 2 15 substituted alkyl, -OS(O) 2 -aryl, -OS(O)2-substituted aryl, -OS(O) 2 -heteroaryl, -OS(O)2-substituted heteroaryl, -OS(O)2,-heterocyclic, -OS(O) 2 -substituted heterocyclic, -OSO 2 -NRR, -NRS(O) 2 -alkyl, -NRS(O) 2 -substituted alkyl, -NRS(O) 2 -aryl, -NRS(O)2-substituted aryl, -NRS(O)2-heteroaryl, -NRS(O) 2 substituted heteroaryl, -NRS(O) 2 -heterocyclic, -NRS(O) 2 -substituted 20 heterocyclic, -NRS(O),-NR-alkyl, -NRS(O)2,-NR-substituted alkyl, NRS(O) 2 -NR-aryl, -NRS(O) 2 -NR-substituted aryl, -NRS(O) 2 -NR-heteroaryl, -NRS(O) 2 -NR-substituted heteroaryl, -NRS(O)2 NR-heterocyclic, -NRS(O)2,-NR-substituted heterocyclic, mono- and di alkylamino, mono- and di-(substituted alkyl)amino, mono- and di-arylamino, 25 mono- and di-(substituted aryl)amino, mono- and di-heteroarylamino, mono and di-(substituted heteroaryl)amino, mono- and di-heterocyclic amino, mono- and di-(substituted heterocyclic) amino, unsymmetric di-substituted amines having different substituents selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted 30 heteroaryl, heterocyclic, and substituted heterocyclic, substituted alkyl WO 99/06437 PCT/US98/16070 253 groups having amino groups blocked by conventional blocking groups and alkyl/substituted alkyl groups substituted with -SO 2 -alkyl, -SO 2 -substituted alkyl, -SO 2 -alkenyl, -SO 2 -substituted alkenyl, -SO 2 -cycloalkyl, -SO2 substituted cycloalkyl, -SO 2 -aryl, -SO2-substituted aryl, -SO 2 -heteroaryl, 5 -SO 2 -substituted heteroaryl, -SO,-heterocyclic, -SO,-substituted heterocyclic or -SO 2 NRR, where R is hydrogen or alkyl; (b) alkoxyaryl substituted on the alkoxy moiety with a substituent selected from the group consisting of carboxyl and -COOR 2 3 where R 23 is alkyl, substituted alkyl, cycloalkyl, aryl, heteroaryl or heterocyclic; 10 (c) aryl and heteroaryl; (d) -NR'R' wherein each R' is independently selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclic and substituted heterocyclic with the proviso that at least one of R' is substituted 15 alkyl, cycloalkyl, substituted cycloalkyl, heterocyclic and substituted heterocyclic and with the further proviso that when R' is substituted alkyl at least one of the substituents on the substituted alkyl moiety is selected from the group consisting of alkoxy, substituted alkoxy, acyl, acylamino, thiocarbonylamino, acyloxy, alkenyl, amino, amidino, alkyl amidino, 20 thioamidino, aminoacyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aryloxy, substituted aryloxy, cyano, nitro, halogen, hydroxyl, carboxyl, carboxylalkyl, carboxyl-substituted alkyl, carboxyl cycloalkyl, carboxyl-substituted cycloalkyl, carboxylaryl, carboxyl substituted aryl, carboxylheteroaryl, carboxyl-substituted heteroaryl, 25 carboxylheterocyclic, carboxyl-substituted heterocyclic, cycloalkyl, substituted cycloalkyl, guanidino, guanidinosulfone, thiol, thioalkyl, substituted thioalkyl, thioaryl, substituted thioaryl, thiocycloalkyl, substituted thiocycloalkyl, thioheteroaryl, substituted thioheteroaryl, thioheterocyclic, substituted thioheterocyclic, heterocyclic, substituted 30 heterocyclic, cycloalkoxy, substituted cycloalkyoxy, heteroaryloxy, WO 99/06437 PCT/US98/16070 254 substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy, oxycarbonylamino, oxythiocarbonylamino, -OS(O) 2 -alkyl, -OS(0)2 substituted alkyl, -OS(0) 2 -aryl, -OS(0) 2 -substituted aryl, -OS(0) 2 -heteroaryl, -OS(O),-substituted heteroaryl, -OS(O) 2 -heterocyclic, -OS(0) 2 -substituted 5 heterocyclic, -OSO 2 -NRR, -NRS(O) 2 -alkyl, -NRS(0) 2 -substituted alkyl, -NRS(0) 2 -aryl, -NRS(O) 2 -substituted aryl, -NRS(0) 2 -heteroaryl, -NRS(O) 2 substituted heteroaryl, -NRS(0) 2 -heterocyclic, -NRS(0) 2 -substituted heterocyclic, -NRS(O) 2 -NR-alkyl, -NRS(O)2,-NR-substituted alkyl, -NRS(0) 2 -NR-aryl, -NRS(0) 2 -NR-substituted aryl, 10 -NRS(0) 2 -NR-heteroaryl, -NRS(O) 2 -NR-substituted heteroaryl, -NRS(0) 2 NR-heterocyclic, -NRS(0) 2 -NR-substituted heterocyclic, mono- and di alkylamino, mono- and di-(substituted alkyl)amino, mono- and di-arylamino, mono- and di-(substituted aryl)amino, mono- and di-heteroarylamino, mono and di-(substituted heteroaryl)amino, mono- and di-heterocyclic amino, 15 mono- and di-(substituted heterocyclic) amino, unsymmetric di-substituted amines having different substituents selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic, substituted alkyl groups having amino groups blocked by conventional blocking groups and 20 alkyl/substituted alkyl groups substituted with -S,0 2 -alkyl, -SO,-substituted alkyl, -SO,-alkenyl, -SO,-substituted alkenyl, -SO,-cycloalkyl, -SO2 substituted cycloalkyl, -SO,-aryl, -SO2-substituted aryl, -SO, 2 -heteroaryl, -SO,-substituted heteroaryl, -SO,-heterocyclic, -SO,-substituted heterocyclic or -SO 2 NRR, where R is hydrogen or alkyl; 25 (e) -alkoxy-NR"R" wherein each R" is independently selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic with the proviso that when each R" is substituted alkyl then at least one of the substituents on the substituted 30 alkyl moiety is selected from the group consisting of alkoxy, substituted WO 99/06437 PCT/US98/16070 255 alkoxy, acyl, acylamino, thiocarbonylamino, acyloxy, alkenyl, amino, amidino, alkyl amidino, thioamidino, aminoacyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aryloxy, substituted aryloxy, cyano, nitro, halogen, hydroxyl, carboxyl, carboxylalkyl, carboxyl 5 substituted alkyl, carboxyl-cycloalkyl, carboxyl-substituted cycloalkyl, carboxylaryl, carboxyl-substituted aryl, carboxylheteroaryl, carboxyl substituted heteroaryl, carboxylheterocyclic, carboxyl-substituted heterocyclic, cycloalkyl, substituted cycloalkyl, guanidino, guanidinosulfone, thiol, thioalkyl, substituted thioalkyl, thioaryl, substituted thioaryl, 10 thiocycloalkyl, substituted thiocycloalkyl, thioheteroaryl, substituted thioheteroaryl, thioheterocyclic, substituted thioheterocyclic, heterocyclic, substituted heterocyclic, cycloalkoxy, substituted cycloalkyoxy, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy, oxycarbonylamino, oxythiocarbonylamino, -OS(O) 2 -alkyl, 15 OS(O) 2 -substituted alkyl, -OS(O) 2 -aryl, -OS(O) 2 -substituted aryl, -OS(O) 2 heteroaryl, -OS(O) 2 -substituted heteroaryl, -OS(O) 2 -heterocyclic, -OS(O) 2 substituted heterocyclic, -OSO, 2 -NRR, -NRS(O) 2 -alkyl, -NRS(O) 2 -substituted alkyl, -NRS(O) 2 -aryl, -NRS(O) 2 -substituted aryl, -NRS(O) 2 -heteroaryl, -NRS(O) 2 20 substituted heteroaryl, -NRS(O) 2 -heterocyclic, -NRS(O) 2 -substituted heterocyclic, -NRS(O) 2 -NR-alkyl, -NRS(O),-NR-substituted alkyl, -NRS(O) 2 -NR-aryl, -NRS(O)2-NR-substituted aryl,-NRS(O),-NR-heteroaryl, -NRS(O) 2 -NR-substituted heteroaryl, -NRS(O) 2 -NR-heterocyclic, -NRS(O) 2 NR-substituted heterocyclic, mono- and di-alkylamino, mono- and di 25 (substituted alkyl)amino, mono- and di-arylamino, mono- and di-(substituted aryl)amino, mono- and di-heteroarylamino, mono- and di-(substituted heteroaryl)amino, mono- and di-heterocyclic amino, mono- and di (substituted heterocyclic) amino, and unsymmetric di-substituted amines having different substituents selected from the group consisting of alkyl, 30 substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, WO 99/06437 PCT/US98/16070 256 heterocyclic and substituted heterocyclic, substituted alkyl groups having amino groups blocked by conventional blocking groups and alkyl/substituted alkyl groups substituted with -SO 2 -alkyl, -SO,-substituted alkyl, -SO 2 alkenyl, -SO2-substituted alkenyl, -SO 2 -cycloalkyl, 5 -SO,-substituted cycloalkyl, -SO,-aryl, -SO,-substituted aryl, -SO 2 heteroaryl, -SO 2 -substituted heteroaryl, -SO,-heterocyclic, -SO 2 -substituted heterocyclic or -SO 2 NRR, where R is hydrogen or alkyl; (f) substituted alkenyl or substituted alkynyl with the proviso that at least one of the substituents on the substituted alkenyl/alkynyl moiety is 10 selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic with the proviso that when substituted with substituted alkyl then at least one of the substituents on the substituted alkyl moiety is selected from the group consisting of 15 alkoxy, substituted alkoxy, acyl, acylamino, thiocarbonylamino, acyloxy, alkenyl, amino, amidino, alkyl amidino, thioamidino, aminoacyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aryloxy, substituted aryloxy, cyano, nitro, halogen, hydroxyl, carboxyl, carboxylalkyl, carboxyl-substituted alkyl, carboxyl-cycloalkyl, carboxyl-substituted 20 cycloalkyl, carboxylaryl, carboxyl-substituted aryl, carboxylheteroaryl, carboxyl-substituted heteroaryl, carboxylheterocyclic, carboxyl-substituted heterocyclic, cycloalkyl, substituted cycloalkyl, guanidino, guanidinosulfone, thiol, thioalkyl, substituted thioalkyl, thioaryl, substituted thioaryl, thiocycloalkyl, substituted thiocycloalkyl, thioheteroaryl, substituted 25 thioheteroaryl, thioheterocyclic, substituted thioheterocyclic, heterocyclic, substituted heterocyclic, cycloalkoxy, substituted cycloalkyoxy, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy, oxycarbonylamino, oxythiocarbonylamino, -OS(O) 2 -alkyl, -OS(O),-substituted alkyl, -OS(O)2,-aryl, -OS(O) 2 -substituted aryl, -OS(0) 2 30 heteroaryl, -OS(O) 2 -substituted heteroaryl, -OS(O) 2 -heterocyclic, -OS(0) 2 - WO 99/06437 PCT/US98/16070 257 substituted heterocyclic, -OSO 2 -NRR, -NRS(O) 2 -alkyl, -NRS(O) 2 -substituted alkyl, -NRS(O) 2 -aryl, -NRS(O) 2 -substituted aryl, -NRS(O) 2 -heteroaryl, NRS(O) 2 -substituted heteroaryl, -NRS(O) 2 -heterocyclic, -NRS(O) 2 substituted heterocyclic, -NRS(O),-NR-alkyl, -NRS(O) 2 -NR-substituted 5 alkyl, -NRS(O) 2 -NR-aryl, -NRS(O),-NR-substituted aryl, -NRS(O) 2 -NR heteroaryl, -NRS(O) 2 -NR-substituted heteroaryl, -NRS(O),-NR-heterocyclic, -NRS(O) 2 -NR-substituted heterocyclic, mono- and di-alkylamino, mono- and di-(substituted alkyl)amino, mono- and di-arylamino, mono- and di (substituted aryl)amino, mono- and di-heteroarylamino, mono- and di 10 (substituted heteroaryl)amino, mono- and di-heterocyclic amino, mono- and di-(substituted heterocyclic) amino, unsymmetric di-substituted amines having different substituents selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic, and substituted alkyl groups having 15 amino groups blocked by conventional blocking groups and alkyl/substituted alkyl groups substituted with -SO,-alkyl, -SO-,-substituted alkyl, -SO 2 alkenyl, -SO, 2 -substituted alkenyl, -SO, 2 -cycloalkyl, -SO-,-substituted cycloalkyl, -SO,-aryl, -SO,-substituted aryl, -SO, 2 -heteroaryl, SO,-substituted heteroaryl, -SO,-heterocyclic, -SO,-substituted heterocyclic or -SO,NRR, 20 where R is hydrogen or alkyl; (g) substituted aryloxy and substituted heteroaryloxy with the proviso that at least one substituent on the substituted aryloxy/heteroaryloxy is other than halogen, hydroxyl, amino, nitro, trifluoromethyl, trifluoromethoxy, alkyl, alkenyl, alkynyl, 1,2-dioxymethylene, 1,2-dioxyethylene, alkoxy, 25 alkenoxy, alkynoxy, alkylamino, alkenylamino, alkynylamino, alkylcarbonyloxy, acyl, alkylcarbonylamino, alkoxycarbonylamino, alkylsulfonylamino, N-alkyl or N,N-dialkylurea; (h) -alkoxy-saturated heterocyclic, -alkoxy-saturated substituted heterocyclic, -substituted alkoxy-heterocyclic and -substituted alkoxy 30 substituted saturated heterocyclic; WO 99/06437 PCT/US98/16070 258 (i) -O-heterocyclic and -O-substituted heterocyclic; (j) tetrazolyl; (k) -NR-SO 2 -substituted alkyl where R is hydrogen, alkyl or aryl, with the proviso that at least one substituent on the alkyl moiety of the 5 substituted alkylsulfonylamino is other than halogen, hydroxyl, amino, nitro, trifluoromethyl, trifluoromethoxy, alkyl, alkenyl, alkynyl, 1,2 dioxymethylene, 1,2-dioxyethylene, alkoxy, alkenoxy, alkynoxy, alkylamino, alkenylamino, alkynylamino, alkylcarbonyloxy, acyl, alkylcarbonylamino, alkoxycarbonylamino, alkylsulfonylamino, N-alkyl or 10 N,N-dialkylurea; (1) alkenylsulfonylamino, alkynylsulfonylamino, substituted alkenylsulfonylamino and substituted alkynylsulfonylamino; (min) substituted alkoxy with the proviso that the substitution on the alkyl moiety of said substituted alkoxy does not include alkoxy-NR"R", as 15 defined above, unsaturated heterocyclyl, alkyloxy, aryloxy, heteroaryloxy, aryl, heteroaryl and aryl/heteroaryl substituted with halogen, hydroxyl, amino, nitro, trifluoromethyl, trifluoromethoxy, alkyl, alkenyl, alkynyl, 1,2 dioxymethylene, 1,2-dioxyethylene, alkoxy, alkenoxy, alkynoxy, alkylamino, alkenylamino, alkynylamino, alkylcarbonyloxy, acyl, 20 alkylcarbonylamino, alkoxycarbonylamino, alkylsulfonylamino, N-alkyl or N,N-dialkylurea; (n) amidine and amidine substituted with from I to 3 substituents independently selected from the consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, heteroaryl and 25 heterocyclic; (o) -C(0)NR'"R'" where each R"' is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and 30 substituted heterocyclic with the proviso that when one R'" is unsaturated WO 99/06437 PCT/US98/16070 259 heterocyclic, aryl, heteroaryl or aryl/heteroaryl substituted with halogen, hydroxyl, amino, nitro, trifluoromethyl, trifluoromethoxy, alkyl, alkenyl, alkynyl, 1,2-dioxymethylene, 1,2-dioxyethylene, alkoxy, alkenoxy, alkynoxy, alkylamino, alkenylamino, alkynylamino, alkylcarbonyloxy, acyl, 5 alkylcarbonylamino, alkoxycarbonylamino, alkylsulfonylamino, N-alkyl or N,N-dialkylurea, then the other R"' is alkyl, substituted alkyl (other than unsaturated heterocyclyl substituted-alkyl), cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, heterocyclic or substituted heterocyclic; 10 (p) -NR 22 C(O)-R 1 8 where R1 8 is selected from the group consisting of alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic, and R 22 is alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, 15 heterocyclic or substituted heterocyclic; (q) -SO,-aryl, -SO,-substituted aryl, -SO, 2 -heteroaryl, -SO,-substituted heteroaryl or -SO 2 -alkyl; (r) -NR'C(O)NR 9 R19 wherein R' is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, 20 substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic and each R 9 is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic: 25 (s) -NR'C(O)ORI 9 wherein R' is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic, and R 1 9 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted WO 99/06437 PCT/US98/16070 260 aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic; (t) -aminocarbonyl-(N-formylheterocylcyl); and (u) -alkyl-C(0)NH-heterocyclyl and -alkyl-C(0)NH-substituted 5 heterocyclyl, and pharmaceutically acceptable salts thereof; with the following provisos: A) when R' is p-methylphenyl, R 2 and R 3 together with their pendent nitrogen and carbon atoms form a pyrrolidinyl ring, R 5 is 10 p-[-OCHCH 2 -(4,5-dihydroimidizol-2-yl), Q is -C(0)NH-, then R 6 is not -O-methyl; B) when R' is 4-fluorobenzyl, R 2 /R 3 together equal L-pyrrolidinyl, and R 5 is 4-hydroxybenzyl, then R 6 is not isopropyl; C) when R 1 is 1 -methylimidazole, R 2 /R 3 together equal L 15 pyrrolidinyl, and R 5 is 4-hydroxybenzyl, then R 6 is not t-butyl; and D) when R' is 4-trifluoromethoxybenzyl, R 2 /R 3 together equal 5,5 dimethylthiazolidin-4-yl, and R 5 is 4-hydroxybenzyl, then R 6 is not t-butyl.

3. A compound of Claims 1 or 2 wherein R' is selected from the 20 group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heterocyclic, substituted heterocylic, heteroaryl and substituted heteroaryl.

4. A compound of Claims 1 or 2 wherein R' is selected from the group consisting of 4-methylphenyl, methyl, benzyl, n-butyl, 4-chlorophenyl, 25 1-naphthyl, 2-naphthyl, 4-methoxyphenyl, phenyl, 2,4,6-trimethylphenyl, 2 (methoxycarbonyl)phenyl, 2-carboxyphenyl, 3,5-dichlorophenyl, 4 trifluoromethylphenyl, 3,4-dichlorophenyl, 3,4-dimethoxyphenyl, 4 (CH 3 C(0)NH-)phenyl, 4-trifluoromethoxyphenyl, 4-cyanophenyl, isopropyl, 3,5-di-(trifluoromethyl)phenyl, 4-t-butylphenyl, 4-t-butoxyphenyl, 4 30 nitrophenyl, 2-thienyl, 1-N-methyl-3-methyl-5-chloropyrazol-4-yl, WO 99/06437 PCT/US98/16070 261 phenethyl, 1-N-methylimidazol-4-yl, 4-bromophenyl, 4-amidinophenyl, 4 methylamidinophenyl, 4-[CH 3 SC(=NH)]phenyl, 5-chloro-2-thienyl, 2,5 dichloro-4-thienyl, 1-N-methyl-4-pyrazolyl, 2-thiazolyl, 5-methyl-1,3,4 thiadiazol-2-yl, 4-[H 2 NC(S)]phenyl, 4-aminophenyl, 4-fluorophenyl, 2 5 fluorophenyl, 3-fluorophenyl, 3,5-difluorophenyl, pyridin-3-yl, pyrimidin-2 yl, 4-(3'-dimethylamino-n-propoxy)-phenyl, and 1-methylpyrazol-4-yl.

5. A compound of Claims 1 or 2 wherein R 2 is selected from the group consisting of hydrogen, methyl, phenyl, benzyl, -(CH 2 ) 2 -2-thienyl, and 10 -(CH,)2-.

6. A compound of Claims 1 or 2 wherein R' and R 2 together with the nitrogen atom bound to R 2 and the SO 2 group bound to R' are joined to form a heterocyclic group or substituted heterocyclic group. 15

7. A compound of Claims 1 or 2 wherein R 3 includes all of the isomers arising by substitution with methyl, phenyl, benzyl, diphenylmethyl, -CH,CH,-COOH, -CH,-COOH, 2-amidoethyl, iso-butyl, t-butyl, -CH,0 benzyl and hydroxymethyl. 20

8. A compound of Claims 1 or 2 wherein R 2 and R 3 together with the nitrogen atom bound to R 2 and the carbon atom bound to R 3 form a saturated heterocyclic group or a saturated substituted heterocyclic group with the proviso that when monosubstituted, the substituent on said saturated 25 substituted heterocyclic group is not carboxyl.

9. A compound of Claims 1 or 2 wherein Q is -C(O)NH- or -C(S)NH-. WO 99/06437 PCT/US98/16070 262

10. A compound of Claims 1 or 2 wherein R 5 is selected from the group consisting ofp-[-OCH(CH 3 )W]benzyl, 4-hydroxybenzyl, 2 carboxybenzyl, 3-carboxybenzyl, 4-carboxybenzyl, 4-(2 carboxyphenoxy)benzyl, 4-(benzyloxy)benzyl, 4-iodobenzyl, 4 5 methoxybenzyl, 4-nitrobenzyl, 4-(tert-butoxy)benzyl, 3,5-diiodo-4 hydroxybenzyl, 4-(benzamido)benzyl, benzyl, 4-hydroxy-3-iodobenzyl, 4 chlorobenzyl, isobutyl, methyl, 4-(acetamido)benzyl, n-butyl, carboxymethyl, 4-aminobutyl, 2-carboxyethyl, 4-(N,N dibenzylamino)benzyl, (N-benzylimidazol-4-yl)methyl, 2-thiomethoxyethyl, 10 hydroxymethyl, (N-methylimidazol-4-yl)methyl, 4-(isopropyl-C(O)NH )butyl, 4-(benzamido)butyl, 4-(benzyl-C(O)NH-)butyl, (N-methylimidazol-5 yl)methyl, 4-(pyridin-2-yl-C(O)NH-)butyl, 4-(6-methylpyridin-3-yl C(O)NH-)butyl, 4-(3-methylthien-2-yl-C(O)NH-)butyl, 4-(pyrrol-2-yl C(O)NH-)butyl, 4-(furan-2-yl-C(O)NH-)butyl, isopropyl, 4-aminobenzyl, 4 15 (4-phenylbutoxy)benzyl, 4-(1-methylindol-3-yl-C(O)NH-)butyl, 4-(4 methanesulfonylphenyl-C(O)NH-)butyl, 4-(4-acetylphenyl-C(O)NH-)butyl, 4-(4-fluorophenyl-C(O)NH-)butyl, 4-[2-(pyridin-2-yl)ethynyl]benzyl, 4-[2 (3-hydroxyphenyl)ethynyl]benzyl, 4-(pyridin-4-yl-C(O)NH-)benzyl, 4 (pyridin-3-yl-C(O)NH-)benzyl, 4-(3-methylphenyl-NHC(O)NH-)benzyl, 4 20 (2,3-dihydroindol-2-yl-C(O)NH-)benzyl, 4-(N,N-dipentylamino)benzyl, 4 (N-pentylamino)benzyl, 4-[2-(N,N-dibenzylamino)ethoxy]benzyl, 3 hydroxybenzyl, 4-(N-n-butyl-N-n-pentylamino)benzyl, 4-(N-4 chlorophenylamino)benzyl, 4-(4-cyanophenyl-NHC(O)NH-)benzyl, 4 (carboxymethoxy)benzyl, 4-(tert-butoxycarbonylmethoxy)benzyl, 4-(5 25 fluoroindol-2-yl-C(O)NH-)benzyl, 4-(1,2,3,4-tetrahydroisoquinolin-3-yl C(O)NH-)benzyl, 4-(3-methoxyphenyl-NHC(O)NH-)benzyl, 4-[2-(indol-3 yl)ethoxy]benzyl, 4 -(4,5-dihydroimidazol-2-ylmethoxy)benzyl, 4-(n-propyl NHC(O)NH-)benzyl, 4-(N-benzylamino)benzyl, 3-methoxybenzyl, 4 (pyridin-2-yl-C(O)NH-)benzyl, 4-(N-4-chlorobenzylamino)benzyl, 4-(2 30 chloromethylsulfonylamino)benzyl, 4-(N,N-dimethylamino)benzyl, 3- WO 99/06437 PCT/US98/16070 263 aminobenzyl, 4-(benzyl)benzyl, 2-hydroxyethyl, 4-nitrobenzyl, 4-(phenyl NHC(S)NH-)benzyl, 4-(pyridin-3-yl-NHC(S)NH-)benzyl, 4-(pyridin-4 ylmethylamino)benzyl, 4-[4CH 2 ,0CH 2 (Boc-HN)CHC(O)NH-]benzyl, 4 (pyridin-3-yl-C(O)NH-)butyl, 4-(pyridin-4-yl-C(O)NH-)butyl, 4-(pyridin-3 5 yl-C(O)NH-)benzyl, 4-(pyridin-4-yl-C(O)NH-)benzyl, 4-(N toluenesulfonylpyrrolidin-2-yl-C(O)NH-)butyl, 4-(piperidin-4-yl-C(O)NH )butyl, 4-(2-Boc-1,2,3,4-tetrahydroisoquinolin-3-yl-NHCH 2 -)benzyl, 4-(2 Boc-1,2,3,4-tetrahydroisoquinolin-3-yl-C(O)NH-)benzyl, 4-(pyridin-3 ylmethylamino)benzyl, 4-[4CH 2 0(O)C(CbzNH)CHCH 2 CH,C(O)NH 10 ]benzyl, 4-(2-methoxybenzamido)benzyl, 4-(2-bromobenzamido)benzyl, 4 (pyrazin-2-yl-C(O)NH-)benzyl, (1-toluenesulfonylimidizol-4-yl)methyl, [1 (N,N-dimethylaminosulfonyl)imidizol-4-yl]methyl, 4 (trifluoromethyl)benzyl, 4-(3,3-dimethylureido)benzyl, 4 (methoxycarbonylamino)benzyl, 4-(1,3,3-trimethylureido)benzyl, 4 15 (methoxycarbonyl-N-methylamino)benzyl, 4-cyanobenzyl, 4-(2-formyl 1,2,3,4-tetrahydroisoquinolin-3-yl-C(O)NH-)benzyl, phenyl, 4 (aminomethyl)benzyl, 4-(1-Boc-piperidin-4-yl-C(O)NHCH,-)benzyl, 4-(1 Boc-piperidin-4-yl-C(O)O-)benzyl, 4-(piperidin-4-yl-C(O)NHCH 2 -)benzyl, 4-[(1 -methylpiperidin-4-yl)-O-]benzyl, 4-(1,2,3,4-tetrahydroquinolin-2-yl 20 C(O)NH-)benzyl, c-methylbenzyl, 4-(trimethylacetamido)benzyl, 4-(2 methylpropionamido)benzyl, 4-(morpholin-4-yl-C(O)NH-)benzyl, 4-(3,3 diethylureido)benzyl, 4-(2-trifluoromethylbenzamido)benzyl, 4-(2 methylbenzamido)benzyl, 4-hydroxy-3-nitrobenzyl, 3-hydroxy-4-($ OC(O)NH-)benzyl, 4-(thiomorpholino-4-yl-C(O)NH-)benzyl, 4-(1,1 25 dioxothiomorpholino-4-yl-C(O)NH-)benzyl, 3-nitro-4 (methoxycarbonylmethoxy)benzyl, (2-benzoxazolinon-6-yl)methyl, (2H-1,4 benzoxazin-3(4H)-one-7-yl)methyl, 4-[N,N-dimethyaminosulfonyl-(N methyl)amino]benzyl, 4-[(2-methylpyrrolidin- 1 -yl)-C(O)NH-]benzyl, (pyridin-4-yl)methyl, 4-(1-methylpiperidin-4-yl-C(O)NH-)benzyl, 4 30 [bis(N.N-dimethylaminothiocarbonyl)amino]benzyl, 4-(N,N- WO 99/06437 PCT/US98/16070 264 dimethylaminosulfonyl)benzyl, 4-(imidazolid-2-one-1-yl)benzyl, 3,4 (ethylenedioxy)benzyl-, 3,4-(methylenedioxy)benzyl- and 4-(3 formylimidazolid-2-one- 1 -yl)benzyl. 5

11. A compound of Claim 2 wherein R 6 is selected from the group consisting of 2,4-dioxo-tetrahydrofuran-3-yl (3,4-enol), methoxy, ethoxy, iso-propoxy, n-butoxy, t-butoxy, cyclopentoxy, neo-pentoxy, 2-a iso-propyl-4-p-methylcyclohexoxy, 2-p-isopropyl-4-p-methylcyclohexoxy, -NH 2 , benzyloxy, -NHCH 2 COOH, -NHCH 2 CH 2 COOH, -NH-adamantyl, 10 -NHCHCH 2 COOCH 2 CH 3 , -NHSO 2 -p-CH 3 -4, -NHOR' where R 8 is hydrogen, methyl, iso-propyl or benzyl, O-(N-succinimidyl), -O-cholest-5-en-3-p-yl, -OCH,-OC(O)C(CH 3 ) 3 , -O(CH 2 )zNHC(O)W where z is 1 or 2 and W is selected from the group consisting of pyrid-3-yl, N methylpyridyl, and N-methyl-1,4-dihydro-pyrid-3-yl, and -NR"C(O)-R' 15 where R' is aryl, heteroaryl or heterocyclic and R" is hydrogen or -CH 2 C(O)OCH 2 CH 3 .

12. A compound selected from the group consisting of: N-(Toluene- 4 -sulfonyl)-L-prolyl-4-(a-methylbenzyloxy)-L-phenylalanine 20 N-(Toluene-4-sulfonyl)-L-prolyl-L-tyrosine N-(Toluene- 4 -sulfonyl)-L-prolyl-4-carboxyphenylalanine 25 N-(Toluene-4-sulfonyl)-L-prolyl-3-(carboxy)phenylalanine N-(Toluene- 4 -sulfonyl)-L-prolyl-4-(2-carboxyphenoxy)-L-phenylalanine N-(Toluene-4-sulfonyl)-L-prolyl-O-(benzyl)-L-tyrosine 30 N-(Toluene-4-sulfonyl)-L-prolyl-4-(iodo)-L-phenylalanine N-(Toluene-4-sulfonyl)-L-prolyl-L-4-(methoxy)-phenylalanine 35 N-(Toluene-4-sulfonyl)-L-prolyl-4-nitro-L-phenylalanine WO 99/06437 PCT/US98/16070 265 N-(Toluene- 4 -sulfonyl)-L-prolyl-4-(O-tert-butyl)-L-tyrosine N-(Toluene-4-sulfonyl)-L-prolyl-L-(3,5-diiodo)-tyrosine 5 N-(Toluene- 4 -sulfonyl)-L-prolyl-L-4-(aminobenzoyl)-phenylalanine N-(Toluene-4-sulfonyl)-L-prolyl-L-(3-iodo-4-hydroxy)-phenylalanine N-(Toluene- 4 -sulfonyl)-L-prolyl-L-(4-chloro)phenylalanine 10 N-(Toluene-4-sulfonyl)-L-prolyl-L-leucine N-(Toluene-4-sulfonyl)-L-prolyl-L-alanine 15 N-(Toluene- 4 -sulfonyl)-L-prolyl-L-4-(acetamido)-phenylalanine N-(Toluene-4-sulfonyl)-L-prolyl-L-isoleucine N-(Toluene-4-sulfonyl)-L-prolyl-L-aspartic acid 20 N-(Toluene-4-sulfonyl)-L-prolyl-L-lysine N-(Toluene-4-sulfonyl)-L-prolyl-L-glutamic acid 25 N-(Toluene- 4 -sulfonyl)-L-prolyl-L-(4-dibenzylamino)-phenylalanine methyl ester N-(Toluene-4-sulfonyl)-L-prolyl-L-(N-benzyl)-histidine 30 N-(Toluene- 4 -sulfonyl)-L-prolyl-L-(4-dibenzylamino)-phenylalanine N-(Toluene-4-sulfonyl)-L-prolyl-L-methionine N-(Toluene-4-sulfonyl)-L-prolyl-L-serine 35 N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)thiaprolylL-(N-benzyl)-histidine N-(Toluene-4-sulfonyl)-L-prolyl-L-(1 -methyl)histidine 40 N-(Toluene-4-sulfonyl)-L-prolyl-D-(N-benzyl)histidine N-(Toluene-4-sulfonyl)-L-glutamyl-L-tyrosine N-(Toluene-4-sulfonyl)-L-prolyl-L-(N-3-methyl)histidine WO 99/06437 PCT/US98/16070 266 N-(Toluene-4-sulfonyl)-L-prolyl-a-amino-2,3-dihydro-(1,4-benzodioxin)-6 propanoic acid N-(Toluene-4-sulfonyl)-L-prolyl-a-amino-1,3-benzodioxole-5-propanoic 5 acid N-(Toluene-4-sulfonyl)-L-prolyl-L-valine N-(Toluene- 4 -sulfonyl)-L-prolyl-L-(4-iodo)-phenylalanine methyl ester 10 N-(Toluene- 4 -sulfonyl)-L-prolyl-L-4-(aminobenzoyl)phenylalanine methyl ester N-(Toluene- 4 -sulfonyl)-L-prolyl-L-(4-chloro)phenylalanine methyl ester 15 N-(Toluene- 4 -sulfonyl)-L-prolyl-L-(4-amino)phenylalanine methyl ester N-(Toluene- 4 -sulfonyl)-L-prolyl-L-(4-acetamido)phenylalanine methyl ester 20 N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)thiaprolyl-L-(N-benzyl)-histidine methyl ester N-(Toluene-4-sulfonyl)-L-prolyl-4-(3-3'-tolylureido)-L-phenylalanine 25 N-(Toluene-4-sulfonyl-L-prolyl-4-[(2,3,3a,7a-tetrahydro- 1H-indole-2 carbonyl)-amino]-L-phenylalanine N-(Toluene- 4 -sulfonyl)-L-prolyl-L-(4-pentylamino)phenylalanine methyl ester 30 N-(Toluene- 4 -sulfonyl)-L-prolyl-L-O-(2-dibenzylamino-ethyl)-tyrosine methyl ester N-(Toluene-4-sulfonyl)-L-prolyl-L-O-[2-(dibenzylamino)ethyl]-tyrosine 35 N-(Toluene- 4 -sulfonyl)-L-prolyl-L-(4-pentylamino)phenylalanine N-(Toluene-4-sulfonyl)-L-prolyl-L-4-(4-chlorobenzylamino)-phenylalanine methyl ester 40 N-(Toluene-4-sulfonyl)-L-prolyl-L-4-[3-(4-cyanophenyl)-ureido]-phenyl alanine methyl ester WO 99/06437 PCT/US98/16070 267 N-(Toluene-4-sulfonyl)-L-prolyl-L-4-[3-(4-cyanophenyl)-ureido]-phenyl alanine N-(Toluene- 4 -sulfonyl)-L-prolyl-L-O-(tert-butoxycarbonylmethyl)-tyrosine 5 methyl ester N-(Toluene- 4 -sulfonyl)-L-prolyl-L-O-(tert-butoxycarbonylmethyl)-tyrosine N-(Toluene-4-sulfonyl)-L-prolyl-L-4-[(3S)-3,4-dihydro-isoquinolin-3-yl 10 aminocarbonyl]-phenylalanine N-(Toluene-4-sulfonyl)-L-prolyl-4-[3-(3-methoxy-phenyl)-ureido]-L phenylalanine methyl ester 15 N-(Toluene-4-sulfonyl)-L-prolyl-4-[3-(3-methoxy-phenyl)-ureido]-L phenylalanine N-(Toluene-4-sulfonyl)-L-prolyl-L-O-(4,5-dihydro- 1 H-imidazol-2-yl methyl)-tyrosine 20 N-(Toluene-4-sulfonyl)-L-prolyl-L-4-(3-propyl-ureido)-phenylalanine N-(Toluene-4-sulfonyl)-L-prolyl-L-(4-benzylamino)phenylalanine 25 N-(Toluene- 4 -sulfonyl)-L-prolyl-L-(4-benzylamino)phenylalanine methyl ester N-(Toluene- 4 -sulfonyl)-L-prolyl-L-4-(4-chlorobenzylamino)-phenylalanine 30 N-(Toluene- 4 -sulfonyl)-L-prolyl)-L-(4-chloromethanesulfonylamino) phenylalanine N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)-thiaprolyl-L-4 (aminobenzoyl)phenylalanine methyl ester 35 N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)-thiaprolyl-L-4 (benzamido)phenylalanine N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)-thiaprolyl-L-tyrosine ethyl ester 40 N-(Toluene-4-Sulfonyl)-L-(5,5-dimethyl)-thiaprolyl-L-tyrosine N-(Toluene-4-sulfonyl)-L-prolyl-L-4-[(pyridin-4 yl)methylamino]phenylanine WO 99/06437 PCT/US98/16070 268 N-(Toluene-4-sulfonyl)-L-prolyl-L-4-[(pyridin-4 yl)methylamino]phenylanine methyl ester N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)-thiaprolyl-L-4-(pyridin-3 5 carboxamido)phenylalanine methyl ester N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)-thiaprolyl-L-4-(pyridine-3 carboxamido)phenylalanine 10 N-(Toluene-4-sulfonyl)-L-prolyl-L-4-[(pyridin-3 ylmethyl)amino]phenylalanine N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)-thiaprolyl-L-4-nitrophenylalanine methyl ester 15 N-(Toluene- 4 -sulfonyl)-L-prolyl-L-4-nitrophenylalanine ethyl ester N-(Toluene-4-sulfonyl)-L-prolyl-L-4-(2-methoxybenzamido)phenylalanine ethyl ester 20 N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)-thiaprolyl-L-(4-nitro)phenylalanine ethyl ester N-(Toluene-4-sulfonyl)-L-prolyl-L-4-(2-bromobenzamido)phenylalanine 25 ethyl ester N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)-thiamorphyl-L-4 aminophenylalanine ethyl ester 30 N-(Toluene-4-sulfonyl)-L-prolyl-L-4-acetamidophenylalanine ethyl ester N-(Toluene-4-sulfonyl)-L-prolyl-L-4-(2-methoxybenzamido)phenylalanine N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)-thiaprolyl-L-4 35 acetamidophenylalanine ethyl ester N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)-thiaprolyl-L-4 acetamidophenylalanine 40 N-(Toluene- 4 -sulfonyl)-L-prolyl-L-4-acetamidophenylalanine isopropyl ester N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)-L-4-(isonicotinamido) phenylalanine ethyl ester WO 99/06437 PCT/US98/16070 269 N-(Toluene- 4 -sulfonyl)-L-prolyl-L-4-(isonicotinamido)phenylalanine ethyl ester N-(Toluene-4-sulfonyl)-L-prolyl-L-(Tr-toluene-4-sulfonyl)histidine methyl 5 ester N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)-thiaprolyl-L-4 (nicotinamido)phenylalanine ethyl ester 10 N-(Toluene-4-sulfonyl)-L-prolyl-L-(O-methyl)tyrosine ethyl ester N-(ca-Toluenesulfonyl)-L-prolyl-L-4-(isonicotinamido)phenylalanine ethyl ester 15 N-(Toluene- 4 -sulfonyl)-L-prolyl-L-4-(2-bromobenzamido)phenylalanine N-(a-Toluenesulfonyl)-L-prolyl-L-4-(isonicotinamido)phenylalanine N-(Toluene-4-sulfonyl)-L-(1,1-dioxo)thiamorpholyl-L-4-(2 20 bromobenzamido))phenylalanine ethyl ester N-(Toluene-4-sulfonyl)-L-(1,1-dioxo)thiamorpholyl-L-4-(2 bromobenzamido)phenylalanine 25 N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)-L-4 (isonicotinamido)phenylalanine N-(ca-Toluenesulfonyl)-L-prolyl-L-4-(2-bromobenzamido)phenylalanine ethyl ester 30 N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)-thiaprolyl-L-tyrosine isopropyl ester N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)-thiaprolyl-L-tyrosine tert-butyl 35 ester N-(Toluene-4-sulfonyl)-L-prolyl-L-tyrosine tert-butyl ester N-(Toluene-4-sulfonyl)-L-prolyl-L-4-(2 40 trifluoromethylbenzamido)phenylalanine ethyl ester N-(Toluene-4-sulfonyl)-L-prolyl-L-4-(2-methylbenzamido)phenylalanine ethyl ester WO 99/06437 PCT/US98/16070 270 N-(Toluene-4-sulfonyl)-L-prolyl-L-4-(2-trifluoromethylbenzamido) phenylalanine N-(4-Fluorobenzenesulfonyl)-L-thiaprolyl-L-tyrosine tert-butyl Ester 5 N-( 4 -Fluorobenzenesulfonyl)-L-(5,5-dimethyl)-thiaprolyl-L-tyrosine tert butyl ester N-(Toluene-4-sulfonyl)-L-prolyl-4-(dimethylamino)-L-phenylalanine 10 N-(Toluene-4-sulfonyl)-L-prolyl-4-[(2-bromo)benzamido]-L-phenylalanine ethyl ester N-(Toluene-4-sulfonyl)-L-prolyl-4-[(pyrazin-2-yl)C(O)NH]-L-phenylalanine 15 methyl ester N-(Toluene-4-sulfonyl)-L-prolyl-4-(4-nitrobenzoyl)-L-phenylalanine ethyl ester 20 N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)thiaprolyl-4-(2-bromobenzamido) L-phenylalanine t-butyl ester N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)thiaprolyl-4-(2-bromobenzamido) L-phenylalanine t-butyl ester 25 N-(Toluene-4-sulfonyl)-L-prolyl-4-(1-H-2-oxo-3 methyltetrahydropyrimidin-1-yl)-L-phenylalanine t-butyl ester N-(Toluene-4-sulfonyl)-L-prolyl-4-(1-H-2-oxo-3 30 methyltetrahydropyrimidin- 1 -yl)-L-phenylalanine N-(Toluene-4-sulfonyl)-L-prolyl-3-chloro-4-(t-butoxy)-L-phenylalanine t butyl ester 35 N-(Toluene-4-sulfonyl)-L-prolyl-3-chloro-4-(hydroxy)-L-phenylalanine t butyl ester N-(Toluene-4-sulfonyl)-L-prolyl-4-(N,N-dimethylureido)-L-phenylalanine t butyl ester 40 N-(4-Fluorobenzenesulfonyl)-L-(5,5-dimethyl)thiaprolyl-3-chloro-4 (hydroxy)-L-phenylalanine t-butyl ester WO 99/06437 PCT/US98/16070 271 N-(4-fluorobenzenesulfonyl)-L-(5,5-dimethyl)thiaprolyl-3-chloro-4 (hydroxy)-L-phenylalanine isopropyl ester N-(Toluene- 4 -sulfonyl)-L-prolyl-4-(2-methoxyphenyl)-L-phenylalanine t 5 butyl ester N-(Toluene- 4 -sulfonyl)-L-prolyl-4-(2-methoxyphenyl)-L-phenylalanine N-(Toluene-4-sulfonyl)-L-prolyl-[(5-N,N-dimethyl ureido)-pyridin-2-yl] 10 alanine N-(Toluene- 4 -sulfonyl)-L-prolyl-4-(N,N-dimethylsulfamyl)-L-phenylalanine N-(Toluene-4-sulfonyl)-L-prolyl-4-(N',N' ,N 2 -trimethylsulfamyl)-L 15 phenylalanine N-(Toluene-4-sulfonyl)-L-prolyl-(1-t-butoxycarbonylmethylimidazol-4-yl) L-alanine methyl ester 20 N-(Toluene-4-sulfonyl)-L-prolyl-[N,N dimethylaminocarbonylmethylimidazol-4-yl]-L-alanine methyl ester N-[4-(dimethyl ureylenyl)-benzenesulfonyl]-L-prolyl-4-hydroxy-L phenylalanine isopropyl ester 25 N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)thiaprolyl-3-chloro-4-hydroxy-L phenylalanine isopropyl ester N-(Toluene-4-sulfonyl)-L-prolyl-3-chloro-4-hydroxy-L-phenylalanine 30 isopropyl ester N-(Toluene- 4 -sulfonyl)-L-prolyl-4-(carboxymethyl)-L-phenylalanine methyl ester 35 N-(Toluene- 4 -sulfonyl)-L-prolyl-4-(2-methylbenzamido)-L-phenylalanine methyl ester N-(Toluene- 4 -sulfonyl)-L-prolyl-4-(N,N-dimethylaminocarbonylmethyl)-L phenylalanine 40 N-(1-methylimidazol-4-sulfonyl)-L-prolyl-4-hydroxy-L-phenylalanine isopropyl ester WO 99/06437 PCT/US98/16070 272 N-(Toluene-4-sulfonyl)-L-prolyl-4-(2,4,5-trioxo-3 phenyltetrahydroimidazol-1-yl)-L-phenylalanine isopropyl ester N-(4-Fluorobenzenesulfonyl)-L-(5,5-dimethyl)thiaprolyl-3-fluoro-4 5 hydroxy-L-phenylalanine isopropyl ester N-(4-Fluorobenzenesulfonyl)-L-(5,5-dimethyl)thiaprolyl-3-chloro-4-t butoxy-L-phenylalanine t-butyl ester 10 N- {N- [(1 S)-2,10-camphorsultamyl]acetyl }-L-tyrosine t-butyl ester N- {N-[(1 S)-2,10-camphorsultamyl]acetyl}-3-chlorotyrosine isopropyl ester N-( 4 -Fluorobenzenesulfonyl)-L-thiaprolyl-4-hydroxy-L-phenylalanine t 15 butyl ester N-(Toluene-4-sulfonyl)-L-prolyl-4-(N,N-dimethylaminocarbonylmethyl)-L phenylalanine t-butyl ester 20 N-( 4 -Nitrobenzenesulfonyl)-L-prolyl-4-(hydroxy)-L-phenylalanine t-butyl ester N-(4-Fluorobenzenesulfonyl)-L-(5,5-dimethyl)thiaprolyl-4-hydroxy-L phenylalanine isopropyl ester 25 N-( 4 -Fluorobenzenesulfonyl)-L-prolyl-4-hydroxy-L-phenylalanine t-butyl ester N-(pyridin-3-sulfonyl)-L-prolyl-4-hydroxy-L-phenylalanine t-butyl ester 30 N-(Toluene- 4 -sulfonyl)-L-prolyl-4-(methanesulfonamido)-L-phenylalanine N-(Toluene-4-sulfonyl)-L-prolyl-4-(2,4,5-trioxo-3-(3-chlorophenyl) tetrahydroimidazol-1-yl)-L-phenylalanine benzyl ester 35 N-(1-methylimidazol-4-sulfonyl)-L-(5,5-dimethyl)thiaprolyl-3-chloro-4 hydroxy-L-phenylalanine ethyl ester. N-(4-Fluorobenzenesulfonyl)-L-(5,5-dimethyl) thiaprolyl-L-3-chloro 40 4-tert-butoxy-phenylalanine tert-Butyl Ester N-[2-(N-2,10-camphorsultamyl) acetyl]-L-3-chloro-4-hydroxyphenylalanine Isopropyl Ester WO 99/06437 PCT/US98/16070 273

13. A method for binding VLA-4 in a biological sample which method comprises contacting the biological sample with a compound of Claims 1 or 2 under conditions wherein said compound binds to VLA-4. 5

14. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of one or more compounds of Claim 1 or 2.

15. A method for treating an inflammatory disease in a 10 mammalian patient which disease is mediated by VLA-4 which method comprises administering to said patient a therapeutically effective amount of the pharmaceutical composition of Claim 14.

16. The method according to Claim 15 wherein said inflammatory 15 disease is selected from the group consisting of asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes (including acute juvenile onset diabetis), inflammatory bowel disease (including ulcerative colitis and Crohn's disease), multiple sclerosis, rheumatoid arthritis, tissue transplantation, tumor metastasis, meningitis, encephalitis, stroke, and other 20 cerebral traumas, nephritis, retinitis, atopic dermatitis, psoriasis, myocardial ischemia and acute leukocyte-mediated lung injury such as that which occurs in adult respiratory distress syndrome.

17. The method of claim 14 wherein R' is selected from the group 25 consisting of alkyl, substituted alkyl, aryl, substituted aryl, heterocyclic, substituted heterocylic, heteroaryl and substituted heteroaryl.

18. The method of claim 14 wherein R 1 is selected from the group consisting of 4-methylphenyl, methyl, benzyl, n-butyl, 4-chlorophenyl, 1 30 naphthyl. 2-naphthyl, 4-methoxyphenyl, phenyl, 2,4,6-trimethylphenyl, 2- WO 99/06437 PCT/US98/16070 274 (methoxycarbonyl)phenyl, 2-carboxyphenyl, 3,5-dichlorophenyl, 4 trifluoromethylphenyl, 3,4-dichlorophenyl, 3,4-dimethoxyphenyl, 4 (CH 3 C(O)NH-)phenyl, 4-trifluoromethoxyphenyl, 4-cyanophenyl, isopropyl, 3,5-di-(trifluoromethyl)phenyl, 4-t-butylphenyl, 4-t-butoxyphenyl, 4 5 nitrophenyl, 2-thienyl, 1-N-methyl-3-methyl-5-chloropyrazol-4-yl, phenethyl, 1-N-methylimidazol-4-yl, 4-bromophenyl, 4-amidinophenyl, 4 methylamidinophenyl, 4-[CH 3 SC(=NH)]phenyl, 5-chloro-2-thienyl, 2,5 dichloro-4-thienyl, 1-N-methyl-4-pyrazolyl, 2-thiazolyl, 5-methyl-1,3,4 thiadiazol-2-yl, 4-[H 2 NC(S)]phenyl, 4-aminophenyl, 4-fluorophenyl, 2 10 fluorophenyl, 3-fluorophenyl, 3,5-difluorophenyl, pyridin-3-yl, pyrimidin-2 yl, 4-(3 '-dimethylamino-n-propoxy)-phenyl, and 1-methylpyrazol-4-yl.

19. The method of claim 14 wherein R 2 is selected from the group consisting of hydrogen, methyl, phenyl, benzyl, -(CH 2 ) 2 -2-thienyl, and 15 (CH2)2- *

20. The method of claim 14 wherein R' and R 2 together with the nitrogen atom bound to R 2 and the SO 2 group bound to R' are joined to form a heterocyclic group or substituted heterocyclic group. 20

21. The method of claim 14 wherein R 3 includes all of the isomers arising by substitution with methyl, phenyl, benzyl, diphenylmethyl, -CH,CH,-COOH, -CH 2 -COOH, 2-amidoethyl, iso-butyl, t-butyl, -CH 2 0 benzyl and hydroxymethyl. 25

22. The method of claim 14 wherein R 2 and R 3 together with the nitrogen atom bound to R 2 and the carbon atom bound to R 3 form a saturated heterocyclic group or a saturated substituted heterocyclic group with the proviso that when monosubstituted, the substituent on said saturated 30 substituted heterocyclic group is not carboxyl. WO 99/06437 PCT/US98/16070 275

23. The method of claim 14 wherein Q is -C(O)NH- or -C(S)NH-.

24. The method of claim 14 wherein R 5 is selected from the group 5 consisting ofp-[-OCH(CH 3 )4]benzyl, 4-hydroxybenzyl, 2-carboxybenzyl, 3 carboxybenzyl, 4-carboxybenzyl, 4-(2-carboxyphenoxy)benzyl, 4 (benzyloxy)benzyl, 4-iodobenzyl, 4-methoxybenzyl, 4-nitrobenzyl, 4-(tert butoxy)benzyl, 3,5-diiodo-4-hydroxybenzyl, 4-(benzamido)benzyl, benzyl, 4-hydroxy-3-iodobenzyl, 4-chlorobenzyl, isobutyl, methyl, 4 10 (acetamido)benzyl, n-butyl, carboxymethyl, 4-aminobutyl, 2-carboxyethyl, 4-(N,N-dibenzylamino)benzyl, (N-benzylimidazol-4-yl)methyl, 2 thiomethoxyethyl, hydroxymethyl, (N-methylimidazol-4-yl)methyl, 4 (isopropyl-C(O)NH-)butyl, 4-(benzamido)butyl, 4-(benzyl-C(O)NH-)butyl, (N-methylimidazol-5-yl)methyl, 4-(pyridin-2-yl-C(O)NH-)butyl, 4-(6 15 methylpyridin-3-yl-C(O)NH-)butyl, 4-(3-methylthien-2-yl-C(O)NH-)butyl, 4-(pyrrol-2-yl-C(O)NH-)butyl, 4-(furan-2-yl-C(O)NH-)butyl, isopropyl, 4 aminobenzyl, 4-(4-phenylbutoxy)benzyl, 4-(1-methylindol-3-yl-C(O)NH )butyl, 4-(4-methanesulfonylphenyl-C(O)NH-)butyl, 4-(4-acetylphenyl C(O)NH-)butyl, 4-(4-fluorophenyl-C(O)NH-)butyl, 4-[2-(pyridin-2 20 yl)ethynyl]benzyl, 4-[2-(3-hydroxyphenyl)ethynyl]benzyl. 4-(pyridin-4-yl C(O)NH-)benzyl, 4-(pyridin-3-yl-C(O)NH-)benzyl, 4-(3-methylphenyl NHC(O)NH-)benzyl, 4-(2,3-dihydroindol-2-yl-C(O)NH-)benzyl, 4-(N,N dipentylamino)benzyl, 4-(N-pentylamino)benzyl, 4-[2-(N.N dibenzylamino)ethoxy]benzyl, 3-hydroxybenzyl, 4-(N-n-butyl-N-n 25 pentylamino)benzyl, 4 -(N-4-chlorophenylamino)benzyl, 4-(4-cyanophenyl NHC(O)NH-)benzyl, 4-(carboxymethoxy)benzyl, 4-(tert butoxycarbonylmethoxy)benzyl, 4-(5-fluoroindol-2-yl-C(O)NH-)benzyl, 4 (1,2,3,4-tetrahydroisoquinolin-3-yl-C(O)NH-)benzyl, 4-(3-methoxyphenyl NHC(O)NH-)benzyl, 4-[2-(indol-3-yl)ethoxy]benzyl, 4-(4,5 30 dihydroimidazol-2-ylmethoxy)benzyl, 4-(n-propyl-NHC(O)NH-)benzyl, 4- WO 99/06437 PCT/US98/16070 276 (N-benzylamino)benzyl, 3-methoxybenzyl, 4-(pyridin-2-yl-C(O)NH-)benzyl, 4-(N-4-chlorobenzylamino)benzyl, 4-(2-chloromethylsulfonylamino)benzyl, 4-(N,N-dimethylamino)benzyl, 3-aminobenzyl, 4-(benzyl)benzyl, 2 hydroxyethyl, 4-nitrobenzyl, 4-(phenyl-NHC(S)NH-)benzyl, 4-(pyridin-3-yl 5 NHC(S)NH-)benzyl, 4-(pyridin-4-ylmethylamino)benzyl, 4 [#CH 2 OCH 2 (Boc-HN)CHC(O)NH-]benzyl, 4-(pyridin-3-yl-C(O)NH-)butyl, 4-(pyridin-4-yl-C(O)NH-)butyl, 4-(pyridin-3-yl-C(O)NH-)benzyl, 4 (pyridin-4-yl-C(O)NH-)benzyl, 4-(N-toluenesulfonylpyrrolidin-2-yl C(O)NH-)butyl, 4-(piperidin-4-yl-C(O)NH-)butyl, 4-(2-Boc-1,2,3,4 10 tetrahydroisoquinolin-3-yl-NHCH 2 -)benzyl, 4-(2-Boc-1,2,3,4 tetrahydroisoquinolin-3-yl-C(O)NH-)benzyl, 4-(pyridin-3 ylmethylamino)benzyl, 4-[4CH 2 0(O)C(CbzNH)CHCHCH 2 C(O)NH ]benzyl, 4-(2-methoxybenzamido)benzyl, 4-(2-bromobenzamido)benzyl, 4 (pyrazin-2-yl-C(O)NH-)benzyl, (1-toluenesulfonylimidizol-4-yl)methyl, [1 15 (N,N-dimethylaminosulfonyl)imidizol-4-yl]methyl, 4 (trifluoromethyl)benzyl, 4-(3,3-dimethylureido)benzyl, 4 (methoxycarbonylamino)benzyl, 4-(1,3,3-trimethylureido)benzyl, 4 (methoxycarbonyl-N-methylamino)benzyl, 4-cyanobenzyl, 4-(2-formyl 1,2,3,4-tetrahydroisoquinolin-3-yl-C(O)NH-)benzyl, phenyl, 4 20 (aminomethyl)benzyl, 4-(1-Boc-piperidin-4-yl-C(O)NHCH 2 -)benzyl, 4-(1 Boc-piperidin-4-yl-C(O)O-)benzyl, 4-(piperidin-4-yl-C(O)NHCH 2 -)benzyl, 4-[(1 -methylpiperidin-4-yl)-O-]benzyl, 4-(1,2,3,4-tetrahydroquinolin-2-yl C(O)NH-)benzyl, a-methylbenzyl, 4-(trimethylacetamido)benzyl, 4-(2 methylpropionamido)benzyl, 4-(morpholin-4-yl-C(O)NH-)benzyl, 4-(3,3 25 diethylureido)benzyl, 4-(2-trifluoromethylbenzamido)benzyl, 4-(2 methylbenzamido)benzyl, 4-hydroxy-3-nitrobenzyl, 3-hydroxy-4-(4 OC(O)NH-)benzyl, 4-(thiomorpholino-4-yl-C(O)NH-)benzyl, 4-(1,1 dioxothiomorpholino-4-yl-C(O)NH-)benzyl, 3-nitro-4 (methoxycarbonylmethoxy)benzyl, (2-benzoxazolinon-6-yl)methyl, (2H-1,4 30 benzoxazin-3(4H)-one-7-yl)methyl, 4-[N,N-dimethyaminosulfonyl-(N- WO 99/06437 PCT/US98/16070 277 methyl)amino]benzyl, 4-[(2-methylpyrrolidin-1-yl)-C(O)NH-]benzyl, (pyridin-4-yl)methyl, 4-(1-methylpiperidin-4-yl-C(O)NH-)benzyl, 4 [bis(N,N-dimethylaminothiocarbonyl)amino]benzyl, 4-(N,N dimethylaminosulfonyl)benzyl, 4-(imidazolid-2-one-1-yl)benzyl, 3,4 5 (ethylenedioxy)benzyl-, 3,4-(methylenedioxy)benzyl- and 4-(3 formylimidazolid-2-one- 1 -yl)benzyl.

25. The method of claim 14 wherein R 6 is selected from the group consisting of 2 ,4-dioxo-tetrahydrofuran-3-yl (3,4-enol), methoxy, ethoxy, 10 iso-propoxy, n-butoxy, t-butoxy, cyclopentoxy, neo-pentoxy, 2-a-iso-propyl 4-p-methylcyclohexoxy, 2-p-isopropyl-4-0-methylcyclohexoxy, -NH 2 , benzyloxy, -NHCH 2 COOH, -NHCH 2 CH 2 COOH, -NH-adamantyl, -NHCH 2 CH 2 COOCH 2 CH 3 , -NHSO 2 -p-CH 3 -4, -NHOR 8 where R 8 is hydrogen, methyl, iso-propyl or benzyl, O-(N-succinimidyl), 15 -O-cholest-5-en-3-p-yl, -OCH,-OC(O)C(CH 3 ) 3 , -O(CH 2 )zNHC(O)W where z is 1 or 2 and W is selected from the group consisting of pyrid-3-yl, N methylpyridyl, and N-methyl-1,4-dihydro-pyrid-3-yl, and -NR"C(O)-R' where R' is aryl, heteroaryl or heterocyclic and R" is hydrogen or -CH 2 C(O)OCH 2 CH 3 . 20

26. The method of claim 14 wherein the compound is selected from the group consisting of: N-(Toluene- 4 -sulfonyl)-L-prolyl-4-(ca-methylbenzyloxy)-L-phenylalanine 25 N-(Toluene-4-sulfonyl)-L-prolyl-L-tyrosine N-(Toluene-4-sulfonyl)-L-prolyl-4-carboxyphenylalanine N-(Toluene-4-sulfonyl)-L-prolyl-3-(carboxy)phenylalanine 30 N-(Toluene- 4 -sulfonyl)-L-prolyl-4-(2-carboxyphenoxy)-L-phenylalanine N-(Toluene-4-sulfonyl)-L-prolyl-O-(benzyl)-L-tyrosine WO 99/06437 PCT/US98/16070 278 N-(Toluene-4-sulfonyl)-L-prolyl-4-(iodo)-L-phenylalanine N-(Toluene- 4 -sulfonyl)-L-prolyl-L-4-(methoxy)-phenylalanine 5 N-(Toluene-4-sulfonyl)-L-prolyl-4-nitro-L-phenylalanine N-(Toluene-4-sulfonyl)-L-prolyl-4-(O-tert-butyl)-L-tyrosine N-(Toluene-4-sulfonyl)-L-prolyl-L-(3,5-diiodo)-tyrosine 10 N-(Toluene- 4 -sulfonyl)-L-prolyl-L-4-(aminobenzoyl)-phenylalanine N-(Toluene-4-sulfonyl)-L-prolyl-L-(3-iodo-4-hydroxy)-phenylalanine 15 N-(Toluene- 4 -sulfonyl)-L-prolyl-L-(4-chloro)phenylalanine N-(Toluene-4-sulfonyl)-L-prolyl-L-leucine N-(Toluene-4-sulfonyl)-L-prolyl-L-alanine 20 N-(Toluene- 4 -sulfonyl)-L-prolyl-L-4-(acetamido)-phenylalanine N-(Toluene-4-sulfonyl)-L-prolyl-L-isoleucine 25 N-(Toluene-4-sulfonyl)-L-prolyl-L-aspartic acid N-(Toluene-4-sulfonyl)-L-prolyl-L-lysine N-(Toluene-4-sulfonyl)-L-prolyl-L-glutamic acid 30 N-(Toluene- 4 -sulfonyl)-L-prolyl-L-(4-dibenzylamino)-phenylalanine methyl ester N-(Toluene-4-sulfonyl)-L-prolyl-L-(N-benzyl)-histidine 35 N-(Toluene-4-sulfonyl)-L-prolyl-L-(4-dibenzylamino)-phenylalanine N-(Toluene-4-sulfonyl)-L-prolyl-L-methionine 40 N-(Toluene-4-sulfonyl)-L-prolyl-L-serine N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)thiaprolylL-(N-benzyl)-histidine N-(Toluene-4-sulfonyl)-L-prolyl-L-(1 -methyl)histidine WO 99/06437 PCT/US98/16070 279 N-(Toluene-4-sulfonyl)-L-prolyl-D-(N-benzyl)histidine N-(Toluene-4-sulfonyl)-L-glutamyl-L-tyrosine 5 N-(Toluene-4-sulfonyl)-L-prolyl-L-(N-3-methyl)histidine N-(Toluene-4-sulfonyl)-L-prolyl-a-amino-2,3-dihydro-(1,4-benzodioxin)-6 propanoic acid 10 N-(Toluene-4-sulfonyl)-L-prolyl-a-amino-1,3-benzodioxole-5-propanoic acid N-(Toluene-4-sulfonyl)-L-prolyl-L-valine 15 N-(Toluene-4-sulfonyl)-L-prolyl-L-(4-iodo)-phenylalanine methyl ester N-(Toluene-4-sulfonyl)-L-prolyl-L-4-(aminobenzoyl)phenylalanine methyl ester 20 N-(Toluene-4-sulfonyl)-L-prolyl-L-(4-chloro)phenylalanine methyl ester N-(Toluene-4-sulfonyl)-L-prolyl-L-(4-amino)phenylalanine methyl ester N-(Toluene-4-sulfonyl)-L-prolyl-L-(4-acetamido)phenylalanine methyl ester 25 N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)thiaprolyl-L-(N-benzyl)-histidine methyl ester N-(Toluene-4-sulfonyl)-L-prolyl-4-(3-3'-tolylureido)-L-phenylalanine 30 N-(Toluene-4-sulfonyl-L-prolyl-4-[(2,3,3a,7a-tetrahydro- 1H-indole-2 carbonyl)-amino]-L-phenylalanine N-(Toluene-4-sulfonyl)-L-prolyl-L-(4-pentylamino)phenylalanine methyl 35 ester N-(Toluene-4-sulfonyl)-L-prolyl-L-O-(2-dibenzylamino-ethyl)-tyrosine methyl ester 40 N-(Toluene-4-sulfonyl)-L-prolyl-L-O-[2-(dibenzylamino)ethyl]-tyrosine N-(Toluene-4-sulfonyl)-L-prolyl-L-(4-pentylamino)phenylalanine WO 99/06437 PCT/US98/16070 280 N-(Toluene- 4 -sulfonyl)-L-prolyl-L-4-(4-chlorobenzylamino)-phenylalanine methyl ester N-(Toluene-4-sulfonyl)-L-prolyl-L-4-[3-(4-cyanophenyl)-ureido]-phenyl 5 alanine methyl ester N-(Toluene-4-sulfonyl)-L-prolyl-L-4-[3-(4-cyanophenyl)-ureido]-phenyl alanine 10 N-(Toluene- 4 -sulfonyl)-L-prolyl-L-O-(tert-butoxycarbonylmethyl)-tyrosine methyl ester N-(Toluene- 4 -sulfonyl)-L-prolyl-L-O-(tert-butoxycarbonylmethyl)-tyrosine 15 N-(Toluene-4-sulfonyl)-L-prolyl-L-4-[(3S)-3,4-dihydro-isoquinolin-3-yl aminocarbonyl]-phenylalanine N-(Toluene-4-sulfonyl)-L-prolyl-4-[3-(3-methoxy-phenyl)-ureido]-L phenylalanine methyl ester 20 N-(Toluene-4-sulfonyl)-L-prolyl-4-[3-(3-methoxy-phenyl)-ureido]-L phenylalanine N-(Toluene-4-sulfonyl)-L-prolyl-L-O-(4,5-dihydro- 1 H-imidazol-2-yl 25 methyl)-tyrosine N-(Toluene-4-sulfonyl)-L-prolyl-L-4-(3-propyl-ureido)-phenylalanine N-(Toluene-4-sulfonyl)-L-prolyl-L-(4-benzylamino)phenylalanine 30 N-(Toluene-4-sulfonyl)-L-prolyl-L-(4-benzylamino)phenylalanine methyl ester N-(Toluene-4-sulfonyl)-L-prolyl-L-4-(4-chlorobenzylamino)-phenylalanine 35 N-(Toluene-4-sulfonyl)-L-prolyl)-L-(4-chloromethanesulfonylamino) phenylalanine N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)-thiaprolyl-L-4 40 (aminobenzoyl)phenylalanine methyl ester N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)-thiaprolyl-L-4 (benzamido)phenylalanine WO 99/06437 PCT/US98/16070 281 N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)-thiaprolyl-L-tyrosine ethyl ester N-(Toluene-4-Sulfonyl)-L-(5,5-dimethyl)-thiaprolyl-L-tyrosine 5 N-(Toluene-4-sulfonyl)-L-prolyl-L-4-[(pyridin-4 yl)methylamino]phenylanine N-(Toluene-4-sulfonyl)-L-prolyl-L-4-[(pyridin-4 yl)methylamino]phenylanine methyl ester 10 N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)-thiaprolyl-L-4-(pyridin-3 carboxamido)phenylalanine methyl ester N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)-thiaprolyl-L-4-(pyridine-3 15 carboxamido)phenylalanine N-(Toluene-4-sulfonyl)-L-prolyl-L-4-[(pyridin-3 ylmethyl)amino]phenylalanine 20 N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)-thiaprolyl-L-4-nitrophenylalanine methyl ester N-(Toluene-4-sulfonyl)-L-prolyl-L-4-nitrophenylalanine ethyl ester 25 N-(Toluene-4-sulfonyl)-L-prolyl-L-4-(2-methoxybenzamido)phenylalanine ethyl ester N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)-thiaprolyl-L-(4-nitro)phenylalanine ethyl ester 30 N-(Toluene-4-sulfonyl)-L-prolyl-L-4-(2-bromobenzamido)phenylalanine ethyl ester N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)-thiamorphyl-L-4 35 aminophenylalanine ethyl ester N-(Toluene-4-sulfonyl)-L-prolyl-L-4-acetamidophenylalanine ethyl ester N-(Toluene-4-sulfonyl)-L-prolyl-L-4-(2-methoxybenzamido)phenylalanine 40 N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)-thiaprolyl-L-4 acetamidophenylalanine ethyl ester WO 99/06437 PCT/US98/16070 282 N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)-thiaprolyl-L-4 acetamidophenylalanine N-(Toluene-4-sulfonyl)-L-prolyl-L-4-acetamidophenylalanine isopropyl ester 5 N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)-L-4 (isonicotinamido)phenylalanine ethyl ester N-(Toluene-4-sulfonyl)-L-prolyl-L-4-(isonicotinamido)phenylalanine 10 ethyl ester N-(Toluene-4-sulfonyl)-L-prolyl-L-(x-toluene-4-sulfonyl)histidine methyl ester 15 N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)-thiaprolyl-L-4 (nicotinamido)phenylalanine ethyl ester N-(Toluene-4-sulfonyl)-L-prolyl-L-(O-methyl)tyrosine ethyl ester 20 N-(a-Toluenesulfonyl)-L-prolyl-L-4-(isonicotinamido)phenylalanine ethyl ester N-(Toluene- 4 -sulfonyl)-L-prolyl-L-4-(2-bromobenzamido)phenylalanine 25 N-(a-Toluenesulfonyl)-L-prolyl-L-4-(isonicotinamido)phenylalanine N-(Toluene-4-sulfonyl)-L-(1,1-dioxo)thiamorpholyl-L-4-(2 bromobenzamido))phenylalanine ethyl ester 30 N-(Toluene-4-sulfonyl)-L-(1,1-dioxo)thiamorpholyl-L-4-(2 bromobenzamido)phenylalanine N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)-L-4 (isonicotinamido)phenylalanine 35 N-(a-Toluenesulfonyl)-L-prolyl-L-4-(2-bromobenzamido)phenylalanine ethyl ester N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)-thiaprolyl-L-tyrosine isopropyl 40 ester N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)-thiaprolyl-L-tyrosine tert-butyl ester WO 99/06437 PCT/US98/16070 283 N-(Toluene-4-sulfonyl)-L-prolyl-L-tyrosine tert-butyl ester N-(Toluene-4-sulfonyl)-L-prolyl-L-4-(2 trifluoromethylbenzamido)phenylalanine ethyl ester 5 N-(Toluene- 4 -sulfonyl)-L-prolyl-L-4-(2-methylbenzamido)phenylalanine ethyl ester N-(Toluene-4-sulfonyl)-L-prolyl-L-4-(2 10 trifluoromethylbenzamido)phenylalanine N-(4-Fluorobenzenesulfonyl)-L-thiaprolyl-L-tyrosine tert-butyl Ester N-(4-Fluorobenzenesulfonyl)-L-(5,5-dimethyl)-thiaprolyl-L-tyrosine tert 15 Butyl Ester N-(Toluene- 4 -sulfonyl)-L-prolyl-4-(dimethylamino)-L-phenylalanine N-(Toluene-4-sulfonyl)-L-prolyl-4-[(2-bromo)benzamido]-L-phenylalanine 20 ethyl ester N-(Toluene-4-sulfonyl)-L-prolyl-4-[(pyrazin-2-yl)C(O)NH]-L-phenylalanine methyl ester 25 N-(Toluene-4-sulfonyl)-L-prolyl-4-(4-nitrobenzoyl)-L-phenylalanine ethyl ester N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)thiaprolyl-4-(2-bromobenzamido) L-phenylalanine t-butyl ester 30 N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)thiaprolyl-4-(2-bromobenzamido) L-phenylalanine t-butyl ester N-(Toluene-4-sulfonyl)-L-prolyl-4-(1-H-2-oxo-3 35 methyltetrahydropyrimidin- 1-yl)-L-phenylalanine t-butyl ester N-(Toluene-4-sulfonyl)-L-prolyl-4-(1-H-2-oxo-3 methyltetrahydropyrimidin- 1 -yl)-L-phenylalanine 40 N-(Toluene-4-sulfonyl)-L-prolyl-3-chloro-4-(t-butoxy)-L-phenylalanine t butyl ester N-(Toluene-4-sulfonyl)-L-prolyl-3-chloro-4-(hydroxy)-L-phenylalanine t butyl ester WO 99/06437 PCT/US98/16070 284 N-(Toluene- 4 -sulfonyl)-L-prolyl-4-(N,N-dimethylureido)-L-phenylalanine t butyl ester N-(4-Fluorobenzenesulfonyl)-L-(5,5-dimethyl)thiaprolyl-3-chloro-4 5 (hydroxy)-L-phenylalanine t-butyl ester N-(4-fluorobenzenesulfonyl)-L-(5,5-dimethyl)thiaprolyl-3-chloro-4 (hydroxy)-L-phenylalanine isopropyl ester 10 N-(Toluene- 4 -sulfonyl)-L-prolyl-4-(2-methoxyphenyl)-L-phenylalanine t butyl ester N-(Toluene- 4 -sulfonyl)-L-prolyl-4-(2-methoxyphenyl)-L-phenylalanine 15 N-(Toluene-4-sulfonyl)-L-prolyl-[(5-N,N-dimethyl ureido)-pyridin-2-yl] alanine N-(Toluene- 4 -sulfonyl)-L-prolyl-4-(N,N-dimethylsulfamyl)-L-phenylalanine 20 N-(Toluene-4-sulfonyl)-L-prolyl-4-(N',N' ,N 2 -trimethylsulfamyl)-L phenylalanine N-(Toluene-4-sulfonyl)-L-prolyl-(1 -t-butoxycarbonylmethylimidazol-4-yl) L-alanine methyl ester 25 N-(Toluene-4-sulfonyl)-L-prolyl-[N,N-dimethylamino carbonylmethylimidazol-4-yl]-L-alanine methyl ester N-[4-(dimethyl ureylenyl)-benzenesulfonyl]-L-prolyl-4-hydroxy-L 30 phenylalanine isopropyl ester N-(Toluene-4-sulfonyl)-L-(5,5-dimethyl)thiaprolyl-3-chloro-4-hydroxy-L phenylalanine isopropyl ester 35 N-(Toluene-4-sulfonyl)-L-prolyl-3-chloro-4-hydroxy-L-phenylalanine isopropyl ester N-(Toluene- 4 -sulfonyl)-L-prolyl-4-(carboxymethyl)-L-phenylalanine methyl ester 40 N-(Toluene- 4 -sulfonyl)-L-prolyl-4-(2-methylbenzamido)-L-phenylalanine methyl ester WO 99/06437 PCT/US98/16070 285 N-(Toluene- 4 -sulfonyl)-L-prolyl-4-(N,N-dimethylaminocarbonylmethyl)-.L phenylalanine 5 N-(1-methylimidazol-4-sulfonyl)-L-prolyl-4-hydroxy-L-phenylalanine isopropyl ester N-(Toluene-4-sulfonyl)-L-prolyl-4-(2,4,5-trioxo-3 phenyltetrahydroimidazol-1-yl)-L-phenylalanine isopropyl ester 10 N-(4-Fluorobenzenesulfonyl)-L-(5,5-dimethyl)thiaprolyl-3-fluoro-4 hydroxy-L-phenylalanine isopropyl ester N-(4-Fluorobenzenesulfonyl)-L-(5,5-dimethyl)thiaprolyl-3-chloro-4-t 15 butoxy-L-phenylalanine t-butyl ester N- {N-[(1 S)-2,10-camphorsultamyl]acetyl}-L-tyrosine t-butyl ester N- {N-[(1 S)-2,10-camphorsultamyl]acetyl }-3-chlorotyrosine isopropyl ester 20 N-( 4 -Fluorobenzenesulfonyl)-L-thiaprolyl-4-hydroxy-L-phenylalanine t butyl ester N-(Toluene- 4 -sulfonyl)-L-prolyl-4-(N,N-dimethylaminocarbonylmethyl)-L 25 phenylalanine t-butyl ester N-( 4 -Nitrobenzenesulfonyl)-L-prolyl-4-(hydroxy)-L-phenylalanine t-butyl ester 30 N-(4-Fluorobenzenesulfonyl)-L-(5,5-dimethyl)thiaprolyl-4-hydroxy-L phenylalanine isopropyl ester N-( 4 -Fluorobenzenesulfonyl)-L-prolyl-4-hydroxy-L-phenylalanine t-butyl ester 35 N-(pyridin- 3 -sulfonyl)-L-prolyl-4-hydroxy-L-phenylalanine t-butyl ester N-(Toluene- 4 -sulfonyl)-L-prolyl-4-(methanesulfonamido)-L-phenylalanine 40 N-(Toluene-4-sulfonyl)-L-prolyl-4-(2,4,5-trioxo-3-(3-chlorophenyl) tetrahydroimidazol-1-yl)-L-phenylalanine benzyl ester N-(1-methylimidazol-4-sulfonyl)-L-(5,5-dimethyl)thiaprolyl-3-chloro-4 hydroxy-L-phenylalanine ethyl ester. WO 99/06437 PCT/US98/16070 286 N-(4-Fluorobenzenesulfonyl)-L-(5,5-dimethyl) thiaprolyl-L-3-chloro 4-tert-butoxy-phenylalanine tert-Butyl Ester N-[2-(N-2,10-camphorsultamyl) acetyl]-L-3-chloro-4-hydroxyphenylalanine 5 Isopropyl Ester